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A chronic wound is any wound that does not progress through the normal stages of 
healing. These wounds can take months or even years to resolve and, in many cases, 
will never fully heal. Chronic wounds are highly prevalent, with up to 3% of people 
over 60 and as many as 5% of people over 80 suffering from a chronic wound. Patients 
with chronic wounds often suffer from chronic pain, limited mobility, social isolation, 
and poorer mental health.  Not only are these wounds highly traumatic for patients, 
but they are also a significant burden for the NHS, with their treatment costing 
approximately £5.3 billion per annum. 
There are several reasons why a wound might fail to heal. The most common cause, 
however, is bacterial infection, and one of the most common causative organisms is 
Pseudomonas aeruginosa. When present in a wound, P. aeruginosa grows primarily 
in the form of a biofilm, a collection of bacterial cells encased in a self-produced 
polymer matrix. This matrix makes the bacteria highly resistant to antibiotic treatment, 
making wound infections very difficult, and often impossible, to eradicate.  
The formation of bacterial biofilms is governed by a process known as quorum 
sensing, in which bacteria produce and detect small signalling molecules known as 
autoinducers. This form of communication allows the cells to coordinate complex, 
population-wide, behaviours such as virulence factor expression, and biofilm 
formation.  
Several methods of disrupting quorum sensing, for example, via enzymatic 
degradation of the signalling molecules, have been proposed. One method competitive 
inhibition wherein a compound which competitively binds to the bacterial quorum 
sensing signalling receptors, effectively blocks the cell’s ability to take part in quorum 
xv 
 
sensing. Many synthetic and natural compounds have been shown to be capable of 
such competitive inhibition but perhaps the most well studied of these are furanones.  
Furanones are one such family of naturally occurring chemicals which are structurally 
similar to the signalling molecules used by P. aeruginosa. This allows furanones to 
competitively bind to the quorum sensing signal receptor, thus, minimising biofilm 
formation by P. aeruginosa populations. 
This thesis aimed to develop a novel method of delivering furanones to chronically 
infected wounds. This work demonstrated that, due to their inherent instability, a 
minimally crosslinked polymer aerogel was the most appropriate system for the 
controlled delivery of these compounds. Further, this thesis has demonstrated that, 
whether they are applied early in the biofilm formation process or to mature biofilms, 
two furanones, 4-hydroxy-2,5-dimethyl-3(2H) furanone (HDMF) and sotolon, are 
capable of significantly reducing biofilm biomass in vitro. The final experimental 
chapter of this thesis aimed to develop a novel, clinically representative, in vitro model 
of chronic wound biofilm that could be used to assess furanone loaded aerogels as 
potential antibiofilm wound therapeutics. The developed model was validated by 
showing efficacy of clinically relevant wound dressings and, subsequently, was used 
to demonstrate that sotolon-loaded aerogels showed great potential for reducing 
biofilm in chronic wounds.  
This thesis concludes that, though complex to include in pharmaceutical formulations, 
naturally occurring furanones have excellent potential to be used as antibiofilm wound 
therapeutics. Furthermore, when incorporated into a minimally crosslinked poly (vinyl 
alcohol) aerogel material, these compounds retain their activity and can be delivered 
to clinically representative biofilms where they reduce biofilm biomass. 
xvi 
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Pseudomonas aeruginosa is a gram-negative bacterium which can be found in a 
diverse range of environments including soil and water. It is also commonly found in 
healthcare settings such as hospitals, clinics and nursing homes. This ubiquitous 
pathogen is capable of causing a range of infections in humans. These infections range 
in severity from mild skin infections to potentially fatal bacteraemia (Rybtke et al., 
2015). P. aeruginosa is an opportunistic pathogen and, as such, often affects 
chronically unwell patients, such as those with long-term respiratory conditions (e.g. 
cystic fibrosis or chronic obstructive pulmonary disease), those with open wounds 
such as burns and open fractures, and those who are immunocompromised (e.g. 
neutropenic patients) (Streeter and Katouli, 2016). One of the main reasons for the 
success of P. aeruginosa as a clinical pathogen is the numerous virulence factors it 
has at its disposal. These include mechanisms for evading host immune processes like 
phagocytosis and opsonisation, as well as the ability to produce enzymes such as 
elastase and collagenase which degrade and damage host tissues. However, while 
these mechanisms allow P. aeruginosa to colonise and attack a host effectively, they 
must be tightly controlled and regulated. As such, many of these virulence factors are 
controlled through a phenomenon known as quorum sensing. 
1.1 Quorum sensing in Pseudomonas aeruginosa 
Quorum sensing (QS) is a cell density dependent method of cell-cell communication 
which is seen in both gram-negative and gram-positive bacterial species as well as 
some species of fungi. Organisms which utilise QS do so to control processes 
including  biofilm formation, cell motility and virulence associated gene expression 
(Fuqua, Winans and Greenberg, 1994). Bacterial QS is a complex process which varies 




widely between species. In general, QS is dependent on the production and detection 
of small signalling molecules. In brief, bacteria constitutively express low molecular 
weight signalling molecules called autoinducers. In gram-negative organisms, the 
primary autoinducers are a group of molecules known as the N-acyl homoserine 
lactones (AHLs). These AHLs either diffuse or are actively effluxed from the cell and 
accumulate in the extra-cellular environment. Once a critical environmental AHL 
concentration is reached the signalling molecules will diffuse across the membrane of 
another, adjacent, bacterial cell and interact with their cognate receptor protein. This 
interaction causes a conformational change in the receptor structure allowing it to act 
as a transcriptional promoter, thus, inducing the expression of a group of target genes. 
These target genes encode a wide range of products including molecules such as 
endotoxins and enzymes and polymers (Lee and Zhang, 2014). While QS often 
upregulates the expression of virulence genes it can also down regulate the expression 
of some genes.  Genes which are downregulated in response to QS include surface 
antigens such as OprH so that a cell may avoid detection by a host’s immune system 
(Arevalo-Ferro et al., 2003).   
1.2 The quorum sensing systems of Pseudomonas aeruginosa  
P. aeruginosa is perhaps the most well characterised QS bacterial species and, indeed, 
it is often used as a model organism in which gram-negative QS can be studied. The 
process of QS in P. aeruginosa is highly complex with several QS systems working 
in tandem, positively or negatively regulating the others. P. aeruginosa has 3 known 
QS systems; the Las system, the Rhl system and the PQS system. A fourth system, 
known as the IQS system, has been proposed but, to date, remains poorly understood 




(Lee et al., 2013). Each of these systems has a cognate autoinducer which controls it. 
Each of these four systems and their autoinducers are discussed here.   
1.2.1 Acyl-homoserine lactones 
AHLs are the primary QS signalling molecules used by gram-negative bacteria 
(Papenfort and Bassler, 2016). These AHLs have a common base structure that 
consists of a lactone ring and an acyl side chain (Figure 1.1).  
 
Figure 1.1 – General structure of AHL molecules. 
 The lactone ring remains constant across all AHL molecules while the acyl chain can 
vary in both length and presence of side groups. 
 
It is variations in the length of this side chain and the various side groups that makes 
the AHLs produced by different organisms so distinct. For example, if an AHL has a 
twelve-carbon chain at R1 it would be oxo dodecanoyl homoserine lactone, the AHL 
used in the Las QS system of P. aeruginosa. However, if the R1 group is a cinnamoyl 




moiety then AHL will be cinnamoyl homoserine lactone, an AHL used by 
Bradyrhizobium spp. (Ahlgren et al., 2011). 
1.2.2 The Las quorum sensing system 
The Las system was the first QS system to be characterised within P. aeruginosa and 
remains the most well-studied system to date. The Las QS system is responsible for 
the production of many virulence factors including the LasA, LasB, and Apr protease 
enzymes (Gambello and Iglewski, 1991; Toder, Gambello and Iglewski, 1991; 
Gambello, Kaye and Iglewski, 1993). While the Las QS system is only one of four QS 
systems used by P. aeruginosa it is typically thought of as being at the top of the QS 
hierarchy, mainly because the activation of the Las system causes a subsequent 
activation of both the Rhl system and the PQS system.   
The Las system makes use of the AHL N-(3-oxododecanoyl)-L-homoserine lactone 
(OdDHL) (Figure 1.2). 
 
Figure 1.2 – Chemical structure of autoinducer N-(3oxododecanoyl)-L-
homoserine lactone (OdDHL).  
This autoinducer, like all AHLs consists of a lactone ring with a 12-carbon acyl chain.  
 




Prior to its isolation and characterisation, it was known that that OdDHL (then known 
as Pseudomonas autoinducer or PAI) had a high structural homology to the 
autoinducer responsible for the regulation of luminescence in the bacterium Vibrio 
fischeri  and, indeed, it was believed that P. aeruginosa may in fact also be using VAI 
as an autoinducer (Jones et al., 1993). However, in 1994, Pearson et al. showed that 
PAI was structurally distinct from its V. fischeri counterpart. While VAI was known 
to be N-(3-oxohexanoyl) homoserine lactone, PAI was found to be the structurally 
similar N-(3-oxododecanoyl) homoserine lactone. 
In the Las QS system, OdDHL is constitutively expressed at low levels by the bacteria 
and is actively transported out of the cell via the MexAB-OprM efflux system 
(Pearson, Van Delden and Iglewski, 1999). This active efflux causes OdDHL to 
accumulate in the extracellular environment and when a critical threshold has been 
reached, OdDHL enters the cell and associates with its cognate receptor which is 
known as LasR. Upon complexing with OdDHL the LasR undergoes a conformational 
change. It has been suggested that the binding of OdDHL causes a LasR to dimerise, 
resulting in a conformational change in the LasR protein (Kiratisin, Tucker and 
Passador, 2002; Schuster, Urbanowski and Greenberg, 2004). This dimeristion and 
conformational change means that LasR can adopt a biologically active form 
(Sappington et al., 2011). This active LasR-OdDHL complex then binds to the target 
genes and activates their transcription. The Las system controls the transcription of 
numerous genes including the virulence factors LasA protease and LasB elastase. In 
addition to increasing transcription of several virulence factors the LasR/OdDHL 
complex also positively regulates the transcription of the AHL synthase gene, LasI. 




The upregulation of this AHL synthase gene causes a greater production of OdDHL 
(Seed, Passador and Iglewski, 1995). This results in the first positive feedback QS 
loop (Figure 1.3).  
 
Figure 1.3 – The Las quorum sensing system of P. aeruginosa.  
(1) OdDHL accumulates in the extracellular environment and when a critical 
threshold concentration is reached it diffuses into the bacterial cell. (2) OdDHL 
complexes with the receptor protein LasR causing a conformational change resulting 
in the active LasR/OdDHL comples. (3) The active LasR OdDHL complex bind to a 
set of target genes initiating their transcription. (4) One of the induced genes is lasI 
which encodes for the production of an AHL synthase which results in increased 
production of OdDHL. (5) The produced OdDHL is actively effluxed from the cell and 
begins to accumulate in the extracellular environment. 
 
As well as the production of virulence factors and additional OdDHL, activation of 
the Las system leads to the transcription of both rhlR (which encodes for the RhlR, the 




receptor protein of the Rhl QS system) and PqsR (which encodes for the PqsR receptor 
protein for the PQS QS system). As stated previously, due to the activation of these 
other QS systems, the Las QS system is considered the most important QS system 
used by P. aeruginosa. 
1.2.3 The Rhl quorum sensing system 
The Rhl QS system is the second QS system of P. aeruginosa and main constituents 
are the Acyl-homoserine lactone synthase, RhlI and the receptor RhlR. The product of 
RhlI synthase is an AHL known as N-butyryl homoserine lactone (BHL). BHL is the 
autoinducer responsible for the activation of the Rhl quorum sensing system (Winson 
et al, 1995) and has a similar mode of action to OdDHL. Binding of BHL to the RhlR 
protein causes RhlR to become active. This activation is again suggested occur via 
dimerization of the receptor protein (Ventre et al., 2003). The RhlR dimer then binds 
to the promoter region of its associated regulon initiating transcription. This QS 
system governs the transcription of a distinct set of virulence associated genes such as 
those involved in rhamnolipid, pyocyanin, and hydrogen cyanide production (Pearson, 
Pesci and Iglewski, 1997; Pessi and Haas, 2000) 
BHL also shares structural homology with both VAI and OdDHL differing only in the 
length of its acyl chain (Figure 1.4).  





Figure 1.4- Chemical structure of N-butyryl-homoserine lactone. 
 This AHL has the characteristic structure of an AHL, consisting of a lactone ring and 
a 4 carbon acyl chain.  
 
As is the case with the Las quorum sensing system, the Rhl QS system is not wholly 
independent. While BHL is constitutively expressed at low levels and subject to a 
positive feedback loop when RhlR is active, the presence of the LasR-OdDHL 
complex activates the expression of both the rhlR and rhlI genes (Papenfort and 
Bassler, 2016) (Figure 1.5). 





Figure 1.5 – The Rhl quorum sensing system of P. aeruginosa.  
(1) LasR/OdDHL complex initiates the transcription of the rhlR gene encoding for the 
RhlR receptor protein. (2) BHL in the extracellular environment enters the cell. (3) 
BHL complexes with the receptor protein RhlR and causes a conformation change. (4) 
The RhlR/BHL complex initiates the transcription of target genes including the AHL 
synthase encoding gene rhlI. (5) BHL is produced and it exits the cell and begins to 
accumulate in the extracellular environment. 
 
The RhlR-BHL complex has been shown to be capable of inhibiting the expression of 
the pqsR gene and the pqsABCDE operon. The inhibition of these genes results in a 
decrease in the autoinducer of the PQS system (Wade et al., 2005). Interestingly, the 
PqsR receptor protein, when in complex with PQS, can induce the expression of both 
RhlR and RhlI. This may suggest that this RhlR-BHL dependant negative regulation 




of the PQS QS system allows for fine control of the genes under both the Rhl and PQS 
systems as well as maintaining an optimal balance between autoinducers.  
1.2.4 The PQS quorum sensing system 
The PQS quorum sensing system is the third system used by P. aeruginosa. The 
autoinducer of this system is 2-heptyl-3-hydroxy-4-quinolone, also known as the 
Pseudomonas quinolone signal or PQS. Although PQS is an autoinducer, it is not part 
of the homoserine lactone family and does not share any structural homology with 
OdDHL or BHL (Figure 1.6).  
 
Figure 1.6 – Chemical structure of 2-heptyl-3-hydroxy-4-quinolone also known 
as the Pseudomonas quinolone signal (PQS).  
This autoinducer is not part of the AHL family of signalling molecule and, thus, does 
not share a structural homology with OdDHL or BHL 
 
PQS is a product of a biosynthetic pathway initiated by an anthranilate-coenzyme A 
ligase, the transcriptional product of pqsA. This biosynthetic pathway is completed by 
the enzyme PqsH, which converts a PQS precursor into the active PQS molecule. As 
noted above, the PQS system is influenced by other quorum sensing systems. The 
transcription of the pqsH gene is positively controlled by LasR and the production of 




the transcriptional activator PqsR is controlled by the LasR/OdDhl complex. Not only 
this, but the production of the transcriptional activator PqsR is negatively regulated by 
RhlR-BHL (Wade et al., 2005) (Figure 1.7).   
 
Figure 1.7 – The PQS quorum sensing system of P. aeruginosa.  
(1-3) The transcription of pqsR and the pqsABCDE operon is positively regulated by 
the LasR/OdDHL complex resulting in the production of the PqsR receptor protein 
and the PQS autoinducer. (4) PqsR and PQS form a complex. (5) The PqsR/PQS 
complex then positively regulated the transcription of the pqsABCDE operon, thus, 
resulting in a positive feedback loop. (6) PqsR/PQS complex positively regulates the 
transcription of RhlI. (7) The RhlR/BHL complex negatively regulates the 
transcription of pqsR.  
 
1.2.5 Integrated quorums sensing system 
The integrated quorum sensing system (IQS) is a recently proposed P. aeruginosa 
communication pathway. The proposed IQS autoinducer has been identified as 2-(2-




hydroxyphenyl)-thiazole-carbaldehyde. As it is neither a quinolone or homoserine 
lactone it is structurally distinct from OdDHL, BHL and PQS (Lee et al., 2013) (Figure 
1.8).  
Currently, the IQS quorum sensing system is not as well studied as other systems, 
however, in their seminal study on IQS, Lee et al. (2013) show that the IQS 
autoinducer may be important for the production of both the PQS and BHL signalling 
molecules.   
 
Figure 1.8 – Chemical structure of 2-(2-hydroxyphenyl)-thiazole-carbaldehyde.  
This compound is the identified autoinducer for the proposed IQS quorum sensing 
system of P. aeruginosa.  
 
The different QS systems and cognate autoinducers used by P. aeruginosa allow 
tighter control of the various virulence factors and phenotypes displayed during an 
infection. The interrelated nature of the three systems also facilitates an element of 
compensation if one system is not fully operational at any time. This is an important 
consideration when investigating QS inhibitors or antagonists against these 




autoinducers. While it is likely that the elimination of one branch of the quorum 
sensing system will attenuate the organism’s virulence, it may not remove virulence 
entirely as each of the systems play a unique role in pathogenicity and virulence. 
1.3 The role of quorum sensing in Pseudomonas aeruginosa 
QS has been shown to have a wide range of functions in P. aeruginosa. These 
functions are either vital for the organism’s survival or provide a distinct advantage 
for the organism when infecting a host. These functions include the production of 
virulence factors, coordination of complex behaviours such as biofilm formation, and 
some types of cell motility. 
1.3.1 Virulence factor production 
Each of the QS systems described above control the production of a distinct set of 
secreted virulence factors which greatly increase the ability of P. aeruginosa to 
colonise and infect a host organism. The Las QS system controls the production of 
several important virulence factors including the degradative enzymes LasA protease, 
LasB elastase and Apr alkaline protease as well as other virulence factors such as 
exotoxin A (Gambello and Iglewski, 1991; Toder, Gambello and Iglewski, 1991; 
Gambello, Kaye and Iglewski, 1993). Similarly, the Rhl system is responsible for 
regulating the production of virulence factors, such as hydrogen cyanide and 
pyocyanin. It should also be noted that, similar to the activation of the QS systems 
there is a certain amount of overlap between the systems responsible for production of 
some virulence factors. It has been shown that the production of hydrogen cyanide, 
for example, can be stimulated by the action of both LasR-OdDHL and RhlR-BHL 
complexes (Pessi and Haas, 2000). The virulence factors employed by P. aeruginosa 




are numerous and for a full review of P. aeruginosa virulence factors the reader is 
referred to Strateva and Mitov. (2011).    
1.3.2 Biofilm formation 
In addition to its role in secreted virulence factor production, QS is an integral part of 
biofilm formation, the process by which planktonic cells form organised communities 
encased in a polymeric substance often attached to a surface (Rasamiravaka et al., 
2015). Briefly, planktonic bacteria will attach to a surface (either biotic or abiotic in 
nature) first reversibly, then irreversibly. This first reversible attachment results in 
changes in the expression of multiple genes involved in the biofilm formation process, 
such as those involved in the production of the polymeric matrix which provides the 
biofilm structure. Bacterial cells then begin to aggregate and form microcolonies, 
encased in the extracellular polymeric substance. These polymers are continually 
produced and gradually accumulate while bacterial cells divide, providing much of the 
three-dimensional structure of the biofilm. Finally, once the biofilm has matured it can 
disperse, thus, returning some of its cells to the planktonic phase. These newly 
planktonic cells relocate and seed new biofilms, thus, beginning the process again 
(Figure 1.9). This dispersal may be brought about through the mature biofilm 
experiencing a damaging mechanical force or it may be triggered by environmental 









Figure 1.9 – The process of biofilm formation and dispersal.  
Planktonic cells attach to a surface first reversibly then irreversibly. Cells begin to 
aggregate and form microcolonies on the surface. Cells then continue to divide and 
produce extracellular polymer further developing the three-dimensional structure of 
the biofilm. Mature biofilms then disperse retuning some of their cells back to the 
planktonic state. These planktonic cells then seed new biofilms. 
 
The role of QS in biofilm formation has been debated for some time with many papers 
reporting contradictory findings. Despite this, QS has been implicated in almost all 
stages of biofilm development in P. aeruginosa. Although there is no evidence to 
suggest that quorum sensing plays a role in the initial attachment of P. aeruginosa to 
a surface, it has been shown that the Las and Rhl controlled process of twitching 
motility is required for the formation of microcolonies during the early stages of 
biofilm formation (O’Toole and Kolter, 1998). This work showed that the ability of P. 
aeruginosa to form a biofilm on an abiotic surface was significantly compromised 
when a mutation was present in the pilBCD genes. These pili biogenesis mutants were 
seen to grow and produce a monolayer on the surface as expected but did not form the 




microcolonies which are characteristic of the early stages of biofilm formation. In 
addition, O’Toole and Kolter (1998) also showed that strains of P. aeruginosa 
defective in flagellum production were unable to effectively form a monolayer. While 
this data indicates that both pili mediated, and flagellar motility are vital for the 
formation of a biofilm Glessner et al. (1999) demonstrated that only the pili mediated 
twitching motility was dependent upon the Las and Rhl QS system. They showed that 
ΔlasI or ΔrhlI P. aeruginosa mutants exhibited highly diminished twitching motility. 
Furthermore, mutants deficient in both genes displayed no detectable twitching 
motility. Subsequently, motility was partially restored through the exogenous addition 
of each corresponding autoinducer (Glessner et al., 1999). Importantly, these findings 
were later repeated with clinical isolates of P. aeruginosa, showing a significant 
positive correlation between twitching motility and the ability to form a biofilm (Otton 
et al., 2017). This correlation was seen in a range of clinical strains including faecal, 
lung, urine and wound isolates. The knowledge that the ability of a strain to form a 
biofilm is related to its capacity for twitching motility is important. It clearly shows 
that QS is involved in the process of biofilm formation from the very early stages and 
may, in fact, be vital for the formation of the microcolonies which form the foundation 
on which the mature biofilm (Figure 1.10) is formed.   





Figure 1.10 – Light micrograph of a mature P. aeruginosa DSM50071 biofilm 
grown on polycarbonate.  
The sample was grown for 24 h and stained with crystal violet prior to visualisation. 
Image taken as 20x magnification using a Nikon ECLIPSE E400 microscope.  
 
As well as having a role in microcolony formation through the regulation of twitching 
motility, QS has also been shown to be involved in the process of biofilm maturation 
and the formation of its three-dimensional structure. An early study by Davies et al.  
(1998) showed that lasI and rhlI deficient mutants of P. aeruginosa were significantly 
less able to form thick biofilms with a three-dimensional structure. Interestingly, 
single lasI mutants showed the same diminished biofilm thickness while single rhlI 
mutants showed no deficit (Davies et al., 1998). Biofilms formed by the lasI mutants 




appeared to have similar numbers of bacterial cells as the wild type, but the biofilms 
had approximately 75% less vertical height above the substratum. As with the 
twitching motility mutants, normal biofilm formation was restored in the lasI mutant 
following the addition of exogenous autoinducer. In addition to this, the authors tested 
the susceptibility of the abnormal biofilms to treatment with a chemical detergent. 
They found that the mutant biofilms were significantly more susceptible to sodium 
dodecyl sulfate treatment when compared to wild type biofilms and completely 
detached and dispersed after exposure. The results presented by Davies et al. (1998) 
demonstrate that not only is the Las QS system involved in the development of a 
biofilms vertical structure, but also plays a role in providing protection against 
detergents. However, it may be the case that the reduced thickness of the biofilm 
simply allowed for deeper penetration of the detergent rather that the mutant strains 
lacking a specific defence mechanism against it. It was later shown by Allesen-Holm 
et al. (2006) that, in addition to having a diminished biofilm thickness, las and rhl 
deficient mutants were significantly less capable of producing extracellular DNA 
(eDNA), an important structural component of biofilms (Allesen-Holm et al., 2006). 
This study also showed that eDNA is localised primarily on the substratum and surface 
of early microcolonies, and later, in the stalks of the mushroom shaped portions of 
mature biofilms. Importantly, it is believed that these mushroom shaped formations 
are heavily involved in the maintenance of the biofilm, providing a route for nutrients 
to the deeper sub-populations and an efficient method of waste removal (Tolker-
Nielsen, 2014). The reduced eDNA production reported by Allesen-Holm et al. (2006) 
may indicate that QS plays a regulatory role in the formation of these structures and, 
thus, has a role in biofilm maintenance systems. Both Davies et al. (1998) and Allesen-




Holm et al. (2006) suggest that QS is an important part of both the construction and 
maintenance of P. aeruginosa biofilms. This is important as it may mean that 
disruption of quorum sensing systems could effectively weaken biofilms making 
treating and eradicating them easier.   
QS has been shown to play a key role in the dispersal of a mature biofilm and the 
subsequent spread of new biofilms. Originally, it was shown that the Las QS sensing 
system was responsible for positively regulating the transcription of a primary P. 
aeruginosa exopolysaccharide known as PEL. This was demonstrated through the use 
of lasI/rhlI mutants which showed a significant drop in pel transcription which could 
subsequently be restored through the addition of exogenous autoinducer (Sakuragi and 
Kolter, 2007). However, a later study claimed that QS may instead negatively regulate 
the formation of biofilms (Ueda and Wood, 2009). The authors of this study showed 
that the deletion of a gene known as tpbA, encoding for a tyrosine phosphate, resulted 
in an increased production of the PEL exopolysaccharide. It was also seen that the Las 
QS system appears to, at least partially, be responsible for the activation of tpbA. 
Interestingly, this would mean that the Las QS system negatively regulates the 
production of PEL and, therefore, may aid in the dispersal of cells back into a 
planktonic state.  
Another class of molecule that has been shown to be important to the maintenance and 
dispersal of mature biofilms are the rhamnolipids. It was shown that these 
rhamnolipids, which are primarily produced in the mushroom like structures within 
the biofilm were vital for the maintenance of the biofilms three-dimensional structure. 
Without them, the channels required for nutrient and waste transport were not 




effectively maintained (Davey, Caiazza and O’Toole, 2003; Lequette and Greenberg, 
2005). As well as being required for biofilm maintenance Boles et al. (2005) showed 
that over expression of rhamnolipids was responsible for increased biofilm detachment 
and dispersal in a hyper-detaching variant of P. aeruginosa (Boles, Thoendel and 
Singh, 2005). Additionally, it was found that addition of exogenous rhamnolipid to 
wild type P. aeruginosa could bring about biofilm detachment. These findings indicate 
that rhamnolipid production, which is controlled by QS, is an important mechanism 
by which biofilms detach from a surface, disperse and subsequently seed new biofilms. 
If QS is indeed involved in the maintenance and dispersal of mature biofilms as 
suggested by the above studies, inhibition of the QS system may be of significant 
clinical interest. If the maintenance of mature biofilms can be disrupted then they may 
be less likely to thrive and, perhaps, become simpler to treat. Similarly, if the dispersal 
of biofilms, and hence one of the main modes of persistence, is lessened, the duration 
and severity of infection may also be reduced.   
1.4 The role of biofilms in human disease 
Biofilms are known to be involved in a wide range of diseases in humans such as cystic 
fibrosis, conjunctivitis, endocarditis and persistent urinary tract infections. Indeed, in 
a public announcement in 2002 the National institutes of Health stated that biofilms 
may account for up to 80% of all microbial infections in the body (National Institutes 
of Health, 2002). 




While biofilms in conditions such as cystic fibrosis and endocarditis are well 
investigated areas of research and studies into novel treatments for these conditions 
are numerous, the treatment of biofilms in chronic wounds is severely under examined. 
1.5 Biofilms and chronic wounds 
It has been shown that almost 80% of chronic wounds have a bacterial biofilm present 
(Malone et al., 2017). These wound biofilms can be caused by a wide range of 
organisms and are often polymicrobial in nature. P. aeruginosa is one of the most 
common causative organisms in wound infections. P. aeruginosa readily forms 
biofilms in a wound environment and, during such infections, it grows almost 
exclusively in this form (Brandenburg et al., 2015; Neopane et al., 2018).  
When present in a wound, biofilms cause a prolonged inflammatory state which, in 
turn, delays the healing process. The presence of biofilms in a wound leads to 
inappropriately high numbers of neutrophils in the wound environment which then 
release continually large amounts of proinflammatory cytokines such as Interleukin-6 
and tissue necrosis factor alpha (Fazli et al., 2011). Due to the highly persistent nature 
of the biofilm this inflammatory state is maintained long-term and results in a 
significant delay of normal wound healing. This results in a wound which is unable to 
heal normally.   
1.5.1 Biofilm development in wounds 
There are numerous routes of infection for open wounds including foreign bodies such 
as dirt or gravel becoming embedded in the wound, infection introduced from the 
source of the wound such as animal and insect bites, and even infection from the 




patient’s own microbiome (including faecal bacteria and skin isolates) (Rothe, Tsokos 
and Handrick, 2015; Hirashima et al., 2019). Following the introduction of bacteria to 
a wound, biofilms can begin to form very rapidly. 
In 1996, Akiyama et al., using a murine wound model, showed that just 6 hours after 
inoculation with S. aureus, small characteristic clusters of cells (micro colonies 
characteristic of a biofilm) had already begun to appear in a wound (Akiyama et al., 
1996). This was later shown also to be the case for P. aeruginosa when tested in vitro. 
Here, the authors showed that some characteristic traits of a biofilm (specifically 
exopolysaccharide production) was detectable within just 5 hours of inoculation 
(Harrison-Balestra et al., 2003; Metcalf, Bowler and Parsons, 2016).  
The rapid formation of a biofilm in a wound environment is highly problematic as it 
provides only a short time frame in which a wound must be disinfected. If effective 
disinfection is not achieved, the formation of a biofilm by the infecting organism may 
result in the prolonged inflammatory state that may result in a non-healing wound.  
1.5.2 The role of biofilm in chronic wound development 
Normal wound healing requires the seamless transition between several distinct 
physiological stages. First, during the haemostasis phase, blood vessels constrict, and 
a fibrinous blood clot is formed in order to prevent further bleeding (Zaidi and Green, 
2019). This is followed by the inflammatory stage of wound healing. During this stage 
immune cells are drawn to the site of the wound and here they act as a primary defence 
against infection by phagocytosing any invading organisms. Other types of immune 
cells such as macrophages are also recruited to help prevent infection. A wide range 




of other immune cells including dendritic cells and T-cells are also involved in this 
complex stage. After the inflammatory stage the proliferative phase begins. This stage 
involves the formation of new blood vessels at the injury site through a process known 
as angiogenesis. This is accompanied by the production of new connective tissues by 
dermal fibroblasts. This is followed by reepithelialisation in which new epithelial cells 
begin to form to replace the protective layer of skin which maintains barrier function 
(Rodrigues et al., 2019). When these stages progress as described an acute wound will 
heal fully. However, many factors can interrupt the wound healing process causing 
failure to heal and a chronic wound will be formed.  
The most common cause of failure to heal in wounds is bacterial infection (Leaper, 
Assadian and Edmiston, 2015) and it has been shown that the wound healing time of 
chronic wounds such as venous leg ulcers increases with each additional organism 
isolated from the wound (Kruszewska, Wesolowska-Gorniak and Czarkowska-
Paczek, 2020). As previously stated, when bacteria are present in a wound they will 
grow primarily as a biofilm. This affords the bacteria high levels of protection against 
host immune defences such as opsonisation and subsequent phagocytosis (Pier et al., 
2001). Biofilms provoke an inflammatory response, but they cannot be cleared by the 
immune system. This means that a persistent inflammatory state is maintained within 
the wound. As the inflammatory stage of wound healing is not resolved the wound 
cannot progress to the proliferative phase and a chronic wound results (Schultz et al., 
2017). Due to the inherent resilience of biofilms, chronically infected wounds may 
persist for many months and in some cases will never heal. A simplified schematic of 




the role of bacterial biofilm formation in the development of a chronic wound is shown 
in figure 1.11 
 
Figure 1.11 – The role of biofilms in the formation of a chronic wound.  
(1) Bacteria are introduced to a wound either from the environment or the patient’s 
own microbiome. (2) Within 6 h bacteria have proliferated and the early stages of a 
biofilm are formed. (3) Bacteria being to proliferate, and biofilms mature. (4) The 
inflammatory state is maintained in the wound environment. Many immune calls are 
continually present at the wound site. Biofilms continue to grow, and bacteria may 
penetrate deeper tissues or even the blood stream causing potentially fatal 
bacteraemia.  
 
It is clear that bacterial biofilms are a significant problem in wounds. However, their 
treatment is often difficult, and many biofilms cannot be eradicated using traditional 
antimicrobials. Novel approaches are, therefore, needed. One approach which may 




provide a means of treating these biofilms involves interfering with or inhibiting the 
QS communication systems that the bacteria use to coordinate the formation and 
maintenance of these biofilms.  
1.6 Quorum sensing inhibitors  
It has been known for some time that the virulence and pathogenicity of many bacteria 
can be attenuated through the inhibition of their QS systems. Early studies such as the 
work of Passador et al. (1996) showed that the cognate autoinducers in QS bacteria 
experienced competition when binding to their corresponding receptor if structural 
homologues of the autoinducer were introduced (Passador et al., 1996).  A study by 
McClean et al. (1997) showed that the production of the purple pigment violacein by 
Chromobacterium violaceum could be inhibited by the addition of homoserine 
lactones which were structurally similar to the C. violaceum cognate autoinducer, N-
hexanoyl-L-homoserine lactone, but differed in the length on their acyl side chain 
(McClean et al., 1997). While QS inhibition was possible through the use of other 
bacterial AHLs, Givskov et al. (1996) also showed that a species of marine algae, 
Delisea pulchra, produced a set of secondary metabolites called furanones which were 
capable of interfering with AHL mediated processes such as swarming motility in 
Serratia liquefaciens (Givskov et al., 1996). These findings were important as they 
clearly showed that QS could be inhibited by molecules from natural sources and did 
not necessarily have to be other homoserine lactones. This realisation then prompted 
further research into other potential quorum sending inhibitors (QSIs) and an increase 
in research focused on discovering and characterising both furanone and non-furanone 
QSIs.   




1.6.1 Non-furanone quorum sensing inhibitors 
In recent years, a number of non-furanone compounds have been shown to have anti-
quorum sensing, anti-biofilm or virulence attenuation capabilities. These compounds 
have ranged from enzymes which degrade the autoinducer molecules to currently used 
medicines such as aspirin (Lin et al., 2003; El-Mowafy et al., 2014).  
1.6.1.1 Microorganism derived QSIs 
In an early study, AHL acylase, a bacterially produced enzyme which actively 
degrades AHLs by separating the acyl chain from the lactone ring (LaSarre and 
Federle, 2013), was shown to be effective in reducing the levels of active autoinducer 
in the extracellular environment. It was also shown to effectively reducing swarming 
motility in P. aeruginosa (Lin et al., 2003). Following the work of Lin et al. several 
studies aimed to characterise AHL acylases from different sources or to better 
understand the enzymes role in various biological processes (Sio et al., 2006; Bokhove 
et al., 2010; Kusada et al., 2017). However, despite showing promise in in vitro work 
these acylase enzymes have not been extensively studied in vivo.     
In addition to AHL degrading enzymes, it has been shown that other compounds 
produced by a range of microorganisms can be effective when used to disrupt QS. For 
example, one research group showed that several compounds isolated from the fungal 
genus Penicillium may have QSI properties (Rasmussen et al., 2005). This study 
demonstrated how two compounds, penicillic acid and patulin, were able to effectively 
disrupt the transcription of quorum sensing controlled genes in P. aeruginosa 
indicating QSI effects. Additionally, patulin was shown to significantly decrease 
levels of the quorum sensing receptor protein detected in culture samples as well as 




increasing P. aeruginosa biofilm sensitivity to treatment with the antibiotic 
tobramycin. Importantly, these effects were seen when patulin was added in 
concentration considerably below the lethal dose, significantly decreasing the 
possibility of introducing selection pressures and, therefore, resistance to the 
compound. In addition to this a 7-day course of intravenous patulin at 2.5 μg g-1 was 
also shown to be effective in increasing the rate at which P. aeruginosa infection was 
cleared from the lungs in a murine respiratory infection model. While the difference 
in mortality between patulin and placebo treated mice was not significant, a clear trend 
was seen.  
1.6.1.2 Plant-derived QSIs 
Another common source of novel QSIs is plants, plant extracts and oils (from both 
marine and terrestrial plants). Several studies have characterised compounds with QSI 
activity from such sources. In 2006, it was shown that a crude extract of vanilla was 
capable of inhibiting the production of violacein by C. violaceum (Choo, Rukayadi 
and Hwang, 2006). The authors showed that the presence of 10 μmol l-1 of exogenous 
autoinducer in cultures of C. violaceum resulted in significant production of the 
pigment. The addition of between 0.25% and 2.00% w/v of crude vanilla extract 
showed a dose dependent reduction in violacein up to an almost 100% reduction 
showing that the vanilla extract could effectively inhibit quorum sensing. Similarly, a 
2009 study showed that a number of plant essential oils, including lavender, clove and 
peppermint, had anti-quorum sensing properties. The authors demonstrate that clove 
oil in particular was able to inhibit the production of QS controlled molecules in a dose 
dependent manner. This was also shown through the inhibition of violacein production 




(Khan et al., 2009). However, such studies often have the same fundamental 
limitation. Essential oils and plant extracts are typically a complex mix of a large 
number of compounds. While these two studies have shown that the various plant 
extracts do indeed have QSI activity the authors have not identified the active 
component. Kahn et al. (2009) were able to show that the main component of clove 
oil, Eugenol, was not responsible for its QSI activity but no further analysis was 
performed. This lack of identification of active compounds limits the applicability of 
these studies, and the potential for their findings to be translated into in vivo work and 
subsequently into clinical practice is significantly reduced.  
One plant-derived QSI which has been relatively well characterised is 
cinnamaldehyde. This organic compound has been shown to significantly reduce 
AHL-mediated fluorescence in a reporter E. coli strain (Niu, Afre and Gilbert, 2006). 
It was demonstrated that a concentration of between 100 - 200 μmol l-1 of 
cinnamaldehyde was able to reduce fluorescence in an E. coli reporter strain by up to 
70%. This effect was achieved without significantly inhibiting the growth of the 
organism meaning that cinnamaldehyde can be used to inhibit the action of two AHLs 
without introducing a significant selection pressure which may lead to the 
development of resistance. The use of this reporter strain demonstrated that 
cinnamaldehyde effectively reduced the action of both N-hexanoyl-L-homoserine 
lactone and 3-Hydroxy-C4-homoserine lactone. Similarly, a study in 2008 showed that 
cinnamaldehyde and its derivatives reduced autoinducer AI-2 mediated fluorescence 
in both wild type V. harveyi and several QS mutants by up to 65%. It was shown that 
the pure cinnamaldehyde was more effective in reducing biofilm formation across a 




number of Vibrio spp. than numerous cinnamaldehyde derivatives (Brackman et al., 
2008). These effects were also achieved without inhibiting bacterial growth. Kalia et 
al. (2015) showed that the addition of cinnamon oil to cultures of P. aeruginosa PAO1 
reduced levels of pyocyanin, alginate, and overall levels of the AHL, OdDHL. The 
addition of the cinnamon oil was also seen to reduce the swarming motility of PAO1 
cells. While this data is promising it lacks clear identification of the active molecule 
in the cinnamon oil and the authors note that the effects they observed may be caused 
by the action of individual components of the oil or a synergistic effect from several 
components (Kalia et al., 2015). However, further insight may be gained from a recent 
study by Ahmed et al. (2019). This study showed treatment specifically with trans-
cinnamaldehyde significantly reduced transcription of QS regulatory and virulence 
genes in P. aeruginosa. This work showed a significant reduction in the expression of 
lasR, rhlR, lasI and rhlI as well as reducing the expression of several virulence 
associated genes those encoding for degradative enzymes and those involved in 
rhamnolipid synthesis (Ahmed et al., 2019).  
El-sayed et al. (2020) showed the efficacy of 8 separate plant extracts in inhibiting 
quorum sensing (as measured as a reduction in biofilm formation using a crystal violet 
assay) in two strains of P. aeruginosa; C21 and E81. With green tea and olive leaf 
extracts resulting in the largest reductions in biofilm formation, the authors showed 
that treatment with sub inhibitory concentrations of these extracts exerted their effects 
via disruption of gene transcription of QS related genes; lasR, lasI, rhlR, and rhlI (El-
Sayed et al., 2020). 




Finally, recent work by Asensio et al. (2020) showed that a nano-emulsion of oregano 
oil was capable of inhibiting quorum sensing in C. violaceum. Treatment with nano 
emulsions containing the highest concentration of oregano oil (0.125 mg mL-1) 
resulted in reductions of violacein production (and therefore QS) of 97.4%. Unlike 
many other studies this work showed that the three main compounds in the oregano 
essential oil were terpinolene, thymol, and γ-terpinene. However, the authors did not 
show the QSI effects of these compounds individually (Asensio et al., 2020).   
While these, and many other studies, have claimed anti-quorum sensing and even 
antibiofilm effects of plant extracts and essential oils, to date, none of these plant 
derived QSIs have progressed beyond in vitro testing and basic animal models 
(Kerekes et al., 2013; Olivero-Verbel et al., 2014) 
1.6.1.3 Other non-furanone QSIs 
In addition to the previously discussed compounds and extracts, several other 
compounds from a range of sources have been shown to have QSI properties. In 2014, 
El-Mowafy et al. showed that the commonly used medication aspirin was capable of 
inhibiting QS in P. aeruginosa PAO1 at sub-inhibitory concentrations. It was shown 
that addition of aspirin resulted in significantly decreased levels of both OdDHL and 
BHL autoinducers detected in culture supernatants by up to 70% and 80% 
respectively. This translated to a dose dependant reduction of numerous virulence 
factors such as elastase and protease as well as a reduction in the swarming and 
twitching motility of the bacteria. It was found that aspirin was affecting the 
expression of several important QS genes namely lasR, lasI, rhlR and rhlI as well as 
pqsA and pqsR. It was suggested by the authors that this change in expression was due 




to a conformational change in the LasR protein meaning it was unable to effectively 
activate transcription of the Las QS system genes. As the Las QS system partially 
regulates both the Rhl and Pqs QS systems, a knock-on effect was seen (El-Mowafy 
et al., 2014). These findings were later supported by Ahmed et al. in 2019 who showed 
decreased in relative expression of lasR, lasI, rhlR and rhlI in P. aeruginosa treated 
with salicylic acid, the primary metabolite of aspirin (Ahmed et al., 2019). 
Ouyang et al. (2016) examined the effect of the flavonoid polyphenol compound 
quercetin on quorum sensing in P. aeruginosa. They showed that quercetin, when 
added to cultures of PAO1, reduced adhesion of bacterial cells to surfaces and reduced 
biofilm biomass by up to approximately 50% without negatively impacting on 
bacterial growth. As with aspirin and salicylic acid a reduction was also seen in the 
production of three key virulence factors; protease, elastase and pyocyanin. This study 
showed quercetin to be equally, or more effective than azithromycin, a commonly 
prescribed antibiotic capable of inhibiting biofilm formation (Favre-Bonte et al., 
2003), in reducing biofilm formation and virulence factor production in P. aeruginosa.  
Although many non-furanone QSIs have been shown to inhibit quorum sensing and 
attenuate the virulence of a range of microorganisms none have progressed beyond the 
preclinical stage. This may be the case for several reasons including safety concerns 
or poor characterisation of molecular mechanisms of action. Despite this apparent lack 
of progress for non-furanone QSIS, the furanones have been well studied since their 
discovery and continue to be examined closely today.   
 




1.6.2 Furanones as quorum sensing inhibitors 
Although furanone compounds have been known for some time, investigations into 
their anti-quorum sensing properties began following the discovery of the halogenated 
furanones in the marine alga Delisea pulchra (de Nys et al., 1993). These halogenated 
furanones were structurally similar to the autoinducer molecules used by many gram-
negative organisms for cell to cell signalling. This observation prompted the work of 
Givskov et al. (1996) who demonstrated that supplementing growth medium with up 
to 100 μg mL-1 of either of the two primary halogenated furanones from D. pulchra 
resulted in a significant reduction in the velocity of swarming motility of S. 
liquefaciens. Additionally, they showed that the presence of these furanones in the 
early log phase of growth reduced bioluminescence in both a bioluminescent reporter 
strain of S. liquefaciens and in the naturally bioluminescent marine organisms V. 
fischeri and V. harveyi. This reduction was particularly evident in the marine 
organisms with up to 100-fold reductions in luminescence. This early study provided 
strong evidence that the halogenated furanones found in D. pulchra interfered with 
AHL-mediated cell to cell communication systems (Givskov et al., 1996).  
Manefield et al. later demonstrated that the halogenated furanones did indeed interfere 
with AHL mediated processes and that this was achieved through the displacement of 
the AHL from its cognate receptor. They showed that the addition of two different 
unnamed furanones, previously shown to be highly inhibitory of bioluminescence in 
a reporter strain, reduced the total percentage of autoinducer bound to LuxR 
(overexpressed in an E. coli strain). They found that when the furanones were added 
to a culture saturated with exogenous autoinducer, at a concentration of 100 µM, that 




autoinducer-LuxR binding was reduced from almost 100% to approximately 25% for 
one furanone and 50% for the other. Importantly, they also showed that that while 
furanones had a significant impact on autoinducer-receptor binding, they did not have 
any deleterious or unexpected off target effects on protein synthesis. This was shown 
through 2D gel electrophoresis and, while this method was not comprehensive, a 
comparison of around 400 individual proteins was possible. Interestingly, this analysis 
showed that the addition of exogenous autoinducer resulted in increased abundance of 
three proteins which were believed to be LuxA, LuxB and LuxD, all of which are 
involved in the Lux QS system. Conversely, the addition of furanone to the culture 
caused these same set of proteins to be down regulated. The addition of furanone also 
prompted the down regulation of three other proteins believed to be an outer 
membrane protein, a chaperone protein and a glutamine synthetase. Several proteins 
were also upregulated (Manefield et al., 1999).   
It is clear that the furanones from D. pulchra could impact several bacterial processes 
mediated by AHL signalling such as swarming motility and bioluminescence. In 2001 
Manefield et al. investigated the effect of furanones on the production of extracellular 
virulence factors. To achieve this, they examined the production of the antibiotic 
carbapenem and the exoenzymes cellulase and protease in the plant pathogen Erwinia 
carotovora. When furanone was added to the culture medium a dose dependant 
reduction in carbapenem activity was seen. It was then confirmed that this reduction 
in carbapenem activity was due to a delay in the production of both CarA and CarC 
proteins which are involved in carbapenem synthesis. This data strongly suggests that 
the furanone acted by inhibiting gene expression rather than interfering with the action 




of these proteins (Manefield et al., 2001). This idea is further supported by the earlier 
findings of Welch et al. (2000) who showed that AHLs directly interact with the 
transcriptional activator protein CarR causing a fundamental change in the protein 
thereby allowing it to bind to, and activate the transcription of, its associated genes 
(Welch et al., 2000). Considering this, it may be the case that the furanone is able to 
bind to the CarR protein (due to structural similarity to AHL) but is unable to cause 
the change in the protein into its active state. Additionally, Manfield et al. (2001) show 
that the presence of furanone reduced the levels of both protease and cellulase enzymes 
produced by E. carotovora. However, it must be noted that the degree to which the 
enzyme activity was reduced was quite variable. This study demonstrates that, in 
addition to impacting innocuous processes such as bioluminescence, furanones have 
the potential to impact the production of harmful virulence factors and, therefore, 
reduce their deleterious effects. 
1.6.3 Effects of furanones on human pathogens 
The apparent success of furanones in attenuating virulence factor production in both 
plant pathogens and marine microorganisms led to an increase in studies focusing on 
the effect of these compounds on human pathogens such as S. aureus, E.coli and, 
particularly, the strong biofilm forming pathogen P. aeruginosa. 
In 2001, Ren et al. showed that a natural furanone from D. pulchra, known as (5Z)-4-
bromo-5-(bromoethylene)-3-butyl-2(5H)-furanone, effectively attenuated the 
virulence of E. coli by reducing its capacity for swarming motility, decreasing overall 
biofilm thickness by 50% and affecting biofilm structure at sub-inhibitory 
concentrations. As well as this decrease in motility and biofilm formation the authors 




found that this natural furanone was a non-specific antagonist. Using a 
bioluminescence assay, they showed that as well as inhibiting QS via E. coli 
autoinducer-2 (a furanone-like autoinducer) it also had antagonistic effects against 
AHLs and autoinducer-2 from the marine organism V. harveyi (Ren, Sims and Wood, 
2001). This finding was important as it shows that, similarly to some antibiotics 
furanones may have a broad spectrum of efficacy and, therefore, may be used against 
many organisms. 
In 2002, Hentzer et al. investigated the effect of a halogenated furanone derivative on 
P. aeruginosa biofilms. They found that a furanone compound, named C-56, was 
capable of interfering with the QS process in P. aeruginosa. Using a PlasB-gfp 
containing PAO-JP2 reporter strain the authors demonstrated that addition of C-56 at 
a concentration of 7.1 µM suppressed lasB-gfp expression despite addition of 
exogenous OdDHL of varying concentrations. This lasB-gfp expression was shown to 
be activated by OdDHL and, at high concentrations, OdDHL could activate this 
expression despite the presence of C-56. The authors suggested that this indicated a 
mechanism of action involving antagonistic activity against the OdDHL for C-56. To 
confirm that the action of C-56 was in fact against the OdDHL and its cognate receptor 
and not another part of the P. aeruginosa QS network, the above experiment was 
conducted in E. coli MT102 (which does not have any native AHL mediated QS 
system) mutant which contained the PlasB-gfp fusion. The QS inhibition was also seen 
in the E. coli PlasB-gfp strain. A variation of the P. aeruginosa PlasB-gfp reporter 
strain was also used to assess the effect of C-56 on QS in biofilms. It was found that 
the addition of OdDHL to established biofilms (24 h old) induced green fluorescence 




whereas addition of OdDHL and furanone C-56 did not. This suggests that C-56 was 
able to inhibit QS in both biofilms and planktonic cultures. As well as being able to 
inhibit quorum sensing, the authors showed that C-56 was also able to reduce the 
production of two virulence factors namely protease and chitinase. Maximum levels 
of both virulence factors were achieved by the addition of exogenous OdDHL and 
BHL to a planktonic culture. Addition of C-56 at concentrations of 3 µg ml-1 or 5 µg 
ml-1 resulted in a significant, dose dependent, decrease in the levels of both chitinase 
and protease. Levels of these enzymes were reduced by approximately 70% and 50% 
respectively when treated with the higher concentration of furanone. Finally, Hentzer 
et al. (2002) demonstrated that C-56 was also capable of inhibiting QS in wild-type P. 
aeruginosa biofilms. They showed that when grown in the presence of 5 µg ml-1 of C-
56 the early stages of biofilm formation were not affected. However, by day 7 of 
growth the biofilm was found to be significantly thinner than the control with less 
green fluorescence being seen (Hentzer et al., 2002).   
Following on from their 2002 study into furanone C-56, Hentzer et al. (2003) 
conducted a study examining the effects of quorum sensing inhibitors on P. 
aeruginosa PAO1. This study aimed to identify changes in gene transcription when 
another synthetic furanone derivative, named C-30, was introduced to the culture 
medium. It was shown that, in the presence of C-30, PAO1 was able to grow well with 
no apparent inhibition. Despite this, a reduction in virulence factor production was 
seen. This was demonstrated by a decrease in the specific activity of the virulence 
factors. Levels of protease, chitinase, and the siderophore pyoverdine were 
significantly decreased in the presence of both 1 µM and 10 µM of C-30 with a greater 




reduction being seen at the higher concentration. Using microarray technology, the 
authors showed that after treatment with 10 μM concentrations of furanone C-30 a 
total of 93 genes were affected with 85 being downregulated and 9 being upregulated 
in response to the treatment. As expected, a large portion of the downregulated genes 
have been previously described as QS-controlled genes such as lasA, lasB and several 
other genes involved in virulence factor production. Interestingly, it was found that 
the fabH1 and fabH2 were highly repressed (Hentzer et al., 2003). These genes encode 
for the 3-oxo-acyl carrier protein (ACP) synthase III enzyme which is thought to be 
involved in the production of AHLs (Parsek et al., 1999). This may suggest that 
furanone C-30 inhibits quorum sensing and subsequently alters gene transcription by 
interrupting the production of ACP, resulting in a decrease in the production of AHLs. 
Similarly, a downregulation of phnAB was seen by Hentzer et al. (2003) suggesting a 
reduction in the production of the PQS signalling molecule. As there is a relationship 
between the Las and Rhl systems and the regulation of the PQS QS system this is not 
unexpected.  
While less numerous, the upregulated genes identified in the work of Hentzer et al. 
(2003) also provided valuable information about the response of PAO1 to C-30. The 
multidrug efflux pump encoding gene mexEF was upregulated in the presence C-30 
as well as genes involved in the ATP-binding cassette transporters and major 
facilitator superfamily transporters. However, one upregulated gene was found to be 
mexR, a repressor for the multidrug resistance operon. This may suggest that treatment 
with C-30 may sensitise PAO1 to some antibiotics by increasing the production of the 
repressor of MexAB, therefore, limiting the cells ability to efflux antibiotics. The 




authors explored this possibility in bacterial PAO1 biofilms and the effect of C-30 on 
biofilm formation was assessed. It was found that while C-30 did not prevent biofilm 
formation there was a significant effect on the sensitivity of the biofilm to tobramycin, 
a commonly used antibiotic. After treatment with C-30 the antibiotic was able to 
penetrate the biofilm more effectively and kill a larger portion of the cells as 
demonstrated by a larger quantity of cells being stained with propidium iodide after 
staining with BacLight. Finally, the authors investigated the effect of C-30 on QS in 
vivo using a mouse model. A fluorescent reporter strain of P. aeruginosa (containing 
a lasB-gfp fusion) was introduced to the lungs and the mice were left for 48 h for the 
infection to become established. The C-30 was then administered intravenously and a 
reduction in the fluorescence, and, thus QS, was seen (Hentzer et al., 2003). This work 
indicates that furanone C-30 was effectively carried to the lungs and retained its 
activity after administration. This inhibition of QS was not permanent and was seen to 
reduce after approximately 6 hours. Additionally, during another experiment, it was 
found that mice treated with subcutaneous C-30 were better able to clear PAO1 from 
the lungs during a similar infection an infection when compared to a placebo. These 
experiments clearly show that furanone C-30 may be highly beneficial in combatting 
P. aeruginosa lung infections in vivo. 
Interestingly, the decrease in siderophore production seen by Hentzer et al. (2003) was 
later contradicted by Ren et al. in their 2005 study (Ren, Zuo and Wood, 2005). Ren 
et al. showed that P. aeruginosa PAO1 and JB2 both experience an increase in 
siderophore production when exposed to the natural furanone (5Z)-4-bromo-5-
(bromoethylene)-3-butyl-2(5H)-furanone while Hentzer et al. (2003) saw a significant 




decrease. This is an important contradiction as one of the primary differences between 
the studies were the difference in structure of the two furanones. While the natural 
furanone has a hydrocarbon chain bound to the furan ring this is replaced with a single 
bromine in the synthetic C-30 (Figure 1.12). The observed differences in effect 
between these two molecules may suggest that alterations in chemical structure of a 
furanone or furanone derivative could have a significant impact on its QSI activity.  
 
Figure 1.12 – Comparison of (a) the natural furanone (5Z)-4-bromo-5-
(bromomethylene)-butyl-2(5H) furanone and (b) the synthetic furanone 
derivative known as C-30. 
 
In a 2004 study by Wu et al., the effect of both C-30 and C-56 on quorum sensing and 
bacterial clearance in a mouse model of lung infection was examined (Wu et al., 2004). 
This study reinforced the findings of Hentzer et al. (2003) and confirmed that 
intravenous administration of C-30 resulted in a decrease in the expression of lasR-
PlasB-gfp in PAO1 reporter strains. In addition to this, confirmation of previous work 
Wu et al. also showed that similar administration of furanone C-56 also resulted in a 
significant decrease in lasR-PlasB-gfp expression, although a much higher dose was 
required to do so (maximum 2 μg g-1 for C-30 and a maximum of 17 μg g-1 for C-56). 




This indicates that C-30 may be a more effective QSI than C-56 when used in vivo 
although, no reason for this is suggested. The authors go on to describe the therapeutic 
effects of both C-30 and C-56 against lung infection. Oral administration of C-56 was 
found to decrease the death rate of mice infected with a lethal dose of P. aeruginosa 
PAO1 from 88% to 55%. It is unclear why the C-56 was administered orally rather 
than intravenously or subcutaneously. This may be due to the need for a larger dose 
of C-56 meaning the volume for injection was too large. It was also shown that oral 
administration of C-56 resulted in significantly better bacterial clearance from the lung 
in mice infected with sub-lethal doses of PAO1. Although no survival rate data is 
provided for C-30, it was shown to be more effective in assisting with bacterial lung 
clearance in infected mice when administered subcutaneously three times daily for 
three days. However, C-30 was only seen to significantly change bacterial clearance 
in the medium and high dose groups (0.5 µg g-1 and 0.75 µg g-1 respectively). In 
addition to these results, the authors found that furanone treated mice had less severe 
lung pathology with fewer abscesses forming in the C-30 group and a more restricted 
area of damage in the C-56 group (no abscesses formed in the C-56 group due to a 
shorter observation period during the experiment) (Wu et al., 2004). As this was one 
of the first larger scale animal model studies into the effects of furanones on P. 
aeruginosa there are few other studies which can confirm these results, but the data 
provided by Wu et al. is encouraging.    
Despite the success of C-30 both in vitro and in vivo, a 2015 study by Garcia-Contreras 
et al. claimed that the furanone derivative may not be an ideal QSI. It has been shown 
that C-30 is able to inhibit QS and virulence factor production in P. aeruginosa without 




inhibiting growth (Hentzer et al., 2003; Wu et al., 2004). This is important as it means 
that no selection pressure is applied to the organism and the possibility of developing 
resistance to the furanone is greatly reduced. However, the work of Garcia-Contreras 
et al. (2015), assessed the effect C-30 on virulence factor production of 50 clinical 
strains of P. aeruginosa isolated from cystic fibrosis patients. They found that, while 
many clinical isolates responded to C-30 with reduced elastase and pyocyanin 
production, several strains showed either no decrease in virulence factor production 
or displayed an increase in production. It was then shown that these strains used 
several different resistance mechanisms. One strain, INP-42, was found to have 
significantly higher C-30 efflux capacity while two other strains were seen to have 
significantly decreased C-30 uptake. While the reason for this decreased uptake is not 
known the authors suggest a possible mutation in some unknown transporter protein.  
Despite many strains responding to the C-30 as expected, Garcia-Contreras et al. warn 
that furanones should be used with caution in the clinical setting as many resistant 
strains already exist and in extreme cases the furanone compound may worsen the 
infection (García-Contreras et al., 2015).  
Although much of the primary data on furanones as QSIs was obtained through 
studying C-30 and C-56, many other furanones have been studied. As is the case with 
C-30 and C-56 many of these furanones are synthetic halogenated furanones, primarily 
brominated furanones. 
In 2013, Shetye et al. synthesised and tested four brominated furanone molecules for 
antibiofilm activity against E. coli and P. aeruginosa. They found that two of these 
furanone compounds, BF8 and BF15, were able to effectively reduce biofilm 




formation in the wild type E. coli strain RP437. The effects of furanone treatment 
included reduced biomass, overall biofilm thickness and total biofilm surface coverage 
(Shetye et al., 2013). This was achieved without negatively affecting bacterial growth. 
Compound BF8 also showed a similar decrease in biofilm production by P. 
aeruginosa PAO1 with an approximate decrease of 40% in biomass and surface 
coverage and a 30% decrease in biofilm thickness. It should also be noted that while 
BF15 was not capable of inhibiting biofilm production it reduced PAO1’s production 
of elastase by 41%. Similarly, BF8 reduced elastase production by 43%. The observed 
difference in the inability of BF15 to inhibit biofilm formation and its ability to reduce 
elastase production may mean that brominated furanones are not global QSIs but may 
affect certain pathways and QS systems more strongly than others. Using a lasI-gfp 
reporter strain, it was seen that the application of both BF8 and BF15 to PAO1 cultures 
resulted in a decrease in lasI transcription. This reduction in lasI transcription indicates 
that the brominated furanones are antagonists of the transcriptional activator LasR. 
This experiment was repeated with a rhlI-gfp reporter strain and it was found that 
rather than displaying an antagonistic effect, both BF8 and BF15 had an agonistic 
effect on rhlI transcription with BF15 being a stronger agonist than BF8 (Shetye et al., 
2013). This result provides further evidence that the action of furanones upon QS 
systems is highly variable and may not always provide an antagonistic effect.  As well 
as inhibiting biofilm formation and reducing elastase production, BF8 has also been 
shown to sensitise PAO1 persister cells, a type of cell found in biofilms which are 
largely dormant (Mulcahy et al., 2010; Fauvart, De Groote and Michiels, 2011), to 
antibiotic treatment.  




In 2012 Pan et al. showed that when treated with BF8 cultures of P. aeruginosa had 
reduced numbers of persister cells. Reductions in persister cell numbers occurred in a 
dose dependent manner between concentrations of 5 μg mL-1 and 100 µg mL-1 with 
reductions of approximately 3 log and 5 log respectively. Importantly, it was also 
shown that this reduction in persister cell numbers also occurred in surface attached 
biofilms as well as planktonic cultures with reductions of approximately 3 log at the 
highest tested dose of BF8 (60 μg mL-1). It was also shown that a relatively low dose 
of BF8 (5 µg mL-1) could be combined with standard antibiotic treatment to increase 
the efficacy of antibiotics such as tobramycin in killing persister cells (Pan et al., 
2012).   
The idea that furanones could effectively supplement antibiotic treatment was further 
reinforced by Kim et al. (2012) who showed that, when combined with ciprofloxacin, 
5-hydroxy-2(3H)-benzofuranone could prevent biofilms from forming on silicone 
tympanostomy tubes and significantly reduce the numbers of planktonic cells as 
demonstrated by SEM analysis. This study is of particular interest as it clearly 
demonstrates the potential for combined furanone/antibiotic therapies. While the 
combination therapy was able to prevent biofilm formation, the treatment with the 
furanone only treatment showed a reduced level of biofilm formation but no reduction 
in the planktonic cell numbers (Kim et al., 2012). This is important as it is likely that 
when furanone treatment is stopped the planktonic cells will then begin to form 
biofilms once again.   
In a later study, Pan and Ren (2013) identified a further two brominated furanone 
compounds which were capable of QS inhibition. These compounds, known as BF9 




and BF11, could effectively sensitise persister cells to antibiotic treatment while others 
could inhibit QS but had no effect on the persister cells. As all these molecules are 
structurally related it seems likely that the differences in activity are dictated by the 
small changes in chemical structure. This idea is further reinforced as two compounds 
which were structurally similar but were non-brominated were found to have no QSI 
activity and no action against the persister cells (Pan and Ren, 2013).  
The next set of synthetic brominated furanones to be tested were synthesised and 
studied by Yang et al. (2014). The so-called bicyclic brominated furanones (BBF) 
were designed around the brominated furanones produced by Pan et al. (2012) and 
were shown to retain the ability to inhibit biofilm formation resulting in significantly 
less biofilm mass when compared to furanone free controls. Furanones 5-BBF, 6-BBF, 
and 7-BBF showed reductions in biofilm of approximately 50%, 70% and 50% 
respectively when compared to an untreated control (Yang et al., 2014). However, 
these 3 BBFs were still found to be considerably less effective that the BF4 compound 
produced by Pan et al. (2012). Despite the poorer performance of the BBFs Yang et 
al. state that they are considerably less cytotoxic to human cells than other furanones. 
They demonstrated that, when compared to the BF8 as used by Pan et al. (2012), BBFs 
showed reduced cell death when added to cultures of human neuroblastoma cells (SK-
N-SH). Furanones 5-BBF, 6-BBF and 7-BBF showed immediate cell death of 
approximately 25%, 25% and 55% respectively. After 48 h incubation cell death was 
at 95%, 50% and 85% respectively. This was compared to BF which showed an 
immediate cell death of 70% increasing to almost 100% after 48 hours. However, the 
authors’ choice of cell line (SK-N-SH) is unusual. Although SK-N-SH cells display 




an epithelial cell morphology they are not epithelial cells (Biedler, Helson and 
Spengler, 1973). Testing furanones on a true epithelial cell line would likely be more 
relevant as furanones, if used in medical applications, are most likely to contact 
epithelial cells (e.g. airway epithelia). While the BBFs are undoubtedly better in terms 
of cytotoxicity further studies are needed. Currently, little data on furanone 
cytotoxicity is available so an accurate comparison cannot be made between the BBFs 
and BF8.  
In addition to the work of Pan et al. and Yang et al., there have been several other 
studies which have examined the effects of synthetic furanones and their derivatives. 
In 2008, Kim et al. showed that six separate furanone derivatives were effective in 
antagonising QS in cultures of a luminescent reporter strain of E. coli. With reductions 
of up to 90% in relative luminescence when compared to an untreated control. They 
also report that all of the tested furanone derivatives partially prevented the initial 
attachment of P. aeruginosa to a substrate and, thus, biofilm formation was 
significantly diminished (Kim et al., 2008). This observation is in direct contradiction 
of Hentzer et al. (2002) who found that when grown in the presence of furanone C-56 
the initial stages of biofilm formation were unaffected (Hentzer et al., 2002). This 
discrepancy in the reported data clearly illustrates the wide range of effects that may 
be seen between two structurally distinct furanone derivatives and highlights the need 
for proper mechanistic studies of new candidate QSIs.  
In 2012, Liu et al. found that, from a selection of 19 candidate molecules, many 
compounds showed biological activity. Three compounds, in particular, resulted in a 
reduction in biofilm formation between 58.7% and 71.8% when tested against P. 




aeruginosa (ATCC 9027). A reduction in biofilm formation was also seen against two 
other strains of P. aeruginosa (ATC27853 and PAOA) (Liu et al., 2012). No further 
information regarding the biological activity of these compounds was given as the 
study was focused primarily on compound synthesis and molecular docking studies.  
In 2012, one study found that triazolyldihydrofuranones (AHLs in which the amide 
group has been replaced with a triazole group) displayed some antagonistic activity 
against LasR dependent QS in P. aeruginosa (Brackman et al., 2012). Interestingly, 
while all triazolyldihydrofuranones tested were capable of inhibiting LuxR dependent 
QS (as tested using a luxR-gfp reporter strain of E. coli) it was found that only 
compounds with a side chain length of ten or twelve carbons could effectively inhibit 
the LasR dependant QS system. The authors found that the anti-QS ability of the 
compounds also translated to antibiofilm activity with the most active compounds 
decreasing both biofilm biomass and the number of viable cells present in the biofilm. 
It was also noted that many of the tested compounds acted agonistically upon either 
the LasR or LuxR dependant QS systems increasing their activity (Brackman et al., 
2012). The authors’ data suggest that the closer a potential QSI is in structure to the 
organism’s cognate autoinducer the better it will perform. However, there is a balance 
to be struck between finding a compound which inhibits QS and one which may 
activate QS, thus, worsening an infection.     
Finally, in 2015 Goh et al. tested the QS inhibition capacity of furanone derivatives, 
known as 1,5-dihydropyrrol-2-ones. Their study showed that these furanone 
derivatives had a wide range of antagonistic activity against QS in a reporter strain of 
E. coli (Goh et al., 2015). Like the work of Liu et al. (2012), this was primarily a 




synthesis and docking study and so no further information regarding QSI inhibition is 
provided.  
Another subset of furanones which have been reported to have anti-QS properties are 
the non-halogenated furanones which can be isolated from a number of natural 
sources. One non-halogenated furanone which has been of particular interest in recent 
years has been 4-hydroxy-2,5-dimethyl-3(2H)-furanone (HDMF) also known as 
furaneol, strawberry furanone or DMHF.  It has been known for some time that HDMF 
is able to inhibit the growth of wild type P. aeruginosa at a concentration of 80 µg 
mL-1 and other gram-negative organisms at concentrations as low as 20 µg mL-1 (Sung 
et al., 2007). However, until recently no studies had examined the compounds 
potential as a QSI. In 2014 Choi et al. provided evidence that HDMF is a potent QSI 
and has good biofilm inhibition activity. Using a crystal violet microtiter assay they 
showed that when cultured for 24 h with 0.1 µM and 1 µM of HDMF biofilm 
production was reduced by 27.8% and 42.6% respectively. Further, when cultured for 
up to 48 hours, additional loss of biofilm was seen indicating that HDMF may facilitate 
the detachment of established biofilms, although it is unclear how this might occur 
(Choi et al., 2014). As well as reducing biofilm formation, the HDMF treated cells 
were found to form poorly constructed biofilms. These appeared as flat monolayers 
with sparsely distributed cells whereas untreated control cultures formed densely 
populated biofilms with good three-dimensional structure. This result, when 
considered alongside the detachment of preformed biofilms may suggest that HDMF 
impacts upon a process necessary for forming a good foundation for the biofilm on the 
substrate material. This puts the findings of Choi et al. against those of Hentzer et al. 




(2002) who found that the early stages of biofilm formation were not significantly 
affected by furanone treatment. Choi et al. (2014) also tested the effects of HDMF on 
the motility of P. aeruginosa and found that when treated with 1.0µM of HDMF the 
swarming motility of P. aeruginosa was greatly reduced (as evidenced by a decrease 
in motility diameter – though no exact figures were reported) while twitching motility 
was unaffected. Again, this is an important finding as it has been shown that swarming 
motility is closely tied to biofilm formation (Verstraeten et al., 2008). Lastly, it was 
shown that HDMF, when added to cultures of P. aeruginosa at a concentration of 1.0 
µM, substantially reduced the production of three separate virulence factors; LasA 
protease, rhamnolipid and pyocyanin. The levels of these three virulence factors were 
reduced by 53.8%, 40.9%, and 51.4%, respectively. The decrease in virulence factors 
was accompanied by a corresponding decrease in the production of the two main 
autoinducer molecules used by P. aeruginosa, OdDHL and BHL. This may indicate 
that HDMF affects many QS controlled processes by interfering with the QS systems 
at a very early stage.  
Unlike the previously discussed halogenated furanones, there is evidence that HDMF 
may be beneficial in a model of primary human airway epithelial cells. It was 
demonstrated by Ruffin et al. (2016) that P. aerugnosa secreted virulence factors such 
as LasA protease and LasB elastase impaired several important functions in airway 
epithelial cells including wound healing, cell proliferation, and cell migration (Ruffin 
et al., 2016; Ruffin and Brochiero, 2019). This was achieved by treating cells with so-
called P. aeruginosa diffusible materials (PsaDM). These are a collection of excreted 
molecules collected from bacterial culture supernatants. It was then shown the 




deleterious effects caused by the presence of PsaDM could be prevented by deletion 
of the key genes involved in QS, specifically lasR. Treatment with PsaDM from these 
Las QS deficient mutants showed no apparent reduction in wound healing indicating 
that the negative effects of the PsaDM are at least partially due to the production of 
QS controlled molecules. The authors then demonstrated that treating P. aeruginosa 
PAO1 cultures with HDMF resulted in a significant decrease in elastase activity of 
approximately 70%, without affecting bacterial growth. It was also seen that, when 
exposed to PsaDM from HDMF treated PAO1 cultures, wound healing rates were 
significantly better than those exposed to PsaDM from untreated PAO1 (Ruffin et al., 
2016). A similar result was also seen in highly differentiated airway epithelial cell 
cultures. Importantly, it was also shown that exposure to HDMF alone did not have a 
negative impact on the wound healing capacity of airway epithelial cells. 
Unfortunately, no data were collected regarding the impact of HDMF on cell viability. 
However, it is reasonable to assume that because wound repair rates were not 
negatively affected by HDMF that cell viability and proliferation was not significantly 
reduced. However, despite this promising study further investigation into the 
cytotoxicity and safety of HDMF is needed.  
The data presented by Choi et al. (2014) and Ruffin et al. (2016) are highly 
encouraging and provide evidence that the non-halogenated furanone HDMF may be 
a viable QSI candidate for use in medical applications, though considerably more 
research is needed.  
Studies such as those detailed here show that natural furanones, halogenated 
furanones, and their synthetic derivatives can be highly effective QSIs. However, the 




work published to date has focused primarily on furanones such as C-30, C-56 and 
HDMF. Due to the wide range of sources they can be isolated from there are hundreds 
of furanone compounds, such as 2-methyltetrahydrofuran-3-one (MTHF) from coffee 
and 4,5-dimethyl-3-hydroxy-2,5-dihydrofuran-2-one (Sotolon) from Fenugreek, that 
are yet to be investigated as QSI compounds.  
In addition to the limited number of furanones that have been tested, those studies 
which have been published have failed to address some of the potential limitations that 
furanones may present.  
1.7 Potential limitations of furanones 
The studies discussed here provide good evidence that both halogenated and non-
halogenated furanones can effectively inhibit QS and, therefore, reduce both biofilm 
formation and the production of numerous virulence factors in vitro. There have been 
a small number of studies showing that furanones are successful in animal and human 
cell models with results such as increased survival rates and improved bacterial 
clearance in murine lung infection models. This makes furanones apparently excellent 
candidates for use in medical applications such as wound dressings, medical 
implants/devices, and any other area in which biofilms and bacterial quorum sensing 
presents a problem. However, while there is considerable evidence that furanones are 
beneficial, some studies have noted that they may have a level of cytotoxicity, with 
some furanones being more harmful than others with one study found a reduction of 
cell viability of nearly 100% after treatment (Yang et al., 2014). Unfortunately, these 
studies focused on different furanones under very different conditions and so a 
meaningful comparison cannot be made. It is clear, therefore, that more focused and 




comprehensive safety studies are also required. However, this is not the only issue 
which needs to be addressed prior to using furanones in a medical setting.  
As there has been no extended animal or human testing of any furanones to date, there 
are many aspects of these compounds which remain unknown. For example, both the 
pharmacokinetics and pharmacodynamics of furanones have not been reported. While 
the application of furanones to human cell cultures may not result in obvious negative 
effects, there may be a cumulative toxic effect when administered over a period of 
time. The inverse may also be true. When administered to a patient the furanone may 
be cleared from the system rapidly through channels such as first pass metabolism 
meaning that a therapeutic dose cannot be reached. While this did not appear to be the 
case in the work of Hentzer et al. (2003) who administered furanone C-30 
intravenously to mice, further study is needed. 
Another concern is that of potential drug interactions.  It has been shown by several 
research groups that dual treatment of furanone and antibiotics is generally more 
efficacious than individual treatment with either component. This is important as it is 
likely that patients who have developed biofilm infections will be prescribed 
antibiotics in tandem. However, biofilms are also problematic in other patient groups 
such as those with diabetic wounds and post-surgical patients (Edmiston et al., 2016; 
Di Domenico et al., 2017). It is also likely that these patients will be on additional 
medications such as hypoglycaemic medications or analgesia so gaining information 
on drug-furanone interactions should be a priority. Similarly, information should be 
gathered on any contraindications for furanone treatment such as safety for patients 
with hepatic or renal failure. 




Finally, and perhaps most importantly, is the issue of antimicrobial resistance. In the 
majority of studies concerning furanones, the authors report that the desired effects 
are seen at sub-inhibitory concentrations. This is important because, as stated 
previously, this limits the introduction of selection pressures and, thus, the chances of 
developing resistance are reduced. However, as Garcia Contreras et al. (2015) showed, 
furanone resistance has been seen in some clinical isolates. Therefore, it is crucial to 
further investigate the conditions under which such resistance might occur and 
methods for minimising this.  
If all of the above knowledge gaps could be addressed, furanones may indeed be 
promising new tool in the treatment and control of biofilm-associated infections and 
their complications.    
1.8 Aims and Objectives 
The studies discussed in this chapter, when considered together, show that, due to their 
structural similarity to native QS signalling molecules, furanone compounds are 
potentially excellent candidates for QSI based treatments. The QSI activity of 
furanones allows them to inhibit biofilm formation both in vitro and in vivo. This thesis 
aims to use naturally occurring furanones to inhibit biofilm formation in chronic 
wounds. The work conducted here aims to develop novel a polymer system to deliver 
furanones to a chronic wound biofilm in a controlled manner, to demonstrate the in 
vitro efficacy of furanones delivered using the developed system, and to show efficacy 
of furanones against clinically representative biofilms using a novel in vitro chronic 
wound model.  
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Hydrogels can be broadly defined as hydrophilic, three dimensional, crosslinked 
polymer networks capable of absorbing and holding large amounts of fluid relative to 
their dry weight (Chai et al., 2017). The first synthetic hydrogels were produced by 
Wichterle and Lim as an alternative to hard plastics for biomedical alloplastic and 
prosthetic applications (Wichterle and Lim, 1960). Since these early studies hydrogels, 
in various forms, have become more prevalent in a wide range of areas including 
cosmetics, biological and tissue engineering, as well as domestic and healthcare use 
(Masuda, 1994; Bae, Nam and Park, 2019; Gupta et al., 2019; Nezhad-Mokhtari et al., 
2019). While polymer hydrogels all fall under the same broad definition, substantial 
variation in the properties and characteristics can be achieved by changing one or more 
aspects of a hydrogel’s formulation. These changes can include polymer concentration 
and polymer type (i.e. natural, synthetic, or co-polymers), crosslinking concentration 
and crosslinking type (i.e. physical or chemical cross linking), gel formation method 
(e.g. in-situ forming or pre-formed) and the addition of rheology modifiers, such as 
plasticisers. This section will give a brief overview of the different types of polymers 
commonly used in the production of hydrogels, the different types of crosslinking used 
and some of the wider applications of hydrogels. Focus will then be placed on the use 
of hydrogels in wound healing and drug delivery. 
2.1.1 Use of natural and synthetic polymers in the production of hydrogels 
Hydrogels can be produced using a wide range of polymers including both naturally 
occurring and synthetically produced polymers. Each polymer type will produce a 
hydrogel with a distinct set of properties and potential uses.  
Natural plant derived polymers, such as alginate or cellulose, and animal derived 
polymers such as silk, gelatin and chitosan have all been previously used to produce 
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hydrogels (Konishi et al., 2003; Rammenssee et al., 2005; Olaru et al., 2018; Bae, 
Nam and Park, 2019; Fan et al., 2019). These natural polymer hydrogels have proven 
useful in a wide range of areas but particularly in medicine. The extensive application 
of these polymers for biomedical purposes is often attributed to their high 
biocompatibility, low toxicity, and their biodegradability (Calvo Catoira et al., 2019). 
Synthetic polymers are also often used in biomedical applications. However, while 
polymers, such as gelatin and alginate are naturally biocompatible, producing 
synthetic polymers from base components or monomers means that these materials 
are highly modifiable. This means that the biocompatibility and physical properties 
can be finely tuned to formulate a hydrogel tailored to serve a particular purpose. By 
exploiting the tunability of synthetically produced polymers, such as poly(vinyl 
alcohol) (PVA) and poly(propylene), highly complex gels can be produced. For 
example, hydrogels which are responsive to changes in local pH or fluctuations in 
environmental temperature are easily achieved (Hibbins et al., 2017; Avais and 
Chattopadhyay, 2019). Similarly, hydrogels with a highly tuned rate of degradation 
are possible meaning that tightly controlled drug release can also be achieved (Ashley 
et al., 2013). 
2.1.2 Crosslinking types in hydrogels 
In order for a hydrogel to form, the macromolecular polymer strands must be linked 
to form a three-dimensional network of interconnected polymer strands. This process 
begins with individual polymer strands in a solution (known as a sol) linking with 
other strands which are in close proximity. As this linking process progresses, a point 
is reached in which the linking is so extensive that the individual polymer strands can 
now be considered a single large macromolecule (known as a gel) (Ross-Murphy and 
McEvoy, 1986). The point at which a sol becomes a gel is known as the sol-gel 
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transition point. This process, known as gelation, can be achieved with a number of 
types of crosslinking. Polymer gels can be sub classified based on the mechanism of 
crosslinking used to form them. They can be classified as physically linked gels, 
chemically crosslinked gels, or entangled network gels. 
Chemically crosslinked gels are hydrogels in which crosslinking is achieved through 
the addition of a chemical crosslinking agent. These chemically crosslinked hydrogels 
can be formed with a number of cross linking methods including free radical 
polymerisation (Jeong et al., 2007), enzymatically mediated crosslinking (Lee, Bae 
and Kurisawa, 2015) and covalent bonding (Marco-Dufort and Tibbitt, 2019). The 
covalent bonds in these hydrogels are often strong and non-reversible due to high bond 
energy (Li et al., 2018). This often means that covalently crosslinked hydrogels are 
more stable under a range of conditions and usually have tuneable physical properties 
(Hu et al., 2019). As such, chemically crosslinked gels are often used in biomedical 
applications such as drug delivery systems (Larrañeta et al., 2018) and the production 
of contact lenses (Rosa dos Santos et al., 2009). 
Physically crosslinked hydrogels are gels in which crosslinking is achieved without 
the use of a chemical crosslinking agent. These gels can be crosslinked through bonds 
such as electrostatic interactions, hydrophobic interactions, physical entanglement of 
the polymer network, and π-π stacking  (Hu et al, 2019). As these gels do not require 
additional chemicals to produce, they are often used to ameliorate issues which arise 
through the use of chemical crosslinking agents such as unwanted off target effects, 
leeching of the crosslinker from the hydrogel, impairment of biocompatibility, and 
interactions with any active compounds entrapped within the gel (Hennink and van 
Nostrum, 2012; Zhang, Zhang and Wu, 2013).  
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The effects of the chosen polymer, crosslinking agent, and choice of liquid phase of a 
hydrogel can interact in a number of ways to result in a wide range of potential 
properties. These properties can be altered and designed to give a hydrogel with 
particular characteristics such as elasticity, durability, flow and degradation. Due to 
their enormous versatility, hydrogels have found use in a wide range of fields.  
2.1.3 Applications of hydrogels 
Hydrogels have been used in a range of purposes in a variety of settings. These include 
use in personal care products, food science and bioremediation. In each of these uses 
the unique proprieties of hydrogels have made them superior to alternative methods.  
The superabsorbent properties of hydrogels, particularly acrylamide, polyacrylate and 
PVA based hydrogels, have been used for many years in both infant and adult 
incontinence products such as nappies and pads. Here, the ability of hydrogels to 
absorb and retain large amounts of liquid offer a clear advantage over cloth only 
products by sequestering moisture and preventing moisture damage to the adjacent 
skin (Bashari, Rouhani Shirvan and Shakeri, 2018; Castrillon et al., 2019).  
In food technology, hydrogels are being used in numerous applications. Recently, 
hydrogels have shown to be highly effective in stabilising oil in water Pickering 
emulsions at low pH as well as allowing for controlled release of a payload at near 
neutral pH (Lim et al., 2020). In this instance, the use of natural calcium alginate 
hydrogels is clearly advantageous due to their relative low cost to manufacture, high 
biocompatibility and food grade status (Ali and Ahmed, 2018). Combination natural 
and food grade synthetic polymer hydrogels have also been used to good effect for the 
oral co-delivery of vitamins and minerals. These pectin-polyethylene glycol (PEG) 
hydrogels showed excellent loading of vitamin D, calcium, vitamin C and iron. Loaded 
pectin-PEG hydrogels exhibited a controlled degradation in an intestinal pH indicating 
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that the vitamin and mineral payload would be released in this environment (Gautam 
and Santhiya, 2019). Again, the biocompatibility and pH responsive nature of these 
hydrogels is a clear advantage.  
Hydrogels also show great utility in the field of bioremediation where they have been 
deployed in several ways. Firstly, hydrogels have been shown to be highly effective 
substrates for the removal of toxic impurities from aquatic environments (Shalla et al., 
2019). For example, in 2019, Lone et al. showed that composite gelatin-chitosan 
hydrogel particles could effectively remove 98% of mercury 2+ ions and 34% of lead 
2+ from water samples (Lone et al., 2019). This removal was attributed to the reactive 
sites on the polymer strands. Similarly, the work of Hui et al. showed the successful 
removal of approximately 11 mg of phosphate, a common pollutant of waterways, per 
gram of a novel PVA hydrogel bead (Hui, Zhang and Ye, 2014). These PVA hydrogel 
beads were functionalised with aluminium 3+ ions. The phosphate in contaminated 
water was removed via an ion exchange reaction and was held within the hydrogel 
resin. These studies show the utility of hydrogels with naturally occurring reactive 
sites but also those hydrogels which have been functionalised to contain non-native 
reactive groups. 
The studies noted here clearly demonstrate that hydrogels are a highly versatile 
material and have a broad range of uses in many areas. One of the main sectors which 
has embraced the use of hydrogels is the biomedical sector. Hydrogels have been used 
in the biomedical field for the production of contact lenses and as scaffolds for tissue 
engineering. However, two applications for hydrogels which are of particular 
relevance to this work are their use as drug delivery vehicles and the use of hydrogels 
as wound therapeutics.  
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2.1.4 Hydrogels as wound therapeutics 
There are a significant number of wound dressings currently in clinical use which 
incorporate hydrogels. These include both amorphous hydrogels, such as Askina Gel, 
and hydrogel sheet dressings such as Actiform Cool (Joint Formulary Comittee, 2019). 
Hydrogel dressings are primarily used in the treatment of dry and necrotic wounds. In 
such wounds, the high water content of hydrogels allows them to donate moisture to 
the dry wound bed effectively, thus assisting with debridement (Koehler, Brandl and 
Goepferich, 2018). Also, it has been known for nearly 60 years that maintaining a 
moist wound environment greatly reduces wound healing time (Winter, 1962) and 
therefore, by donating moisture and maintaining that moist environment, hydrogels 
assist wound healing on two fronts. 
2.4.1.1 Non-medicated hydrogel wound dressings 
Some hydrogel dressings are claimed to not only help reduce reported wound pain in 
patients but also helping to remove slough (the mass of loose dead tissue often found 
in wounds) and increasing wound granulation and epithelialisation (Holger Kapp, 
2006; Zoellner, Kapp and Smola, 2007). While these particular studies were funded 
by the manufacturer of the dressing being tested, many independent studies have 
shown the benefits of hydrogel dressings in wound healing.  
In a systematic review and meta-analysis of 43 studies conducted between 1998 and 
2018, Zhang et al. (2019) found that the application of hydrogels was highly beneficial 
in a range of wound types including acute traumatic wounds such as animal bites, 
thermal injuries such as second-degree burns, and chronic wounds like diabetic foot 
ulcers. The application of a hydrogel dressing in these cases was found to not only 
reduce wound healing time but also to reduce the overall pain associated with the 
wound (Zhang et al., 2019).   
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2.4.1.2 Antimicrobial hydrogels as wound dressings 
Due to the compelling evidence that non-medicated hydrogels are highly beneficial in 
both reducing wound pain and expediting wound closure there has been much research 
into the development and assessment of antimicrobial hydrogel wound dressings. 
Infections, and, in particular, bacterial infections in the form of a biofilm, are the most 
common cause of delayed healing in wounds (Leaper, Assadian and Edmiston, 2015). 
Therefore, the development of an antimicrobial hydrogel that can both prevent, or 
eradicate, infections while simultaneously promoting wound closure and reducing 
pain is an obvious goal for clinicians. Such a therapy would also greatly improve 
clinical outcomes for patients.   
There has been an abundance of research surrounding the development and assessment 
of antimicrobial hydrogels in recent years. These hydrogels have often been 
formulated from inherently antimicrobial polymers such as chitosan. Hydrogels have 
also been loaded with an antimicrobial compound such as silver, and with traditional 
antibiotics, antimicrobial peptides or natural phytochemicals (Boonkaew et al., 2014; 
Annabi et al., 2017; Kim et al., 2020; Tamahkar et al., 2020). Many of these 
antimicrobial hydrogels have been shown to be highly effective in reducing bacterial 
viability. In 2014, Boonkaew et al. showed that the a 2-acrylamido-2-methylpropane 
sulfonic acid (AMPS) based hydrogel loaded with in situ formed silver nanoparticles 
was effectively able to reduce numbers of viable cells of four bacterial strains; 
Staphylococcus aureus (both methicillin resistant and methicillin sensitive), 
vancomycin resistant Enterococcus faecalis and Acinetobacter baumanii. Reductions 
of 99%, 99%, 97.5% and approximately 90% were reported for these bacteria, 
respectively. Similarly, the work of Tsou et al. (2005) demonstrated that a 
ciprofloxacin-loaded, 2-hydroxymethacrylate hydrogel was capable of both releasing 
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the antimicrobial and inhibiting growth of S. aureus and P. aeruginosa. Interestingly, 
this work also showed that by increasing the amount of cross linking in the gel, the 
drug release and therefore the antimicrobial effects, could be significantly prolonged. 
This ability to modulate drug release from hydrogels also makes them an excellent 
candidate for drug delivery vehicles. 
2.1.5 Hydrogels as drug delivery vehicles 
It is clear that hydrogels are a highly versatile material with numerous applications 
across many fields of study. However, possibly the most widely investigated 
application is the use of hydrogels as drug delivery systems.  
2.1.5.1 Hydrogels in drug delivery 
Hydrogels, in many different forms, have been shown to be effective drug delivery 
mechanisms. For example, thin hydrogel films have been investigated for their 
potential in releasing several different active compounds. The work of El-Aassar et al. 
in 2015 showed up to 100% release of a model dipeptide, l-carnosine, from biopolymer 
hydrogel films made of κ-carageenan and hyaluronic acid (El-Aassar et al., 2015). 
Similarly, dual polymer hydrogel films made of carboxymethylcellulose and PVA 
were reported to release the aminoglycoside antibiotic gentamicin sulphate effectively. 
Gentamicin was released in a controlled manner (showing first order kinetics) 
reaching a total release of up to 90% of the total loaded dose over 24 h (Ghorpade et 
al., 2019). Hydrogel films have also been shown to be useful in the delivery of drugs 
to specific sites such as the buccal mucosa and have even been suggested as potential 
delivery mechanisms to the brain (Alopaeus et al., 2020; Singh, Kumar and Rohit, 
2020). 
Other forms of hydrogel which have been used as drug delivery systems include 
nanogels, monolithic hydrogels (hydrogels consisting of one single piece, often cast 
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moulded) and injectable hydrogels (Chen et al., 2019; Xing et al., 2019; Bender et al., 
2020; García-Fernández et al., 2020; Mandal et al., 2020). All of these hydrogel forms 
have been shown to be acceptable for drug delivery in various medical conditions or 
delivery to specific sites. However, the use of PVA-borate hydrogels as drug delivery 
systems has not been so extensively studied.   
2.1.5.2 PVA-borate hydrogels in drug delivery 
PVA-borate hydrogels have been previously shown to be effective drug delivery 
systems for a range of compounds including vitamins, anaesthetics and antimicrobials 
(Loughlin et al., 2008; Tang, Pang and Wang, 2017; Tavakoli and Tang, 2017). Tang 
et al. (2017) demonstrated that a PVA hydrogel, crosslinked with a combination of 
borate glass and freeze-thaw cycles, was able to release vitamin B12 into a phosphate 
buffered saline (PBS) receiver phase with a total drug release of up to 80% over 90 
min. This indicated that borate crosslinked PVA hydrogels could be an excellent drug 
delivery vehicle for bioactive molecules (Tang, Pang and Wang, 2017). Similarly, a 
2017 study by Tavakoli and Tang showed that a Manuka honey/PVA hydrogel 
crosslinked with borate was an effective delivery system for the release of the 
macrolide antibiotic erythromycin. While the exact total percentage release of the 
erythromycin achieved is unclear in their paper, the authors show a definite controlled 
release profile and demonstrate that the released antibiotic retained its bactericidal 
activity against S. aureus (Tavakoli and Tang, 2017). In 2009, Donnelly et al. showed 
that PVA-borate hydrogels could effectively release two photodynamic antimicrobial 
chemotherapy agents, namely methylene blue, and meso-tetra (N-methyl-4-pyridyl) 
porphine tetra tosylate, at volumes of 16.08% and 17.05% of the total loaded doses 
respectively over 6 h (Donnelly et al., 2009).  Loughlin et al. (2008) used PVA-borate 
hydrogels to good effect when delivering the local anaesthetic lidocaine, showing 
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release of approximately 75% of the total loaded drug at a physiologically relevant 
temperature and pH. 
When the studies detailed here, and their previous successful use as drug delivery 
systems in our group are considered, it is clear that hydrogels are a remarkable material 
with a range of unique properties that make them highly useful in many areas. 
Although the use of borate crosslinked PVA hydrogels as drug delivery vehicles is not 
widely reported in the literature, they appear to have significant potential for the 
delivery of a number of different compounds.    
2.1.6 Rheology of polymer hydrogels 
Rheology is a branch of materials science focused on the deformation and flow of soft 
matter materials. More specifically, rheology deals with the characterisation of a 
material’s time-dependent response to an applied stress or force (Struble and Ji, 2001). 
This response can be measured in several ways. These include measuring how the 
material flows in response to an applied stress or, in the case of non-Newtonian 
materials, how its viscosity changes in response to a force. This section will focus on 
the rheology of amorphous PVA-borate hydrogels for use in wound treatment and 
healing.  
Whether intended for use as a drug delivery system or a wound therapeutic, the 
rheological properties of hydrogels are of great importance. For example, in the case 
of amorphous hydrogels the ability of the material to flow and conform to the shape 
of the wound allows for total contact between the wound bed and the hydrogel 
(Loughlin et al, 2008). Not only does rheology affect the use of hydrogels as a wound 
therapeutic but the rheology of materials has been shown to have a profound effect on 
their ability to release drugs (Martinez et al., 2014). 
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PVA-borate hydrogels have a number of unique properties that make them excellent 
candidates for wound dressings. These materials display a unique property known as 
dilatancy (Murphy et al, 2012). These dilatant properties mean that the hydrogel 
material becomes more viscous when a high shear force is applied and is less viscous 
when no force is applied (Savins, 1968). These properties allow the PVA-borate 
hydrogels to flow into a wound without the requirement for external forces, therefore, 
minimising pain and trauma for the patient. Conversely, the application of a force, 
such as the removal of the gel from a wound, causes the material to increase in 
viscosity meaning that it may be removed from the wound simply and in one cohesive 
piece (McCarron et al., 2011).  
In this chapter the properties of the formulated hydrogels will be assessed using five 
measurements. These measurements include defining the linear viscoelastic region, 
assessing the viscoelastic profile of the material, confirmation of the viscoelastic 
profile by measuring phase angle shift, assessing changes in viscosity upon the 
application of a force and, finally, a measurement of the adhesiveness of the materials. 
Each measurement and the reason for its selection is detailed here. 
2.1.6.1 Linear viscoelastic region 
The linear viscoelastic region (LVR) is defined as the region in which the material’s 
properties are independent of the magnitude of the stress being applied. This linear 
behaviour is due to the balancing of the destruction of the internal structure of the 
material (due to flow) being matched by the formation of new areas of structure due 
to Brownian motion (Koetting et al, 2015). Simply put, the LVR defines the range of 
shear forces that a material can experience without experiencing the destruction of the 
internal structure. This is an important measurement to make as it ensures that all 
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subsequent testing is conducted at a shear force that will not affect the internal 
structure of the gel and, therefore, not influence other measurements.   
2.1.6.2 Viscoelasticity 
In this work the viscoelastic properties of the gel will be assessed by measuring both 
the storage and loss moduli (G´ and G″ respectively) over a range of shear frequencies. 
G´ can be considered as the solid portion of the hydrogel and represents the elastic 
energy stored in the polymer network. G″, alternatively, can be considered to be the 
liquid portion of the gel and represents the energy lost from the system as heat due to 
material flow (Franck, 2004). Both moduli are measured over a range of shear 
frequencies and in instances where G´ is greater that G´´ the material is acting more 
like a solid material. The converse is also true. When G″ is dominant over G´ this 
indicates the material is behaving more like a liquid (Malvern Intruments Limited, 
2016). When G´ and G″ profiles are plotted as a function of shear frequency a 
crossover point can be identified. The point at which this crossover occurs represents 
the force required to induce fluid-like flow in the material. This is an important 
measurement for an amorphous hydrogel wound dressing as the requirement for a high 
force to induce flow would be disadvantageous as the gel would not readily flow into 
the wound.  
2.1.6.3 Phase angle shift 
Phase angle shift (δ) is the observed lag between an applied sinusoidal stress and the 
deformation of the material being tested. For a completely solid material, such as 
concrete, no lag between the stress and the response would be observed and, thus, δ 
would be 0°. For samples which show viscoelastic properties there is a delay between 
the application of the shear force and the response of the material. This lag would be 
measured between 1 and 90° with more fluid like samples having a larger δ. For shear 
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sensitive PVA-borate hydrogels a shear frequency dependent change in δ should be 
apparent with lower angle shifts seen at higher shear frequencies (indicating solid like 
behaviour) and δ measurements tending towards 90° at low shear frequencies 
(indicating liquid like behaviour) (Malvern Intruments Limited, 2016). In this work, 
phase angle measurements will be used as a validation of the viscoelastic profile of 
the hydrogel. 
2.1.6.4 Viscosity 
Viscosity is a measure of the resistance of a fluid to deformation and it is caused by 
internal intermolecular forces within a material. As previously stated, PVA-borate 
hydrogels show a force-dependent increase in viscosity known as dilatancy (Murphy 
et al., 2012). Several suggestions have been made as to why shear thickening occurs 
but the generally accepted explanation is that the application of shear causes local 
clustering of solid material in the gel structure, resulting in structural heterogeneity 
and a general increase in material viscosity (Braun and Rosen, 2000).  Measuring the 
shear frequency-dependent change in viscosity of the PVA-borate hydrogels is crucial. 
The dilatant nature of the hydrogels is what will allow them to be removed from a 
wound in one piece (McCarron et al., 2011) and, thus, demonstrating that the 
hydrogels possess this quality is essential.   
2.1.6.5 Adhesiveness 
It has been shown previously that the removal of adhesive wound dressings is not only 
a source of significant worry and pain for patients but that it is also a potential cause 
of so-called micro-traumas such as removal of the uppermost layers of the skin 
(Matsumura et al, 2013; Charlesworth et al, 2014). Therefore, it is vital to ensure that 
the formulated hydrogels display as little adhesiveness as possible as the aim is to 
ensure minimisation of likelihood further damage to the wound area upon removal.  
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PVA-borate hydrogels will be produced and, using the rheological measurements 
detailed here, the formulations with the most appropriate physical properties will be 




















2.2 Aims and objectives 
This experimental chapter will focus on the formulation and rheological 
characterisation of a PVA hydrogel which has been crosslinked with sodium 
tetraborate decahydrate (referred to as borate).   
The primary aim of the work detailed in this chapter is to develop and characterise a 
novel PVA hydrogel for use as a mechanism to deliver furanone compounds to chronic 
wound biofilms. To achieve this, the following objectives will be addressed. First, a 
method for the production of PVA hydrogels will be developed. This will include 
identifying the best production method as well as the optimal grades of polymer to 
use. Second, an ideal hydrogel formulation will be identified. This will be achieved 
by rapidly characterising a range of hydrogel formulations using the shear modulus 
(G) as an indicator for the overall flow properties of the hydrogel. Once the most 
appropriate candidate formulations have been identified a full rheological 
characterisation will be undertaken so that an ideal formulation can be identified. Next, 
the ideal hydrogel formulation will be used to prepare furanone-loaded gels which will 
then be characterised rheologically to assess the impact of furanone loading on the 
physical properties of the hydrogel. Finally, the release kinetics of the furanone 








2.3 Materials and methods 
2.3.1 Materials and equipment  
Poly(vinyl alcohol), molecular weight  31,000-50,000, 98-99% hydrolysed, Poly(vinyl 
alcohol, molecular weight 31,000-50,000, 87-89% hydrolysed, and sodium tetraborate 
decahydrate were purchased from Sigma Aldrich (Gillingham, Dorset, UK) and were 
used without further modification. 
4-hydroxy-2,5-dimethyl-3(2H) furanone (HDMF), 2-methyltetrahydrfuran-3-one 
(MTHF), 5-(1,2-dihydroxyethyl)-3,4-dihydroxy-2(5H)-furanone (ascorbic acid) and 
3-hydroxy-4,5-dimethyl-2(5H) furanone (sotolon) were all purchased from Sigma 
Aldrich (Gillingham, Dorset, UK) and used without further modification.  
Poly(vinyl alcohol), 100% hydrolysed, was purchased from Spectrum Chemicals 
(Wallaston, UK) and used without further modification. 
Cuprophan 150M dialysis membrane (MWCO 10,000Da) was purchased from 
Medicell Membranes (Liverpool, UK) 
A Malvern Kinexus Pro Rheometer (Malvern, UK) was used with the included 20mm 
diameter parallel plate geometry for all rheological testing. 
A Varian Cary 50 ultraviolet-visible spectrophotometer (Gatwick, UK) was used for 
all UV absorbance measurements. 
A Jenway 351201 pH meter with integrated thermal probe (Jenway, UK) was used for 





2.3.2 Identification of an ideal hydrogel production method  
2.3.2.1 Production of hydrogels from stock solutions    
PVA hydrogels were produced using a simple thermal process. Hydrogels were first 
produced using liquid components (i.e. PVA and borate stock solutions). Following 
assessment of this method optimisation was performed.  Appropriate amounts of a 
30% w/w PVA solution and 5% w/w borate solution were weighed out according to 
the final polymer and crosslinker percentages required for the formulation (see Table 
2.1). Solutions were added to a 100 mL beaker and deionised water was added to give 
a final weight of 50 g. The beaker and total contents were re-weighed, and the weight 
was recorded. This mixture was briefly stirred and then covered with aluminium foil 
and placed in a static water bath preheated to 90 °C. Gels were heated at 90 °C for 3 h 
and stirred using a glass rod every 30 min. Gels were removed from the water bath 
once a homogenous mixture had formed. Each beaker and contents were weighed, and 
any mass lost was presumed to be water lost through evaporation and was replaced 
with fresh deionised water (ensuring a final gel weight of 50 g). Gels were allowed to 
cool to room temperature and were then transferred to air-tight sample jars. Gel 
samples were then left at room temperature for a further 18 h prior to rheological 
testing.  
Table 2.1 - A summary of each hydrogel formulation prepared using the liquid 
component method. Values given in the grey boxes are the required weight (g) of 
a 30% w/w PVA stock and values in white are the required volume of a 5% borate 
stock. The highlighted formulation (14% PVA and 3% borate) was not prepared 
as the required volumes of stock solution would have resulted in a gel of greater 
than 50g.  
 
6 8 9 10 11 12 14
10 13.3 15 16.6 18.3 20 23.3
10 10 10 10 10 10 10
10 13.3 15 16.6 18.3 20 23.3
20 20 20 20 20 20 20
10 13.3 15 16.6 18.3 20 23.3














2.3.2.2 Preparation of hydrogels from dry components  
Hydrogels were also prepared using dry powdered components in place of stock 
solutions. PVA and borate powders were weighed out in appropriate quantities into a 
beaker. Deionised water was added to give a final weight of 50 g. The beaker and 
contents were reweighed, and the weight was noted. This mixture was briefly stirred 
and then covered with aluminium foil and placed in a static water bath preheated to 90 
°C. Gels were heated at 90 °C for 3 h and stirred using a glass rod every 30 min. Gels 
were removed from the water bath once a homogenous mixture had formed. Each 
beaker and contents were reweighed, and any lost mass was replaced with fresh 
deionised water to ensure a final gel weight of 50 g. Gels were allowed to cool to room 
temperature and were then transferred to air-tight sample jars. Gel samples were then 
left at room temperature for a further 18 h prior to rheological testing.  For accurate 
comparison to the liquid method, an 8% PVA 2% borate gel was made using the 
powder method.  
2.3.2.3 Preparation of varying PVA percentage hydrolysis gels 
Gels were prepared using PVA of differing percentage hydrolysis. Gels were prepared 
using the dry component method outlined in section 2.3.2.2 using 87-89%, 98-99% 
and 100% hydrolysed PVA. For direct comparisons 8% w/w PVA and 2% w/w borate 
hydrogels were produced using the various percentage hydrolysis PVA.  
2.3.2.4 Rheological assessment of each production method 
Hydrogels produced using both the liquid and dry powder methods were assessed to 
establish their shear moduli using a Malvern Kinexus Pro Rheometer (Malvern, UK). 
The rheometer was used according to the manufacturer’s guidelines. Briefly, a 20 mm 
diameter parallel plate geometry was used during all testing of hydrogels and a 
constant shear gap of 1 mm was used throughout all experiments. To measure shear 
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modulus of the hydrogels a frequency sweep with crossover analysis was performed. 
The sample was subjected to an increasing range of shear frequencies (0.1 Hz to 150 
Hz) and both storage and loss moduli (G′ and G″ respectively) were measured at each 
shear frequency. Crossover analysis was undertaken to identify the shear modulus (G). 
The shear modulus can be defined as the point at which G′ is equal to G″. 
2.3.3 Identification of an ideal gel formulation 
Using the ideal gel production method identified in section 2.3.2.2 a range of hydrogel 
formulations were produced and compared to identify the ideal formulation for a PVA 
– borate hydrogel. The formulations prepared and the quantity of PVA and borate used 
to produce them are summarised in Table 2.2. Gels were compared in terms of shear 
moduli to identify four potential formulations. Each of these formulations was then 
subjected to full rheological testing. From this data, an optimal hydrogel formulation 
was identified. All rheological tests used a Kinexus Pro rheometer (Malvern, UK) and 
20 mm diameter parallel plate geometry unless otherwise stated. 
 
2.3.3.1 Production and assessment of PVA-borate hydrogel formulations 
A range of hydrogel formulations (Table 2.2) were produced using the powder method 
described in section 2.3.2.2 and 98-99% hydrolysed PVA (Sigma Aldrich, Dorset UK) 
was used. Each hydrogel formulation was assessed rheologically to identify the shear 
modulus as described in section 2.3.2.4. Gels with a shear modulus in the range of 1.5 
kPa – 5.5 kPa were considered for further characterisation.  
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Table 2.2 - A summary of each hydrogel formulation prepared using the powder 
component method. Values given in the grey boxes are the required weight (g) of 
PVA and values in white are the required weight of borate. 
 
2.3.3.2 Full rheological characterisation of chosen hydrogel formulations 
Hydrogels chosen for further characterisation in section 2.3.3 were fully characterised 
rheologically to identify their LVR, assess their overall viscoelastic profile, assess 
their viscosity profile, and finally, to assess their adhesiveness.  
To identify the LVR of each gel, samples were subjected to an amplitude sweep. This 
placed the sample under increasing shear strains over time while measuring both G′ 
and G″. The amplitude sweep was conducted over a shear strain range of 0.01-200% 
at a frequency of 1 Hz and 10 samples per decade. Viscoelastic profiles of each gel 
were assessed by conducting a frequency sweep beginning at a force frequency at 0.01 
Hz and ending at a force frequency of 150 Hz (these values representing the upper and 
lower frequency limit of the rheometer). Measurement of G′, G″ and the phase angle 
were taken at each frequency tested. The viscosity of the gels was measured at a range 
of shear frequencies from 50 Hz to 150 Hz using a frequency sweep test. Gel 
adhesiveness was measured using a pull away test. Normal force was measured over 
time as the rheometer geometry holding the gel was separated. A greater negative 
normal force measure on the spindle of the rheometer during the pull-away test 
indicated a more adhesive gel. These tests were then repeated for each of the chosen 
gel formulations.   
6 8 9 10 11 12 14
3 4 4.5 5 5.5 6 7
0.5 0.5 0.5 0.5 0.5 0.5 0.5
3 4 4.5 5 5.5 6 7
1 1 1 1 1 1 1
3 4 4.5 5 5.5 6 7













2.3.4 Assessment of furanone release kinetics 
Furanone-loaded PVA aerogels were then prepared and their drug release kinetics 
assessed. 
2.3.4.1 Preparation of furanone-loaded hydrogels 
Furanone-loaded hydrogels were prepared using a similar method to that detailed in 
section 2.3.2.2 with one amendment. PVA and borate powders were weighed out 
according to the quantities shown in Table 2.2 for desired hydrogel formulation. Both 
powders were added to a beaker that had been paced on a previously zeroed balance. 
The furanone to be loaded into the hydrogel, either HDMF, MTHF, ascorbic acid or 
sotolon (Figure 2.1) was weighed out and added to the beaker. A standardised 
concentration of 1% w/w of furanone was used so that initial testing of a loaded gel 
could be performed. Deionised water was added the powder components to give a final 
weight of 50 g. The protocol was completed and furanone-loaded hydrogels were 






Figure 2.1 – The chemical structures of (a) HDMF, (b) MTHF, (c) sotolon, and 
(d) ascorbic acid show a high degree of similarity with each compound having a 
central lactone ring with varying side groups.  
 
2.3.4.2 Assessment of furanone release kinetics 
The release of furanone compounds from loaded hydrogels was assessed using a Franz 
diffusion cell (Figure 2.2 a). The diffusion apparatus was prepared as follows. Each 
cell was rinsed thoroughly with 100% ethanol followed by three deionised water rinses 
to ensure that no contaminants were present. Each cell was filled with 15 mL deionised 
water to act as receiver phase for the furanone ensuring that a slight meniscus was seen 
above the neck of the cell and that the sampling port was filled to the 500 µL mark 
(Figure 2.2 b). A 2 cm x 2 cm square of semi permeable Cuprophan 150M dialysis 
membrane (MWCO 10,000 Da) (Medicell Membranes, Liverpool, UK) was placed on 
top of the diffusion cell ensuring good contact between the membrane and the receiver 
phase and avoiding the introduction of bubbles into the system. The sample chamber 
was then placed on top of the diffusion cell and clamped to hold the membrane in 
place. The magnetic stirrers were started, the water pump was set to 37 °C and the 
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temperature was allowed to equilibrate for 60 min. Samples of loaded hydrogel were 
weighed out into 1 g amounts. Each sample was placed in the sample chamber of the 
diffusion cell ensuring good contact between the membrane and the sample. A 500 µL 
volume of the receiver phase was taken from the sampling port of the diffusion cell 
and 500 µL of fresh receiver phase was added to the diffusion cell ensuring the sample 
port was filled to the mark. Samples of receiver phase were then analysed via 
ultraviolet-visible spectroscopy over the full range of wavelengths (190 - 800 nm) to 
quantify furanone concentrations in the receiver phase. Furanone release was then 
calculated and plotted as a percentage release of the total furanone concentration in 
the hydrogel sample. Measurements of the furanone release were taken every 60 min 
for 8 h and then again after 24 h. All samples were tested in triplicate and data was 








Figure 2.2 – (a) a three-dimensional schematic of a Franz diffusion cell and (b) 
an orthogonal view of a Franz diffusion cell. 
 
(a) A sample is placed in the sample chamber [1] and drug is released through a semi 
permeable membrane [2]. Samples of receiver phase are removed from the sample 
port [3] for analysis. A water jacket [4] ensures that the receiver phase in the cell [5] 
is kept at a constant temperature. (b) An orthogonal view of a Franz diffusion cell.  
 
2.3.5 Stability of furanone compounds  
Furanone compounds were assessed for their stability under a range of conditions. 
Each furanone was tested in aqueous solution, in a solution of 1% sodium tetraborate 
and in pH adjusted solution with a pH similar to that of a 1% sodium tetraborate 
solution. Furanones were tested under these conditions at room temperature and 90 
°C. These conditions were selected to mimic the conditions which the compounds 
would be exposed to during the formation of a hydrogel. 
2.3.5.1 Assessment of furanone stability by UV spectrometry. 
Furanones were dissolved into 50 mL deionised water to give a solution with a 
concentration of 1% furanone by weight. These stock solutions were then incubated 
under each of the different conditions noted above. Each furanone was tested for 
95 
 
degradation under each condition individually and in combination with other 
conditions. The conditions used were;  
• Incubation in aqueous solution at room temperature 
• Incubation in aqueous solution at 90 °C  
• Incubation at room temperature in the presence of 1% borate  
• Incubation at 90 °C in the presence of 1% borate  
• Incubation at room temperature at pH 9.31 (equivalent to a 1% borate solution) 
• Incubation at pH 9.31 at 90 °C.  
These conditions represented the conditions under which the gels are formed. Tests 
performed at pH 9.31 served to establish if any observed degradation was caused by 
the borate and its associated chemistry specifically or if pH changes caused by borate 
was the cause. During the incubation of the furanone stock solutions 1 mL samples of 
furanone solution were removed every 5 min up to 30 min incubation then every 20 
min up to 90 min incubation. Samples were analysed in a UV spectrophotometer 
(Varian, Gatwick, UK) over the full range of wavelengths (190 – 800 nm) to measure 
absorbance at the compounds corresponding λmax and to assess any changes in the full 
absorbance spectrum. Any reduction or increase in the UV-Vis absorbance or change 
in λmax over the 90 min incubation was assumed to be due to degradation or changes 
in the structure of the furanone compound.   
2.3.5.2 Assessment of furanone pH under hydrogel forming conditions.  
To assess the change in pH of each furanone during heating and identify the 
temperature at which pH changes may occur, solutions of 1% w/w borate and 1% w/w 
of a furanone were prepared in triplicate. The solutions were covered and placed on a 
hot plate and heated to 70 °C. The pH of the solution was recorded after every 5 °C 
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increase in solution temperature using a Jenway 351201 pH meter with integrated 
thermal probe (Jenway, UK). The temperature probe was used at all times throughout 
the experiment to ensure that the recorded pH was adjusted for the temperature of the 
solution. This method was used to assess each furanone and a borate only solution as 
a control. The pH was plotted as a function of temperature.   
As the hot plate method described above was not suitable for assessing the long-term 
effects of heating a second method was used. Furanone/borate solutions were prepared 
as described above. These solutions were covered and placed in a water bath pre-
heated to 90 °C for 3 h (representative of the average time to prepare a hydrogel). The 
pH of the solutions was measured every 30 min for the duration of the experiment and 
the solutions were removed from the water bath. Finally, the pH was measured again 
once the solutions had cooled to room temperature. The pH was then recorded as a 














2.4.1 Identification of an ideal hydrogel production method. 
Investigation into the ideal production method for the PVA hydrogels showed that the 
liquid method showed high variability in the viscoelastic properties of the hydrogels. 
It was subsequently shown that a production method in which powder components 
were used in place of the stock solutions eliminated this issue.  
2.4.1.1 Production of hydrogels using the liquid method 
To identify the ideal formulation for a PVA-borate hydrogel a range of hydrogels were 
produced with varying concentration of both PVA and borate using the previously 
established liquid method. A summary of the formulations produced, including their 
concentrations of both polymer and cross linker can be seen in Table 2.1 in section 
2.3.2.1. The shear modulus of each hydrogel formulation was measured and compared. 
No relationship between the concentration of PVA and shear modulus was observed 
at any concentration of borate (Figure 2.3 a-c). Similarly, no relationship between 
shear modulus and borate concentration was noted. Higher concentrations of borate 
generally resulted in higher shear moduli. However, there were several exceptions 




Figure 2.3 - A comparison of the shear moduli (G) of hydrogels with varying 
formulations.  
Hydrogels were prepared with (a) 1% w/w borate, (b) 2% w/w borate and (c) 3% w/w 
borate. Hydrogel formulations where tested rheologically to measure the shear 
moduli. No relationship between shear modulus and PVA concentration was found 
when borate concentration remained the same. Similarly, no relationship between 
borate concentration and shear modulus was observed. All values represent mean 
values of independent triplicates (± SD).   
 
2.4.1.2 Comparison of the liquid and powder methods of hydrogel production 
A comparison of the shear moduli of hydrogels produced using liquid stocks of each 
component and those made using dry powder components was made.  It was found 
that the hydrogels produced using the dry powder components had a lower overall 
lower standard deviation in the shear modulus between independent samples (Figure 
2.4). It was discovered that hydrogels containing 8% w/w PVA and 2% w/w borate 
produced using powdered components had an average shear modulus of 3717 Pa 
±238.7 Pa while hydrogels produced using liquid stocks of both components had an 






















Figure 2.4 - A comparison of the mean shear modulus (G) of hydrogels produced 
by two distinct methods.  
Powder hydrogels were produced using dry powder components and liquid hydrogels 
were produced using liquid stocks of component chemicals. Powder hydrogels had an 
average shear modulus of 3717 Pa ± 238.7 whereas hydrogels produced using the 
liquid stocks had an average shear modulus of 8592 Pa ± 1027.2. Values shown 
represent mean values of independent triplicates ± standard deviation (SD). Data 
analysed using a two-tailed t-test. P= 0.0028 
 
Due to the lower standard deviation between samples and the consequent increase in 
consistency between batches, the dry powder method was carried forward and used in 
the production of all subsequent hydrogels. 
2.4.1.3 Assessment of the impact of PVA type on hydrogel properties 
Using the dry powder production method identified above, hydrogels were produced 
using a range of PVA types with varying hydrolysis percentages. All hydrogels 
contained 8% w/w PVA and 2% w/w borate. The PVA types tested were 87-89% 
hydrolysed, 98-99% hydrolysed and 100% hydrolysed. Comparison of the shear 
modulus of each hydrogel showed no significant difference between gels produced 
using the 87-88% hydrolysed and 98-99% hydrolysed PVA with an average shear 
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modulus of 3635 Pa ± 248.1 and 3717 Pa ± 238.7 respectively. A significant difference 
in shear modulus was seen in hydrogels produced using the 100% hydrolysed PVA 
with an average shear modulus of 8356 Pa ± 13.9 (Figure 2.5).  It was decided that 98-
99% hydrolysed PVA would be used in all future hydrogel formulation due to its low 
























Figure 2.5 - A comparison of the mean shear modulus (G) of hydrogels produced 
using a range of PVA types with varying hydrolysis percentages.  
Hydrogels produced using 87-88% hydrolysed PVA had an average shear modulus of 
3635 Pa ± 248.1 while gels produced using 98-99% hydrolysed PVA and 100% 
hydrolysed PVA had average shear moduli of 3717 Pa ± 238.7 and 8356 Pa ± 13.9 
respectively. Statistical significance was calculated using a 1-way ANOVA with a 
post-hoc Tukey’s multiple comparison test (*** p<0.001). All measurements represent 
mean values of independent triplicates (± SD). 
 
2.4.2 Identification of an ideal hydrogel formulation 
Following the identification of an optimised hydrogel production method an ideal 
hydrogel formulation was identified. The same range of formulations prepared using 
the liquid method (Table 2.1) were prepared using the dry powder method and their 
shear moduli were measured. 
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2.4.2.1 Rapid assessment of hydrogel formulations produced using an optimised 
method 
The dry powder method of producing hydrogels was shown to superior to the liquid 
component method. It was found that with the dry powder method there was a clear 
positive correlation between PVA concentration and hydrogel shear modulus (Figure 
2.6 a-c). It was also shown that hydrogels with a higher concentration of crosslinker 
generally had a higher shear modulus. These correlations were expected when 
producing polymer hydrogels but was only apparent when using the dry powder 
method.   
 
Figure 2.6 - A comparison of the shear moduli (G) of hydrogels with varying 
formulations produced using dry powder components.  
Hydrogels were prepared with (a) 1% w/w borate, (b) 2% w/w borate and (c) 3% w/w 
borate. Hydrogel formulations where tested rheologically to measure the shear 
moduli. A clear correlation between shear modulus and PVA concentration was found 
when borate concentration remained the same. Similarly, a correlation between 
borate concentration and shear modulus was observed. All values represent mean 
values of independent triplicates (± SD).   
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2.4.2.2 Full rheological characterisation of selected formulations 
Each of the four candidate hydrogels selected in section 2.3.3.1 were subjected to 
further rheological characterisation. This characterisation included establishing the 
LVR of the material, assessing their overall viscoelastic profile, characterising their 
viscosity and finally measuring the hydrogels adhesiveness or tackiness. All tests were 
conducted using the Malvern Kinexus Pro rheometer as detailed in section 2.3.3.2  
6% w/w PVA, 1% w/w borate 
Hydrogels containing 6% w/w PVA and 1% borate showed that both the storage and 
loss moduli were unaffected at shear strains below 6.3% (Figure 2.7 a). All future tests 
were carried out below this shear rate to ensure accurate results. Assessment of the 
viscoelastic profile of this hydrogel formulation showed that the elastic component of 
the gel was dominant (G′>G″) at shear frequencies greater than approximately 1.7 Hz 
while the viscous component of the gel was dominant (G′<G″) at lower shear rates 
(Figure 2.7 b). This indicates that the sample acts more like a solid when a force is 
applied rapidly and acts more like a viscous liquid when force is applied slowly. These 
findings were further confirmed by the measurement of the phase angle (θ) over the 
same shear frequency range. As shear frequency increased the phase angle tended 
towards 0° and tended towards 90° when a lower shear frequency was applied 
indicating more solid like and more fluid like behaviour respectively (Figure 2.6 b). 
The cross over point (G′=G″) was 2274 Pa, meaning that a force greater than 2274 Pa 
was required to initiate liquid-like flow in this gel. At high frequency shear forces (>50 
Hz) the viscosity of this hydrogel increased with shear frequency indicating dilatant 
behaviour (Figure 2.7 c). This finding is in keeping with real world observations of 
the shear sensitive nature of the hydrogel. Finally, adhesiveness testing of this 
hydrogel formulation showed a peak normal force of -6.607 N. over 0.11 s indicating 
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some adhesiveness which is easily overcome with a small amount of force (Figure 2.7 
d). 
 
Figure 2.7 – A full rheological profile of a 6% PVA 1% borate hydrogel including 
measurement of the (a) LVE (b) viscoelastic profile (c) viscosity profile and (d) 
adhesiveness of the gel.  
(a) Measurements of both the storage and loss moduli (G′ and G″ respectively) over a 
range of shear strains showed no change in either modulus below a shear strain of 
6.3%. This indicated that no destruction of the polymer network has occurred below 
this shear strain. (b) At high shear frequencies the elastic component of the hydrogel 
is dominant (G′>G″) indicting solid-like behaviour. At low frequencies the liquid 
component of the hydrogel is dominant (G′<G″) indicating fluid-like behaviour. This 
is confirmed by phase angle measurement which tend towards 0° at higher frequencies 
indicating solid-like behaviour and tend towards 90° at lower frequencies indicating 
fluid-like behaviour. (c) This sample showed dilatant behaviour, increasing in 
viscosity with increased shear frequency. (d). Adhesiveness testing of this hydrogel 
showed a peak normal force of -6.607 N experienced over 0.11 s indicating that this 
hydrogel had a small amount of adhesiveness which released rapidly after the 
application of a pulling force. All values represent the mean of independent triplicates 
(± SD). 
 
6% w/w PVA, 2% w/w borate  
Rheological testing showed that the storage and loss moduli of a 6% w/w PVA and 
2% w/w borate hydrogel were unchanged over the shear rate range of 0% to 7.9%. 
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This indicates that no destruction of the polymer network had occurred before this 
upper shear rate (Figure 2.8 a). A gel with a shear rate in this range was used for all 
further rheological testing. Characterisation of the viscoelastic profile of the hydrogel 
showed that the elastic component of the gel was dominant at higher shear frequencies 
(G′>G″) while the liquid component dominates at lower shear frequencies (G′<G″). 
This data was further confirmed with phase angle measurements that showed a phase 
angle that tended towards 0° at higher shear frequencies, typical of materials behaving 
more like solids and phase angle measurements that tend towards 90° at lower shear 
frequencies indicating fluid-like behaviour (Figure 2.8 b). Similar to the 6% PVA and 
1% borate, this formulation showed dilatant behaviour with increasing viscosity at 
very high shear rates (Figure 2.8 c).  Adhesiveness testing showed a peak normal force 
of -15.3667 N exerted over approximately 0.09 s indicating that this formulation is 







Figure 2.8 – Full rheological profile of a 6% w/w PVA, 2% w/w borate hydrogel 
including measurement of the (a) LVE (b) viscoelastic profile (c) viscosity profile 
and (d) adhesiveness of the gel.  
(a) G′ and G″ were unchanged over a range of shear strains of 0% to 7.9%. This 
indicated that no destruction of the polymer network has occurred below this shear 
strain. (b) At high shear frequencies the elastic component of the hydrogel is dominant 
(G′>G″) indicting solid-like behaviour. At low frequencies the liquid component of the 
hydrogel is dominant (G′<G″) indicating fluid-like behaviour. This is confirmed by 
phase angle measurement which tend towards 0° at higher frequencies indicating 
solid-like behaviour and tend towards 90° at lower frequencies indicating fluid-like 
behaviour. (c) This hydrogel was found to show dilatant behaviour and increase in 
viscosity with increasing shear frequency. (d) Adhesiveness testing of this hydrogel 
showed a peak normal force of -15.3667 N experienced over 0.09 s. All values 
represent the mean of independent triplicates (± SD). 
 
6% w/w PVA, 3% w/w borate 
Rheological testing of a 6% w/w PVA and 3% sodium tetraborate hydrogel showed a 
stiffer gel overall. Assessment of the linear viscoelastic region showed no changes in 
the storage and loss moduli at shear rates below 7.9% (Figure 2.9 a). Assessment of 
the viscoelastic profile of this hydrogel showed a similar profile to those tested thus 
far with the storage modulus being dominant at high shear speeds and the loss modulus 
dominating at low shear speeds. This data was again confirmed with phase angle 
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measurements. The crossover point for this gel formulation was found to be 4770 Pa 
at a frequency of approximately 0.5 Hz (Figure 2.9 b). Viscosity measurements over 
a range of high frequency shear forces this gel formulations showed an increase in 
viscosity up indicating dilatant behaviour (Figure 2.9 c). Adhesiveness testing of the 
6% w/w PVA and 3% w/w borate gel showed a maximum normal force of -19.5267 
N exerted over approximately 0.07-0.09 s indicating that this formulation is highly 
adhesive when compared to previously tested formulations (Figure 2.9 d). 
 
Figure 2.9 – Full rheological profile of a 6% w/w PVA, 3% w/w borate hydrogel 
including measurement of the (a) LVE (b) viscoelastic profile (c) viscosity profile 
and (d) adhesiveness of the gel.  
(a) Measurements of both the storage and loss moduli (G′ and G″ respectively) over a 
range of shear strains showed no change in either moduli below a shear strain of 
7.9%. This indicated that no destruction of the polymer network has occurred below 
this shear strain. (b) At high shear frequencies the elastic component of the hydrogel 
is dominant (G′>G″) indicting solid-like behaviour. At low frequencies the liquid 
component of the hydrogel is dominant (G′<G″) indicating fluid-like behaviour. This 
is confirmed by phase angle measurement which tend towards 0° at higher frequencies 
indicating solid-like behaviour and tend towards 90° at lower frequencies indicating 
fluid-like behaviour. (c) This hydrogel was found to show dilatant behaviour and 
increase in viscosity with increasing shear frequency. (d) Adhesiveness testing of this 
hydrogel showed a peak normal force of -19.526  N experienced over 0.09 s indicating 
that this hydrogel had a small amount of adhesiveness which released rapidly after 
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the application of a pulling force. All values represent the mean of independent 
triplicates (± SD). 
 
8% w/w PVA, 1% w/w borate 
Characterisation of the 8% w/w PVA and 1% w/w sodium tetraborate hydrogel 
showed a gel with similar properties to the previously tested gels. Investigation of the 
linear viscoelastic region showed that this gel formulation experienced no changes in 
storage or loss modulus at shear rates below 12.5% (Figure 2.10 a). Assessment of the 
viscoelastic profile showed a dominant storage modulus at high shear speeds and a 
dominant loss modulus at low shear speeds. This was confirmed by phase angle 
measurements showing a phase angle that tended towards 0° at higher shear rates. The 
crossover point for this gel formulation was found to be 6515 Pa at a frequency of 
approximately 2.5 Hz (Figure 2.10 b). Viscosity measurements showed an increase in 
gel viscosity with increasing shear frequency. This data shows that the 8% PVA and 
1% sodium tetraborate displays shear thickening behaviour (Figure 2.10 c). 
Adhesiveness testing showed that the 8% w/w PVA 1% hydrogel was slightly 
adhesive to the steel rheometer geometry surface. A peak normal force of -18.80 N 
was exerted by the gel in 0.9s. The adhesion of the gel released rapidly once the pulling 





Figure 2.10 – Full rheological profile of an 8% w/w PVA, 1% w/w borate 
hydrogel including measurement of the (a) LVE (b) viscoelastic profile (c) 
viscosity profile and (d) adhesiveness of the gel.  
(a) Measurements of both the storage and loss moduli (G′ and G″ respectively) over a 
range of shear strains clearly showed no change in either moduli below a shear strain 
of 12.5%. (b) At high shear frequencies the elastic component of the hydrogel is 
dominant (G′>G″) indicting solid-like behaviour. At low frequencies the liquid 
component of the hydrogel is dominant (G′<G″) indicating fluid-like behaviour. This 
is confirmed by phase angle measurement which tend towards 0° at higher frequencies 
towards 90° at lower frequencies (c) This formulation was found to show shear 
thickening behaviour and increase in viscosity with increasing shear frequency. (d) 
Adhesiveness testing of this hydrogel showed a peak normal force of -18.80 N 
experienced over 0.09 s indicating that this hydrogel had a small amount of 
adhesiveness which released soon after the application of a pulling force. All values 
represent the mean of independent triplicates (± SD). 
 
2.4.3 Selection and drug loading of an ideal formulation 
From the rheological characterisation of each hydrogel formulation, the 6% w/w PVA 
and 1% w/w borate formulation was chosen and carried forward for drug loading due 
to its low shear modulus and low adhesiveness and ease of handling. These 
characteristics ensured this formulation would flow easily into a wound and would not 
adhere to the wound bed, causing further trauma upon removal.  
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Drug-loaded hydrogels were prepared using the protocol outlined in section 2.3.4.1. 
All hydrogels were loaded with 1% w/w of each furanone so that direct comparisons 
could be made between loaded samples. 
When loaded with 1% w/w of HDMF, the hydrogels shear modulus was significantly 
reduced resulting in a very soft gel that that did not hold its shape under gravity. This 
change in shear modulus was coupled with an obvious colour change from colourless 
to bright yellow (Figure 2.11 a). When initially mixed with the PVA and the borate 
solution the HDMF dissolved to form a colourless solution. Upon heating to produce 
the hydrogel a bright yellow colour was observed, indicating a possible reaction 
between the HDMF and one or more components of the hydrogel. When loaded with 
ascorbic acid the hydrogel did not form and the sample remained entirely liquid. A 
slight colour change was seen from colourless to a faint yellow (Figure 2.11 b). This 
colour change increased in intensity over a period of five days resulting in a dark 
brown/orange discoloration (Figure 2.11 b – inset). When the hydrogels were loaded 
with sotolon at a concentration of 1% w/w the samples did not gel and remained 
entirely liquid. A very slight pale-yellow colour was observed in the hydrogels (Figure 
2.11 c). When hydrogels were loaded with 1% w/w MTHF a clear, homogenous gel 
was formed (Figure 2.11 d). No discolouration was noted during the production or 




Figure 2.11 - Images of 6% w/w PVA and 1% w/w borate hydrogels loaded with 
1% w/w furanone.  
(a) HDMF-loaded hydrogel showed a stark colour change from colourless to bright 
yellow after the heating step of gel production. The hydrogel formed poorly resulting 
in a gel which did not hold shape well. (b) Ascorbic acid-loaded hydrogels did not 
form well and the sample was entirely liquid. A slight colour change from colourless 
to straw yellow was seen post heating that gradually darkened to a brown/orange over 
5 days (inset). (c) Sotolon-loaded gels did not form and the sample remained entirely 
liquid. (d) MTHF-loaded hydrogel formed homogenous gels with an appropriate 
consistency and no colour change was observed.   
 
2.4.4 Furanone release from loaded hydrogels 
The release kinetics of both HDMF and MTHF from a 6% w/w PVA and 3% w/w 
borate hydrogel were assessed using the protocol outlined in section 2.3.4.2. Ascorbic 
acid and sotolon-loaded samples were unsuitable for testing due to their significantly 
altered viscosity. 
HDMF was released in a steady manner over 24 h reaching a maximum release of 
45% of the total loaded drug (Figure 2.12 a).  
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MTHF-loaded hydrogels also showed a steady release profile over 24 h. However, 
when cumulative release was calculated the apparent total release of MTHF was 
approximately 2000% of the total loaded drug volume (Figure 2.12 b). 
 
 
Figure 2.12– Drug release profiles of two furanones; HDMF (a) and MTHF (b) 
from a 6% w/w PVA and 1% w/w borate hydrogel.  
The HDMF-loaded gel showed a steady release of compound over 24 h with a 
maximum release of 45% of the total loaded drug. The MTHF-loaded hydrogel also 
showed a steady release profile. However, the calculated release values were above 
100% of the total loaded drug. Further investigations into the cause of this are 
needed. 
 
It was suspected that although the MTHF hydrogels had formed well and no colour 
changes were observed the furanone had either degraded or reacted with a hydrogel 
component resulting in a product which was highly absorbent, thus, giving release 
readings of over 100% of the total loaded drug volume. This finding then prompted 
investigations into the stability of the furanones in both aqueous solution and under 
hydrogel forming conditions. 
2.4.5 Stability of furanones under hydrogel forming conditions. 
The discovery of possible degradation of MTHF during the production of an MTHF-
loaded hydrogel prompted an investigation of the stability of all furanones used in this 















































work. Compounds were tested for their stability under a range of conditions. The 
conditions tested were representative of those present during the formation of the 
hydrogels namely; exposure to high temperatures, presence of borate and increased 
pH.  
Furanones were subjected to a range of conditions both individually and in 
combination. The UV spectra of the furanones were measured to identify any loss of 
compound or possible changes in compound structures. An aqueous solution of each 
furanone was subjected to incubation at room temperature with and without 1% borate, 
incubation at 90 °C with and without 1% borate and finally exposure to a pH 
representative of that of 1% borate.  
2.4.5.1 MTHF degradation 
It was shown that when in aqueous solution at room temperature MTHF was 
apparently stable for the duration of the test with no changes in absorbance and no 
changes in the λmax of the compound (Figure 2.13 a). This was also seen to be the case 
when the MTHF was exposed to 90 °C in aqueous solution (Figure 2.13 b). When 
exposed to 1% borate in aqueous solution at room temperature the absorbance of the 
MTHF showed some variability over time but this was attributed to variance in the 
UV-Vis spectrophotometer as no net increase or decrease in absorbance was observed 
over time (Figure 2.13 c). However, when exposed to a combination of 1% borate and 
90 °C temperatures in aqueous solution an obvious increase in absorbance at 285 nm 
was observed during the experiment (Figure 2.13 d). Analysis of the full absorbance 
spectrum clearly showed that the entire absorbance spectrum of the compound was 
both flattening and increasing giving an apparent increase in concentration of MTHF. 
This finding clearly explains the unusual readings of a more than 100% release seen 
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in section 2.4.4 (Figure 2.13 e).  As the above experiments clearly demonstrate the 
presence of the 1% borate and the 90 °C temperature appear to act synergistically to 
cause the changes in the absorbance of the MTHF. It was then necessary to identify if 
the degradation was due to the presence of borate specifically or, rather, due to the 
change in pH caused by the borate. MTHF was then exposed to a pH representative of 
that of 1% borate (pH 9.31). It was discovered that MTHF was stable in the presence 
of a pH altered solution at both room temperature (Figure 2.13 f) and at 90 °C (Figure 
2.13 g). Therefore, it was concluded that the observed changes in the MTHF 
absorbance was caused specifically by the presence of borate and not simply due to 





Figure 2.13 – Degradation profile of MTHF under hydrogel forming conditions 
including (a-b) aqueous environment at ambient temperature and 90°C, (c-e) in 
the presence of 1% borate at ambient temperature and 90°C, and (f-g) at pH 9.31 
at ambient temperature and 90°C.  
(a-c) MTHF was found to be stable in aqueous solution at both temperatures tested 
and in 1% borate at ambient temperature. (d) At 90°C in 1% borate a gradual increase 
in the absorptivity of an MTHF solution was seen. (e) This was caused by a gradual 
flattening of the UV absorbance spectrum throughout the test. (f-g) MTHF was found 
to be stable at a pH representative of a 1% borate solution. All values represent the 




2.4.5.2 HDMF degradation  
Due to the stability issues observed with MTHF it was decided that similar stability 
studies should be undertaken for HDMF. It was found that HDMF was stable at room 
temperature in aqueous solution over the course of the experiment (Figure 2.14 a). 
When exposed to 90 °C in aqueous solution the absorbance of HDMF rapidly 
decreased over 90 min suggesting that the compound is heat labile (Figure 2.14 b). 
When exposed to a 1% borate solution a slight, immediate decrease in the absorbance 
was seen from 0.97 (as seen in Figure 2.14 a) to 0.69 as well as a change in the overall 
λmax of the compound from 285 nm to 335 nm (Figure 2.14 c). There was no further 
change in the absorbance during the rest of the experiment. This suggested that there 
was an immediate reaction on exposure to borate possibly resulting in a product with 
a lower overall absorptivity as well as an altered λmax. When exposed to 1% borate and 
90 °C the same immediate changes in absorptivity and in λmax were seen as well as a 
rapid reduction in the total absorbance of the solution with the absorbance reaching 
zero in just 70 min (Figure 2.14 d). The changes in the full absorbance spectrum of 
HDMF when exposed to 1% borate and 90 °C were investigated. It was found that 
when exposed to these conditions the shape of the HDMF UV-Vis absorbance 
spectrum shifted towards longer wavelengths (λmax 335 nm) and became asymmetric. 
The total absorbance was reduced immediately (even prior to placing the sample in a 
90 °C water bath) (figure 2.14 e). When exposed to the 1% borate and 90 °C, this 
‘new’ absorbance spectrum did not change over time, but the total absorbance did 
gradually decrease over time. The role of pH in the observed changes in the absorbance 
properties of HDMF was investigated (Figure 2.14 f). It was shown that at room 
temperature an increase in pH did not have any effects on the absorbance or λmax of 
HDMF (Figure 2.14 g) while a decrease in total absorbance was seen in on exposure 
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to 90 °C (figure 2.14 h). These data indicate that HDMF can be degraded by exposure 
to high temperatures and that exposure to 1% borate may cause a change in the 
structure of HDMF leading to a change in the λmax. This change in λmax is likely caused 
specifically by interactions with borate and is not due to the change in pH associated 








Figure 2.14 - Degradation profile of HDMF under hydrogel forming conditions 
including (a-b) aqueous environment at ambient temperature and 90°C, (c-e) in 
the presence of 1% borate at ambient temperature and 90°C, and (f-g) at pH 9.3 
at ambient temperature and 90°C.  
(a-b) HDMF was found to be stable in aqueous solution at ambient temperature. But 
unstable at 90°C in aqueous environment. (c) HDMF was stable in the presence of 
1% borate at ambient temperature but a change in λmax from 285nm to 335nm was 
observed. (d) At 90°C in 1% borate HDMF underwent the same change in λmax as 
previously and the solution gradually decreased in absorptivity. (e) The change in 
absorbance spectrum between HDMF in water and HDMF exposed to 1% borate 
showed the maintenance of one absorbance peak but a shift in absorbance to longer 
wavelengths. (f) The absorbance spectrum of the borate exposed HDMF remained 
constant when exposed to 90°C but the sample gradually decreased in absorptivity. 
(g-h) HDMF was largely stable in a solution with a pH representative of 1% borate 
at ambient temperature but apparently unstable at 90°C. All values represent the 
mean of three independent replicates ± S.D. 
 
2.4.5.3 Ascorbic acid degradation   
The effects of hydrogel forming conditions on ascorbic acid were then investigated. 
In simple aqueous solution at room temperature, ascorbic acid was unstable and a 
gradual decrease in total absorbance over 90 min was seen (figure 2.15 a). This 
reduction in total absorbance was greatly accelerated by exposure to 90 °C 
temperatures (Figure 2.15 b). When exposed to 1% borate at room temperature the 
reduction in total absorbance was accelerated compared to that in water only. A change 
in λmax from 250 nm to 265 nm was also seen (Figure 2.15 c). When exposed to 1% 
borate and 90 °C, a similar change in λmax was seen and the decrease in total 
absorbance was rapid with absorbance readings reaching zero in under 5 min (Figure 
2.15 d). The full absorbance spectrum of ascorbic acid under hydrogel forming 
conditions was investigated. It was shown that when exposed to 1% borate the UV 
absorbance spectrum shifted to the right, from 250 nm to 265 nm. The total absorbance 
also became highly variable (Figure 2.15 e). The role of pH in the above described 
absorbance changes was investigated. It was found that an increase in pH also caused 
a change in λmax from 250 nm to 265 nm as was seen with exposure to 1% borate 
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(Figure 2.15 f). This change in λmax was also seen in the pH altered solution at 90 °C 
(Figure 2.15 g). This suggests that the change in λmax seen during the formation of an 










































































































3 Ascorbic acid in water






































































Figure 2.15 - Degradation profile of ascorbic acid under hydrogel forming 
conditions including (a-b) aqueous environment at ambient temperature and 
90°C, (c-e) in the presence of 1% borate at ambient temperature and 90°C, and 
(f-g) at pH 9.3 at ambient temperature and 90°C.  
(a-b) Ascorbic acid was found to be unstable in aqueous solution at ambient 
temperature and 90°C in aqueous environment showing a gradual and rapid decrease 
in absorptivity respectively. (c-d) Ascorbic acid was unstable in the presence of 1% 
borate at both ambient temperature and at 90°C rapidly decreasing in absorptivity in 
both conditions. Ascorbic acid displayed a change in λmax from 250nm to 265nm at 
both temperatures in the presence of borate. (e) The change in λmax showed the 
maintenance of one absorbance peak but a shift in absorbance to longer wavelengths 
and an increase in the variability of absorbance measurements. (f) Ascorbic acid 
underwent a similar change in λmax and was unstable in a solution with a pH 
representative of 1% borate at ambient temperature and very unstable at 90°C. All 
values represent the mean of three independent replicates ± S.D. 
 
2.4.5.4 Sotolon degradation 
The stability of sotolon under hydrogel forming conditions was investigated. In 
aqueous solution at room temperature sotolon was stable with no change in λmax or 
total absorbance over 90 min (Figure 2.16 a). When exposed to 90 °C temperatures in 
aqueous solution sotolon showed no change in λmax but a slight and gradual increase 
in total absorbance was seen over the 90 min (Figure 2.16 b). When exposed to 1% 
borate at room temperature a slight initial decrease in total absorbance was apparent 
and an obvious change in λmax was seen from 230 nm to 265 nm. No further change in 
total absorbance was seen (Figure 2.16 c). When exposed to both 1% borate and 90 
°C a similar change in λmax was observed and a rapid decrease in total absorbance over 
90 min was seen (Figure 2.16 d). This finding indicates that the change causing a shift 
in λmax was a change from sotolon to a much less thermally stable compound. The 
effect of pH on the absorbance spectrum of sotolon was investigated. It was found that 
when exposed to pH 9.31 at room temperature a change in λmax similar to that seen in 
the borate solution occurred but the total absorbance did not change significantly 
(Figure 2.15 e). When exposed to the altered pH at 90 °C a change in λmax was also 
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seen and a rapid decline in total absorbance was apparent (figure 2.16 f). These data 



















Figure 2.16 -  Degradation profile of sotolon under hydrogel forming conditions 
including (a-b) aqueous environment at ambient temperature and 90°C, (c-d) in 
the presence of 1% borate at ambient temperature and 90°C, and (e-f) at pH 9.3 
at ambient temperature and 90°C.  
(a-b) Sotolon was found to be stable in aqueous solution at ambient temperature and 
at 90°C. (c-d) Sotolon was stable in the presence of 1% borate at ambient temperature 
and seemingly unstable at 90°C in a 1% borate solution, rapidly decreasing. Sotolon 
also displayed a change in λmax from 230nm to 265nm at both temperatures in the 
presence of borate. (e-f) Sotolon underwent a similar change in λmax and was stable 
in a solution with a pH representative of 1% borate at ambient temperature and was 
unstable at 90°C. All values represent the mean of three independent replicates ± S.D. 
 






























































































































2.4.6 Assessment of furanone pH under hydrogel forming conditions 
Changes in the pH of each furanone were assessed in order to identify any temperature 
threshold at which pH change, and so compound degradation, may occur. It was found 
that upon gradual heating from 20 °C to 70 °C the pH of a 1% borate solution 
decreased from 9.18 to 8.86. A similar change of 9.21 to 8.83 was seen in a 1% borate 
solution with MTHF indicating no effect of MTHF on the overall pH of the hydrogel 
system. The addition of both HDMF and ascorbic acid to the borate solution caused a 
reduction in pH to 8.61 and 8.58 respectively even before any heat was applied. During 
heating, the pH of the ascorbic acid and borate solution further decreased to 8.29 while 
the HDMF/borate solution reduced to a pH of 8.08. Finally, the addition of sotolon to 
the borate solution did not cause a significant initial reduction in pH but did result in 
a gradual decrease in pH to 8.45 over the course of the experiment (Figure 2.17). 

















Figure 2.17 – Changes in pH of solutions of borate and each furanone when 
subjected to increasing temperatures up to 70 °C.  
The pH of a borate only solution decreased slightly over the time course of the 
experiments. The addition of MTHF had no effect on this. The addition of sotolon to 
the solution resulted in a reduction in pH up to a temperature of 30°C then remaining 
stable. Both the addition of HDMF and ascorbic acid to the borate solution caused an 
initial decrease in a reduction in solution pH that was then exacerbated upon heating. 




Similar furanone and borate solutions were then subjected to prolonged heating at 90 
°C for 3 h to mimic the conditions used in hydrogel formation. As before the addition 
of MTHF and sotolon to the borate solution caused no initial decrease in pH. However, 
upon heating both the MTHF/borate and sotolon borate solutions decreased in pH (to 
8.73 and 8.53 respectively) over the first 30 min and then remained stable for the 
remainder of the experiment. Both HDMF and ascorbic acid caused an initial drop in 
pH to 8.71 and 8.52 respectively. Both solutions then showed gradual decreased in pH 
up to 90 min of heating then remaining stable giving a final pH of 7.92 for HDMF and 
7.51 for ascorbic acid (Figure 2.18). 

















Figure 2.18 – Changes in the pH of borate and furanone solutions during 
prolonged heating at 90°C.  
The presence of MTHF did not cause a significant decrease in the pH of the system 
over the time course of the experiment. A significant reduction in pH was observed in 
samples containing sotolon, HDMF and ascorbic acid. All values represent the mean 
of three independent replicates ± S.D. 
 
Samples were also assessed for colour change before and after prolonged heating. It 
was found that HDMF, MTHF, ascorbic acid, and sotolon all showed a significant 
colour change from a colourless solution to a vibrant yellow (HDMF) and a straw 
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yellow (MTHF and ascorbic acid) and a very pale yellow (sotolon) when heated to 90 
°C for 3 h in the presence of 1% borate. Borate only solutions showed no obvious 
colour change (Figure 2.19).   
 
Figure 2.19 – A comparison of the colour of furanone solutions before (top) and  
after (bottom) heating to 90°C for 3 h in the presence of 1% w/v borate. 
Solutions are (a) borate only, (b) HDMF, (c) sotolon, (d) ascorbic acid, and (e) 







Semi-solid, PVA-borate, hydrogels are an ideal material for use as wound dressings. 
Due to their inherent viscoelastic and dilatant properties they can be placed in a wound 
and allowed to flow in order to fill the wound. This is important as flowing and filling 
of the wound environment ensures total contact of the gel with the wound bed (Murphy 
et al., 2012). Upon the application of a rapid force (as would be experienced during 
wound dressing removal) these materials act as a more solid-like material, thus, 
facilitating their easy removal from the wound in one piece. Further, their non-
adherent nature helps to minimise trauma and further damage to the epithelialising 
tissues found in healing wounds (McCarron et al., 2011).  
Not only do the viscoelastic properties of semi-solid PVA-borate hydrogels make 
them excellent candidates for basic wound dressings but the ability to load these 
formulations with high concentrations of hydrophilic drugs makes them potentially 
excellent dressing/drug delivery hybrid systems. Indeed, these hydrogels have 
previously been loaded with a range of compound for the improvement of wound 
healing or the treatment of wound infections (Donnelly et al., 2009; Abdelkader et al., 
2016, 2018). While these formulations are easily loaded with various active 
compounds it should be noted that incorporation of a drug into a PVA-borate hydrogel 
has the potential to interfere with and disrupt the viscoelastic properties of the material 
(Loughlin et al., 2008). 
In this chapter, which aimed to formulate and characterise PVA-borate hydrogels for 
use as a drug delivery system capable of delivering furanones to bacterial biofilms, the 
method for the production of PVA-borate hydrogels was optimised in terms of 
polymer hydrolysis degree and starting gel component form (liquid components or dry 
powder components). A range of PVA-borate hydrogels were then formulated, and 
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their shear moduli measured using oscillatory rheometry. Several candidate 
formulations with appropriate shear moduli were then selected and subjected to in 
depth rheological characterisation to fully explore their viscoelastic properties and 
adhesiveness. Finally, one ideal hydrogel formulation was selected and was loaded 
with four naturally occurring furanone compounds. The impact of compound loading 
on the hydrogels was then investigated.  
To begin, a range of hydrogel formulations with varying polymer and cross linker 
concentrations were produced using a liquid component method. The shear modulus 
of each formulation was then tested. Considering previous work, it was expected that 
hydrogels would generally become stiffer with increasing PVA concentration and 
increasing borate concentration due to increased formation of PVA-borate cross links 
(as shown in Figure 2.20) as previously reported by Murphy et al. (2012).  
 
Figure 2.20 – The process of cross linking between PVA and borate.  
The dissociation of boric acid in water yields the negatively charged borate anion. 
Borate ions then form a mono-diol complex with one PVA molecule. The borate then 
binds to the hydroxyl groups of an adjacent PVA molecule forming a link between the 




However, unlike the work of Murphy et al., the work detailed here did not show any 
linear relationship between either PVA concentration borate concentration and shear 
modulus in this work (Murphy et al., 2012). It was found that, while hydrogels with 
high concentrations of PVA (14% w/w) had the highest shear modulus, the shear 
modulus in hydrogels with PVA concentrations between 6% and 12% w/w showed no 
obvious correlation. Due to this unexpected finding it was decided that optimisation 
of the hydrogel production method should be undertaken to identify and mitigate any 
potential reasons for the variability. 
Changes in the starting component form between aqueous solutions of PVA and borate 
and dry powder PVA and borate were assessed. It was believed that the use of liquid 
components was causing variation in the concentrations of PVA added during 
production. The PVA stock solution used was a 30 % w/w solution and was solid at 
room temperature. This meant that melting of the stock prior to adding PVA to the 
formulation was required. This step may have introduced some variation due to 
incomplete melting of the PVA stock or improper mixing of the melted PVA stock 
before adding to the borate resulting in areas of high and low PVA concentration 
within the viscous stock solution. When dry powder components were used consistent 
concentrations of PVA during formulation were achieved and the variability in 
hydrogel properties was greatly reduced. In addition to this reduction in variability it 
was found that the overall stiffness of the gel (as indicated by a change in shear 
modulus) was significantly reduced from 8.5k Pa to 3.7k Pa. The increased shear 
modulus may be due to dehydration of the PVA stock over time. Loss of water from 
the PVA stock solution through evaporation during storage and rapid evaporation 
during exposure to 90 °C temperature required may have led to a gradual increase in 
the concentration of the stock solution. This would have meant that greater 
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concentrations of PVA were being added to the formulation than was expected. This 
idea is partially supported by the fact that increasing polymer concentrations in PVA 
borate hydrogels has been shown to result in a stiffer material. Murphy et al. (2012) 
showed that increasing PVA concentration (while maintaining borate concentration) 
resulted in increased hardness of a hydrogel sample. In this instance hardness was 
defined as the force necessary to produce a set deformation in the material. The 
measurement of hardness is largely comparable to shear modulus measurements used 
in this work which measure the force required to produce a deformation, in the form 
viscous flow, in the hydrogels. This indicates that the increased shear modulus 
between hydrogels produced using the liquid component method was likely due to an 
unintentional increase in PVA concentration.  
The impact of differing degrees of PVA hydrolysis was then assessed. It was shown 
that PVA with 87-89% hydrolysis and 98-99% hydrolysis produced very similar 
hydrogels with shear moduli of 3.6k Pa and 3.7k Pa respectively with low variation 
between gels. Fully hydrolysed PVA (hydrolysis degree of 100%) produced a 
hydrogel with a significantly higher shear modulus. Despite the increased shear 
modulus, the fully hydrolysed PVA produced gels with very low variability between 
samples (30-40 Pa variation across three replicates). Although the variability between 
gels was low, the 100% hydrolysed PVA was not used for further experimentation as 
the high shear modulus led to poor flow properties. The 98-99% hydrolysed PVA was 
selected for all further hydrogels as it produced a softer gel and the relatively high 
percentage hydrolysis would mean the hydrogels had lower bio adhesion and lower 
rates of component dissolution (Murphy et al., 2012).   
Once the method of hydrogel production had been optimised the same set of 
formulations prepared using the liquid component method were prepared using the 
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now optimised method. When these samples were analysed rheologically it was found 
that there was a close relationship between both the concentration of the PVA used in 
the formulation and the shear modulus, with shear modulus increasing with PVA 
concentration. Similarly, a positive correlation between the concentration of the borate 
cross linker and the shear modulus was also seen. This was in keeping with previously 
published works (Murphy et al., 2012; Abdelkader et al., 2016).  
Of the formulations tested, four were selected based on their shear modulus and their 
texture when handled. To be selected, hydrogels needed to have a shear modulus 
between 1.5 kPa and 5k Pa and were required to not be noticeably heterogeneous in 
texture and not excessively adhesive when handled. The four formulations chosen 
contained 6% PVA and 1%, 2% and 3% borate and also the formulation containing 
8% PVA and 1% borate. The chosen formulations were then subjected to full 
rheological characterisation. 
Prior to full characterisation the LVR of each formulation was identified using an 
amplitude sweep. It was found that as the LVR was increased with increased polymer 
concentration but not necessarily by cross linker concentration. The limit of the linear 
viscoelastic region for the 6% PVA gels were 6.3%, 7.9% and 7.9% (for 1%, 2%, and 
3% borate respectively). This is in direct contradiction to the findings of Wong et al. 
(2015) who reported that the linear viscoelastic region of UV crosslinked polyethylene 
oxide/pentaerythritol tetra-acrylate hydrogels was extended with increasing 
crosslinking (as measured by an increase in the critical strain value) (Wong, Ashton 
and Dodou, 2015). Similarly, the work of Shengmao and Gu (2015) found that gel 
stiffness increased with crosslinking density in collagen. While these reports 
contradict the data described here, the mechanisms of cross linking are, however, very 
different, making direct comparisons difficult.  When the PVA concentration in the 
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hydrogels was increased to 8% w/w, the upper limit of the LVR was increased to 
12.5%. As the LVR denotes the range of shear strains that a material can withstand 
without experiencing internal structure compromise (Koetting et al., 2015) this result 
suggests that the 8% w/w PVA hydrogel has greater integrity of the internal polymer 
network than hydrogel containing 6% PVA. A potential explanation for the increased 
internal structural integrity of the higher PVA concertation gels is noted by Zhang et 
al. (2019). This group suggested that increasing polymer concentration brings the 
polymer solution closer to the critical overlap concentration (COC). This COC is the 
concentration at which overlapping of polymer molecules begins to occur in dilute 
solutions (Skelland and Meng, 1996). Zhang et al. (2009) suggest that as this 
concentration is approached physical interactions between polymer strands also 
increases (Zhang, Wehrman and Schultz, 2019). If this is indeed the case, the increase 
of PVA concentration from 6% w/w to 8% w/w may cause an increase in physical 
interactions (e.g. polymer chain tangling) and this may give a higher degree of 
structural integrity, thus, increasing the upper limit of the LVR.  
Assessment of the total viscoelastic profile of each hydrogel revealed that all 
hydrogels displayed dilatant behaviour, in which the material displays solid-like 
properties when a high frequency force is applied and a liquid or viscous-like 
properties when at rest or when a low frequency force is applied. These measurements 
were validated by measuring phase angle shift in the samples during the tests. These 
results are consistent with previous reports that have shown PVA-borate hydrogels to 
display obvious dilatancy (Savins, 1968; Murphy et al., 2012). In addition to these 
measurements, the G′ G″ crossover point, also known as the shear modulus, was 
measured. This point (which denotes the force required to initiate liquid-like viscous 
flow) was found to increase with both borate concentration and PVA concentration 
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with 6% PVA hydrogels displaying a shear modulus of 2.27 kPa, 5.19 kPa, and 4.77 
kPa when 1%, 2% and 3% w/w borate was added, respectively. This is in keeping with 
the results of Abdelkader et al. (2016), who showed that an increase in borate 
concentration resulted in an increase in the shear modulus of their PVA-borate gels, 
as assessed using oscillating rheometry (Abdelkader et al., 2016). These authors also 
reported shear moduli in the range of 3.3 - 4.6 kPa for hydrogels consisting of 6% w/w 
PVA and containing between 1 % and 2.5% w/w borate. The observed shear modulus 
of an 8% PVA 1% borate hydrogel in the present experimental work was 6.515 kPa 
indicating a stiffer gel than the 6% PVA gels. This difference in shear moduli was also 
observed by Abdelkader et al. (2016).   
Both the shear dependent viscosity and the adhesiveness of each of the four hydrogel 
formulations was assessed. The viscosity measurements of all formulations revealed 
obvious dilatant behaviour with viscosity increasing relative to the shear frequency. 
These observations are in keeping with the seminal work of Inoue and Osaki (1993) 
who were the first to demonstrate the shear thickening behaviour of PVA-borate gels. 
They reported that, at 25 °C, no apparent change in viscosity of a 1% PVA gel 
(containing an unspecified amount of borate) was seen until approximately 110 Hz at 
which point the viscosity rapidly increased (Inoue and Osaki, 1993). The gels in the 
present work showed an increase in viscosity above frequencies of 50 Hz. This is likely 
due to the increased polymer concentration in the formulations used compared to those 
of Inoue and Osaki (1993).   
When formulation adhesiveness was assessed it was found that adhesiveness increased 
relative to both borate concentration and PVA concentration. Peak normal force, 
which was measured as the pulling force exerted on the rheometer geometry by the 
gel (giving rise a negative force values) increased from -6.6 N to -15.3 N to -19.5 N 
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for hydrogels containing 6% PVA and 1% 2% and 3% borate respectively. This 
finding is in direct contradiction to several other works who showed a borate 
dependent decrease in adhesiveness (Murphy et al., 2012; Abdelkader et al., 2016). 
However, it should be noted that both of these studies examined adhesiveness on 
porcine skin whereas this work examined adhesiveness using the stainless-steel 
surface of the rheometer geometry. The vast differences in the stainless-steel surface 
compared to a biotic surface such as skin is likely to have affected the adhesiveness 
test.  Following full rheological testing the 6% PVA 1% borate formulation was 
selected for all further tests due to its low shear modulus (allowing for easier flow into 
a wound bed) and its low adhesiveness (which would minimise trauma to the wound 
bed upon removal).  
Hydrogels were then loaded with 1% by weight of four furanone compounds (HDMF, 
MTHF, sotolon and ascorbic acid). Significant changes in both the texture and 
physical appearance of the hydrogels was observed. When loaded with HDMF the 
hydrogel failed to fully form a gel with the sample remaining very soft. This effect 
was also noted in hydrogels loaded with sotolon and ascorbic acid. It was hypothesised 
that the change in texture is due to a change in the overall pH of the system.  It is 
known that the formation of a PVA-borate hydrogel is highly dependent on pH. This 
is due to the limited dissociation of boric acid in more acidic environments 
(Kochkodan, Darwish and Hilal, 2015). If boric acid does not dissociate, no borate 
ions are formed and thus crosslinking of PVA cannot take place efficiently. This 
means that a softer gel will be formed, or no gelation will occur. With a pKa of 4.2, 
ascorbic acid is weakly acid and as such should be expected to interfere with the 
crosslinking process of PVA by borate. This was indeed the case in this work. 
However, with pKa values of 8.56 (measured) and 9.28 (predicted) for HDMF and 
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sotolon, respectively, these compounds are weakly basic (Chen and Sidisky, 2011; 
Yeast Metabolome Database, 2020). As such, these compounds should not interfere 
with the dissociation of boric acid. It was hypothesised that, when exposed to the high 
temperatures required for hydrogel formation, the furanone compounds degraded and 
that it was the degradation products which resulted in a decrease in the pH of the 
system. Indeed, it has been shown previously that HDMF undergoes thermal 
degradation (at 160 °C) to products such as 2,3-pentanedione and acetoxy acetone, 
among others (Shu, Mookherjee and Ho, 1985). Unfortunately, neither of these 
compounds have reported pKa values and consequently determining if their presence 
was the cause of gelation failure is not possible. As HDMF is heat labile, and 
considering similarities between the molecules, it is likely that sotolon experiences a 
degree of thermal degradation as well though there are no reports of this in the 
literature. The colour changes seen during the hydrogel forming process may also 
indicate a structural change in the furanone molecules as colour change is an indicator 
of compound degradation in many other instances, particularly in other 
phytochemicals such as betalains and xanthophylls (Chandran et al., 2014; Dini et al., 
2019).  
When MTHF was incorporated into the hydrogel formulation, no changes in hydrogel 
texture or colour were seen and it was, therefore, concluded that MTHF did not 
degrade under gel forming conditions. Considering this data, it was hypothesised that 
the degradation products being produced during hydrogel formation were decreasing 
the overall pH of the system. As stated previously, a more acidic environment would 
limit the dissociation of boric acid, leading to formation of fewer borate ions and, 
subsequently, less cross linking and poorer gelation.   
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Despite the observed changes in hydrogel texture and colour, the release of HDMF 
and MTHF from a PVA hydrogel were assessed. These furanones were tested as 
MTHF formed a suitable hydrogel and HDMF formed a very soft but still slightly 
workable hydrogel when incorporated into a 6% PVA 1% borate formulation. It was 
found that an HDMF-loaded hydrogel released a maximum of 45% of the total loaded 
compound over 24 h. The efficiency of drug delivery from PVA-borate hydrogels 
reported in the literature varies widely. Reports range from approximately 16 % total 
release for methylene blue to almost 80% for lidocaine hydrochloride (Loughlin et al., 
2008; Donnelly et al., 2009). This variation may be due to a number of factors 
including differences in the polymer and crosslinking concentrations (Censi et al., 
2009; Martinez et al., 2014) or differences in the loaded drugs themselves such as 
polarity, molecular mass or interaction with the hydrogel matrix (Li and Mooney, 
2016). The release profile of MTHF from the hydrogel formulation was also assessed. 
When total drug release was calculated it was noted that maximum release was nearly 
2000% of the total loaded drug. As this is not possible, and, following the elimination 
of any calculation and measurement errors as causes, it was hypothesised that while 
the there was no effect on hydrogel texture and no observed colour change, MTHF 
was also being degraded during the hydrogel production process.  
Due to the changes in hydrogel properties, obvious colour changes and unexpected 
drug release profiles, further investigations into the stability of furanone compounds 
during hydrogel production were planned. Aspects to be investigated included; 
elevated temperature, exposure to borate and general stability in aqueous 
environments.  
Degradation and loss of active compounds in pharmaceutical formulation is a 
significant problem for several reasons. Primarily, with a reduction in active 
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compound comes a reduction or total loss of efficacy of the formulation. Drug 
degradation in pharmaceutical formulation can occur for a number of reasons 
including interactions with one or more excipients, conditions required to make the 
formulation (e.g. heat or mixing), or simply time (Snape, Astles and Davies, 2010).  
The stability of each of the four furanone compounds, MTHF, HDMF, ascorbic acid 
and sotolon, under hydrogel-forming conditions was examined. The effect of elevated 
temperature, presence of water, presence of borate, and altered pH were individually 
assessed. The presence of borate and altered pH were then assessed in combination 
with elevated temperature to accurately represent the conditions present when forming 
a hydrogel.  
Due to the anomalous release profile of MTHF in which data suggested that maximum 
drug release was in excess of 1500% of the total loaded dose this compound was 
examined first. Exposure of MTHF to an aqueous environment at ambient temperature 
or at 90 °C for 6 h showed no obvious changes in UV absorbance or the λmax which 
remained at 285 nm. However, when the MTHF was exposed to both 90 °C and the 
presence of 1% borate a gradual increase in the absorbance of the sample was seen. 
This increase in absorbance was identified as the cause of the over estimation of 
released MTHF in section 2.4.4. When the full UV absorbance spectrum of MTHF 
over the course of the experiment was examined it was found that the absorbance 
spectrum was becoming flatter and absorbance at shorter wavelengths was increasing 
over time. This suggests that the degradation products produced by exposing MTHF 
to elevated temperature and borate were more broadly absorptive than the original 
compound. Finally, the experiment was repeated with one amendment. The MTHF 
was exposed to 90 °C in a buffer adjusted to a pH equivalent of that of a 1% borate 
solution and it was found that no changes in the absorbance of MTHF occurred. This 
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indicates that the reaction leading to degradation of the compound was due to the 
neither the presence of borate or altered pH alone but caused by a synergy between 
the borate and the elevated temperature. It is possible that the presence of borate at 
ambient temperature would have caused the same degradation if left for an extended 
period of time, but the addition of heat catalysed the reaction. Stability issues have 
been reported for several compounds similar to MTHF in the literature. For example, 
it has been shown that several furan-based compounds found in coffee (as MTHF is) 
undergo significant degradation after heat treatment. In 2003 Kumazawa and Masuda 
found that autoclaving at 121 °C for 10 min effectively reduced the concentration of 
2-furfurylthiol (a benzylic thiol consisting of furanone ring with an attached 
sufanylmethyl group). Furthermore, these authors showed that this reduction in 2-
furfurylthiol was exacerbated by increasing pH. Compounds in lower pH (pH 3-5) 
solutions degraded significantly less than those in less acidic solutions (pH 6-7). 
Interestingly, the converse was true for 3 other furanone compounds; furfural, furfuryl 
alcohol and difurfuryl disulphide which appeared to be more stable at higher pH 
(Kumazawa and Masuda, 2003). Similarly, the work of Charles-Bernard et al. (2005) 
showed that the degradation of 2-furfurylthiol was dependent upon two factors 
namely; electrophilic addition and the presence of radical species. This was concluded 
as the addition of a nucleophile and an inert atmosphere had a stabilising effect on the 
compound (Charles-Bernard et al., 2005). These data, when taken together, show that 
the degradation of these compounds, and likely other furanones, is a complex and 
multifaceted process with many contributing factors. This supports the hypothesis that 
the degradation of MTHF in hydrogels results from a synergistic process between 
borate and temperature.  
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The stability of HDMF was then investigated and it was found that HDMF was stable 
at room temperature in aqueous solution but rapidly degraded at 90 °C. This data 
strongly supports previous reports that HDMF (also known as DMHF in some reports) 
is unstable in a range of aqueous buffer solutions. For example, at pH values close to 
neutral the half-life of HDMF was only 10 days (Roscher, Schwab and Schreier, 
1997). Additionally the work of Shu et al. (1985) showed that, at pH 7.1, HDMF was 
extensively degraded at 160 °C into a wide range of degradation products including 
other furanones (Shu, Mookherjee and Ho, 1985). It is, therefore, unsurprising that the 
addition of excessive heat would accelerate the degradation of HDMF in this work. It 
was also discovered that although the levels of absorbance of HDMF remained stable 
when exposed to borate the λmax was changed, shifting from 285 nm to 335 nm. This 
shift occurred rapidly upon addition of HDMF to the borate solution with the change 
being observed in less than 10 s. When the full absorbance spectrum was investigated 
it was noted that a slight decrease in the overall level of absorbance occurred in 
addition to the λmax shift. In contrast to the changed spectrum of MTHF, when the 
absorbance spectrum of HDMF was altered, a clear, single, absorbance peak was still 
present. Although no reports of HDMF degradation in the presence of borate has been 
reported in the literature, it seems likely that, due to the maintenance of a single peak 
in the UV absorbance spectrum that the HDMF is not being degraded to a range of 
degradation products but, rather, to a single product. This hypothesis is further 
supported when the effect of altered pH on HDMF is considered. It was shown that 
exposure to a pH representative of that of a 1% borate solution at ambient temperature 
did not have a significant effect on HDMF stability and no change in λmax was 
observed. Further, at 90 °C and pH 9.31 the degradation of HDMF was similar to that 
in pure deionised water at elevated temperature. This led to the hypothesis that, while 
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the degradation of HDMF (as measured by a loss of absorptivity) was caused solely 
by exposure to elevated temperature, the change in λmax was mediated by the presence 
of borate and not simply by the change in pH the presence of borate would have 
caused.  
Degradation of ascorbic acid occurred under all conditions tested. Loss of 
approximately 50% of the loaded volume occurred over 90 min in aqueous solution at 
ambient temperature was observed. At 90 °C, total degradation was apparent in just 
10 min. In the presence of 1% borate, rapid degradation also occurred with total loss 
of drug being seen in 20 min and 5 min for ambient temperature and 90 °C 
respectively. However, similarly to HDMF, a shift in λmax was seen. The shift from 
250 nm to 265 nm occurred upon exposure to borate and, again, this shift was seen 
immediately after adding ascorbic acid to the borate solution. Further, when exposed 
to a solution of pH 9.31, the degradation rate of ascorbic acid remained similar to that 
seen when exposed to borate at both ambient and elevated temperature. At altered pH, 
the shift in λmax was again seen suggesting that this change was in fact due to the pH 
change caused by borate rather than by the presence of borate itself. Degradation of 
ascorbic acid in an aqueous environment is well reported in the literature. In 1998, 
Yuan and Chen showed that, in aqueous solution under heating, ascorbic acid degrades 
into four primary products dependent upon pH. At acidic pH ascorbic acid degraded 
preferentially to either furfural, 3-hydroxy-2-pyrone or 2-furoic acid whereas at a more 
alkaline pH ascorbic acid appeared to degrade to an unknown compound. The authors 
suggest several possible pathways for the degradation of ascorbic acid in aqueous 
solution each of which involves opening of the furan ring structure (Yuan and Chen, 
1998). However, degradation via these pathways to furfural, 3-hydroxy-2-pyrone 
likely does not explain the observed degradation of the ascorbic acid in this work. In 
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their study Yuan and Chen also show that the three degradation products have very 
distinct absorbance profiles with furfural, 2-furoic acid, 3-hydroxy-2-pyrone having 
λmax values of 277 nm, 252.3 nm and 294.8 nm respectively. If the ascorbic acid in this 
work had degraded to any of these products, they would have been clearly visible 
during UV absorbance readings. Similarly, the unknown compound showed a λmax of 
287.7 nm and so it is unlikely that the ascorbic acid had degraded to that product either. 
It remains unclear exactly how the ascorbic acid used in the work described here was 
degrading in pure aqueous solution. However, the change in λmax observed with 
ascorbic acid in the presence of borate or altered pH may be easily explained. In 1970, 
Ogata and Kosugi showed that the negatively charged ascorbate monoion has a λmax 
of 265.5 nm (Ogata and Kosugi, 1970). This is in keeping with our observations of 
maximal absorbance at 265 nm in borate and high pH exposed samples. When these 
studies are considered it can be suggested that in pure aqueous solution ascorbic acid 
is degrading via an unknown pathway to products which do not readily absorb light in 
the UV-visible range. Furthermore, the observed shift in λmax when ascorbic acid is 
exposed to conditions similar to those found in a forming hydrogel (namely high pH 
and 1% borate) are likely due to dissociation of the compound to form the ascorbate 
monoion.   
The stability of sotolon was also assessed. Sotolon was found to be stable in aqueous 
solution at both ambient temperature and 90 °C. However, as with ascorbic acid a 
change in λmax occurred upon addition of sotolon to a 1% borate solution. This was a 
change from 230 nm to 265 nm and, while the altered form of sotolon was stable at 
ambient temperature, it steadily degraded at 90 °C. When exposed to pH 9.31 the same 
change in λmax occurred. Interestingly, while the altered form of sotolon produced by 
exposure to borate was stable at ambient temperature, the altered form obtained by 
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exposure to pH 9.31 in the absence of borate was not. This may suggest that, although 
the change in λmax was identical between the borate and the altered pH exposed 
samples, the final product was not the same. The altered λmax was the same as that of 
the presumed ascorbate ion discussed above. This similarity may be due to the inherent 
structural similarities between ascorbic acid and sotolon. Indeed, there have been 
several chemical pathways suggested in which several isotopomers of sotolon can be 
synthesised using ascorbic acid as a precursor (Konig et al., 1999; Pons et al., 2010). 
It may be that the structures of the ascorbate monoion responsible for the absorbance 
peak at 265 nm is also present in the altered form of sotolon. This possibility is 
represented in Figure 2.21 where it can be seen that both sotolon ascorbic acid and 
sotolon share a central structure consisting of a heterocyclic furan ring with an oxygen 
side group at position two on the ring and a double bond between position three and 
four in the ring.  
 
Figure 2.21 – A comparison of the structures of a) sotolon and b) the ascorbate 
mono ion.  
These two compounds share a structural similarity in the furan ring and oxygen at 
position C1. It is likely that this structure or a portion of this structure is the cause of 
the observed UV absorbance at 265nm in both samples.  
 
It is hypothesised that the presence of borate causes a change in the structure of sotolon 
resulting in a product that is stable in aqueous solution at ambient temperature but heat 
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labile. Further, this work suggests that exposure to pH 9.31 causes a different change 
in the structure of sotolon to yield a product which is unstable in aqueous solution 
independent of temperature.  
Finally, the effect of furanone degradation on hydrogel system pH was examined. To 
assess the effect of hydrogel forming conditions on the pH, solutions of furanone and 
borate were subjected to two methods of heating. Firstly, the solution was heated 
slowly to identify a temperature at which a reduction in pH occurred. Secondly, 
solutions were incubated under hydrogel forming conditions (90 °C for 3 h). It was 
shown that when gradually heated to 70 °C there was no single temperature at which 
decreases in pH occurred. Instead the decrease was gradual. When heated at 90 °C for 
3 h the change in pH was more pronounced and all furanones showed an initial 
decrease in pH and a lower final pH when compared to the borate only solution. It 
should be noted that the decrease brought about by the addition of MTHF was 
considerably less than the other furanones. This is also noteworthy as when loaded 
hydrogels were prepared the samples loaded with MTHF were able to gel 
appropriately while all other did not. This data strongly supports the hypothesis that 
furanone degradation caused a decrease in the pH of the hydrogel system, causing a 
reduction in boric acid dissociation, limiting the crosslinking in the gel. 
While the mechanism of degradation for the compounds in this work is unknown it is 
likely very similar due to the similar structure that the furanones share. A potential 
mechanism of degradation may be found in the work of Bombarelli et al 2013, who 
showed that, in neutral and alkaline solutions (as 1% borate is) lactone compounds 
such as furanones degrade through the hydrolysis and opening of the lactone ring 
structure (Gómez-Bombarelli, Calle and Casado, 2013). This would mean that each of 
the furanone compounds use din this work may be degrading in this manner, yielding 
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a range of linear molecules such as succinic acid (Hashem and Senning, 1999). While 
this mechanism of degradation is supported by the literature there may be one or more 
other mechanisms occurring simultaneously in this work. However, further 
investigation into these mechanisms is beyond the scope of this project.    
Due to the obvious impact the process of forming a loaded hydrogel has on the 
furanone compounds an alternative method of loading furanones into hydrogels is 
needed. If this is not possible a new drug delivery system for the application of 





















An optimal method for the repeatable production of PVA borate hydrogels was 
developed. It was found that repeatable hydrogels could be produced using dry powder 
components instead of liquid stock solutions as starting materials and that using 100% 
hydrolysed PVA yielded the least variation in gel stiffness but that over all stiffness 
was significantly higher. Therefore, as 98-99% hydrolysed PVA yielded softer gels 
yet still exhibited relatively low variation in stiffness, this polymer was selected for 
production of hydrogels. The hydrogels formed using the optimised method were 
assessed rheologically and several candidate formulations selected. Following full 
rheological characterisation, a hydrogel formulation containing 6% w/w PVA and 1% 
w/w borate was selected as the optimal formulation for the delivery of furanones to 
wounds due to its low shear modulus and low adhesiveness. This formulation was 
loaded with four furanone compounds, all of which resulted in significant changes in 
hydrogel textural properties, with some furanones (sotolon and ascorbic acid) causing 
complete failure of gelation and causing samples to remain entirely liquid. 
Additionally, one furanone (HDMF) significantly reduced gel stiffness giving a very 
soft and sticky gel. Significant colour changes were also noted in three furanones 
(HDMF sotolon and ascorbic acid). Investigation of the release profiles of HDMF and 
MTHF from the hydrogels revealed a total release percentage of approximately 2000% 
of the total loaded drug for MTHF, whereupon it was concluded that the changes in 
hydrogel texture, colour and anomalous release profiles were due to furanone 
degradation under hydrogel forming conditions. Upon investigation it was found that 
the conditions present during the formation of a hydrogel including elevated 
temperature, presence of borate and elevated pH exerted a significant effect on the 
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stability of each of the 4 furanones tested.  It was therefore decided that either an 
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The stability of active ingredients used in pharmaceutical formulations is of the utmost 
importance. Degradation of the active ingredients in a formulation can not only affect 
the efficacy of a product, but can also impact upon formulation safety and physical 
properties (Blessy et al., 2014). Avoiding these unwanted effects is the primary reason 
stability studies must be carried out when formulating a new drug product. The 
production of PVA-borate hydrogels, while simple, has many aspects which may have 
led to the degradation of the four furanone compounds which are the focus of this 
work. As such, an alternative method of preparing furanone-loaded hydrogels is 
required. However, prior to developing a novel method for loading furanones into 
hydrogels while avoiding degradation, the possible sources of degradation must be 
understood. 
3.1.1 Drug degradation in PVA-borate hydrogels  
When considering the production and use of PVA-borate hydrogels as a drug delivery 
mechanism there are three possible causes of compound degradation; thermal 
degradation, pH and borate mediated degradation, and hydrolytic degradation. 
Thermal degradation may be caused by the requirement for temperatures of 90 °C 
when forming the hydrogel. This stage is likely unavoidable as, without the elevated 
temperature, PVA would not dissolve to form the sol phase.  
The requirement for borate as a crosslinking agent results in the system having an 
alkaline pH. Due to its relatively high pKa value (9.2) boric acid does not readily 
dissociate in an acidic environment. This means that, under acidic conditions, the 
borate anion required for mono- and di-diol formation (see figure 2.20 in chapter 2) is 
159 
 
not present (Kochkodan, Darwish and Hilal, 2015). Therefore, attempts to reduce the 
pH of the hydrogel system will result in incomplete gel formation. 
Finally, hydrolytic degradation may occur due to the aqueous environment required 
for the successful formation of a hydrogel. Indeed, regarding drug stability, hydrogels 
and other semi-solid formulations with a high percentage water content are often 
considered in the same way as single-phase liquids (Loftsson, 2014). However, 
hydrolysis in this aqueous environment may also be encouraged by the elevated 
temperature, and the increased pH in the system. These potential mechanisms of 
degradation will be discussed in the context of furanones.  
3.1.2 Degradation of furanones 
Furanones are most commonly associated with various terrestrial and marine plants. 
It has been previously noted, in fields such as nutraceutical manufacture, that the 
formulation factors affecting the stability and degradation of botanical compounds 
remain largely unknown (Hoag, 2001). As such, the incorporation of phytochemicals 
such as furanones into pharmaceutical products is likely to be highly complex. As 
stated previously, during the formation of PVA-borate hydrogels the furanone 
compounds would experience a range of harsh conditions, including elevated 
temperatures, elevated pH and a potentially hydrolytic environment. The stability of 
furanones under each of these conditions is considered.  Unfortunately, due to the 
limited use of furanones in pharmaceutical products, reports of the stability of these 
compounds in this context are extremely limited.  
3.1.2.1 Thermal stability of furanones 
Furanones have previously been shown to be heat labile. Shu et al. (1985) showed that 
when subjected to high temperatures (160 °C) for 30 minutes in aqueous solution, the 
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furanone HDMF (also known as DMHF) is readily degraded to produce a wide range 
of products such as 2,3-entanedione and acetoxy acetone. The authors suggest that the 
degradation process begins with the opening of the furan ring followed by further 
degradation of the resultant linear molecule (Shu, Mookherjee and Ho, 1985). 
Interestingly, in this study, Shue et al. found the extent of thermal degradation and the 
products formed was found to be largely dependent on pH.   
3.1.2.2 pH mediated degradation of furanones 
Shu et al. (1985) showed that the thermal degradation of HDMF was significantly 
influenced by the environmental pH. The furanone displayed higher rates of 
degradation (i.e. greater mass of degradation products was detected) at lower pH but 
furanone degradation resulting in a wider range of degradation products was noted at 
a higher pH. These high pH degradation products included 3 separate furanone 
derivatives; 2,4,5-trimethyl-furanone, 2-ethyl-5-methyl-furanone, and 2,4-dimethyl-
5-ethyl-3(2H)-furanone.  This is not the only report of pH mediated structural changes 
in furanone compounds. A study by Raab et al. in 2003 showed that HDMF underwent 
rapid change from a mono-enantiomeric sample to a racemic mixture as pH increased. 
Conversely, HDMF was found to undergo minimal racemisation at a pH of between 
3.8 and 5 (Raab et al, 2003). This indicates that in aqueous solution pH can have a 
profound effect on the structure of this furanone. Finally, the work of Roscher et al. 
(1997) demonstrated that HDMF was unstable in an aqueous environment over a range 
of pH (2.0-8.0). The authors showed that, at the upper and lower pH values tested, the 
half-life of HDMF was 4 days and 7 days, respectively. It was found that the optimal 
pH to maintain HDMF stability was 3.5, with a reported half-life of 141 days (Roscher, 
Schwab and Schreier, 1997). Again, this work clearly demonstrates the effects of pH, 
particularly in the alkaline range, can have a significant effect on furanone stability.  
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Similarly, the stability of ascorbic acid has been shown to be closely related to the pH 
of the solution. Bandelin et al. (1955) showed that at concentrations of 1 mg mL-1 or 
5 mg mL-1 in aqueous solution ascorbic acid was degraded by 100% and 94% 
respectively over 24 hours at pH 6. This degradation was significantly reduced as the 
pH of the solution was reduced (Bandelin and Tuschhoff, 1955). The authors also note 
that ascorbic acid is merely oxidised at a pH of less than 7.2 but truly decomposed at 
a pH of 7.2 and above. This is significant as the pH of PVA-borate hydrogels, while 
variable depending on the ratio of PVA and borate, is universally above pH 7.2.  
These data on the pH dependent degradation of ascorbic acid supports the idea that it 
is not just the stability of HDMF that is affected by varying pH but a wider range of 
furanones.  
In order to ameliorate any potential furanone degradation due to increased temperature 
and raised pH in the hydrogel production process, a cold loading method that did not 
expose furanones to heat or free borate was trialled. This method aimed to eliminate 
the two main factors causing degradation in the hydrogels which are elevated 
temperature, and the presence of free borate ions. The development and use of a novel, 
minimally crosslinked, polymer aerogel, in place of hydrogels, was also investigated 
as a potential solution furanone degradation.  
3.1.3 Polymer aerogels 
There has been much debate in recent years surrounding the definition of an aerogel. 
Often these definitions are based on the properties of the produced material, and the 
effect of the drying process on the polymer network (Vareda, Lamy-Mendes and 
Durães, 2018). Depending on the drying process used and the degree of shrinkage in 
the polymer network during drying, similar materials may also be classed as a cryogel 
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or a xerogel (Maleki, Durães and Portugal, 2014).  However, for the purposes of this 
work the original definition of an aerogel will be used. Kistler defined a aerogels as “a 
gel in which the liquid phase has been replaced with a gas phase” (Kistler, 1931; 
Vareda, Lamy-Mendes and Durães, 2018). 
Aerogels often have a low density, high levels of internal structure, and high porosity 
(García-González et al, 2019).  Due to these properties, aerogels have been primarily 
used in fields such as engineering and aerospace but their use in the biomedical 
sciences is gaining popularity.  
 3.1.3.1 Aerogel production 
Aerogels can be produced using a number of different methods including supercritical 
drying, ambient temperature and pressure drying, and lyophilisation. While these 
methods vary significantly, the main mechanism of replacing a gel’s liquid phase with 
a gas phase remains constant (Figure 3.1).  
 
Figure 3.1 – A schematic of the general mechanism of aerogel formation.  
A polymer network swollen with a liquid phase (gel) undergoes a process in which the 
liquid phase is removed either by simple evaporation, freezing and subsequent 
sublimation, or replacement with a supercritical fluid such as super critical CO2. This 
liquid phase is then replaced with a gas, resulting in a three dimensional, highly 
porous, polymer network with very low density and very high surface area.   
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The main method for aerogel production reported in the literature is supercritical CO2 
drying, and this method is used primarily to make silica aerogels. The process involves 
preparing a tetramethyl orthosilicate (TMOS) gel followed by several solvent 
exchange steps. The TMOS gel, swollen with an organic solvent such as methanol, is 
then subjected to solvent exchange with supercritical CO2. The supercritical CO2 is 
then evaporated off as CO2 gas (García-González et al, 2012). This method, while 
effective, is time consuming and expensive due to the solvent exchange steps, the cost 
of TMOS, and the equipment required to produce and maintain supercritical CO2. In 
addition to these limitations, because of the requirement for incredibly high pressures, 
the process is not without risk. To address these limitations other materials and other 
methods of drying aerogels have been used. 
Ambient temperature and pressure drying has been used to good effect to produce 
aerogels from a range of materials including graphene, carbon spheres, and silica 
(Bhagat et al., 2007; Kanamori et al., 2007; Shao et al., 2010; Dubey et al., 2014). 
These methods have exploited the volatility of the solvents used to form the gel. 
Primarily, organic solvents such as methanol, methylnonafluorobutylether and hexane 
are used. The use of ambient pressure and temperature drying addresses the safety 
issues with supercritical drying but remains a lengthy process due to the numerous 
solvent exchange steps, and the time required to properly air dry the gel. It should be 
noted that in the literature an aerogel produced under ambient temperature and 
pressure may often be referred to a xerogel.  
Finally, the process of lyophilisation can also be used. A freeze drying process has 
been previously used to produce a range of aerogel types including silica aerogels, 
polymer composite aerogels, and graphene aerogels (Pei, Zhai and Zheng, 2014, 2015; 
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Li et al, 2016). This process is advantageous over the previous methods as the 
lyophilisation process is often more rapid than ambient drying. While freeze-dry 
prepared gels often still require a solvent exchange step in their production these steps 
appear to be shorter than their air-dried counterparts.  
With the numerous methods of production and the multiple variations in properties 
aerogels have been suggested as potential materials for a diverse range of applications 
such as domestic insulation, electrodes in next generation electronics, and as particle 
collectors for use in space missions (Jones, 2006; Luo et al., 2020; Yuan et al., 2020). 
However, one application which is gaining popularity is the use of aerogels as drug 
delivery systems. 
3.1.3.2 Polymer aerogels in drug delivery 
Aerogels have been used to good effect in the delivery of several classes of drug. For 
example, Lovskoya and Menshutina (2020) showed that alginate aerogel particles 
loaded by drug adsorption, were effectively able to hold and release two non-steroidal 
anti-inflammatory drugs and a common antihistamine, namely ketoprofen, 
nimesulide, and loratadine respectively. The authors reported release of 100% of all 
three active compounds within 50 minutes when tested in vitro, with aerogels 
displaying a rapid burst release of each drug (T1/2 of 1.2, 25, and 0.5 minutes, 
respectively) (Lovskaya and Menshutina, 2020). Similarly, the work of Li et al. (2019) 
demonstrated the use of a halloysite nanoclay aerogel for the dual controlled release 
of ibuprofen and dexamethasone. They showed total release percentages of 
approximately 70% and 80%, respectively, at a gastric pH (1.2), and 80% and 90% at 
pH7.4. Furthermore, the authors showed that these aerogel particles did not 
significantly inhibit the proliferation of murine intestinal epithelia (Li et al., 2019) 
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suggesting a level of biocompatibility. This study clearly displays the potential utility 
of aerogels as drug delivery systems. In addition to these particular studies, success in 
drug delivery has been shown with silica aerogels, starch aerogels and alginate 
aerogels among others (García-González et al., 2015; Gonçalves et al., 2016; 
Follmann et al., 2018).     
3.1.3.3 Antimicrobial aerogels 
With their proven ability to deliver a range of drugs in a controlled manner, the use of 
aerogels to deliver antimicrobials is an area of research that is gaining popularity. For 
example, in 2019 Afrashi et al. showed that a novel, fluconazole-loaded, multilayer 
composite aerogel could effectively release the drug with a total release of 
approximately 80% over 300 minutes. Further, the loaded aerogel was shown to 
effectively inhibit the growth of Candida albicans as demonstrated by a standard agar 
diffusion assay (Afrashi et al, 2019). Similarly, chitosan aerogel particles were shown 
to effectively release the glycopeptide antibiotic vancomycin (López-Iglesias et al., 
2019). These particles released bactericidal quantities of the drug and, indeed, 
treatment with vancomycin-loaded particles showed a 1.5-log decrease in viable S. 
aureus bacteria after 6 hours, a 4-log reduction in viable cells at 24 hours post-
treatment, and total bacterial killing after 48 hours in a suspension test. The authors 
also demonstrate that the vancomycin-loaded aerogel particles showed good 
biocompatibility with a fibroblast cell line that exhibited >80 % total cell viability after 
treatment (López-Iglesias et al., 2019). Finally, in 2019 Ma et al. reported an 
antimicrobial effect with a PVA-alginate composite aerogel loaded with the 
nanomaterial graphene oxide, and the fluoroquinolone antibiotic norfloxacin. The 
authors showed an increase in the zone of inhibition against both E. coli and S. aureus  
in a standard agar diffusion assay(Ma et al., 2019). However, the results showed a 
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maximum increase in zone diameter of 0.5 mm. A more conclusive result could have 
been obtained if the authors had used a suspension test and quantified loss of viable 
CFU mL-1.    
It is noteworthy that aerogels, loaded with traditional antimicrobials and antimicrobial 
materials, are not the only form of antimicrobial aerogel that have been tested. For 
example, the work of Jing et al. (2018) demonstrated the efficacy of a novel aerogel 
material made entirely of titanium dioxide and silver. This material was able to kill up 
to 100% of E. coli growing on agar plates and 99.86% of S. aureus in the same assay. 
This killing was found to be directly correlated with the concentration of silver in the 
material, with higher concentrations of silver showing a greater percentage killing 
(Jing et al., 2018).   
3.1.3.4 Aerogels as wound dressings 
Several studies have suggested aerogels as potential candidates for use in wound 
dressings. As well as their documented ability to deliver antimicrobials and analgesic 
drugs, aerogels have been used in a range of other capacities for the improvement of 
wound healing. In 2016 Vincent-Edwards et al. showed that a cellulosic composite 
aerogel material, functionalised with a fluorescent peptide, could effectively detect as 
little as 0.13 units mL-1 of human neutrophil elastase (Vincent Edwards et al., 2016). 
This enzyme, which is usually present in chronic wounds at concentrations of 20-30 
units mL-1 (Ferreira et al., 2017), is important in the wound healing process as it aids 
in the destruction of bacteria in the wound bed. However, it also destroys host tissue 
which may lead to the inhibition of epithelialisation and, thus, lead to the deterioration 
of the wound (Briggaman et al., 1984). Therefore, detection of very low levels of this 
enzyme could facilitate early treatment for chronic wounds. Alternatively, 
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Govindarajan et al. (2017) showed that a hybrid aerogel material consisting of 
collagen and wheat grass showed the ability to promote angiogenesis in an embryonic 
chicken model versus an untreated control. Although limited improvement over a 
control was seen in in vivo wound healing experiments, the authors suggest that this 
material may make for an excellent wound therapeutic which can mimic the natural 
extracellular matrix (Govindarajan et al., 2017). While this study showed only a small 
effect of aerogel treatment on in vivo models, a more recent study by Concha et al. 
showed a significantly more rapid wound closure with chitosan/chondroitin sulphate 
aerogel treatments up to 8 days post wounding in rabbits (Concha et al., 2018). Finally, 
the previously discussed work of Ma et al. showed that treatment of dorsal wounds in 
mice with their PVA-alginate-graphene oxide aerogel material resulted in a 15% 
increase in wound closure versus treatment with gauze only, after 14 days. Wound 
closure was further improved after treatment with PVA/alginate/graphene oxide 
aerogels loaded with norfloxacin. A wound closure of 90% after 14 days was seen 
compared to gauze only, which yielded only 65% closure (Ma et al., 2019). 
When considered together these studies clearly demonstrate the potential of aerogels 
as wound dressings. These materials have been demonstrated as effective drug 
delivery systems as well as potential biocompatible wound healing scaffolds and 
biosensors for the diagnosis of wound inflammation. As such, this chapter aims to 







3.2 Aims and Objectives 
The work described here aims, firstly, to develop a cold loading method for producing 
furanone-loaded hydrogels, while eliminating the exposure of furanones to high 
temperatures and free borate ions. Second, this chapter will develop and characterise 
a novel, minimally crosslinked PVA aerogels for the delivery of furanones to chronic 
wound biofilms. Finally, furanone release from the developed delivery mechanisms 






















3.3 Materials and Methods  
3.3.1 Materials and equipment 
Poly(vinyl alcohol), molecular weight  31,000-50,000, 98-99% hydrolysed, sodium 
tetraborate decahydrate, 4-hydroxy-2,5-dimethyl-3(2H)-furanone ≥98%, FG 
(HDMF), 2-methyltetrahydrofuran-3-one ≥ 97% FG (MTHF), L-ascorbic acid 99% 
and 4,5-Dimethyl-3-hydroxy-2,5-dihydrofuran-2-one ≥97% FG (Sotolon) were 
purchased from Sigma Aldrich (Gillingham, Dorset, UK) and used without further 
modification. 
A Labconco FreeZone 4.5 bench top freeze dryer was used to perform drying of all 
samples (Labconco, Kansas, USA) 
A Malvern Mastersizer 2000 was used with a Scirocco dry sampler for the 
determination of powder particle sizes (Malvern, UK).  
3.3.2 Formulation and characterisation of a freeze-dried hydrogel 
To overcome the compound degradation issues a new method of loading the hydrogels 
was required. A cold loading method involving the rehydration of a freeze-dried 
unloaded hydrogel in a furanone solution was developed. 
3.3.2.1 Determination of optimal freeze-drying time 
A PVA-borate hydrogel containing 8% PVA and 2% borate was prepared using the 
method developed in section 2.3.2.2, chapter 2. This gel was then divided in to either 
5 g or 10 g samples. These samples were then placed in a 6 well uncoated, tissue 
culture plate and then stored at -30 °C for 6 hours to ensure the samples were 
completely frozen. The 6 well plate was then transferred to a freeze drier and hydrogel 
samples were lyophilised, uncovered for 36 hours at -80 °C and 0.04 mBar pressure. 
The samples were periodically removed from the freeze drier to be weighed so that 
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water loss could be assessed.  Percentage water loss was calculated using the following 
equation 1. Where Twc is the total water content of the sample (g) and Wl is the weight 




) 𝑥 100    Equation 1. 
3.3.2.2 Preparation and characterisation of a rehydratable freeze-dried hydrogel 
powder 
A standard PVA-borate hydrogel containing 8% PVA and 2% sodium tetraborate was 
prepared using the method developed in section 2.3.2.2. An 8% PVA and 2% borate 
hydrogels were used so that comparisons could be made to earlier experiments. The 
gel was divided into 5 g samples which were then lyophilised as outlined in section 
3.3.2.1. Once the hydrogel was completely dry the samples were weighed, and the 
exact volume of water lost was calculated. The samples were crushed to a coarse 
powder using a pestle and mortar, and then further processed using a standard 
domestic spice grinder (Kenwood, UK) to give a fine, free-flowing powder. This 
powder was then assessed for average particle size and particle size distribution using 
a Malvern Mastersizer. Briefly, 5 g of powdered freeze-dried material was loaded into 
the Scirocco 2000 dry sampler and samples were assessed for particle size with a run 
time of 10.5 s. The powder was then passed through a fine fabric mesh to separate the 
fine particulate that would rehydrate more quickly and evenly. Both the pass-through 
and the size excluded material were sized using the above described protocol. 
3.3.2.3 Comparison of freeze-dried hydrogels to standard hydrogels 
To ensure the freeze drying and rehydration process did not negatively affect the 
properties of the hydrogels, the similarity of a standard PVA-borate hydrogel to a 
freeze dried and fully rehydrated hydrogel was assessed rheologically.  
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A standard PVA-borate hydrogel containing 8% PVA and 2% sodium tetraborate was 
prepared using the method developed in section 2.3.2.2. The shear modulus of this gel 
was measured as per section 2.3.2.4. The gel was divided into 5 g samples which were 
then lyophilised as outlined in section 3.3.2.1. Once the hydrogel was completely dry, 
they were weighed, and the exact volume of water lost was calculated. The samples 
were powdered as per section 3.3.2.2. 
To rehydrate the hydrogel, the powdered gel was placed in a beaker and deionised 
water was added at a volume equivalent to the volume of water lost in lyophilisation. 
The sample was stirred and mixed thoroughly and then incubated at room temperature 
for 24 hours to allow for complete rehydration. The rehydrated gel was then assessed 
for any changes in the shear modulus and a full rheological characterisation was 
performed as per section 2.3.2.4. 
3.3.2.4 Further characterisation of freeze-dried hydrogel 
The tunability of the shear modulus of a freeze-dried hydrogel was investigated. To 
assess this, samples of dried and powdered hydrogel were rehydrated with 100%, 
110%, 120%, 130%, 140% and 150% of the total water lost during lyophilisation.  
Briefly 0.2 g of powdered hydrogel was weighed out and deionised water was added 
in an appropriate volume (Table 3.1). This was then mixed and incubated at room 
temperature for 24 hours to allow complete rehydration to occur. Rehydrated samples 





Table 3.1 – Target percentage rehydration and the volumes of water required to 
rehydrate 0.2 g of freeze-dried hydrogel powder.  









3.3.2.5 Preparation of a furanone-loaded freeze dried hydrogel  
To load a hydrogel without causing compound degradation, the following cold loading 
method was developed.  
A hydrogel of the previously identified ideal formulation (6% PVA and 1% borate) 
was prepared using the method outlined described in section 2.3.2.2. The hydrogel 
was then frozen and processed to give a fine free flowing powder as detailed in section 
3.3.2.2.  
All drug-loaded hydrogels were made up to give a final gel weight of 10 g. First, 0.8 
g of powered hydrogel was weighed out into a glass scintillation vial. A furanone 
solution of a suitable concentration was made so that the fully rehydrated gel would 
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contain 1% furanone by weight. The concentration of furanone solution required was 
calculated using the following equation.  
𝐶𝑅𝐻 𝑥 𝑊𝑅𝐻
𝐻
     Equation 2 
Where CRH is the desired concentration of furanone in the final rehydrated gel (mg g
-
1), WRH is the final weight of the fully rehydrated gel (g) and H is the weight of water 
to be added to fully rehydrate the gel (g). Once an appropriate furanone stock solution 
was prepared 9.2 g of furanone stock solution was added to the 0.8 g of hydrogel 
powder. This was then thoroughly mixed and incubated at room temperature for 24 
hours to allow complete rehydration to occur.  
3.3.3 Formulation of an aerogel drug delivery system 
In order to overcome the poor rehydration time, poor gelation and apparent 
degradation of the furanones that was observed in the freeze-dried and rehydrated 
hydrogel, a minimally crosslinked PVA aerogel delivery system was developed. 
3.3.3.1 Preparation of PVA aerogels 
PVA aerogels were prepared using PVA solutions of varying concentrations and a 
simple lyophilisation method. A 10% PVA solution was prepared using Mw 31,000-
50,000, 98-99% hydrolysed PVA (Sigma Aldrich, Gillingham, UK). The solution was 
placed in a water bath preheated to 90 °C for 2 hours with intermittent stirring to 
completely dissolve the PVA. The PVA solution was then removed from the water 
bath and allowed to cool to room temperature. Once cooled, 2 g of PVA solution was 
pipetted into each well of a 12 well tissue culture plate. The tissue culture plate was 
then placed in a -30 °C freezer for 6 hours to ensure all samples were frozen. The 
frozen samples were then removed from the freezer and placed, uncovered in a freeze 
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dryer at 0.04 mBar of pressure and a temperature of -80 °C for 24 hours. Once dry, 
samples were removed from the 12 well plate and stored in an airtight container. This 
process was then repeated for PVA solutions containing 7.5%, 5% and 1% PVA. 
3.3.4 Structural characterisation of PVA aerogels 
The structure of the developed aerogels was assessed using three techniques. Firstly, 
stereo zoom microscopy was used to assess the macro scale internal structure of the 
aerogels. Secondly, scanning electron microscopy was used in order to assess both the 
surface morphology and internal structure of the aerogels. Finally, X-ray micro 
computerised tomography was used to assess the internal structure and homogeneity 
of the aerogels. 
3.3.4.1 Stereo zoom microscopy of aerogels 
The general morphology of the developed aerogels was images using stereo zoom 
microscopy. Samples were prepared as per section 3.3.2.1. Once the aerogels were 
dry, they were divided in two so that the outer surface and the inner aerogel structure 
could be viewed simultaneously. Aerogels were then visualised at a magnification of 
10x using a Nikon SMZ1500 stereo zoom microscope. Images were captured using 
the native Nis-Elements software (version 3.2).  
3.3.4.2 Scanning electron microscopy of aerogel surface and internal structure 
The structure of the aerogels was assessed using scanning electron microscopy. To 
prepare aerogels for SEM analysis samples were prepped as per section 3.3.2.1. Once 
aerogels were dry, they were removed from the 12 well plate and divided into quarters. 
This division of the samples allowed for SEM analysis of both the surface morphology 
and the internal structure simultaneously. Samples were then affixed to a metal SEM 
stub using adhesive carbon pads and sputter coated in a gold / palladium alloy to ensure 
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the aerogels had a conductive surface. Samples were then imaged with a beam 
acceleration of 30 kV using a Quanta 200 Environmental SEM system. 
3.3.4.3 X-ray micro computerised tomography of aerogel internal structure  
In order to assess and characterise the internal microstructure of the developed 
aerogels it was decided that micro X-ray computerised tomography (micro CT) would 
be used. For this project the micro CT analysis of the novel aerogels was performed 
in conjunction with the Henry Moseley X-ray imaging facility in Manchester 
University using a Zeiss Xradia 520 Versa Micro CT scanner.   
Aerogel samples were prepared as per section 3.3.2.1 with the following amendments. 
Aerogels were prepared in a 96 well plate. A 100 µL sample of either 10%, 7.5%, 5% 
or 1% PVA solution was pipetted into a 96 well plate and frozen at -30 °C for 6 hours. 
Frozen samples were then transferred to a freeze drier and dried at -80 °C and 0.04 
mBar for 48 hours to ensure gels were completely dry. This method produced aerogel 
samples with an approximate diameter of 5 mm.  
To prepare aerogel samples for micro CT analysis samples were fixed to the top of a 
metal spindle using 3M super 77 spray adhesive (3M, Bracknell, UK). So that images 
could be taken in triplicate, 3 aerogel samples were stacked on each spindle as shown 
in Figure 3.2 a. The sample spindle was then placed in a chuck grip positioned between 





Figure 3.2 – (a) 10% PVA aerogels prepared for Micro CT analysis.  
A small aerogel disc was affixed to the sample spindle head using 3M super 77 spray 
adhesive. In order for samples to be imaged in triplicate, 2 more aerogels were stacked 
on top of the initial sample. b) The sample spindle was then placed in a chuck grip [1] 
between the x-ray detector [2] and the x-ray source [3].  
 
To minimise the scan time a 1 mm3 section in the centre of each aerogel was imaged 
rather than scan the entire sample. This approach also allowed images to be taken 
without interference from the outer surface of the gel and from any excess adhesive 
used to mount the samples.  
Samples were imaged using an x-ray source with a power of 70 kV at 71 µA. The 
sample was positioned 11.55 mm from the x-ray source and 9.55 mm from the x-ray 
detector. Each 1 mm3 area within the samples had 1600 individual projections taken. 
These projections were then stacked using ImageJ (v1.52). ImageJ was then used to 
compile a 3-dimensional projection of the scan. Due to limitations in processing power 
that was available only a representative 3D projection of each 1mm3 sample could be 




3.3.5 Preparation and optimisation of furanone-loaded aerogels 
In order to assess the suitability of PVA aerogels to deliver furanones to chronic 
wounds furanone aerogels were prepared and drug release profiles were measured.   
3.3.5.1 Preparation of a furanone-loaded aerogel 
Furanone-loaded aerogels were prepared as follows. A 10% PVA solution was 
prepared. Once cooled to room temperature 10 mL of PVA solution was transferred 
to a glass vial. A furanone was then added to the 10 mL of PVA solution to give the 
desired final concentration per millilitre of PVA solution. A 1 g amount of the PVA 
furanone mixture was pipetted into each well of a 12 well tissue culture plate. The 
samples were then placed in a -30 °C freezer for 6 hours to ensure that all samples 
were frozen. Once frozen samples were placed, uncovered in a freeze drier for 48 hours 
to ensure all water was removed. Once dry, aerogels were transferred to an airtight 
container for storage. This process was repeated to make furanone-loaded 5% and 1% 
PVA aerogels. 
3.3.5.2 Assessment of drug loss during aerogel formation 
As the furanone compounds had previously been shown to be unstable when being 
loaded into PV-borate hydrogels the levels of furanone in loaded aerogels were 
assessed.  
To assess the levels of furanone in loaded aerogels, the aerogels were prepared as per 
the protocol detailed above. Once furanone-loaded aerogels had been prepared the 
aerogels were placed in 50 mL of deionised water and vortexed until the aerogel had 
been completely dissolved. Samples of this solution were then analysed using the UV-
Vis spectrophotometer. The values obtained were then converted to concentrations of 
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furanones using pre-prepared calibration plots and the levels of furanone in the aerogel 
were calculated using the following formula: 
𝐹𝑅𝑃 × 𝑉𝑅𝑃 = 𝐹𝐴𝐸𝑅     Equation 3 
Where FRP is the concentration of furanone measured in the deionised water receiver 
phase (mg mL-1), VRP is the volume of the receiver phase (mL) and FAER is the 
concentration of furanone in the aerogel. From this, the percentage drug loss was then 
calculated. Each loaded aerogel formulation was tested in triplicate. 
3.3.5.3 Drug loss during pre-freezing  
To assess the effect of pre-freezing on furanone concentration, a stock furanone 
solution of known concentration was prepared using deionised water as a solvent. The 
UV absorbance of this stock solution was measured using a UV spectrophotometer. A 
full scan of all wavelengths was performed to obtain a full absorbance spectrum for 
the sample. The stock solution was then placed in a -30 °C freezer for 6 hours to allow 
for ensure complete freezing of the sample. Once completely frozen the stock solution 
was removed from the freezer and allowed to thaw completely at room temperature. 
Once the sample was thawed and had come up to room temperature again the UV 
absorbance of the stock solution was measured a second time, and the furanone 
concentration was interpolated from the calibration plot. The furanone concentration 
of the non-frozen sample was taken to be 100% drug concentration and of the freeze 
thawed sample was reported as a percentage of the non-frozen sample. Each furanone 






3.3.5.4 Identification of optimal aerogel drying time 
Unloaded PVA aerogels were produced from a 10% PVA solution as detailed in 
section 3.3.3.1 and furanone-loaded aerogels were prepared as per the protocol 
detailed in section 3.3.5.1. To identify optimal drying time, samples were removed 
from the freeze dryer and weighed intermittently to assess percentage water loss.  
Percentage water loss was calculated similarly to before using the equation in section 
3.3.2.5. Each aerogel was tested in triplicate. The optimal drying time was taken to be 
the earliest time point after which the weight of the aerogel did not reduce further 
(indicating no further loss of water). 
3.3.6 Characterising furanone release from PVA aerogels 
Furanone release from PVA aerogels was characterised. Furanone-loaded aerogels 
containing 10%, 5% and 1% PVA aerogels were prepared as previously described. 
Due to the rigid nature of the aerogels the use of a Franz diffusion cell was not 
appropriate as total contact between the aerogel and the semi-permeable membrane 
could not be guaranteed. An alternative dissolution method was used. Briefly, 
deionised water was added to a beaker to a volume of 30 mL. This was placed on a 
magnetic stirrer and kept stirring at a constant speed. A furanone-loaded aerogel was 
added to the beaker and a 100 µL of receiver phase was removed and diluted 
appropriately. The absorbance of the diluted sample was read in a UV-Vis 
spectrophotometer. A full scan of the sample absorbance at all wavelengths was used 
so that changes in the λmax or the UV absorbance spectrum could be identified. 





3.4 Results  
3.4.1 Development and assessment of a cold loading technique for the preparation 
of furanone-loaded hydrogels  
As the requirement for high temperatures and the presence of borate caused significant 
changes in the absorbance spectra of the furanone compounds, it was decided that a 
method of loading the hydrogel in which temperature and quantity of free, unbound, 
borate should be kept to a minimum was needed. Thus, the rehydration of a lyophilised 
PVA-borate hydrogel using a furanone solution was tested. 
3.4.1.1 Optimisation of the hydrogel lyophilisation time 
The time required to completely lyophilise PVA-borate hydrogel was assessed. It was 
found that 5 g hydrogels were totally dried after 18 hours and 10 g hydrogels took 
approximately 24 hours to become totally dried (Figure 3.3 a-b). A gel was defined as 
totally dry when there was no mass loss between two consecutive time points.  
 
Figure 3.3 – Hydrogel weight and water content measured against lyophilisation 
time.  
(a) When freeze dried in 5g amounts hydrogels were totally dried within 18 hours. (b) 
When dried in 10 g amounts hydrogels took approximately 24hours to become 






3.4.1.2 Characterisation of a freeze-dried hydrogel powder 
As monolithic gels were found to rehydrate poorly and unevenly, dried hydrogels were 
powdered prior to rehydration. It was hypothesised that a powdered dried hydrogel, 
having greater surface area, would rehydrate more rapidly and evenly than a 
monolithic gel. This would give a more homogenous final gel with more even 
distribution of furanone. Therefore, the freeze-dried hydrogel was powdered using a 
commercial spice grinder. The powder obtained using this method was assessed for 
average particle size and particle size distribution. It was found that when processed 
using only a commercial spice grinder the hydrogel powder had an average particle 
size of 487 µm. This powder was then passed through a fabric mesh in order to exclude 
the larger pieces of gel and it was found that this method of processing reduced the 
average particle size of the powder to 181 µm (Figure 3.4). This process was then used 
for the production of all future lyophilised gel powders. 
































Figure 3.4 – Average particle sizes of freshly powdered dry hydrogel and 
hydrogel powder processed using a size exclusion mesh.  
When processed using just the commercial spice grinder the hydrogel powder had an 
average particle size of 487µm. When passed through a fabric size exclusion mesh the 
average particle size was reduced to 181µm. Data points represent the mean of 3 
independent replicates ± S.D. 
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3.4.1.3 Comparison of standard and rehydrated hydrogels 
To ensure that the freeze drying, and rehydration process did not negatively affect the 
rheological properties of the hydrogel, a dried and rehydrated gel was compared to a 
portion of the same gel which had not been subjected to lyophilisation. It was found 
that in terms of the shear modulus of the hydrogel there was no significant difference 
between the standard hydrogel and the freeze dried gel indicating that drying and 
rehydrating had no negative impact on the rheology of gel and, thus, this method of 
cold loading could be used to produce a viable loaded gel (Figure 3.5). 
 
Figure 3.5 – A comparison of the shear moduli of a standard hydrogel and a 
freeze dried and rehydrated hydrogel. 
 The standard hydrogel has an average shear modulus of 4245 Pa ± 830.94 while the 
freeze dried and rehydrated hydrogel had an average shear modulus of 4140.67 PA ± 
1043.50. Data was compared using a paired t-test. Data represent the mean of 3 
independent replicates ± S.D. n.s. = not significant.  
  
3.4.1.4 Full rheological characterisation of a rehydrated hydrogel 
To ensure that the freeze drying, and rehydration process did not significantly impact 
the rheological profile of the hydrogel, a full rheological characterisation of a dried 






























extended to 100% shear strain before a reduction in G′ and G″ was seen (Figure 3.6 
a). The viscoelastic profile showed a gel in which G′ dominated at high shear 
frequencies and G″ was dominant at low shear frequencies indicating a shear 
thickening gel. These measurements were confirmed by phase angle measurements 
which tended towards 0° at higher shear frequencies. The crossover point between G′ 
and G″ was 3060 Pa at a shear frequency of approximately 1 Hz (Figure 3.6 b). 
Viscosity measurements showed an increase in the viscosity of the rehydrated gel with 
increasing shear frequency above 50 Hz and up to 150 Hz (Figure 3.6 c). Adhesiveness 
testing indicated a gel with very low adhesiveness with a peak normal force of -1.24 
N exerted over approximately 0.1 s (Figure 3.16 d).    
 
Figure 3.6 – A full rheological characterisation of a freeze dried and rehydrated 
6% PVA and 1% borate hydrogels. 
(a) Assessment of the linear viscoelastic region of the gel showed that both G′ and G″ 
were largely unchanged up to a shear strain of 100%. (b) The viscoelastic profile of 
the gel showed that G’ was dominant at high shear frequencies and G″ was dominant 
at lower shear frequencies indicating a gel which displayed more solid like behaviour 
at high shear frequencies. This finding was confirmed by phase angle measurements. 
(c) Assessment of the viscosity profile of the gel showed a steady increase in viscosity 
as shear frequency increased indicating shear thickening behaviour. (d) Adhesiveness 
testing showed the gel could exert a peak force of -1.24N over 0.1 s. Data represent 
the mean of 3 independent replicates ± S.D. 

































































































3.4.1.5 Tunability of the shear modulus of rehydrated hydrogels 
The extent to which the shear modulus of a freeze dried and rehydrated hydrogel could 
be modulated using variable rehydration percentages was investigated. It was found 
that, when freeze dried hydrogels were rehydrated with volumes of water greater than 
100% of the water removed during freeze drying, the shear modulus decreased (Figure 
3.7 a). The correlation between rehydration percentage and shear modulus was 
assessed and it was found that the relationship was indeed linear (Figure 3.7 b) and, 
therefore, an approximate final shear modulus for any given rehydration percentage 
could be calculated. Conversely, if the shear modulus of the hydrogel prior to freeze 
drying was known, the volume of water of rehydration required to give a rehydrated 
gel with a specific shear modulus can be calculated.  
 
Figure 3.7 – An assessment of the tunability of a rehydrated hydrogels shear 
modulus.  
(a) When freeze dried hydrogels were rehydrated with greater than 100% of the weight 
of water lost the shear modulus of the rehydrated gel was reduced. (b) The relationship 
between the rehydration volume and the final shear modulus was shown to be linear 
(Pearson’s coefficient -0.9802, R2 0.9607 p-value =0.0006). Data represent the mean 





























































3.4.2 Cold loading of hydrogels with furanone compounds  
It was found that when loaded with HDMF, the rehydrated hydrogel became 
significantly softer (reduced shear modulus) and became discoloured with a clouded 
white appearance (Figure 3.8 a). When loaded with sotolon, the gel did not form, and 
the sample became entirely liquid. No discoloration of the sample was observed 
(Figure 3.8 b). When loaded with MTHF the hydrogel formed well and no 
discolouration or changes in the hydrogels texture was observed (Figure 3.8 c). When 
loaded with ascorbic acid the gel formed poorly and the sample remained largely 
liquid. An obvious orange/brown discolouration was seen which darkened in the days 
following the drug loading (Figure 3.8 d). The image shown in Figure 3.9 d shows an 
































3.4.3 Preparation and characterisation of PVA aerogels 
As issues were still being encountered when cold loading the furanones into freeze 
dried PVA hydrogels, it was hypothesised that the main contributing factor was the 
continued presence of borate ions in any form (free borate and borate bound in 
crosslinks). To overcome these issues borate was removed from the PVA hydrogel 





Figure 3.8 - Samples of freeze-dried hydrogel loaded with furanone using a 
cold loading method.  
(a) HDMF-loaded hydrogels were softer than unloaded gels and became cloudy 
and discoloured. (b) Sotolon-loaded hydrogels formed poorly with samples being 
entirely liquid. (c) MTHF-loaded hydrogels formed well with no obvious changes 
in hydrogel texture and no discolouration. (d) Ascorbic acid-loaded hydrogels 
formed poorly remaining entirely liquid with heavy brown/orange discoloration 
which worsened over 48 hours 
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3.4.3.1 Formulation and production of PVA aerogels 
Several formulations of PVA aerogel were tested and the final products had a wide 
range of appearance and texture. A PVA aerogel prepared from both 10% and 7.5% 
PVA solutions produced a firm but slightly pliable aerogel coupons which displayed 
minimal shrinkage in volume after freeze drying. Aerogels produced using 5% PVA 
solution resulted in a soft product that held its shape and displayed minimal shrinkage 
in volume. Finally, aerogels produced using a 1% PVA solution yielded a product with 
a very soft texture similar to that of cotton wool. This formulation was very fragile 
and had reduced in volume slightly after freeze drying. The 10% PVA aerogel was 
selected to be taken forward for drug loading. 
3.4.3.2 Structural characterisation of PVA aerogels 
PVA aerogels were structurally characterised first by examining their macro structure 
under stereo zoom microscopy. This was followed by scanning electron microscopy 
to assess the micro-scale physical structure of the aerogels. Finally, to assess the 
structure homogeneity the aerogels were imaged using micro CT scanning.  
When viewed under stereo zoom microscopy a level of organisation was seen in the 
internal structure of the aerogels. This took the form of apparent fibres in the gel. This 
organisation of the internal structure of the gel was most apparent in the 10% PVA 
aerogels with the majority of fibres being aligned along the vertical axis (perpendicular 
to the upper and lower surfaces of the gel). This structure was also apparent in the 
7.5% PVA aerogel. In the 5% PVA aerogel some apparent organisation remained in 
the structure of the gel. However, the organisation in the 5% PVA aerogel took the 
form of distinct areas of fibre organisation. Each area was highly organised within 
itself, but each area was disorganised compared to the others. Finally, the 1% PVA 
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aerogel showed no organisation in internal structure with the fibres appearing loosely 
packed and resembling fibreglass (Figure 3.9 a-d).  
 
Figure 3.9 – Stereo zoom images of the internal structure of a (a) 10%, (b) 7.5%, 
(c) 5% and (d) 1% PVA aerogels under 10x magnification.  
High levels of organisation can be seen in the 10% aerogel with fibres running 
vertically. The same order can be seen in the 7.5% aerogel. In the 5% aerogel the 
organisation is less obvious but small localised areas of organisation of fibres can be 
seen. No apparent organisation can be seen in the 1% PVA aerogels.  
 
When viewed under SEM, the findings of the stereo zoom imaging were confirmed. 
The 10% PVA aerogel was found to have a high level of fibre organisation. Again, 
fibres were organised along one axis. The 7.5% PVA gel showed the same level of 
organisation along a single axis. The 5% PVA aerogel showed distinct areas of high 
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fibre organisation. Under SEM the 1% PVA aerogel showed structure that was loosely 
packed and largely disordered (Figure 3.10 a-h). 
 
 
Figure 3.10 – SEM analysis of a (a-b) 10%, (c-d) 7.5%, (e-f) 5% and (g-h) 1% 
aerogels.  
SEM analysis of the internal structure of the aerogels confirmed the findings of the 
stereo zoom microscopy with high levels of fibre organisation seen in the higher 
concentration PVA gels and less organisation in the lower concentration PVA gels. 
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Finally, samples of each aerogel were imaged using micro CT scanning. This allowed 
for the assessment of the homogeneity of the internal structure of each aerogel 
formulation. It was found that the 10% aerogel was partially homogeneous but had 
veins of material with differing density throughout the structure. These areas of altered 
density suggested that the packing of the fibre strands in the gel was less ordered here 
(Figure 3.11 a-c).   
 
Figure 3.11 – Micro CT scans of a 10% PVA aerogel showing (a) a three-
dimensional representation of an orthogonal slice through the scanned section (b) 
a cross section of the scanned section of the gel and (c) a full three-dimensional 
representation of the scanned portion of the gel.  
Darker regions indicate areas of lower density. Veins of lighter material can be seen 
throughout the internal structure of the gel. This indicates areas of more tightly packed 
fibres and therefore a degree of structural heterogeneity within the gel. Images shown 
are representative images selected from 3 independent replicates.  
191 
 
When imaged using micro CT the 7.5% aerogel appeared similar to the 10% PVA gel 
with areas of homogenous density and areas of differing density. The areas of 
heterogeneity were less numerous than those found in the 10% PVA aerogel but were 
larger in area (Figure 3.12 a-c).  
 
Figure 3.12 -Micro CT scans of a 7.5% PVA aerogel showing (a) a three-
dimensional representation of an orthogonal slice through the scanned section (b) 
a cross section of the scanned section of the gel and (c) a full three-dimensional 
representation of the scanned portion of the gel.  
Darker regions indicate areas of lower density. Veins of lighter material can be seen 
throughout the internal structure of the gel. Greater homogeneity is seen in the 7.5% 
PVA aerogel compared to the 10% PVA gel. Images shown are representative images 




The 5% PVA aerogel showed significantly more heterogeneity in density with the 
areas of higher density, and, therefore, tightly packed fibres, being considerably 
smaller and more evenly distributed throughout the sample than were seen in the 10% 
and 7.5% PVA aerogels (Figure 3.13 a-c). However, although regions of higher 
density were more numerous, they were evenly distributed and so the density of the 
sample is likely more even.  
 
Figure 3.13 - Micro CT scans of a 5% PVA aerogel showing (a) a three-
dimensional representation of an orthogonal slice through the scanned section (b) 
a cross section of the scanned section of the gel and (c) a full three-dimensional 
representation of the scanned portion of the gel. 
 Lighter regions indicate areas of higher density. Areas of lighter, and therefore more 
densely packed material, are more evenly distributed in this sample. This suggests a 
higher degree of homogeneity in the samples internal structure. Images shown are 
representative images selected from 3 independent replicates. 
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Finally, the 1% PVA aerogel appeared to be significantly less dense than the previous 
samples when viewed under micro CT with areas of higher density materials being 
less prominent in the sample. Areas of higher density were smaller in size and evenly 
distributed (Figure 3.14 a-c).   
 
Figure 3.14 - Micro CT scans of a 1% PVA aerogel showing (a) a three-
dimensional representation of an orthogonal slice through the scanned section (b) 
a cross section of the scanned section of the gel and (c) a full three-dimensional 
representation of the scanned portion of the gel.  
Darker regions indicate areas of lower density. This sample appears to be very low 
density with areas of tightly packed material being smaller in size and more evenly 
distributed throughout the sample compared to aerogels with higher concentrations 




When the homogeneity and distribution of density of each aerogel was examined it 
was found that the 10% PVA aerogel was the least homogenous in structure with areas 
of higher density material (highlighted in red) irregularly distributed throughout the 
aerogel. The homogeneity increases as PVA concentration decreased (Figure 3.15 a- 
d).  
 
Figure 3.15 – Cross sectional images of (a) 10%, (b) 7.5%, (c) 5% and (d) 1% 
PVA aerogels with areas of higher density highlighted in red.  
The 10% PVA aerogel showed the least structural homogeneity with areas of denser 
materials being irregularly distributed throughout the gel. Homogeneity of the 
materials increased as PVA concentration was reduced. Images shown are 




3.4.3.3 Stability of furanone compounds during aerogel production 
Due to the problems encountered during the loading of furanones into both hydrogels 
and freeze-dried hydrogels the stability of furanones during the PVA aerogel 
production process was investigated. It was found that the concentration of HDMF 
present in the aerogel after it was produced was reduced by 47.68% of the total loaded 
volume while sotolon concentrations were reduced by 100%. Similar to the hydrogels, 
the concentration of MTHF was seen to increase significantly by 9591.79%. Ascorbic 



































Figure 3.16 – Relative concentrations of furanone present in a loaded 10% PVA 
aerogel following preparation using a lyophilisation method.  
HDMF concentrations decreased by 47.68 % and sotolon concentrations were 
reduced by 100%. Both MTHF and ascorbic acid concentrations showed an apparent 
increase of 9591.79% and 37.14% respectively. Data represent the mean of 3 







3.4.3.4 Impact of freeze-drying process on furanone concentrations 
To identify the cause of the observed loss of furanone the effect of the lyophilisation 
process on the concentration of furanones in loaded aerogels was explored. Firstly, the 
impact of the pre-freezing step in the aerogel production method on furanone 
concentrations in the final aerogel product was investigated. It was shown that 
undergoing a freeze-thaw cycle had little impact on the overall concentrations of 
furanone stock solutions with HDMF, Sotolon, MTHF and ascorbic acid showing a 



































Figure 3.17 – The effect of the pre-freezing step of lyophilisation on the stability 
of furanones in aqueous solution.  
Furanone stock solutions that were prepared and frozen at -30°C and thawed showed 
no significant reduction in furanone concentrations with HDMF, Sotolon, MTHF and 
ascorbic acid showed reductions of 3.45%, 2.40%, 1.66% and 6.02% of the total 
loaded drug volume. Data represents the mean of three independent replicates ± S.D. 
 
3.4.3.5 Optimisation of the freeze-drying process. 
It was hypothesised that the volatile furanone compounds were being lost during the 
freeze-drying process. The freeze-drying protocol was therefore carefully optimised 
in order to minimise the loss of furanone as far as possible. It was found that both 
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blank and loaded aerogel formulations were totally dry within 20 hours (Figure 3.18 
a). This represented a 28 hours reduction in drying time compared to what had 
previously been used in this work when preparing the aerogels. Once an optimised 
freeze-drying process had been identified loaded aerogels were prepared and the 
concentrations of each furanone post freeze drying were measured. It was found that, 
after drying under optimised conditions, HDMF concentrations were reduced by only 
1.64% and sotolon concentrations were reduced by only 6.15%. However, MTHF and 
ascorbic acid still showed apparent increased in concentrations of 7192.37% and 
110.92% respectively (Figure 3.18 b). 
 
Figure 3.18 - The development and confirmation of an optimised 10% PVA, 
furanone-loaded aerogel production method.  
(a) Water loss during freeze drying was measured and it was shown that all loaded 
10% PVA aerogel formulations were dry after 20 hours. (b) Aerogels produced using 
the optimised method were assessed for drug concentrations post freeze drying. 
HDMF and sotolon concentrations were reduced by 1.64% and 6.15% respectively 
while MTHF and ascorbic acid concentrations shoed and apparent increase of 
7192.37% and 110.92% respectively. Data represent the mean of 3 independent 
replicates ± S.D 
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3.4.5 Furanone release kinetics from PVA aerogels 
The release kinetics of furanone compounds from 10%, 5% and 1% PVA aerogels. 
Both ascorbic acid and MTHF had poor release profiles. No aerogel formulation 
showed significant release of ascorbic acid (Figure 3.19 a). Those formulations loaded 
with MTHF showed greater than 100% release from a 1% and 10% PVA aerogels and 
no significant release from a 5% aerogel (Figure 3.19 b). HDMF showed no significant 
release from a 1% PVA aerogel but showed a rapid burst release from a 5% PVA 
aerogel releasing 84% of the total loaded drug in 30 minutes with a total drug release 
of 90% of the total loaded volume over the full 5 hours. HDMF also showed a more 
controlled initial release from a 10% PVA aerogel which resulted in a total release of 
70% of the total loaded drug (Figure 3.19 c). The release of sotolon from a 1% PVA 
aerogel was not tested as the aerogel did not form appropriately. However, sotolon 
showed a rapid burst release from a 5% PVA aerogel over 10 minutes with a final 
release of 85% of the total loaded drug. Sotolon showed a rapid initial burst release 
from a 10% PVA aerogel, releasing 65% of the total loaded drug in 30 minutes and 





Figure 3.19– Release kinetics of each furanone from a 1%, 5% and 10% PVA 
aerogel.  
(a) Ascorbic acid showed no significant release from any of the three aerogel 
formulations. (b) MTHF showed greater than 100% release from both the 1% and 
10% PVA aerogel formulations and no significant release from the 5% PVA 
formulation. (c) HDMF showed no significant release from the1% PVA formulation 
but showed rapid burst release from the 5% PVA formulation and a more controlled 
release from the 10% PVA formulation. (d) Release of sotolon from a 1% PVA aerogel 
formulation was not tested. Sotolon showed initial burst release from both the 5% and 







































































































































As no single aspect of the hydrogel production process (i.e. elevated temperature, free 
borate or altered pH) was found to be universally responsible for the degradation of 
the four furanones (as shown in chapter 2), a method of cold loading the hydrogels in 
the absence of free borate was developed. This method involved total dehydration of 
an unloaded hydrogel, and rehydration of the resultant dry gel in a furanone solution. 
The hydrogels were originally dried in a standard oven at 40 °C or air dried at ambient 
temperature for 24 hours to 48 hours but it was found that this produced a compact, 
highly brittle, glass-like material which did not fully rehydrate when placed in a 
furanone solution. This was likely due to the nature of the drying process resulting in 
the formation of a material known as a xerogel. These materials are hydrogels which 
have been dried with no restrictions on network shrinkage. As the liquid phase leaves 
the gel by evaporation, high capillary pressure is introduced to the pores of the polymer 
network causing these pores to collapse (Duräes et al., 2012; Rodríguez-Dorado et al., 
2019). The result is a material with a highly compacted and tight network of polymers 
which cannot easily take up liquid during rehydration. To solve this issue, a method 
of drying the hydrogels based on lyophilisation was investigated. It was hypothesised 
that the lyophilisation process would result in a dried hydrogel with a fully open pore 
structure as reported by Hou et al. in 2003. This study showed that lyophilisation could 
produce highly porous materials with porosities of up to 98% (Hou, Grijpma and 
Feijen, 2003). It was hypothesised that maintaining a high porosity in the in the dried 
gels used here would facilitate rapid rehydration in furanone solution. This method of 
furanone loading also avoided exposing the furanones to excessive heat and it was 
believed that as the hydrogel was cross linked before drying that the free borate ions 
would be at a minimum, thus, reducing their interaction with the furanone compounds. 
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Hydrogels were found to take between 18 to 24 hours to be completely dehydrated in 
a freeze dryer and, once submerged in a liquid phase, were largely rehydrated after 24 
hours. However, it was observed that monolithic dried gels (i.e. a dried gel which 
remained as one piece after drying) often had areas near the centre of the gels which 
were poorly rehydrated while the edges were fully, or even over hydrated. It was 
decided that the rehydration process could be improved by increasing the surface area 
of the dried gel and minimising the total distance which liquid had to penetrate into 
the dried gel. To achieve this, dried gels were processed and powdered using a 
commercial spice grinder. Dried and powdered gel was then passed through a fine 
cloth mesh to remove any large pieces. This resulted in a dry gel powder with an 
average particle size of 181 μm.  This powder was found to be easily rehydrated within 
24 hours and the smaller particle size reduced the uneven rehydration, resulting in a 
homogeneous hydrogel. This is significant as extended rehydration times would not 
be suitable for the large scale, commercial preparation of these hydrogels. 
The effect of lyophilisation and rehydration on the rheological properties of the 
hydrogel were assessed as significant changes in rheological properties may have 
meant that this method of cold loading of furanones was unsuitable. It was found that 
lyophilisation and rehydration had no effect on the overall shear modulus of the 
hydrogel. Further, the full viscoelastic profile and viscosity profile remained suitable 
for use in chronic wounds. It was shown that hydrogels retained their dilatant nature 
following the lyophilisation process. However, two primary changes in rheological 
properties were observed. First was the change in adhesiveness of the lyophilised and 
rehydrated gel. The normal 8% PVA, 2% borate hydrogel showed a peak normal force 
of -6.607 N while the lyophilised and rehydrated gel of the same formulation showed 
a peak normal force of -1.24N. This reduction in adhesiveness is both interesting and 
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potentially beneficial in the production of a wound dressing. This lower adhesiveness 
would likely result in a reduction in trauma to a wound bed upon dressing removal 
(McCarron et al., 2011; Murphy et al., 2012). A possible explanation for the reduction 
in adhesiveness is suggested by McCarron et al. (2011) who found that the 
adhesiveness of PVA-borate hydrogels to skin was dependent on the concentration of 
crosslinker in the formulation. While the concentration of crosslinker in the standard 
and lyophilised samples tested in this work were the same, the degree of crosslinking 
in the gel may have increased. It has been noted that PVA solutions subjected to freeze 
thaw cycles formed so-called supermolecular particles (Peppas, 1975). It is now 
known that when exposed to freeze thaw cycles PVA forms physical crosslinks due to 
the development of regions of high crystallinity within the gel network. When a 
hydrogel sample is cooled, the water in the gel network forms ice, swelling in volume 
and forcing PVA polymer strands together. This results in areas of high PVA 
concentration and, thus, areas of high crystallinity. In these areas of high crystallinity 
PVA strands form hydrogen bonds with adjacent polymer strands. When the ice in the 
structure thaws and shrinks in volume, these polymer areas remain crosslinked 
(Peppas, 1975; Hassan and Peppas, 2000; Holloway, Lowman and Palmese, 2013). 
These areas of high crystallinity are known as crystallites. It is likely that, during the 
pre-freezing stage of the lyophilisation process used in this work, the formation of 
crystallites in the hydrogel’s polymer network occurred. This would have meant a 
higher degree of crosslinking in the gel and, potentially, a lower adhesiveness. The 
formation of these crystallites may also explain the second observed change in the 
rheological properties of the hydrogel post lyophilisation. It was observed that the 
linear viscoelastic region measured in the lyophilised gel was significantly greater than 
that of the standard hydrogel with the upper limits of the region being measured at 6% 
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for the standard gel and 100% for the lyophilised and rehydrated sample. If the 
hypothesis posited above is correct with crystallites forming in the hydrogel, and 
therefore, increasing crosslink density in the sample, an increase in the linear 
viscoelastic region would be expected. As the linear viscoelastic region represents the 
amount of force a system can be subjected to without experiencing destruction of the 
internal structure, an increase in crosslink density would have meant that any 
experienced force would be spread among a greater number of crosslinks. This would 
likely result in a network that could withstand greater pressure before yielding.  
The minimal of impact of drying and rehydration on the shear modulus of the 
hydrogels then prompted investigations into the use of excess hydration to tune the 
rheological properties of the gels. It was found that hydration of the lyophilised 
hydrogels, with more than 100% of the water lost during drying, was effectively able 
to reduce the shear modulus. This was expected as it has been shown several times 
that decreasing the total mass of PVA and borate results in a softer, more fluid like gel 
(Loughlin et al., 2008; McCarron et al., 2011; Murphy et al., 2012). As over hydration 
of the lyophilised gel effectively decreases the percentage of both polymer and cross 
linker by weight, a reduction in shear modulus is to be expected. This decrease in shear 
modulus was also demonstrated to be linear, suggesting that even hydrogels with non-
ideal shear moduli could be lyophilised and rehydrated sufficiently to give a final 
product with the desired consistency, if the shear modulus of the original gel is known.  
The data presented in this thesis, taken together in light of published work indicates 
that rehydrating a lyophilised hydrogel with a furanone solution presented a 
potentially useful method for preparing furanone-loaded hydrogels without exposing 
the compound to heat or free borate. As such, lyophilised gels were rehydrated with a 
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volume of furanone solution that would give a 100% rehydrated gel. After 24 hours 
rehydrating in a furanone solution, hydrogels were not suitable for use. HDMF-loaded 
gels became turbid in appearance and had a significantly softer texture. Sotolon and 
ascorbic acid caused the rehydrated hydrogels to become entirely liquid with a dark 
orange/brown discoloration observed in the ascorbic acid-loaded sample. As with the 
standard hydrogels, the MTHF-loaded samples formed well with no change in 
rheological properties or colour. The changes in the hydrogels after furanone loading 
were similar to those seen in the standard hydrogel production method. As temperature 
had been eliminated in this method, it was hypothesised that either some excess borate 
remained in the system after cross linking, the borate that was bound to PVA strands 
was still able to interact with the furanone compounds causing degradation, or, in the 
case of ascorbic acid, simply the presence of water resulted in compound degradation. 
If free borate does indeed remain in the system following cross linking the addition of 
a polyol sugar such as mannitol may help to ameliorate the borates negative effects. 
The addition of mannitol to a PVA borate hydrogel formulation was shown to 
effectively bind to free borate ions in a system just making them unavailable for cross 
linking (Loughlin et al., 2008). If the same principal could be applied to the lyophilised 
gels the changes in texture and colour upon loading with furanone might be avoided. 
Overall, it was decided that due to the requirement for high temperatures, the presence 
of free borate and the inherently aqueous environment meant that hydrogels, in any 
form, could not be used to deliver furanones to chronic wounds. 
In order to overcome the issues faced in the production of furanone-loaded hydrogels 
it was decided that the possible formation of crystallites (as discussed previously) 
during the pre-freezing stage of lyophilisation could be exploited in order to produce 
a completely dry, borate-free, furanone delivery system. The developed material 
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consisted of a polymer solution (of varying concentration) that was frozen to cause the 
formation of crystallites in the network structure giving a small degree of crosslinking. 
The frozen solution was then lyophilised to result in a low density, highly porous, 
completely dry aerogel–like material. The internal structure of this aerogel material 
was then characterised. The macro structure of the aerogel was examined under stereo 
zoom microscopy. Interestingly, a degree of regularity in the internal structure was 
apparent. This regularity was also seen to decrease, giving a more disordered internal 
structure, as polymer concentration decreased. In 2005, a similar alignment was 
observed in freeze dried PVA solutions that were subjected to highly controlled 
directional freezing (Zhang et al., 2005). Here, the authors suggest that the uniaxial 
alignment of the PVA strands was caused by phase separation during the freezing 
process. Indeed, the authors showed that the formation of ice crystals in the sample 
occurred in a single direction and that this freezing likely forced the alignment of 
polymer strands. The reduction in order, seen in the aerogels produced in this work, 
as polymer concentration decreases may be explained by the occurrence of a 
phenomenon known as freeze concentration. Briefly, on cooling, as solvent crystals 
form, a solute may be forced out of the freezing solvent (phase separation). This results 
in a higher concentration of solute at the boundary between the frozen solvent and the 
non-frozen solvent (the interface). This effectively concentrates the solute in the non-
frozen liquid phase (Butler, 2001, 2002). It is hypothesised that, in the work presented 
in this thesis, freeze concentration of the 10% polymer solution resulted in greater 
concentration of PVA at the interface, forcing the strands into alignment. Conversely, 
freeze concentration of the 5% and 1% polymer solutions resulted in comparatively 
lower concentrations of polymer strands at the interface, thus, allowing greater 




Figure 3.20 – A representation of freeze concentration of a high polymer 
concentration solution and a low polymer concentration solution.  
Upon freezing of the polymer solutions, the polymer strands are separated from the 
liquid phase causing them to concentrate between ice crystals. In solutions with higher 
concentrations of polymer a greater concentration of polymer strands is present 
between ice crystals thus forcing them into alignment. For low concentration polymer 
solution, a lower number of polymer strands would be present between ice crystals 
thus allowing for a greater level of strand disorder in these samples. 
 
The polymer strand alignment and gradual reduction in structure with decreasing 
polymer concentration was subsequently confirmed by SEM imaging of the 
microstructure of the gels. This imaging showed tightly packed unidirectional fibres 
in the aerogel made from a 10% PVA solution. These fibres remained unidirectional 
but appeared less tightly packed in the 7.5% PVA aerogel. Interestingly, under SEM, 
the 5% PVA aerogel showed localised areas of ordered fibres which were loosely 
packed. Finally, the 1% PVA aerogel showed no obvious fibres in the internal structure 
instead being ordered into a loosely packed, flat layers. The reason for this change in 
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structure from bundled fibres to flat lamellar sheets is unclear but it may be that the 
structure of the low-density, cotton-like, gel structure was compacted during sample 
preparation leading to a flattened lamellar appearance. Finally, the homogeneity of the 
aerogel internal structure was assessed by micro CT. It was found that the 10% PVA 
aerogel had the least homogeneous internal structure of all formulations tested with 
large areas of significantly more dense material throughout its internal structure. 
Structural homogeneity increased with decreasing polymer concentration. This was 
unexpected as the higher polymer concentrations showed greater structural order. This 
phenomenon has not been reported previously in the literature and so determining the 
cause is difficult. However, it is currently thought to be due to the uncontrolled 
freezing of the polymer solutions prior to drying. Unlike the work of Zhang et al. 
(2005), the polymer solutions used in this work were allowed to freeze with no defined 
directionality. As previously stated, the formation of ice crystals in the solution will 
likely have led to freeze concentration. With unidirectional freezing the ice crystals 
form in a regular pattern, leaving the areas of concentrated solute in a regular pattern 
or structure. However, as this work used non-regulated freezing ice crystals will have 
formed throughout the solution giving rise to irregular areas of solute concentration.  
Following assessment of the internal structure of the aerogels, the stability of the 
furanone compounds during aerogel formation was assessed. It was discovered that 
the concentration of furanones in an aerogel was indeed affected by the process of 
aerogel formation. It was found that the concentration of HDMF was reduced by 48%, 
sotolon was reduced by 100% and both MTHF and ascorbic acid were apparently 
increased in concentration by 9500% and 37%, respectively. This was highly 
unexpected as the three primary sources of compound degradation in hydrogel 
formation (temperature, borate and altered pH) had now been eliminated. It was 
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thought that the pre-freezing step required for lyophilisation was causing degradation 
of the furanone compounds. This effect has been reported for other drug compounds 
including biological drugs such as proteins and antibodies (Authelin et al., 2020). 
While furanones are biological compounds, their different chemistries mean that their 
stability profiles are likely very different from complex molecules such as proteins. 
Despite this, the process of freezing could potentially degrade the furanones. As such, 
the extent of furanone loss after a freeze thaw cycle was investigated. However, it was 
found that the process of freezing and thawing a stock solution of furanone did not 
cause the loss (or apparent increase) of any of the four compounds. This is in keeping 
with several previous reports which have shown that freeze thaw cycles often do not 
have an effect on the stability of a range of active compounds (Kozikowski et al., 
2003; Rayfield et al., 2017; Lai et al., 2019). The discovery that pre-freezing had no 
effect on compound degradation suggested that the freeze-drying process itself was 
the cause of the altered compound concentrations. It was hypothesised that due to the 
high volatility of the some of the furanone compounds (as evidenced by their strong 
aroma), they may have been volatilised under the vacuum required for the freeze-
drying process. This would have resulted in a loss of furanone compounds which 
would have been seen after drying the aerogels. While this explanation is suitable for 
changes in HDMF and sotolon concentration it does not explain the apparent increase 
in MTHF and ascorbic acid concentrations. Nevertheless, the freeze-drying process 
was optimised in order to minimise the amount of time aerogels were under vacuum, 
with the aim of minimising the loss of volatile furanones. It was found that blank and 
furanone-loaded gels reached a constant mass (indicating they were completely dry) 
within approximately 20 hours. After undergoing optimised drying, the HDMF and 
sotolon aerogels lost only 1.64% and 6.15 % of the total loaded drug respectively. 
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MTHF and ascorbic acid aerogels showed apparent increased in drug concentration of 
approximately 7100 % and 110 % respectively. As these gels are novel, particularly 
when loaded with active compounds, there are no previous reports surrounding drug 
stability during production. However, as discussed in chapter 2 it is likely that the 
degradation of the compounds to more absorptive products (giving rise to apparent 
increases in drug concentrations) is due to the inherently hydrolytic aqueous 
environment that the compounds are exposed to. As HDMF and sotolon are not 
degraded by loading into the aerogels it might be that these compounds can withstand 
the aqueous environment until the water is removed by freeze drying. Conversely both 
MTHF and ascorbic acid appear to be unable to tolerate the aqueous environment even 
for a short time.  
However, based on the data in this work it was concluded that, due to their inherent 
instability, MTHF and ascorbic acid were not viable for loading into PVA based 
hydrogel or aerogel drug delivery systems. HDMF and sotolon were both successfully 
loaded into PVA aerogels at high concentrations.  
Finally, the release of each of the four compounds from the aerogels was examined. It 
was found that ascorbic acid, despite increasing in apparent concentration after drying, 
released less than 2% of the total loaded drug. This is contradictory to reports of 
ascorbic acid release from other polymeric carriers. For example, in 2016 Mangir et 
al. showed that ascorbic acid was effectively released from electrospun poly (lactic 
acid) fibres at concentrations of between 50 and 90% of the total loaded drug volume 
(Mangir et al., 2016). Similarly, Voss et al. (2018) showed between 60% and 90% 
release of ascorbic acid from a newly developed PVA/polysaccharide film wound 
dressing (Voss et al., 2018). The success of these studies in releasing ascorbic acid 
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further reinforces the hypothesis that one or more aspects of the aerogel production 
process have resulted in the poor stability and release of this compounds. As with the 
hydrogels, the release of MTHF remained highly anomalous with total release 
percentages of up to 600% being observed. This also suggests that the stability and 
absorptivity MTHF is negatively affected by the lyophilisation process. Despite the 
failure of ascorbic acid and MTHF-loaded aerogels, both HDMF and sotolon showed 
favourable drug release profiles with HDMF releasing up to 90% and sotolon also 
releasing up to 90% of the total loaded drug volume. When released from a 5% PVA 
aerogel both HDMF and sotolon showed a rapid burst release with 80% of the total 
loaded drug volume being released. This is similar to previous reports of drug release 
from aerogel materials many of which show rapid burst release effects of drugs such 
as triflusal, paracetamol, nicotinic acid, and ketoprofen (Mehling et al., 2009; 
Veronovski, Novak and Knez, 2012; Murillo-Cremaes et al., 2013; Goimil et al., 
2017). These burst release effects were reduced when HDMF and sotolon were 
released from an aerogel with a higher concentration of polymer. This is not 
unexpected as it has been shown that an increase in polymer concentration can slow 
the release of drugs from a polymeric system (Erös et al., 2003). These data suggested 
that 10% PVA aerogels could be used to deliver furanones to wound biofilms as while 
avoiding burst release. These properties make PVA aerogels potentially excellent 








A method of cold loading lyophilised hydrogels, with the aim of producing a furanone-
loaded gel in which the furanone compounds did not degrade was developed. This was 
shown to be an unsuitable method for the production of furanone-loaded gels due to 
likely interactions between the active compounds and borate causing significant 
degradation of the furanones. To overcome these issues a novel, minimally 
crosslinked, PVA aerogel was developed and characterised. It was shown that 
aerogels, made using a high polymer concentration PVA solution, displayed 
unidirectional fibres in its internal structure. It was suggested that this structure was 
caused by ice crystals forming within the sample freezing causing a phenomenon 
known as freeze concentration. This observed structure decreased as the concentration 
of polymer in the aerogel was reduced. Upon further investigation it was discovered 
that the high degree of internal structure seen in high polymer concentration aerogel 
was not consistent throughout the aerogel structure with some areas consisting of 
much denser material. It was hypothesised that this was due to the lack of controlled 
directionality of the freezing of the samples causing irregular freeze concentration 
within the sample. The homogeneity of the internal structure of the aerogel was 
increased as polymer concentration decreased. It was discovered that during the 
production of furanone-loaded aerogel a significant percentage of HDMF and sotolon 
were lost. The impact of the pre-freezing step on furanone concentration was 
investigated and shown to have minimal effects. The lyophilisation process was then 
optimised and losses of HDMF and sotolon were significantly reduced. Due to 
continued degradation it was decided that MTHF and ascorbic acid were not suitable 
for use in the aerogel delivery system. Finally, the release kinetics of each of the 
furanones from several aerogel formulations was examined. It was demonstrated that 
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both HDMF and sotolon exhibited favourable release profiles from 10% PVA aerogels 
and, thus, this furanone delivery formulation was carried forward for testing against 
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Furanones as antibiofilm molecules 















P. aeruginosa is a ubiquitous gram-negative pathogen. It is present in a wide range of 
environmental niches including plants, soil, water, and farm animals (Mushin and Ziv, 
1973; Green et al., 1974). In recent years P. aeruginosa has become one of the most 
prevalent nosocomial infections in the developed world, making up 10.1% of reported 
hospital acquired infections in the United States in 1990. While this percentage has 
remained stable over time the prevalence of multidrug resistance in P. aeruginosa 
isolates has increased greatly. Indeed, imipenem, quinolone, and third generation 
cephalosporin resistance has increased in hospital P. aeruginosa isolates by 15%, 9% 
and 20% respectively between 2002 and 2003. (National Nosocomial Infection 
Surveillance System, 2004; Hirsch and Tam, 2010). Additionally, it was estimated that 
multi-drug resistant P. aeruginosa caused over 32,000 infections in hospitalised 
patients in 2017 leading to 2,700 deaths in the US alone (CDC, 2019). As well as the 
high levels of antimicrobial resistance seen in this organism,  P. aeruginosa has the 
ability to form biofilms on a range of biotic and abiotic surfaces (Rasamiravaka et al., 
2015). These biofilms, which consist of a collection of bacterial cells encased in a self-
produced polymer matrix, provide several advantages for P. aeruginosa including 
protection from physical stresses, such as mechanical force and desiccation, as well as 
protection from the host organism’s own immune system, as well as classical 
antibiotic treatments (Limoli, Jones and Wozniak, 2015). The regulation of bacterial 
biofilm formation is governed by a process known as quorum sensing (QS) and, by 





4.1.1 Quorum sensing 
QS is a cell density dependant method of bacterial communication used by many 
different organisms to coordinate complex behaviours and to respond to various 
external stimuli or stresses (Abisado et al., 2018). Although the signalling molecules 
used by gram-negative and gram-positive organisms for QS often differ significantly, 
the general mechanism remains the same. Briefly, bacterial cells constitutively express 
one or more signalling molecules, which exits the cell either by active transport or 
simple diffusion. These molecules then accumulate in the extra cellular environment 
(Ng and Bassler, 2009). This signalling molecule is detected by a recipient cell and 
this detection cause changes in the gene expression of the detecting cell. This process 
occurs simultaneously throughout large communities of organisms. By regulating 
population-wide gene expression, bacterial communities are able to coordinate 
complex behaviours such as the production of secreted virulence factors, swarming 
motility, and biofilm formation (Andersson et al., 2000; Cvitkovitch, Li and Ellen, 
2003; Hammer and Bassler, 2003; Brackman et al., 2012). The coordination of these 
behaviours gives the bacteria a distinct advantage during the infection of a host or 
when living in close proximity to other bacterial species (Koutsoudis et al., 2006; An 
et al., 2014). 
4.1.1.1 Quorum sensing in Pseudomonas aeruginosa 
QS in P. aeruginosa has been well studied and the organism is often used as a model 
to study various aspects of gram-negative QS. This organism does not utilise a single 
QS system but rather three interconnected, yet completely distinct, systems. The QS 
systems of P. aeruginosa are the Las system, Rhl system, PQS system. A fourth QS 
system known as the IQS system has been recently proposed but has not been 
extensively characterised (Lee et al., 2013). This section will discuss the Las, Rhl and 
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PQS system as they have been well studied. These QS systems are associated with the 
regulation of processes such as biofilm formation and virulence associated gene 
expression. They do not function in isolation as activation of one system leads to the 
activation or suppression of another (Pesci et al, 1997; McKnight, Iglewski and Pesci, 
2000; Welsh et al, 2015) and, as such, QS in P. aeruginosa is a complex process. In 
brief, P. aeruginosa constitutively expresses low molecular weight signalling 
molecules known as autoinducers (AI). In P. aeruginosa these molecules are known 
as N-(3-oxo-dodecanoyl)-homoserine lactone (OdDHL), N-(butyryl)-homoserine 
lactone (BHL) and the Pseudomonas quinolone signal (PQS). Both OdDHL and BHL 
are from a group of molecules known as the N-Acyl homoserine lactones (AHLs) 
while PQS is from a group of molecules known as quinolones. These signalling 
molecules are the cognate AI for the Las, Rhl and PQS systems respectively. These 
AHLs are produced and released by the bacteria accumulating in the extracelluar 
environment. Once a critical environmental AI concentration is reached the signalling 
molecules will interact with their cognate receptors and induce the expression of their 
target genes. The regulation of these target genes can result in the production of 
molecules such as endotoxins and enzymes (Lee and Zhang, 2014) or down regulation 
of surface antigens such as OprH (Arevalo-Ferro et al., 2003) to avoid detection by a 
host’s immune system.  
While the Las QS system is not the only QS system used by P. aeruginosa it is 
regarded as the top of the QS hierarchy. This is due to the fact that the action of the 
Las system can result in the activation of both the Rhl system and the PQS systems. 
As well as the regulation of the Rhl and PQS systems, the Las system has been shown 
to be responsible for the production of many virulence factors including the LasA, 
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LasB, and Apr protease enzymes (Toder, Gambello and Iglewski, 1991; Gambello, 
Kaye and Iglewski, 1993; Pearson, Pesci and Iglewski, 1997). 
Activation of the Rhl QS system controls the transcription and subsequent expression 
of distinct virulence associated genes including those involved in rhamnolipid, 
pyocyanin, and hydrogen cyanide production (Pearson, Pesci and Iglewski, 1997; 
Pessi and Haas, 2000). As with the Las QS system, the Rhl QS system does not act 
independently. As previously stated the Rhl system can be activated by the Las system 
but it can also supress the activation of the PQS QS system (Wade et al., 2005). In 
turn the PQS system can activate the Rhl system (McKnight, Iglewski and Pesci, 2000; 
Mukherjee et al., 2018). This interrelation of the various QS systems allows P. 
aeruginosa to compensate for the loss or inhibition of one QS system and still remain 
virulent. Figure 4.1 shows the interrelated nature of the Las, Rhl and PQS systems in 
P. aeruginosa. The complexity of bacterial QS and the ability of many species to 
compensate for the loss of one or more QS systems makes exploiting the inhibition of 
QS a particularly challenging task.  
While inhibiting QS in P. aeruginosa can be very complex, it is a highly attractive 
target and the subject of much research. The successful inhibition of P. aeruginosa QS 
would mean the reduction of the majority of the organisms’ virulence factor 
production, possible re-sensitisation of the organism to classical antibiotics and, 




Figure 4.1 - A schematic diagram of the known quorum sensing systems of P. 
aeruginosa.  
[1] OdDHL is produced by the organism and accumulates in the extracellular 
environment. [2] OdDHL enters the cell and interacts with the LasR transcriptional 
regulator. [3] The LasR/OdDHL complex initiates the transcription of genes such as 
lasl resulting in further production of OdDHL. [4] LasR/OdDHL also activates the 
trascrition of another QS system known as the Rhl system.[5] The transcription of rhlR 
results in the production of another transcriptional regulator (RhlR). [6] The 
transcription of rhlI results in the production of a second autoinducer molecule known 
as BHL. [7] BHL then diffuses out of the cell and begins to accumulate in the 
extracellular environment. [8] BHL then enters the cell and binds to RhlR and further 
activates the transcription of rhlI (and thus promotes the production of BHL and 
compounds such as pyocyanin and ramnolipids). [9] The RhlR/BHL complex also acts 
to negatively regulate the PQS system. [10-12] The PQS system is activated by the 
Las/OdDHL complex which causes the transcription of pqsH resulting in the 
production of the Pseudomonas Quinolone Signal (PQS). [13-14] As with the previous 
systems PQS then binds to PqsR and initiates transcription of the PQS operon which 
then positively regulates RhlR production and the production of virulence factors such 
as hydrogen cyanide. Figure from Proctor, McCarron and Ternan (2020).   
 
4.1.1.2 Biofilm formation 
Biofilms are groups of sessile cells attached to a biotic or abiotic surface by means of 
a self-produced polymer matrix. These biofilms have been implicated in a number of 
human diseases including cystic fibrosis (Lam et al., 1980; Singh et al., 2000), 
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infective endocarditis (Di Domenico et al., 2019), periodontal disease (Sanz et al., 
2017) and colonisation of indwelling medical devices such as urinary catheters 
(Trautner and Darouiche, 2004). The ubiquity of biofilms in human disease has made 
them a primary target for the development of new anti-infective therapeutics. 
However, in order to develop novel therapies against biofilms the mechanisms 
surrounding their development must be understood.  
 The formation of a biofilm is a complex process governed, at each stage, by QS 
(Rasamiravaka et al, 2015). Briefly, planktonic bacteria will attach, first reversibly 
then irreversibly, to a surface. This attachment results in changes in the expression of 
multiple genes involved in the biofilm formation process, such as the genes involved 
in the production of the polymeric matrix which provides the biofilm structure. 
Bacterial cells begin to aggregate to form microcolonies, encased in the extracellular 
polymeric substance. These polymers accumulate while bacterial cells continually 
divide. This provides much of the three-dimensional structure of the biofilm. Finally, 
once the biofilm has matured, large quantities of surfactants such as rhamnolipid are 
produced. These surfactants allow the biofilm to disperse, returning some of its cells 
to a planktonic state. Cells which have become planktonic again are then free to 
relocate and seed new biofilms. (Kostakioti, Hadjifrangiskou and Hultgren, 2013). 
The role of QS in biofilm formation has been debated for some time with many papers 
providing contradictory reports. Despite this, QS has been implicated in many stages 
of biofilm development by P. aeruginosa. QS controlled twitching motility has been 
shown to be involved in the formation of the microcolonies in the early stages of 
biofilm formation. As well as having a role in microcolony formation through the 
regulation of twitching motility, QS has also been shown to be involved in the process 
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of biofilm maturation and the formation and maintenance of its three-dimensional 
structure (Davies et al., 1998). 
As QS is indeed involved in the formation and maintenance of biofilms, the inhibition 
of the various QS systems in P. aeruginosa is of significant clinical interest. If the 
early stages of biofilm formation can be disrupted a weaker more treatable biofilm 
may be formed or there may be total prevention of biofilm formation. Similarly, if the 
maintenance of mature biofilms can be disrupted then it may be less likely to thrive 
and become less complex to eradicate. The potential for attenuating the impact of 
biofilms in human disease makes bacterial QS systems and their disruption a 
promising target for new therapeutics. 
Preventing biofilm formation in human disease by inhibiting QS as well as the 
development of novel QS inhibitors (QSI) molecules has been the subject of much 
research in recent years.   
4.1.2 Inhibition of quorum sensing 
The inhibition of QS can be achieved in a number of ways. These include the 
enzymatic degradation of the signalling molecules in the extracellular environment. 
This approach is known as quorum quenching. Quorum quenching has been shown to 
be effective in the past in reducing the virulence factor production by various plant 
pathogens such as Pectobacterium carotovorum (previously known as Erwinia 
carotovora) (Dong et al, 2001; Kusada et al, 2017). Efficacy has also been shown in 
human pathogens such as P. aeruginosa (Lin et al., 2003). However, this chapter will 
focus on the use of AHL structural analogues for the inhibition of QS. In particular, 




4.1.2.1 AHL structural homologues for quorum sensing inhibition  
Many studies have shown efficacy of various AHL analogues in inhibiting QS in a 
range of pathogens. These studies most often develop compounds in which one part 
of the AHL molecule (either the acyl side chain or the lactone ring) have been replaced 
or modified. Examples of these include the work of Morohoshi et al.(2007) and Ishida 
et al.(2007) and who showed that structural analogues of AHL, in which the lactone 
ring was replaced with a cyclopentane and the acyl side chain length varied from 4 
carbons to 12 carbons, were effectively able to inhibit virulence factor production in 
Serratia marcescens and P. aeruginosa respectively (Ishida et al., 2007; Morohoshi et 
al., 2007).   
As well as the synthesis of novel AHL analogues several naturally occurring 
compounds have been shown to be equally effective in attenuating virulence in a range 
of organisms. The natural aldehyde compound cinnamaldehyde has repeatedly been 
shown to be an effective QSI both downregulating the expression of key virulence 
factors in P. aeruginosa and potentiating the killing of Burkholderia biofilms by 
traditional antibiotics (Brackman et al., 2008, 2011; Ahmed et al., 2019). Further, even 
crude extracts of plants such as garlic have been shown to be highly effective in 
improving bacterial clearance in a mouse model of P. aeruginosa lung infection 
(Bjarnsholt et al., 2005).  
However, one family of natural compound that have shown promise as AHL analogues 
are furanones.    
4.1.2.2 Furanones as quorum sensing inhibitors 
The furanones are a class of natural molecules that are primarily found in marine and 
terrestrial plants where they often act as flavour and aroma compounds. They can be 
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extracted from a range of sources including seaweeds, strawberries, pineapple, coffee, 
herbs and spices (de Nys et al., 1993; Slaughter, 1999). These compounds are not 
exclusive to plants and some fungal species also produce the compounds (Bao et al., 
2017; Phainuphong et al., 2017; Zhou et al., 2018). It is also possible to produce 
furanones in a number of ways including direct chemical synthesis from simple 
precursors such as ketones and acetals (Caine and Ukachukwu, 1985; Tanabe and 
Ohno, 1988). Furanones are also produced as a by-product of processes such as the 
Maillard reaction which occurs during the browning of cooked foods (Wang and Ho, 
2008; Arihara, Yokoyama and Ohata, 2019). Although the structure of furanones had 
been tentatively characterised as early as the mid 1960’s their similarity to bacterial 
signalling molecules would not be noted until the discovery of autoinduction in 1970 
and the characterisation of the first AI in 1981 (Rodin et al., 1965; Nealson, Platt and 
Hastings, 1970; Eberhard et al., 1981). Indeed, the first characterised bacterial AI was 
named as N-(3-oxo-hexanoyl)-3-aminodihydro-2(3H)-furanone.  
The first investigations into the QS inhibition potential of furanones showed that a 
natural furanone from the red seaweed, D. pulchra, could attenuate QS mediated 
behaviours such as the swarming motility of S. liquifaciens and the bioluminescence 
of some Vibrio species (Givskov et al., 1996).  Since this early study furanones have 
been shown to inhibit QS in a range of non-human pathogens such as S. liquifaciens, 
V. harveyi. and P. carotovorum. The utility of furanones against these pathogens lead 
to an interest in their utility against human pathogens. 
Both synthetic and natural furanones have been shown to be effective in inhibiting QS 
controlled behaviours in both E. coli and P. aeruginosa. The natural furanone (5Z)-4-
bromo-5-(bromomethylene)-3-butyl-2(5H)-furanone has been shown to effectively 
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inhibit biofilm formation by up to 87% in E.coli (Ren et al., 2001). Similarly, a large 
number of natural furanones have been shown to inhibit not only biofilm formation 
but also virulence factor production and antibiotic resistance in vitro (Hentzer et al., 
2002, 2003; Pan et al., 2012).  
Furanones have also shown efficacy in in vivo models of Pseudomonas infections. 
Treatment with a furanone known as C-30 showed reduced QS by P. aeruginosa in 
the murine lung and that a 3-day treatment regime with C-30 allowed mice to better 
clear P. aeruginosa from the lungs. (Hentzer et al., 2003; Wu et al., 2004)  
For a comprehensive overview of the use of furanones as QSI the reader is referred to 
















4.2 Aims and objectives  
 The aim of the work described in this chapter is to characterise the antibiofilm effects 
of furanone compounds against the wound pathogen P. aeruginosa PAO1. This will 
be achieved by first characterising PAO1 growth and biofilm formation kinetics under 
ideal growth conditions. The minimum bactericidal concentration of each furanone 
will then be determined and validated. The biofilm formation kinetics of PAO1 will 
then be investigated under conditions of exogenous furanone treatment including 
treatment at the time of inoculation and, more realistically, a delayed biofilm treatment 
protocol. All furanone treatments will be conducted at sub-inhibitory concentrations 
to be determined in this chapter. Once the efficacy of each furanone has been assessed, 
biofilms will be treated using aerogels loaded with the most effective furanones. This 
will ensure the compounds’ efficacy is retained when loaded into the novel polymer 
aerogel delivery system. To assess the effect of furanone treatment on bacterial cell 












4.3.1 Materials and equipment 
All chemicals used were purchased from Sigma Aldrich (Poole, UK) and used without 
further modification unless otherwise stated. 
All bacterial culture media was purchased from Oxoid (Basingstoke, UK) and used as 
per the manufacturers guidelines unless otherwise stated 
BacLight cell viability stain was purchased from Thermo Fisher (Milton Keynes, UK) 
and used as per the manufacturer’s guidance 
4.3.2 Bacterial strain  
Bacterial strain DSM50071 was purchased from Deutchse Sammlung von 
Mikrooganismen und Zellkulturen (DSMZ) (Braunschweig Germany) as a lyophilised 
culture. Strain DSM50071 is identified by DSMZ as Pseudomonas aeruginosa 
(Schroeter 1897) Migula 1900, a PAO1 type strain. DSM50071 was selected for this 
project as a full genome sequence has recently been deposited in GenBank under 
accession number CP012001 (Nakano et al., 2015).  
4.3.3 Biochemical characterisation  
The purchased bacterial strain DSM50071 was verified as Pseudomonas aeruginosa 
PAO1 using several methods. DSM50071 was tested using a Gram stain, catalase test, 
oxidase test, and genetic identification.  
4.3.3.1 Gram stain  
A bacterial smear was prepared by placing 10 μL of sterile deionised water on a clean 
microscope slide. Using a sterile inoculation loop an individual colony was collected 
from a previously prepared streak plate of DSM50071 and mixed thoroughly with the 
235 
 
water. The suspended bacteria were then spread thinly across the glass slide and the 
slide was then passed rapidly through a flame to heat fix the smear. The heat fixed 
smear of was covered with 3-5 drops of Gram’s crystal violet solution (Sigma-Aldrich, 
Poole UK) and left for 60 s. The crystal violet was rinsed of using an indirect stream 
of deionised water. The bacterial smear was then covered with 3-5 drops of Gram’s 
iodine (Sigma-Aldrich, Poole UK) and left for 60 s. Gram’s iodine was washed off the 
smear using 95% ethanol solution until the ethanol ran clear (approximately 15 s). The 
smear was then covered with 3-5 drops of Gram’s safranin solution (Sigma-Aldrich, 
Poole UK) and left for 60 s. Safranin solution was washed off using an indirect stream 
of deionised water until the water ran clear. The bacterial smear was then visualised 
with a light microscope using oil immersion.  
4.3.3.2 Cytochrome C oxidase test  
Cytochrome c oxidase test was conducted using oxidase detection strips (Oxoid, 
Basingstoke UK). Using a sterile plastic inoculation loop an individual colony from a 
previously prepared streak plate was transferred to an oxidase detection strip and left 
for 5-10 s. As per the manufacturer’s guidance the use of a nichrome inoculation loop 
was avoided as this may have produced a false positive result. The oxidase test strip 
was observed for a colour change from white to blue/violet which would indicate a 
positive result.  
4.3.3.3 Catalase test  
Catalase test was conducted using the slide drop method. Using a sterile inoculation 
loop an individual colony was transferred from a previously prepared streak plate to a 
clean glass microscope slide. The use of a platinum wire inoculation loop was avoided 
as this may have produced a false positive result. One drop of 3% hydrogen peroxide 
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solution (Sigma-Aldrich, Poole UK) was added and observed for effervescence, 
indicative of a positive result.  
4.3.4 Genetic characterisation of DSM50071  
The purchased strain was confirmed as P. aeruginosa PAO1 DSM50071 using next 
generation Illumina sequencing. Sequencing and genome assembly were conducted 
through MicrobesNG. The purchased strain was grown on nutrient agar as per the 
MicrobesNG guidance and all biomass was removed from the plate and transferred 
to the provided sample tube. 
4.3.5 Microbiological characterisation of DSM50071  
A number of baseline microbiological experiments were performed to characterise the 
behaviour of PAO1 DMS50071 under ideal growth conditions. This was to allow for 
better design future experiments in which furanone treatment would be used. The 
baseline experiments undertaken were a standard growth curve, and a biofilm 
formation assay including CFU mL-1 measurements of viable cells in biofilm culture 
supernatants.  
4.3.5.1 Growth curve  
The growth kinetics of DMS50071 were characterised using a standard growth curve 
protocol. Overnight cultures of DSM50071 were prepared by transferring an 
individual colony from a previously prepared streak plate to 10 mL of sterile tryptone 
soy broth (TSB) (Oxoid, Basingstoke UK). Cultures were incubated at 37 °C with 
shaking at 200 rpm for 18 hours. A 1 mL aliquot of each overnight was transferred to 
99 mL of fresh, sterile, TSB in a sterile 250 mL Erlenmeyer flask giving a final dilution 
of 1:100. The optical density of the culture was then read at 600 nm (OD600) using a 
benchtop UV spectrophotometer. The OD600 was measured every 60 minutes for 8 
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hours and a final reading was taken after 24 hours. Growth curves were performed in 
independent, biological triplicates. 
4.3.5.2 Biofilm formation kinetics  
Biofilm assays were conducted using a standard crystal violet biofilm biomass assay 
(O’Toole, 2011) which was adapted for use in a 12 well tissue culture plate. Overnight 
cultures (three biological replicates) were prepared as described in section 4.3.5.1. 
From each biological replicate an aliquot of 600 μL was added to 59.4 mL of fresh, 
sterile TSB giving a final dilution of 1:100. Each plate was inoculated with 2 mL of 
the 1:100 overnight dilution. Each 12-well plate had three technical replicates of each 
biological replicate as well as three uninnoculated control wells containing sterile 
broth only as shown below in Figure 4.2. Plates were incubated at 37 °C in a static 
incubator for 4 hours, 6 hours, 8 hours, 12 hours, 18 hours, 24 hours, 36 hours, 48 
hours, and 72 hours. At each time point one plate was sacrificed. Prior to processing 
plates for assessment of biofilm biomass plates were gently shaken to resuspend 
planktonic cells. From each biological replicate an aliquot of 100 μL of culture 
supernatant was transferred to a sterile micro centrifuge tube. This aliquot was stored 
at 4 °C for later assessment of CFU mL-1. Plates were sacrificed for assessment of 
biofilm biomass by emptying out both the media and planktonic cells and rinsing the 
wells by rinsing the wells with clean deionised water from a squirt bottle. Plates were 
then blotted dry on clean tissue paper. Each well of the plate then had 2 mL of a 0.1% 
crystal violet solution added and was incubated for 10 minutes at room temperature 
on a plate rocker. After 10 minutes incubation, crystal violet was emptied out of each 
plate and plates were submerged in clean deionised water 3 times and blotted dry on 
clean tissue. Stained and rinsed plates were left in an inverted position and allowed to 
air dry overnight. After overnight drying, the biofilm bound crystal violet stain was 
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solubilised using 30% acetic acid in water solution. Each well had 2 mL of 30% acetic 
acid solution added to it and plates were incubated for 10 minutes at room temperature 
on a plate rocker. After 10 minutes of incubation, 100 μL of solubilised crystal violet 
in acetic acid was transferred to a new 96-well plate and absorbance at 550 nm was 
read using 30% acetic acid in water as a blank using a FluoStar Omega plate reader 






4.3.5.3 Assessment of CFU mL-1  
Aliquots of culture supernatants were collected from biofilm assay plates as previously 
described. CFU mL-1 values were assessed by serially diluting a 100 μL sample of 
biofilm supernatant in sterile PBS (Oxoid, Basingstoke UK). Each 100 μL of culture 
supernatant was briefly vortexed to break up any bacterial aggregates then added to 
900 μL of sterile PBS and mixed thoroughly to give a 10-2 dilution. A further 100 μL 
of this dilution was transferred to a fresh micro centrifuge tube containing 900 μL of 
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Figure 4.2 - A schematic showing the set up used for in vitro biofilm experiments.  
Well A-C 1 are uninnoculated broth. Wells A 2-4 contain three technical replicated of 
the first biological replicate. Similarly, wells B 2-4 and C 2-4 contain technical 
replicates of the second and third biological replicates respectively. 
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concentrations from10-2 to 10-8. Finally, a 100 μL volume of each dilution was plated 
on nutrient agar and incubated overnight at 37 °C. After incubation colonies were 
counted and average CFU mL-1 was calculated. This process was repeated for each 
time point.  
4.3.6 Assessment of minimum bactericidal concentration of furanone compounds  
To ensure that the concentrations of all furanone compounds tested in this project were 
the highest possible concentration without imposing a significant selection pressure 
on the bacterial cells minimum bactericidal concentrations (MBC) were measured for 
each compound. The MBC of each furanone compound was assessed using a broth 
dilution method and was confirmed using a streak plate method and a 2,3,5 triphenyl 
tetrazolium chloride (TTC) colorimetric assay.  
Overnight cultures of DSM50071 were prepared as described in section 4.3.5.1. After 
18 hours growth the overnight cultures were then diluted to a 1:50 dilution in fresh 
Meuller Hinton Broth (MHB) (Oxoid, Basingstoke, UK). Broth dilution plates were 
prepared by adding 1 mL of fresh sterile TSB aseptically to each well. A stock solution 
of the compound to be tested was prepared. For all four furanones tested stock 
solutions were prepared by making a saturated solution (according to the reported 
solubility of each compound) of the furanone in TSB. This stock solution was then 
filter sterilised using a 0.45μm syringe filter. For MTHF, which is a liquid at room 
temperature, a 500 μg mL-1 w/v stock solution was prepared in TSB and filter sterilised 
using a 0.45μm syringe filter. A 1 mL volume of a the furanone stock solution was 
added to the first well (A1) of the tissue culture plate and was mixed thoroughly by 
repeated gentle pipetting giving a 1:2 dilution of the furanone stock solution. Then 1 
mL of the contents of well A1 were removed and transferred to well A2. This was then 
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thoroughly mixed with repeated gentle pipetting to give a 1:4 dilution of the furanone 
stock solution. This was repeated for all wells up to and including well C2. After 
mixing the contents of well C2 thoroughly a 1 mL volume was removed from this well 
and discarded. Well C3 contained TSB only. Once the tissue culture plates were 
prepared with the furanone 1 mL of the 1:50 overnight dilution was added to each well 
to give a final dilution of 1:100 of the overnight culture and further diluting the 
furanone solution by 50%. The tissue culture plate was then incubated for 18 hours at 
37 °C with shaking. After 18 hours of incubation the tissue culture plate was removed 
from the incubator. Each well of the plate was gently pipetted several times to 
resuspend any settled cells. A 100 μL volume of culture was removed from each well 
and transferred to a fresh sterile 96-well tissue culture plate. To each well 100 μL of 
sterile 0.1% TTC in deionised water solution was added. Each well was thoroughly 
mixed by repeated pipetting. The plate was then wrapped in aluminium foil and 
incubated at 37 °C for 30 minutes. After 30 minutes, plates were assessed for a colour 
change with a red colour indicating the presence of metabolically active cells at that 
concertation of furanone.  
To confirm the results of the TTC assay a streak plate method was also used. A sterile 
inoculation loop was dipped into each well of the 12-well tissue culture plate and then 
streaked onto nutrient agar plates. These plates were incubated for 18 hours at 37 °C. 
After 18 hours of incubation, plates were inspected for bacterial growth. Absence of 
growth indicated a lack of viable cells at that concentration of furanone and so a 






4.3.7 Biofilm inhibitory effects of furanone compounds  
4.3.7.1 Biofilm inhibition of sub-inhibitory concentrations of furanones 
Experiments were undertaken to assess the efficacy of furanone compounds at sub-
MBC levels. P. aeruginosa PAO1 DSM50071 biofilms were grown in the presence of 
each furanone at half the previously measured MIC, one quarter, one eighth, one 
sixteenth and one thirty second of the previously measured MIC. Concentrations of 
furanone used are shown in Table 4.1. Biofilm plates were prepared as follows. Three 
biological replicate overnight cultures of PAO1 DSM50071 were diluted 1:100 into 
fresh TSB containing the concentration of furanone to be tested. A 2 mL volume of 
this overnight culture dilution was then pipetted into wells of a 12 well tissue culture 
plate as shown previously in Figure 4.2. This was repeated for each of the 5 
concentrations for each furanone. Tissue culture plates were then incubated for 24 
hours in a static incubator. After 24 hours incubation tissue culture plates were 
removed and biofilms were stained, destained and quantified as per section 4.3.5.2. 
Table 1 – A summary of the concentrations of each furanone investigated for 
antibiofilm effects against Pseudomonas aeruginosa PAO1.  
MBC Fraction HDMF MTHF Sotolon Ascorbic acid 
1/2 4 mg mL-1 1.95 μL mL-1 4.33 mg mL-1 5.50 mg mL-1 
1/4 2 mg mL-1 0.98 μL mL-1 2.16 mg mL-1 2.75 mg mL-1 
1/8 1 mg mL-1 0.49 μL mL-1 1.08 mg mL-1 1.38 mg mL-1 
1/16 0.5 mg mL-1 0.25 μL mL-1 0.54 mg mL-1 0.69 mg mL-1 
1/32 0.25 mg mL-1 0.12 μL mL-1 0.27 mg mL-1 0.34 mg mL-1 
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4.3.7.2 Biofilm inhibition assay  
The effect of furanone treatment on bacterial biofilms was assessed by assessing 
changes in biofilm biomass using a standard crystal violet assay. Overnight cultures 
of DSM50071 were prepared as described in section 4.3.5.1. Overnight cultures were 
diluted 1:100 into fresh, sterile TSB supplemented with a sub inhibitory dose of the 
compound to be tested. Sterile 12-well tissue culture plates were inoculated with 2 mL 
of 1:100 diluted overnight culture. Plates were incubated for 24 hours, 48 hours and 
72 hours at 37 °C. At each time point plates were sacrificed and stained with crystal 
violet, dried, destained and quantified as per section 4.3.5.2.  
4.3.7.3 Delayed treatment experiment 
To assess the impact of delayed treatment on the antibiofilm effects of the furanones 
a range of delayed treatment experiments were conducted. In these experiments PAO1 
DMS50071 biofilms were allowed to grow and become established for 24 hours or 48 
hours prior to treatment. Biofilm plates were prepared as previously described and 
biofilms were incubated for an appropriate amount of time. After incubation plates 
were removed from the incubator and a sub MBC (MBC/2) concentration of furanone 
(in 100 µL sterile deionised water) was added to each well. Plates were then returned 
to the incubator for a further 24 or 48 hours. Post treatment incubation plates were 
removed from the incubator and were stained, destained and quantified. 
4.3.8 Cell viability fluorescence imaging 
To assess the impact of furanone treatment on bacterial cell viability within the biofilm 
Live/Dead fluorescence staining was used. BacLight Live/Dead stain was used for the 
differentiation of cell viability based on cell wall permeability. This stain uses SYTO9 
to stain live cells green and propidium iodide (PI) to stain non-viable cells red. 
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4.3.8.1 Preparation of biofilms for BacLight staining  
Biofilms were prepared for BacLight staining using several substrates to identify an 
optimal method for growing a P. aeruginosa biofilm for Live/Dead staining. Biofilms 
were grown on 1cm x 1cm glass coverslips, polycarbonate chips and polycarbonate 
membranes (0.2 µm cut off) (Merck Millipore, UK). The protocol was similar for each 
substrate.  
Overnight cultures of P. aeruginosa PAO1 DSM50071 were grown in TSB for 18 
hours at 37 °C shaking at 200 rpm. The overnight culture was then diluted 1:100 in 
fresh TSB or TSB supplemented with sub-MBC concentrations of furanone to prepare 
the inoculum. To seed the biofilm plates, 2 mL volumes of the inoculum were pipetted 
aseptically into the wells of a 12 well plate. 
4.3.8.2 Preparation and application of the growth substrate 
Each of the substrates were sterilised by soaking in 70% ethanol and air drying in a 
laminar flow hood. A representative sample of each substrate was sterilised and placed 
in fresh TSB an incubated at 37 °C with 200 rpm shaking for 24 hours to confirm 
sterility. Once sterile, one type of substrate (glass, polycarbonate chip or membrane) 
was placed in each of the inoculated wells and pushed to the bottom of the well using 
a sterile plastic inoculation loop. This ensured that the substrate stuck to the bottom of 
the plate minimising the amount of biofilm that would form on the underside of the 
substrate. Inoculated plates with the growth substrates were then incubated in a static 
incubator at 37 °C for 24 hours or 48 hours. Following incubation, the substrates were 
carefully removed from the 12-well plates and rinsed by gentle submerging in sterile 
deionised water to remove any remaining planktonic cells and unbound biofilm 
matrix. Rinsed substrates were then then transferred to a fresh 12 well tissue culture 
plate for BacLight staining. 
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4.3.8.3 BacLight staining  
Bacterial biofilm in treated and untreated biofilms was assessed using a BacLight 
Bacterial Cell viability Kit (ThermoFisher, UK). A working BacLight reagent was 
prepared by mixing 4 µL of component A (1.67 mM SYTO9 and 1.67 mM PI) and 6 
µL of component B (1.67 mM SYTO9 and 18.3 mM PI) and 1.5 mL of sterile 
deionised water. Once prepared the working solution was protected from light 
whenever possible. Cleaned and rinsed substrates were stained with the BacLight 
working solution by adding sufficient volumes of the working solution for that the 
entire surface of the substrate was covered. Stained substrates were incubated for 30 
minutes in the dark at room temperature. Following the staining step, substrates were 
then removed from the 12-well plate and rinsed by gentle submerging in sterile 
deionised water to ensure any excess BacLight reagent had been removed. Substrates 
were then mounted on glass microscope slides. Biofilms were visualised at x40 
magnification using a Nikon ECLPISE E400 microscope with a dual band emission 
filter (450-490 nm and 510-560 nm. Images were captured using the Nikon NIS-
Elements BR software version 3.22.09. 
4.3.9 Efficacy of aerogel delivered furanones 
Once the antibiofilm activity of the furanone compounds had been established as 
described above the efficacy of furanones delivered using a novel polymer aerogel 
was assessed. Aerogel delivered furanones were tested when applied at the point of 
inoculation and using the more realistic delayed treatment protocol. 
4.3.9.1 Early application of furanone-loaded aerogels 
Furanone-loaded aerogels were prepared as per section 3.3.5.1 with one amendment. 
Furanones were loaded with sufficient concentrations of furanone so that the released 
portion of the total loaded drug (as identified in section 3.3.6) was equivalent to a sub-
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MBC dose. Biofilm plates were prepared an inoculated as per section 4.3.5.2. Once 
biofilm plates were prepared a furanone-loaded aerogel was applied to the surface of 
the broth using sterile forceps, ensuring good contact between the aerogel and the 
liquid surface. Unloaded aerogels were applied to control wells. Biofilm plates were 
then incubated at 37 °C in a static incubator for 24 hours or 48 hours.  After incubation 
aerogels and remaining planktonic cells were removed from each well and the wells 
were stained, destained and biofilm biomass quantified as outlined in section 4.3.5.2. 
4.3.9.2 Application of furanone-loaded aerogels using a delayed treatment approach 
The efficacy of aerogel application of furanones was tested using a more clinically 
relevant delayed treatment approach. Furanone-loaded aerogels were prepared as per 
section 3.3.5.1. The protocol was performed as described previously in section 4.3.9.1 
with one amendment. Once biofilms had been grown for the required 24 or 48 hours, 
rather of adding a volume of furanone solution, a furanone-loaded aerogel was applied 
to each well using sterile forceps and the plates were then incubated for a further 24 
hours or 48 hours. Biofilms were stained and quantified as detailed in section 4.3.5.2.  
4.3.10 – Assessment of furanone resistance to furanones 
As a number of genes with potential involvement in furanone resistance were 
identified from the literature (Maeda et al., 2012; García-Contreras et al., 2013; 
Heacock-Kang et al., 2018), the whole genome data previously gained from 
MicrobesNG was interrogated to identify the presence or absence of these genes in the 
strain used in this work. Strains deficient in nalC and mexR have been shown to have 
a greater resistance to furanones through enhanced efflux due to limited repression of 
the MexAB-oprM efflux transporter which is ordinarily repressed by nalC / mexR. 
Further, both MdrR1 and MdrR2 have both been shown to be repressors of MexAB-
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oprM and an additional efflux transporter, EmrAB. Absence of the genes encoding for 
these proteins would suggest the strain has an increased capacity for furanone efflux. 
First, a previously published sequence for DSM50071 was interrogated for the 
presence or absence of the four genes. This was achieved using the National Centre 
for Biotechnology Information (NCBI) BlastN tool to search the genome for areas that 
had high sequence homology compared to the sequence of the genes of interest.   
Secondly, the annotated genome of the strain used in this work (constructed by 
MicrobesNG) was searched for the presence of four separate genes; nalC, mexR, 
MdrR1, and MdrR2. If named genes were not found within the annotated genome, the 
complete FASTA sequence of the strain was interrogated for sequences showing high 
homology when compared with previously published base sequences of each gene. If 
no areas of high homology were found in the FASTA sequence it was concluded that 




















The antibiofilm efficacy of 4 furanone compounds; MTHF, sotolon, HDMF and L-
ascorbic acid, was tested using a number of methods. The efficacy of each compound 
was tested against P. aeruginosa PAO1 (DSM50071) biofilms.  
4.4.1 Basic characterisation of PAO1 DSM50071 
Some basic tests were conducted to assess the behaviour of PAO1 DSM50071 under 
ideal growth conditions. The growth kinetics in liquid medium, biofilm formation 
kinetics and the viable cell count in the liquid phase of biofilm cultures were assessed. 
A growth curve at 37 °C and 200 rpm shaking showed the expected growth kinetics 
with a lag in growth until 2 hours and logarithmic growth thereafter. A final culture 
optical density of approximately 3 (measured at 600 nm) was observed (Figure 4.3 a).  
Biofilm kinetics were assessed using the O’Toole and Kolter crystal violet method 
adapted for use in a 12-well tissue culture plate. Biofilm growth showed the expected 
gradual increase in biofilm biomass over the first 8 hours followed by a period of 
fluctuation in overall biofilm biomass (Figure 4.3 b). The numbers of CFU mL-1 in the 
culture liquid phase of the biofilm cultures was also assessed and the data showed a 
gradual increase in CFU mL-1 over the first 12 hours followed by a stationary phase 
until approximately 24 hours followed by a gradual decline in viable cell numbers 





4.4.2 Assessment of the antimicrobial and antibiofilm activity of furanones 
The minimum bacteriostatic concentration of each furanone was assessed using a TTC 
colorimetric assay and the minimum bactericidal concentration was confirmed using 
a streak plate method.  
 
 





















































 Figure 4.3 – Basic characterisation of PAO1 DSM50071 growth and biofilm 
formation.  
(a) A growth curve of the organism under ideal conditions showed a lag phase of 2 
hours followed by exponential growth as expected. (b) Examination of biofilm 
formation kinetics of PAO1 DSM50071 showed variable biofilm biomass over time as 
expected. (c) Assessment of the number of viable bacteria in the liquid phase of the 
biofilm cultures showed a gradual increase in CFU/mL over 12 hours followed by a 




4.4.2.1 Determination of the minimum bactericidal concentration of furanone 
compounds 
Each furanone was assessed for antimicrobial activity and the MBC was identified. 
Using a TTC assay HDMF was shown to have an MBC of 8 mg mL-1, MTHF showed 
an MBC of 3.9 µg mL-1, ascorbic acid had an MBC of 11.01 mg mL-1 and sotolon 
showed an MBC of 8.65 mg mL-1. Each of these concentrations was further confirmed 
using a streak plate method (Figure 4.4). 
 
 
Figure 4.4 – Determination of the minimum bactericidal concentration (MBC) of 
each furanone using a streak plate method and a 2,3,5 triphenyl tetrazolium 
chloride (TTC) assay.  
The streak plate method showed that P. aeruginosa PAO1 was effectively killed when 
treated with 8 mg mL-1 of HDMF, 3.90 µg mL-1 of MTHF, 11.01 mg mL-1 of ascorbic 
acid and 8.65 mg mL-1 of sotolon. These results were confirmed using a TTC assay. 
Lack of a colour change to red indicated a lack of metabolically active cells in the 






4.4.2.2 Antibiofilm effects of sub-inhibitory concentrations of furanones 
An assessment of the antibiofilm effects of each furanone at a concentration of 
between half of the MBC and one thirty second of the MBC was conducted. It was 
found that after treatment for 24 hours there was no significant reduction in biofilm in 
cultures treated with any concentration ascorbic acid (Figure 4.5 a). This was also seen 
to be the case for cultures treated with MTHF with no reduction in biofilm at any 
furanone concentration (Figure 4.5 b). However, in cultures treated with HDMF a 
significant reduction in biofilm at one half MBC and one quarter MBC concentrations 
of 62.36% and 58.7% was observed (Figure 4.5 c). These furanone concentrations 
correspond to 4 mg mL-1 (one half MBC) and 2 mg mL-1 (one quarter MBC) of HDMF 
in tryptone soy broth. When treated with sotolon, significant reductions in biofilm of 
62.73% and 54.67% were seen in cultures treated with one half MBC and one eighth 
MBC respectively (Figure 4.5 d). These concentrations correspond to 4.33 mg mL-1 




Figure 4.5 – The antibiofilm effects of a range of sub inhibitory furanone 
concentrations when applied at the point of inoculation.  
(a) Ascorbic acid showed no antibiofilm effect at any sub inhibitory concentration. (b) 
MTHF showed no significant reduction in biofilm biomass at any concertation tested. 
(c) HDMF showed an antibiofilm effect (62.36% reduction) at one half and one 
quarter of the established MBC and an antibiofilm effect when treated with one 
quarter of the established MBC (58.7% reduction). (d) Sotolon showed an antibiofilm 
effect at one half and one eighth pf the established MBC (62.73% and 54.67% 
reductions respectively). Data represents the average of 3 biological replicates and 3 
technical replicates ±S.D. Data was analysed using independent T tests. 
 
4.4.2.3 Antibiofilm effects of sub-inhibitory concentrations of furanones over 72 h 
The antibiofilm effects of sub-inhibitory concentrations of each furanone was assessed 
over 72 hours. When treated with a sub-inhibitory concentration (5.5 mg mL-1) of 
ascorbic acid, no antibiofilm effects were seen at 24 hours or 48 hours. However, at 
72 hours an increase in biofilm biomass was of 406% was observed (Figure 4.6 a). 
When treated with a sub-inhibitory concentration of MTHF (1.95 µL mL-1), no 
antibiofilm effects were seen at 24 hours. A slight reduction in biofilm biomass of 
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26.45% was observed at 48 hours and a slight increase in biofilm biomass of 47.23% 
was observed at 72 hours (Figure 4.6 b). When treated with a sub-inhibitory dose of 
HDMF (4 mg mL-1), consistent reduction in biofilm biomass were seen when 
compared with an untreated control. Reductions of 76.67%, 77.02% and 88.33% were 
seen at 24 hours, 48 hours and 72 hours respectively (Figure 4.6 c). When cultures 
were grown in the presence of a sub-inhibitory dose of sotolon (4.33 mg mL -1) 
reductions in biofilm biomass of 87.20%, 86.58% and 66.13% were observed at 24 
hours, 48 hours and 72 hours, respectively (Figure 4.6 d)  
 
Figure 4.6 – Antibiofilm effects of each furanone at one half the established 
minimum bactericidal concentration when applied at the point of inoculation.  
(a) Ascorbic acid treatment did not result in any antibiofilm effect at 24 hours or 48h 
post infection but did show a strong promotion of biofilm formation at 72h post 
inoculation with an increase in biofilm biomass of 406%. MTHF (b) showed no 
significant antibiofilm activity 24h post inoculation but saw a significant reduction in 
biofilm biomass of 26.45% at 48 hours post inoculation and a significant increase of 
47.23% at 72 hours post inoculation. HDMF (c) showed a 77.67% reduction in biofilm 
biomass 24 hours post inoculation, a 77.02% reduction at 48 hours post inoculation 
and an 88.33% reduction at 72 hours post inoculation. Sotolon (d) showed an 87.2% 
reduction in biofilm biomass 24 hours post inoculation, an 86.58% reduction 48 hours 
post inoculation and a 66.13% reduction at 72 hours post inoculation. Data represents 
the average of 3 biological replicates and 3 technical replicates ±S.D. Data was 
analysed using 2-way ANOVA. *** p<0.001, **p<0.01, * p<0.05  
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4.4.3 Effects of furanones on cell viability in biofilms 
The effect of furanone treatment on the viability of biofilm bound PAO1 cells was 
assessed using fluorescence microscopy and BacLight cell viability stain.  
4.4.3.1 Cell viability in treated immature biofilms 
PAO1 biofilms were grown in the presence or absence of a sub–inhibitory 
concentration of each furanone and visualised using BacLight cell viability stain with 
live cells being stained green by SYTO9 and dead cells being stained red by PI. At 24 
hours untreated control biofilms presented as uniform in appearance with cell evenly 
spread across the growth substrate. Some non-viable cells are seen throughout the 
biofilm. At 48 hours the biofilms remain evenly populated, a slight increase in non-
viable cells are noted in a small number of localised clumps (Figure 4.7). 
 
Figure 4.7- BacLight staining of an untreated control biofilm at 24 hours and 48 
hours post inoculation.  
Live cells are shown in green in images a and d. (a) At 24 hours the biofilm appears 
to be evenly populated with live cells evenly distributed across the substrate. (b) At 48 
hours numbers of viable cells have increased and remain evenly distributed over the 
growth surface. Non-viable cells are shown in red in images b and e. (b) At 24 hours 
only small numbers of non-viable cells are present within the biofilm. (e) At 48 hours 
more non-viable cells are apparent. These cells appear localised to dense clumps of 
aggregated cells. Images c and f represent a composite of images a and b, and d and 




Biofilms grown in the presence of 4 mg mL-1 HDMF showed significant clumping and 
aggregation of cells with large areas of substrate with no cells apparent after 24 hours. 
No obvious increase in non-viable cells was seen. At 48 hours the clumping appeared 
to have dispersed although some small aggregates were apparent. Amounts of non-
viable cells appeared to remain constant (Figure 4.8). 
 
Figure 4.8- BacLight staining of an HDMF treated biofilm at 24 hours and 48 
hours post inoculation.  
Live cells are shown in green in images a and d. (a) significant clumping of cells was 
apparent in biofilms grown in the presence of HDMF. (d) this clumping then dispersed 
at 48 hours. Non-viable cells are shown in red in images b and e. (b) Small amounts 
of non-viable cells can be seen localised primarily in the larger cell aggregates. (e) 
After 48 hours the non-viable cells had been dispersed similarly to the live cells. 
Images c and f represent a composite of images a and b, and d and e respectively. All 
results shown are representative images of 3 independent replicates. 
 
Biofilms grown in the presence of 4.33mg mL-1 of sotolon presented as poorly 
populated biofilms composed primarily of small aggregates on the growth substrate 
after 24 hours. Similar quantities of non-viable cells were observed when compared to 
both untreated controls and HDMF treated biofilms. At 48 hours aggregates had 
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dispersed but cells remained sparse on the substrate. No obvious increase in non-viable 
cells was observed over the 24 hours biofilms (Figure 4.9). 
 
Figure 4.9- BacLight staining of a sotolon treated biofilm at 24 hours and 48 
hours post inoculation.  
Live cells are shown in green in images a and d. (a) Clumping of small amounts of 
cells was seen in the presence of sotolon. (d) this clumping then dispersed at 48 hours. 
Non-viable cells are shown in red in images b and e.(b) Small amounts of non-viable 
cells can be seen in the clumps of cells. (e) After 48 hours the non-viable cells had 
been dispersed similarly to the live cells. Images c and f represent a composite of 
images a and b, and d and e respectively. All results shown are representative images 
of 3 independent replicates. 
 
When treated with 1.95µg mL-1 of MTHF, biofilms presented as well populated but 
heavily clumped films at 24 hours. At this point non-viable cells appeared to be located 
entirely within the clumps of cells which had formed. At 48 hours clumping was still 
apparent and it appeared that very few viable cells were present outside of the large 
aggregates which had formed. Non-viable cells again appeared primarily within the 




Figure 4.10 - BacLight staining of an MTHF treated biofilm at 24 hours and 48 
hours post inoculation.  
Live cells are shown in green in images a and d. Non-viable cells are shown in red in 
images b and e. (a-b) At 24h biofilms were well populated but showed aggregation of 
both viable and non-viable cells. (d-e) At 48h clumping remained apparent in biofilms 
and few viable cells were present on the growth substrate outside of the aggregates. 
Non-viable cells were located primarily within the clumps. Images c and f represent a 
composite of images a and b, and d and e respectively. All results shown are 
representative images of 3 independent replicates. 
 
When treated with 5.50mg mL-1 of ascorbic acid, biofilms were well populated but 
appeared to show a degree of clumping of both viable and non-viable cells. At 48 
hours biofilms remain well populated a clumping remains present for both viable and 





Figure 4.11- BacLight staining of an ascorbic acid control biofilm at 24 hours and 
48 hours post inoculation. 
 Live cells are shown in green in images a and d. Non-viable cells are shown in red in 
images b and e. (a-b) At 24 hours biofilms were evenly populated with small 
aggregates of viable and non-viable cells evenly distributed across the growth 
substrate. (d-e) At 48 hours biofilms remained well populated and clumping was still 
apparent. Images c and f represent a composite of images a and b, and d and e 
respectively. All results shown are representative images of 3 independent replicates. 
 
Viability staining of biofilms grown in the presence of sub-inhibitory concentrations 
of each furanone demonstrated that both HDMF and sotolon resulted in significantly 
less biofilm formation compared to untreated controls. Conversely, biofilm growth in 
the presence of sub inhibitory concentrations of MTHF appeared to be enhanced. 
Finally, treatment with sub inhibitory concentrations of ascorbic acid had no apparent 
effect on biofilm formation when compared with an untreated control. 
4.4.4 Antibiofilm effects of sub-inhibitory concentrations of furanones on mature 
biofilms  
The effects of furanone treatment on mature biofilms was also assessed as this 
represents a more accurate scenario likely to be encountered with a chronic wound. 
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When treated with 4 mg mL-1 HDMF, 24 hours old biofilms were shown to be reduced 
by 60.01% after 24 hours of treatment and 67.13% after 48 hours treatment (Figure 
4.12 ai). When treated with a similar concentration of HDMF, 48 hours old biofilms 
were increased by 226% after 24 hours of treatment and showed no significant 
difference after 48 hours of treatment (Figure 4.12 a ii). When treated with 4.33mg 
mL-1 of sotolon, a 24 hours old biofilm showed a reduction in biofilm biomass of 
77.66% and 56.12% at 24 hours post treatment and 48 hours post treatment 
respectively (Figure 4.12 bi). When treated with the same dose of sotolon, 48 hours 
old biofilms showed no significant changes in biofilm biomass (Figure 4.12 b ii). 
Delayed treatment with 1.95 µL mL-1 of MTHF a 46.36% reduction in biofilm biomass 
was seen in 24 hours old biofilms after 24 hours treatment. No significant reduction 
was seen after 48 hours of treatment (Figure 4.12 ci). No significant reductions in 
biofilm biomass was seen when a 48 hours old biofilm was treated with MTHF (Figure 
4.12 cii). When both 24 hours and 48 hours old biofilms were treated with 5.50mg 
mL-1 of ascorbic acid, no significant reductions in biofilms were seen at any time point 
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4.4.5 Aerogel-mediated delivery of furanones 
The antibiofilm effects of furanone compounds when delivered using the novel 
aerogel system was assessed. Both HDMF and Sotolon-loaded aerogels were assessed 
using an unloaded aerogel as a control.  
4.4.5.1 Treatment of immature biofilms with aerogel delivered furanones 
The effects of application of aerogel delivered furanones to early stage PAO1 biofilms 
was assessed. When applied at the point of inoculation, an unloaded aerogel showed 
no significant decrease in biofilm biomass when compared to an untreated control at 
either 24 hours or 48 hours post treatment (Figure 4.13 a). When treated with an 
HDMF-loaded aerogel at the time of inoculation, a reduction of 81.08% and 70.00% 
in biofilm biomass was observed 24 hours and 48 hours post treatment respectively 
(Figure 4.13 b). When a sotolon aerogel was applied at the time of inoculation, a 100% 
and 94.72% reduction in biofilm biomass was observed at 24 and 48h, respectively, 
when compared to a blank aerogel control (Figure 4.13 c). This result was repeated 
Figure 3.12 - Treatment of mature PAO1 biofilms with furanone compounds. 
(a i) Treatment with 8mg mL-1 HDMF resulted in a 60.01% and 67.13% reduction 
in the biomass of a 24 hours old biofilm at 24 and 48 hours post treatment 
respectively. (a ii) This treatment cause a 226% increase in biofilm biomass and no 
significant change in biofilm biomass of a 48 hours old biofilm at 24 and 48 hours 
post treatment respectively (b i).Treatment with 4.33mg mL-1 of sotolon showed a 
77.66% and a 56.12% reduction in biomass of a 24 hours old biofilm at 24 and 48 
hours old biofilm respectively (b i). Treatment with 4.33mg mL-1 sotolon showed no 
significant decrease in biofilm biomass in a48 hours biofilm (b ii). When treated with 
1.95µg mL-1 of MTHF, a 24 hours biofilm showed a 46.36% reduction in biofilm 
biomass 24 hours post treatment and no significant change in biofilm biomass 48 
hours post treatment (c i). MTHF treatment of a 48 hours old biofilm showed no 
significant changes (c ii). Treatment with 5.50mg mL -1 ascorbic acid showed no 
significant changes in biofilm biomass in either a 24 hours old biofilm or a 48 hours 
old biofilm (d i-ii). Data represents the average of 3 biological replicates and 3 




and verified independently, and a 98.37% and 100% reduction were observed at 24 
and 48h post treatment respectively (data not shown).   
 
Figure 4.13 - The antibiofilm effects of aerogel delivered furanones when 
delivered at the time of inoculation.  
(a) When treated with an unloaded aerogel cultures of PAO1 showed no significant 
decreases in biofilm biomass either 24 or 48 hours post treatment. (b) When treated 
with an HDMF-loaded aerogel biofilm biomass was reduced by 81.08% and 70.00% 
at 24 and 48 hours post treatment respectively. (c) When cultures of PAO1 were 
treated with a sotolon-loaded aerogel a 100% reduction in biofilm biomass was 
observed 24h post treatment as a 94.72% reduction was observed 48 hours post 
treatment. This finding was then confirmed using a new PAO1 culture and was 
validated as the repeated experiment showed a 98.37% and 100% reduction in biofilm 
biomass at 24 and 48h post treatment – data not shown. Data represents the average 
of 3 biological replicates and 3 technical replicates ±S.D. Data was analysed using 
independent t-tests   
 
4.4.5.2 Treatment of mature PAO1 biofilms with aerogel delivered furanones 
The antibiofilm effect of aerogel delivered furanones were assessed against mature 
biofilms. When a 24 hours old biofilm was treated with an unloaded control aerogel, 
an increase of 40.67% biomass was seen at 24 hours post treatment and no significant 
change was seen 48 hours post treatment (Figure 4.14 a). When a 48 hours old biofilm 
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was similarly treated, no significant effect was seen after 24 hours and a 35.24% 
reduction in biofilm biomass was seen 48 hours post treatment (Figure 4.14 b). When 
treated with an HDMF-loaded aerogel, a 24 hours old biofilm showed a 41.14% 
decrease in biofilm biomass 24 hours post treatment and a 41.87% reduction in 
biomass 48 hours post treatment when compared to an untreated control. These 
reductions increased to 58.41% and 54.80% respectively when compared to a blank 
aerogel treatment (Figure 4.14 a). When a 48 hours old biofilm was treated with an 
HDMF-loaded aerogel, a 43.64% reduction was seen 24 hours post treatment when 
compared to an untreated biofilm, but no significant difference was observed when 
compared to an unloaded aerogel treatment. A 71.01% reduction in biomass was seen 
48 hours post HDMF aerogel treatment when compared to no treatment but only a 
61.61% reduction when compared to an unloaded gel treatment (Figure 4.14 b). When 
a 24 hours old biofilm was treated with a sotolon-loaded aerogel, no significant 
changes in biofilm biomass were observed at either 24 hours or 48 hours post treatment 
when compared to the blank aerogel treatment but an increase in biofilm biomass of 
25.75% was seen 24 hours post treatment of a 24 hours old biofilm when compared to 
the untreated control (Figure 4.14 a). Similarly, no significant reduction in biofilm 
biomass were observed when 48 hours old biofilms were treated with a sotolon aerogel 
after either 24 hours or 48 hours post treatment when compared to an unloaded aerogel 
(Figure 4.14 b). A decrease of 24.46% was observed 48 hours post treatment of a 48 







Figure 4.14 – Delayed treatment of mature biofilms with aerogel delivered 
furanones. 
 (a) When a 24 hours biofilm was treated with an unloaded aerogel a 40.67% increase 
was observed 24 hours post treatment. No significant change was noted following 48 
hours of treatment when compared to untreated controls. HDMF treatment of a 24 
hours old biofilm showed a 41.14% decrease in biofilm biomass 24 hours post 
treatment and a 41.87% reduction versus an unloaded aerogel treatment 48 hours 
post treatment. Sotolon treatment of a 24 hours old biofilm showed no significant 
changes in biofilm biomass over a blank aerogel treatment 24 hours and 48 hours post 
treatment. (b) When a 48 hours old biofilm was treated with a blank aerogel no effect 
was seen after 24 hours and a 35.24% reduction was observed after 48 hours 
treatment. HDMF treatment of a 48 hours old biofilm showed a 43.64% decrease in 
biofilm biomass 24h after treatment and no significant changes after 48 hours. Sotolon 
treatment of a 48h old biofilm showed no significant changes in biofilm biomass 24 or 
48 hours post treatment when compare to a blank aerogel control. Data represents 
the average of 3 biological replicates and 3 technical replicates ±S.D. Data was 
analysed using independent t-tests   
 
4.4.6 Assessment of DSM50071 genetic elements conferring resistance  
A previously published genome for DMS50071 was interrogated using the NCBI 
Blastn tool for the presence or absence of 4 genes believed to be involved in furanone 
resistance; nalC, mexR, MdrR1, and MdrR2.  These genes were found not to be present 
in the published genome for DSM50071. The whole genome sequence provided by 
MicrobesNG was interrogated to confirm the presence or absence these genes in the 
strain used in this work. It was found that the DSM50071 strain used in this work had 
no sequences within the genome that were homologous to nalC, mexR, MdrR1 or 
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MdrR2, thus, confirming the hypothesis that the limited efficacy of furanones shown 

























P. aeruginosa is one of the most common pathogens isolated from chronic wounds 
(Serra et al., 2015). When present in a wound, P. aeruginosa primarily grows in the 
form of a biofilm and it is the presence of these biofilms that often cause an acute 
wound to fail to heal, thus, becoming chronic (Wolcott, Rhoads and Dowd, 2008; Zhao 
et al., 2013). Due to their prominent role in the development and maintenance of 
chronic wounds, novel treatments against P. aeruginosa biofilms are greatly needed. 
Therefore, the aim of this chapter was to conduct an assessment of furanones as 
potential QSIs and antibiofilm compounds against the common wound pathogen P. 
aeruginosa PAO1 (DSM50071).  
Prior to applying furanone treatments an understanding of the baseline characteristics 
of the organism was required. Organism growth kinetics in liquid media were in 
keeping with expectations. Biofilm formation kinetics in a 12-well tissue culture plate 
showed continuous rise and fall of adhered biomass (as measured by retained crystal 
violet). This finding is in keeping with the work of Murray et al.(2017) who showed 
a similar pattern of increasing and decreasing biofilm biomass in P. aeruginosa. 
(Murray et al., 2017). It is thought that these changes in biofilm biomass may be due 
to maturation and subsequent dispersal of the biofilm. The numbers of viable cells in 
the liquid phase of the biofilm cultures was also assessed. It was shown that a steady 
increase in planktonic cells occurred from 4 hours to 18 hours post-incubation after 
which stationary phase was reached and after 24 hours a decline in viable cell numbers 
in begins.  
Following this initial characterisation of the strain, the MBC of each furanone was 
measured. For the purposes of this work a sub-inhibitory dose of each furanone were 
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used. The reason for doing so was twofold. First, if a sub-inhibitory concentration of 
furanone is used it is more likely that any reduction in biofilm is due to QSI effects 
rather than reductions in viable cell numbers. Second, when using a sub-inhibitory 
dose of furanone, a greatly reduced selection pressure is placed on the organism, 
therefore, minimising the chance of resistance developing. While the development of 
resistance to the compounds has little importance in in vitro testing, if the use of 
furanones was translated to use in humans, this would be a significant problem. 
Indeed, it has already been shown that some bacterial isolates have an inherent 
resistance to furanone compounds with some P. aeruginosa strains being able to efflux 
furanones more effectively (Maeda et al., 2012; García-Contreras et al., 2013). In this 
work it was shown that the MBC of HDMF, MTHF, ascorbic acid and sotolon were 
8mg mL-1, 3.90μL mL-1, 11.01mg mL-1 and 8.65 mg mL-1, respectively. To ensure 
concentrations used for each experiment were sub inhibitory half of the MBC was 
used. (4 mg mL-1, 1.95 μL mL-1, 5.50 mg mL-1 and 4.33 mg mL-1 for HDMF, MTHF, 
ascorbic acid and sotolon, respectively). The MBC values identified in this work are 
significantly higher than values previously reported for other organisms. For example, 
Sung et al. (2007) reported an MIC value 80 μg mL-1 for HDMF against wild type P. 
aeruginosa and a value of 120 μg mL-1 against vancomycin resistant enterococci 
(VRE)(Sung et al., 2007). Similarly, Xu et al. reported MIC values for HDMF of 
between 19 and 39 μg mL-1 for a range of dental pathogens (Xu, Howard and Xie, 
2016). In 2014 Choi et al. reported an MIC for HDMF when used against P. 
aeruginosa KCTC1637 of 624.8 μM or 80.06 μg mL-1. This means that the MBC for 
HDMF presented here is more than thirty-three time greater than the highest 
previously reported MIC, and some fifty times higher than previously reported MIC 
values against P. aeruginosa specifically. One study reported the MIC of sodium 
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ascorbate (the sodium salt of ascorbic acid) to be 100 mg mL-1. This is almost ten 
times greater than the MBC of ascorbic acid reported in this work. This may be due to 
an effect reported in 1992 by Oh and Marshall, who found that reducing the pH of a 
bacterial medium subsequently reduced the MIC of a surfactant known as monolaurin 
(Oh and Marshall, 1992). As ascorbic acid dissociates in an aqueous environment, 
such as bacterial growth media, it produces ascorbate mono ions and positively 
charged hydrogen ions. The production of excess hydrogen ions would lower the pH 
of the medium. If the effect reported by Oh and Marshall holds true for ascorbic acid 
this reduction in pH may potentially reduce the MBC of the compound below the 
reported MBC for sodium ascorbate. Unfortunately, due to the limited use of 
furanones in the literature reliable, reports of MBC values for MTHF and sotolon are 
not available and so comparisons to the findings reported here cannot be made. Despite 
this, the MBC values identified in this chapter were shown to be accurate using both 
a streak plate method and orthogonally validated using a colorimetric TTC assay. As 
such these data are robust.    
The antibiofilm effects of each furanone at a range of concentrations were rapidly 
assessed by incubating P. aeruginosa PAO1 with a range of furanone concentrations 
from half MBC to one thirty second of the established MIC. Biofilm inhibition was 
assessed and reported as a reduction in total biofilm biomass after 24 hours. It was 
shown that neither ascorbic acid nor MTHF showed any effects on PAO1 biofilm 
biomass at any tested concentration.  HDMF showed a significant reductions of equal 
magnitude in biofilm at one half and one quarter MBC (4mg mL-1 and 2mg mL-1) 
while sotolon showed significant decreases (also similar in magnitude) in total biofilm 
biomass at half MBC and one eighth MBC (4.33mg mL-1 and 1.08mg mL-1).  It was, 
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therefore, decided that half MBC would be used as the treatment dose of each furanone 
for all subsequent experiments.  
The antibiofilm effect of each furanone was assessed at a concentration of half MBC 
over 72 hours when administered at the point of inoculation. It was shown that ascorbic 
acid had no effect on quantities of biofilm biomass at 24 hours or 48 hours post 
inoculation. However, at 72 hours ascorbic acid treated biofilms were seen to have 
406% more biomass when compared to untreated controls. This is in direct contrast to 
the two recent studies by El-Mowafy et al. (2014) and Pandit et al. (2017). It was 
demonstrated by El-Mowafy that sodium ascorbate effectively reduces the formation 
of biofilm by P. aeruginosa PAO1 by over 60% at one eighth of the established MBC 
(equal to 12.5 mg mL-1 in their study) and by approximately 50% at one twentieth of 
the established MIC (equivalent to 5 mg mL-1 in their study) (El-Mowafy, Shaaban 
and Abd El Galil, 2014). These findings suggest that the concentration of ascorbic acid 
used in this work (5.5 mg mL-1) should have had a significant effect on biofilm 
formation. Similarly the work of Pandit et al. showed a biofilm inhibitory effect of 
sodium ascorbate at a concentration of 3.96 mg mL-1 and greater (Pandit et al., 2017). 
This, again, indicates that the concentration used in this work should have shown an 
antibiofilm effect. As it has been previously shown that ascorbic acid is unstable in 
aqueous environment it is hypothesised that one or more degradation products of 
ascorbic acid caused the increase in biofilm. This may occur either by the degradation 
product acting as a QS agonist or simply by providing a chemical insult causing the 
bacteria to rapidly form a protective biofilm.  
The use of MTHF showed no notable effect on biofilm biomass 24 hours post 
treatment, a 26.45% reduction at 48 hours and a 47.23% increase in biomass at 72 
269 
 
hours. As no previous reports exist of the use of MTHF for the inhibition of biofilm 
these findings cannot be compared to previous work. However, as with ascorbic acid 
the previously demonstrated instability of MTHF may have resulted in degradation 
product which cause an increase in biofilm formation in P. aeruginosa. While ascorbic 
acid and MTHF were largely unsuccessful in inhibiting biofilm formation in PAO1 
both HDMF and sotolon showed high levels of biofilm inhibition when applied at the 
point of inoculation. HDMF treatment resulted in reductions in biofilm biomass of 
77.67%, 77.02%, and 88.30% at 24 hours, 48 hours and 72 hours respectively. These 
reductions are in excess of those reported in other studies. For example, the work of 
Choi et al. in 2014 showed that when applied at a concentration of 0.1 μM (12.81 ng 
mL-1) and 1.0 μM (128.13 ng mL-1) HDMF reduced biofilm biomass 27.8% and 42.6% 
after 24 hours and 66.3% and 84.8% at 48 hours respectively. While the reductions 
reported in this work were greater than in the work of Choi et al., the concentration of 
furanone used here was several orders of magnitude greater. This may be problematic 
as the requirement for a larger concentration of compound may result in greater 
pressure on the organism forcing the development of resistance. Furthermore, if 
furanones were taken forward to be tested in vivo the greater the required dose, the 
greater the possibility of adverse reactions and toxicity (Liebler and Guengerich, 
2005). Under the same test conditions as HDMF, sotolon showed reductions in biofilm 
biomass of 87.20%, 86.50%, and 66.13% at 24 hours, 48 hours and 72 hours post-
treatment. Again, these reductions are substantial.  
It was decided that, despite the poor performance of MTHF and ascorbic acid, all 
furanones would be carried forward for testing in the treatment of mature biofilms. 
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The effect of furanone treatment on bacterial cell viability was assessed using 
BacLight cell viability staining. It was shown that when compared to untreated 
biofilms, those grown in the presence of HDMF showed a high degree of clumping 
with large aggregates being apparent at 24 hours and smaller but more numerous 
aggregates present after 48 hours. This change in morphology was also observed in 
biofilms grown in the presence of sotolon. MTHF biofilms appeared to be more 
densely populated after 24 hours and large, densely populated aggregates were 
apparent compared to untreated controls. Finally, ascorbic acid appeared as well 
populated biofilms similar to those seen in controls. Several studies have shown that 
interference with QS signalling can lead to the formation of biofilms with altered 
morphology (Huber et al., 2001; Francolini et al., 2004; Cady et al., 2012). Francolini 
et al. showed that biofilms grown on polymer discs impregnated with the biofilm 
inhibitor usinic acid resulted in a P. aeuginosa biofilm that was less wide spread and 
which appeared to be clumped (Francolini et al., 2004). Similarly, Cady et al. (2012) 
showed that treatment with various organosulfur compounds resulted in a poorly 
populated biofilm in which cells had aggregated into small clumps as shown by 
confocal microscopy. It is, therefore, likely that the altered biofilm morphology 
observed in the HDMF and sotolon treated biofilms was a result of quorum sensing 
inhibition leading to disordered biofilm formation. The changes observed in the 
MTHF biofilms may simply be a response of the cells to a non-lethal chemical insult. 
Indeed, in 2018 Wu et al. demonstrated that treatment of Enterococci with sub-
inhibitory doses of antibiotics resulted in enhanced biofilm formation (Yu, Hallinen 
and Wood, 2018). If the same is true for the use of MTHF against P. aeruginosa this 
may explain the apparent increase in biofilm population density when the compound 
was present. Finally, the presence of these furanones did not appear to cause an 
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increase in non-viable cells. This was in keeping with previous reports of the use of 
furanones for the inhibition of biofilm which showed that these compounds could be 
used as QSIs at sub inhibitory concentration (Hentzer et al., 2002; Choi et al., 2014).  
Mature biofilms (24 hours or 48 hours old) were then treated with each furanone. This 
approach was used as the majority of chronic wounds already have a biofilm present 
and assessing delayed treatment of a wound biofilm was more clinically relevant. 
When treated with ascorbic acid, it was shown that the compound had no effect on the 
levels of biofilm biomass of PAO1 at any time point tested. When measured 24 hours 
post MTHF treatment, a 24 hours old biofilm was reduced in biomass by 46.36%. 
However, in the following 24 hours this reduction became non-significant. Treatment 
of a 48 hours old biofilm with MTHF showed no obvious reduction in biofilm biomass. 
HDMF treatment of a 24 hours old biofilm resulted in reductions of 60.01% and 
67.13% 24h and 48h post treatment. This represents a lower reduction than was seen 
when treatment was applied at the point of inoculation. This may be due to poor 
penetration of the compound into the pre-formed biofilm leading to poorer disruption 
of QS. It has been previously reported that, with antimicrobials such as vancomycin, 
as little as 20% of the administered dose is able to penetrate a bacterial biofilm (Dunne, 
Mason and Kaplan, 1993). If this also the case for furanones and P. aeruginosa 
biofilms, it may be that biofilm bound cells are receiving lower doses of furanone than 
anticipated. In contrast to the treatment of 24 hours old biofilms, HDMF treatment of 
48 hours old biofilms caused an increase in biofilm biomass 24 hours after the 
application of the furanone and no significant increase 48 hours post treatment (though 
a trend was seen). This was highly unexpected as treatment with HDMF had caused 
significant reduction in biofilm biomass under all other conditions. It is hypothesised 
that 48 hours old biofilms differ vastly from 24 hours old biofilms both metabolically 
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and transcriptomically. This hypothesis is supported by the findings of Waite et al. 
(2005) who showed that developing and mature P. aeruginosa biofilms had distinct 
transcriptomic profiles. Mature biofilms showed upregulation of genes involved in 
carbon compound catabolism and general metabolism while developing biofilms 
favoured motility and small molecule transport (Waite et al., 2005). This idea is 
supported by the subsequent work of Waite et al. (2006) who showed that in 
developing biofilms (8 hours post inoculation), gene expression was largely focused 
around cell motility and attachment, with over a quarter of upregulated genes being 
involved in these processes. However, gene expression in mature biofilms (48 hours 
post inoculation) was primarily focused on DNA repair and metabolism (Waite et al., 
2006; Schmidt et al., 2011). The differences in transcription profiles between mature 
and immature biofilms would likely make them respond to treatments and chemical 
insults very differently, possibly accounting for the differences in response to furanone 
treatment. Finally, treatment of a 24 hours old biofilm with sotolon showed a decrease 
in biofilm biomass of 77.66% and 56.12% after 24 hours and 48 hours respectively. 
This reduction was not seen when treating a 48 hours old biofilm and no significant 
reduction in biomass was seen at any time point tested. This is likely also explained 
by the inherent differences between a newly formed, 24 hours old biofilm, and a more 
mature 48 hours old biofilm. However, it may also be the case that 24 hours after 
inoculation, when the early treatment was applied, the biofilm was still forming and 
the presence of the furanone prevented further QS and subsequent biofilm formation 
during the following 24 hours. This would not have been the case for the untreated 
biofilm which was able to continue growing in the subsequent 24 hours prior to 
quantification. In samples grown for 48 hours, prior to the application of the late 
treatment, biofilms will have been more fully formed, thus, quorum sensing controlled 
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biofilm formation was likely limited. This would have meant that the application of 
the furanones would have no significant effect. This is strongly supported by the 
findings of Waite et al. (2006) who showed, using gene clustering, that no significantly 
upregulated genes in a 48 hours old biofilm were related to cell division or chemotaxis. 
This is in contrast to a developing biofilm (represented in their work by an 8 hours old 
biofilm) in which approximately 7.5% of significantly upregulated genes were 
dedicated to cell division. This suggests that, by 48 hours, P. aeruginosa biofilms have 
slowed in the division of cells and may no longer be producing significant amounts of 
biomass.  
Following the success of both HDMF and sotolon in the preceding experiments, it was 
decided that these compounds would be tested against biofilms using loaded aerogels 
as a delivery mechanism. Due to their limited effects, MTHF and ascorbic acid were 
omitted from further testing. 
Furanone-loaded aerogels were applied to bacterial cultures at the point of inoculation 
to imitate a rapid treatment scenario in which a furanone aerogel dressing is applied 
to a wound as soon as it is sustained. Firstly, it was shown that the application of an 
unloaded aerogel had no effect on biofilm formation at any tested time point. HDMF-
loaded aerogels were shown to reduce biofilm biomass by 81% and 70% at 24 hours 
and 48 hours post treatment respectively. When treated with sotolon, biofilm biomass 
was reduced by 100% and 94.72% over the same time period. The very high levels of 
reduction in biofilm biomass by sotolon were subsequently replicated using a new 
overnight culture and aerogels produced in a different batch. The substantial 
reductions in biofilm seen here indicate that both HDMF and sotolon retain their 
biological activity after being loaded into a PVA aerogel. Additionally, it clearly 
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demonstrates that controlled release of HDMF and sotolon is a potentially viable 
treatment to prevent the formation of P. aeruginosa biofilms in acute wounds. This 
would be advantageous in a real-world scenario as it has been shown that, in acute 
wounds, biofilms begin to form within 6 hours of the injury being sustained (Bowen 
and Richardson, 2016). As the presence of a biofilm is a major contributing factor to 
wounds progressing to a chronic state (Leaper, Assadian and Edmiston, 2015; Malone 
et al., 2017; Schultz et al., 2017), a reduction of this initial biofilm formation would 
likely lead to a reduction in number of chronic wounds.    
The effect of aerogel delivered furanones on mature biofilms was then assessed. This 
experiment mimicked the use of furanone-loaded aerogels to treat established chronic 
wounds in which a biofilm was already present. A significant decrease in biofilm 
formation (41.14%) was seen 24 hours post treatment when HDMF was used to treat 
a 24 hours old biofilm. This reduction was maintained after 48 hours post treatment 
when compared to an untreated control. Conversely, when sotolon was used to treat a 
24 hours old biofilm, it was found that a small increase in biofilm biomass  was seen 
24 hours post-treatment and no effect on biofilm biomass was observed 48 hours after 
treating a 24 hours old biofilm When used to treat a 48 hours old biofilm, a modest 
reduction in biofilm biomass was seen 48 hours after the application of the treatment. 
These results are largely contradictory to those seen when furanones were applied 
directly to the biofilm cultures. While the reason for the differences between the two 
methods of furanone application are unclear it may be that, when applied using the 
aerogel, the concentration of furanone in the culture is gradually increased (due to the 
controlled release of furanone from the gel). This would mean that the therapeutic dose 
of furanones was reached sometime after the application of the aerogel. This is in 
contrast to the direct application of the furanone which would have resulted in an 
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instantaneous therapeutic concentration of furanone. While the release studies 
reported in chapter 3 of this thesis showed that approximately 60-100% of the total 
loaded compound should have been released from the formulations, the aerogels used 
here are highly novel and as such several unidentified factors may have an effect on 
their drug release properties. For example, several factors such as pH of the solution 
into which a drug is being released can affect the drug release profile (Park et al., 
1998; Kenawy et al., 2008). It is therefore possible that furanone release into the 
bacterial growth medium is not the same as was measured in chapter 3, causing the 
biofilms to be under dosed. However, this does not appear likely as results showing 
that aerogel delivered furanone performed better than directly added furanone when 
applied at the point of inoculation. This suggests that furanone release into the 
bacterial growth medium is not significantly altered when compared to the previously 
conducted release studies. Another explanation may be that, due to their protected 
nature, mature biofilms have a degree of resistance to the furanones, just as they have 
increased resistance to antibiotics. This hypothesis would explain why, when applied 
at the point of inoculation, furanones showed a potent biofilm inhibition effect both 
when applied directly, and when applied using an aerogel. Furthermore, this may 
explain why the direct application of furanones to mature biofilms showed a greater 
effect than the controlled release of furanones from an aerogel. Immediate application 
would have resulted in an instantaneous, high concentration treatment, while 
controlled release from an aerogel may have allowed the bacterial cells to respond by 
enhancing furanone efflux or perhaps producing enzymes such as lactonases which 
may cause degradation of the furan ring structure of the furanones. This possibility 
was considered further.   
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Resistance to furanones has been previously reported (Maeda et al., 2012; García-
Contreras et al., 2013; García-Contreras, Peréz-Eretza, et al., 2015). Maeda et al. 
(2012) showed that resistance to the furanone C-30 is possible in P. aeruginosa with 
resistant strains showing no significant reduction in several QS controlled phenotypes 
following furanone treatment. The authors of this paper showed that furanone resistant 
mutants of P. aeruginosa, which were produced using random transposon 
mutagenesis, were deficient in mexR or nalC. Both of these genes encode repressors 
of the MexAB-oprM multidrug efflux transporter (Maeda et al., 2012; 
Pseudomonas.com, 2020a, 2020b). The authors show that when treated with furanone 
C-30, the mutants showed no significant reduction in pyocyanin production when 
compared with C-30-treated wild-type P. aeruginosa PA14. As well as this, the 
authors showed that C-30 treatment of furanone resistant organisms (particularly those 
deficient in mexR) enhanced swarming motility rather than simply having no effect as 
was expected. The authors also demonstrated that C-30 treatment of mexR deficient 
strains induced the expression of 23 QS-related genes, including genes encoding for 
efflux pumps and the LasR and RhlR transcriptional regulators. Finally, the authors 
demonstrated that the ability of wild-type PA14 to kill Caenorhabditis elegans 
nematodes was ameliorated with the use of C-30, with a reduction in lethality from 
50% in untreated worms to 20% in treated worms being observed. However, in worm 
infections caused by mexR deficient strains, the mortality of 60% in untreated worms 
was only reduced to 50% mortality in C-30 treated worms. This study clearly 
demonstrates that bacterial resistance to furanones is possible and that this resistance 
arises when repressors of the MexAB-oprM operon are lost (Maeda et al., 2012). An 
additional study in 2015 showed that P. aeruginosa PA14 strains which were deficient 
in mexR (and thus resistant to furanones) showed significant changes in response to a 
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stress following furanone treatment. The authors showed that when treated with C-30, 
wild type strains sensitivity to various stressors (heat, hydrogen peroxide, cadmium 
chloride, and sodium chloride) was increased by up to 8.2-fold. This indicated that 
furanone treatment could render P. aeruginosa more sensitive to common stresses. 
Conversely, mexR deficient strains treated with furanone C-30, experiencing the same 
stressors showed a maximum 1.5-fold change in sensitivity when exposed to C-30. 
These data indicate that strains resistant to furanones were not as effectively sensitised 
to various stresses by furanone treatment (García-Contreras, Nuñez-López, et al., 
2015).  
In light of the studies described above, the previously published genome of PAO1 
DSM50071 (accession number CP012001) was assessed for the presence of the mexR 
and nalC genes.  It was found that the published DSM50071 genome did not contain 
sequences homologous to the mexR and nalC genes. Furthermore, it was shown by 
whole genome sequencing that the DSM50071 strain used in this study also lacked 
these two genes.  
As well as lacking the mexR and nalC genes, both the previously published genome 
and the genome sequence produced during this work lacked sequences homologous to 
two more genes; MdrR1 and MdrR2. This is important as these genes have also 
previously been reported to be repressors of MexAB-oprM and another efflux pump 
known as EmrAB (Heacock-Kang et al., 2018).  
Taken together, these data suggest that the hypothesis stating that the limited efficacy 
of the furanones as an antibiofilm treatment was the result of furanone resistance in 
the strain used in this work is correct. This hypothesis is further supported by the 
established MBC values for each furanone in this work. As previously discussed, the 
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MBC values reported here were many orders of magnitude greater than those reported 
in the literature. Due to the deficiency of DSM50071 in the two efflux repressors, and 
the subsequent greatly increased capacity for furanone efflux, this strain would require 
significantly increased concentrations of furanones to kill the cells.  
The possibility of increased furanone efflux may also help to explain other findings in 
this work such as the improved antibiofilm effects of furanones when applied at the 
point of inoculation. It may be that, as bacterial cell numbers were lower at the point 
of inoculation, the high concentration of furanone was not able to be effluxed as 
rapidly or effectively meaning that the furanone was able to bind the AHL receptors 
and the expected anti QS effects of the furanones were seen. This idea is further 
supported by our observation that when 24 hours old biofilms were treated with 
furanones, smaller reduction in biofilm biomass were seen. Enhanced efflux of 
furanones by the bacterial cells may also explain the increase in biofilm formation 
seen in several experiments after furanone treatment. Garcia-Contreras et al. (2015) 
showed that mexR deficient strains, when grown in the presence of a furanone, 
exhibited a difference in response to stresses compared to non-deficient strains 
(García-Contreras, Nuñez-López, et al., 2015). It may hold true that, as DSM50071 is 
deficient in mexR and other repressors, exposure to the furanones tested here may 
cause an abnormal response to stresses, such as depletion of nutrients in liquid culture, 
changes in medium pH, and changes in oxygen levels. It has been shown that nutrient 
density can significantly impact on the process of biofilm formation inducing 
processes as formation of mushroom type structures, or biofilm dispersal (Sauer et al., 
2004; Ghanbari et al., 2016). It has also been shown that stresses such as pH and 
temperature also affect levels of biofilm formation (Ramli et al., 2012). Considering 
this, it is not unreasonable to assume that the altered stress responses reported by 
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Garcia-Contreras et al. in 2015 may extend to other stressors and that the conditions 
found in bacterial cultures would, therefore, impact upon levels of biofilm.  
Resistance to furanones has also been shown in clinical P. aeruginosa isolates. One 
study showed that some clinical isolates from cystic fibrosis patients were able to more 
effectively efflux furanone C-30 when compared to wild-type PA14. Further, one 
strain in particular, named INP-42, was able to efflux the furanone at levels 
approximately equivalent to the mexR deficient strain (García-Contreras, Peréz-
Eretza, et al., 2015). An earlier study showed that several clinical isolates from a 
hospital in Mexico showed increased production of several virulence factors, 
particularly elastase and alkaline protease, when treated with C-30 (García-Contreras 
et al., 2013). While the authors of these studies did not explore the mechanism of 
furanone resistance in these clinical isolates, both suggest that it is likely to be a similar 
mechanism to the mexR and nalC mutants previously described. 
As the strain used in this chapter for the assessment of furanones as antibiofilm was 
itself likely resistant to furanones the findings detailed here are not broadly applicable 
to all P. aeruginosa strains. However, the work reported here has shown that with 
early application of high dose HDMF and sotolon, even furanone resistant strains may 
be inhibited from effectively forming a biofilm. This is an important finding as it 
suggests that furanone-loaded aerogels may, in fact, be a suitable first-line wound 
treatment which would lessen or entirely inhibit the early stages of biofilm formation 
that often occur within the first hours after a wound is sustained. While this is a 
promising prospect, the methods used here are limited in their applicability to a real 





The use of furanones for the inhibition of biofilm formation in P. aeruginosa 
DSM50071 was investigated. It was shown that, when applied at the point of 
inoculation, sub-inhibitory doses of both HDMF and sotolon were effectively able to 
inhibit biofilm formation when compared to an untreated control. Under the same 
circumstances MTHF and ascorbic acid showed no appreciable reduction in biofilm 
formation and after 72 hours of treatment the presence of ascorbic acid significantly 
increased biofilm biomass. Using cell viability staining it was shown that, when grown 
in the presence of HDMF and sotolon, biofilm morphology changed from a well 
populated homogenous biofilm to a poorly populated biofilm that appeared to consist 
primarily of bacterial cell aggregates. MTHF treatment resulted in a biofilm that 
appeared to be more densely populated than the control with large densely populated 
aggregates formed after 48 hours. Biofilms grown in the presence of ascorbic acid 
appeared similar to the controls. When added directly to mature biofilm, HDMF and 
sotolon retained their antibiofilm properties while MTHF and ascorbic acid were less 
effective. When applied at the point of inoculation using a furanone-loaded aerogel, 
HDMF remained effective and sotolon was shown to be highly effective in inhibiting 
biofilm formation. It was demonstrated that when applied to mature biofilms using 
loaded aerogels both HDMF and sotolon were less effective in the inhibition of biofilm 
than when applied early. Finally, the possibility of DSM50071 having high levels of 
resistance to furanone compounds by means of increased furanone efflux was 
explored. The findings that furanone-loaded aerogels could be an effective early 
treatment for the prevention of biofilm formation in wounds is promising. However, 
the methods used in this chapter have limited applicability to a real-world scenario and 
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A chronic wound is any wound which fails to progress through the normal healing 
process. This failure can be caused by a wide range of both internal and external 
factors. For example, the autoimmune disease diabetes mellitus often causes patients 
to develop chronically non-healing wounds by causing chronic inflammation, local 
hypoxia, and circulatory dysfunction (Baltzis, Eleftheriadou and Veves, 2014). 
However, one of the most common causes of chronic wound formation is bacterial 
colonization, and subsequent formation of a biofilm in the wound environment 
(Malone et al., 2017). The warm and moist environment of a wound is ideal for the 
growth of bacteria. S. aureus and P. aeruginosa, are the two bacterial species which 
most commonly colonise and form biofilms in wounds (Fazli et al., 2009; Rhoads et 
al., 2012).  
When present in a wound, a bacterial biofilm causes a prolonged state of inflammation. 
This inflammatory state is maintained long-term and, thus, the host’s immune system 
is unable to progress to the final stages of wound healing. This failure to progress 
through the normal wound healing process gives rise to a chronic wound (Wolcott, 
Rhoads and Dowd, 2008). 
Due to the significant role that biofilms play in the formation and persistence of 
chronic wounds, new treatments should always consider addressing biofilm as a 
priority. However, it is difficult, both logistically and ethically, to study chronic wound 
biofilms in humans (Grada, Mervis and Falanga, 2018). Due to the complexity of 
studying biofilms in humans, animal models of wound healing are considered the gold 
standard for such investigations. However, the development and testing of novel 
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antibiofilm wound therapies using these models is challenging in itself for a number 
of reasons.  
5.1.1 In vivo wound models 
There are several common choices of animal when using a wound model. There are 
rodent models such as mouse and rat, rabbit models, and pig models as well as many 
others which are less commonly used.  
The use of mice is both cost effective and an efficient use of space and facilities. When 
using mice there are several model options. These include the use of a dorsal wound 
in transgenic, leptin deficient Db/Db, mice which are designed to model the impaired 
wound healing seen in diabetes (Beer, Longaker and Werner, 1997). However, the 
loose skin and striated subcutaneous muscle layer found in mice means such models 
are not truly representative. Wound healing in dorsally wounded animals occurs 
primarily through tissue contraction rather than the growth of new tissue as is the case 
in humans (Grada, Mervis and Falanga, 2018). While rats may be used as an 
alternative to mice, the similar dorsal skin and muscle structure presents the same 
issues. Another limitation of using mice and rats for the study of wound healing is the 
wound healing time. Wounds in mice and rats have been shown to heal much more 
rapidly than human wounds and are, therefore, not truly representative. To circumvent 
this, a mouse tail vein model was developed. (Falanga et al., 2004). This model used 
a scalpel to produce wounds on the dorsal aspect of the tail of the mouse. These 
wounds were shown to require up to twenty-five days to fully heal making them more 
representative of a chronic wound healing time frame. However, despite this, this 
model does not appear to have been widely adopted in the literature to study wound 
infection.   
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Unfortunately, the differences in the wound healing mechanism and time are not the 
only barrier to using an animal model in wound biofilm studies. Other issues include 
the method of wound infliction. When initiating a wound in an animal, processes such 
as surgical wounding, friction or sanding and punch biopsies are all commonly used 
(Ermolaeva et al., 2011; Gurjala et al., 2011; Asada et al., 2012; Petreaca et al., 2012; 
Roche et al., 2012; Thompson et al., 2014; Watters et al., 2014). While these methods 
allow researchers to induce reproducible wounds, they often leave the wound poorly 
representative of the conditions present in a chronic wound. This makes the translation 
of the findings to chronic wounds in humans difficult (Brackman and Coenye, 2016; 
Trøstrup et al., 2016). Furthermore, the maintenance of both the biofilm and the wound 
itself for a chronic timeframe in such models is often highly challenging, further 
limiting their relevance to real-world clinical scenarios. 
5.1.2 In vitro wound models 
In order to address these issues and establish a biofilm with a high degree of similarity 
to a real-world scenario, many researchers opt to use an in vitro wound biofilm model. 
There are numerous in vitro wound models described in the literature, each with a 
range of different characteristics designed to mimic the chronic wound environment 
so that representative biofilms can be grown. However, as with the in vivo models, 
each in vitro model has both strengths and weaknesses.  
5.1.2.1 The Lubbock chronic wound model 
The most well-known and widely used in vitro chronic wound model is the Lubbock 
Chronic Wound Model. This wound model, first reported by Sun et al. in 2008, most 
commonly uses a plastic pipette tip ejected into a liquid growth medium to act as the 
wound bed. While a pipette tip does indeed provide a good substrate for the formation 
of a biofilm it is poorly representative of a biotic surface, such as a wound bed. 
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Furthermore, the growth medium used in the Lubbock model consists of Bolton Broth 
with 50% bovine plasma and 5% laked horse blood. As Bolton Broth is a chopped 
meat based medium it was chosen made to mimic the excess of cellular debris and 
extracellular media components that would be found in the chronic wound 
environment (Sun et al., 2008). While the presence of these components does help to 
mimic the nutrient profile of a wound environment, it is not a perfect representation 
as any standard bacterial growth medium will be rich in vitamins and minerals which 
may not be present in a wound environment. Subsequent models, which will be 
discussed here, attempt to rectify this through the use of a wound-like growth medium. 
5.1.2.2 The collagen matrix model 
This model, developed by Werthén et al. in 2010, replaced the Bolton broth with a 
simulated wound fluid solution consisting of 50% physiological saline and 50% foetal 
calf serum. Alternatively, they also suggest a mix of 50% TSB and 50% simulated 
wound fluid (Werthén et al., 2010). The use of saline and calf serum does appear to 
be more representative of a wound environment, but this simulated wound fluid is 
likely lacking components, such as blood and other salts, that are be present in a wound 
environment. The use of TSB presents the same problems as the use of Bolton broth 
in the Lubbock model in that there are likely several nutrients what would be present 
in a wound that are not present in this simulated wound fluid. In this model, the authors 
grew biofilms on matrices consisting of rat tail collagen and simulated wound fluid. 
Although this model is good representation of the wound environment, its main 
disadvantage is the high cost of the materials such as rat tail collagen. For many 
researchers aiming to characterise novel antibiofilm compounds or to test the efficacy 
of novel delivery drug mechanisms, the potential cost of high throughput testing, in 
which large volumes of wound fluid or wound bed is required, may be prohibitive.  
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5.1.1.3 Poloxamer hydrogel model 
Another, similar, wound model which has been proposed includes the use of a 
poloxamer hydrogel matrix hydrated with Mueller-Hinton broth as a growth substrate. 
The authors state that the use of this gel cause the organisms to display a more 
clinically relevant biofilm phenotype which allows for an accurate representation of a 
wound infection (Percival, Bowler and Dolman, 2007). The authors show that both 
antibiotic sensitive and antibiotic resistant strains grown on the poloxamer gel (P. 
aeruginosa, C. albicans, Klebsiella pneumoniae, E. faecalis, E.coli, and S. aureus) 
displayed a higher resistance to silver containing dressings when compared to 
organisms grown directly on Mueller-Hinton agar. While this model shows that the 
nutrient source and growth substrate used during an experiment may affect the 
response of an organism to a wound treatment, the model has the same limitations the 
previous two models considered above. Furthermore, the use of Mueller-Hinton broth 
as the nutrient source is not representative of a chronic wound environment.  
5.1.2.4 Cellulose agar model  
A model developed by Hammond et al. (2011) used cellulose discs as a growth 
substrate for biofilm growth (Hammond et al., 2011). As with the previous models 
this approach used a standard bacteriological growth medium as the nutrient source. 
In this case, standard lysogeny broth (LB) agar was used. This work showed that 
number of viable cells in biofilms grown in this model were effectively reduced 
through treatment with either a single antibiotic ointment (containing 0.1% gentamicin 
sulphate or 2% mupirocin) or an ointment containing an antibiotic combination. The 
use of the cellulose discs allowed for the simple collection and quantification of the 
treated and control biofilms. This also allowed for the visualisation of the biofilms 
using a fluorescent stain. These are useful attributes for a wound model to have. 
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Despite this, the use of a standard nutrient medium is, again, limiting to the relevance 
of the results.   
5.1.2.5 Artificial wound bed model  
Finally, a wound model consisting of an artificial wound bed was developed by Kucera 
et al. in 2014 for the testing of antimicrobial wound dressings. This model adapted the 
Lubbock model discussed above for use in the production of an artificial wound bed. 
The model involved the growth of a biofilm on a plastic pipette tip as per the Lubbock 
model. The artificial wound bed was prepared by pouring a thin layer of wound-like 
agar (Bolton broth with 1.0% w/v gelatin and 1.2% w/v agar) into the bottom of a petri 
dish. Once set a sterile magnetic stir bar was placed on the surface of the agar and a 
second layer of agar was poured on top of the first. Once this layer was set, the stir bar 
was removed aseptically leaving an artificial wound-like void in the agar. Pre-formed 
biofilms were then placed into the formed artificial wound bed (Kucera et al., 2014). 
It is unclear whether the biofilm was somehow removed from the pipette tip or if the 
pipette tip itself was placed in the wound bed to inoculate. This model has the same 
limitation as all other models discussed here as it uses a non-representative nutrient 
source. 
 It is clear that while there are many in vitro models of chronic wound biofilms they 
have a common set of problems including the use of a growth substrate which is poorly 
representative of a wound bed or use of a growth medium which is poorly 
representative of a chronic wound nutrient profile. (Percival, Bowler and Dolman, 
2007; Thorn and Greenman, 2009; Kostenko et al., 2010; Lipp et al., 2010; Hammond 
et al., 2011; Ngo, Vickery and Deva, 2012). It is, therefore, the aim of this chapter to 
develop a novel, low cost, wound biofilm assay consisting of a simulated soft wound 
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bed with a nutrient profile that is representative of a mammalian wound environment 
for the assessment of novel antimicrobial and antibiofilm compounds and the in vitro 























5.2 Aims and objectives 
The aim of this chapter is to develop a novel, representative, in vitro chronic wound 
model. Firstly, a suitable growth substrate on which to grow biofilms will be 
identified. An appropriate method of quantifying the biofilms will then be chosen. 
Several methods will be assessed including crystal violet staining, fluorescent staining 
of the biofilm matrix, live/dead fluorescent staining of the biofilm bound cells, and 
direct enumeration of viable cells per biofilm. A suitable nutrient source will then be 
identified for the growth of representative chronic wound biofilms. Finally, the 
developed wound model will be used to assess the efficacy of commonly used clinical 
wound dressings and then used to assess the effect of furanone-loaded aerogel on 













5.3 Materials and Methods 
5.3.1 Materials and equipment 
All chemicals and reagents used in the work detailed here were purchased from Sigma 
Aldrich (Poole, UK) and used without further modification or purification unless 
otherwise stated.  
Porcine muscle was purchased from a local butcher to ensure no additional water or 
preservatives had been added prior to use in the wound model. 
Clinically relevant wound dressings were purchased from Medisave. 
5.3.2 Identification of a suitable growth substrate and wound-like nutrient source 
To develop a novel wound model an appropriate growth surface was identified. In 
parallel, a range of wound-like nutrient sources were developed and tested.  
5.3.2.1 Preparation of simulated body fluid and body fluid agar  
To prepare simulated body fluid (SBF), which is chemically similar to human serum, 
the method detailed by Huang et al. (2013) was used. This protocol was adapted to 
produce a 5 times concentrated stock solution (Huang et al., 2013). To prepare the 
concentrated body fluid a solution of 0.68 M sodium chloride, 27 mM potassium 
chloride, 1.25 mM sodium phosphate dibasic, 2.2 mM potassium phosphate dibasic 
trihydrate, 6.5 mM calcium chloride, 5 mM magnesium sulphate, 21 mM sodium 
bicarbonate, and 27.5 mM glucose was prepare in deionised water. The concentrations 
and masses of each component used are shown in Table 5.1. This solution was 
sterilised as required by passing through a 0.2 μm syringe filter. The use of autoclaving 
resulted in the caramelisation and browning of the sugars which may have added 
variability between batches of the simulated wound fluid. 
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Table 5.1 – Concentrations and masses of each component used to prepare 
simulated wound fluid for both the 5x concentrated stock solution and the 1x 
working solution.  
 
To prepare simulated body fluid agar with blood the protocol described above was 
followed with the following amendment. A solution of 6 g of technical agar in 375 mL 
of deionised water (1.6% w/v) was prepared and sterilised by autoclaving. Once cool, 
100 mL of sterile simulated body fluid and 25 mL of laked horse blood (Oxoid, UK) 
were added (final conc. 5% v/v of laked blood). Plates were poured and sterility was 
confirmed by incubating an uninnoculated plate for 24 hours at 37°C.  Absence of 
visible growth was used as an indication of sterility. 
5.3.2.2 Growth of biofilms on artificial growth surfaces 
Biofilms were grown on a range of semi-permeable membranes to assess their 
suitability as a biofilm growth substrate. Polycarbonate, nylon and nitrocellulose 
membranes were assessed. Nylon and nitrocellulose membranes were prepared by 
cutting 13 mm discs of membrane from large sheets of each membrane. To ensure 
discs were reproducible, a 13 mm paper punch tool was used. Polycarbonate 
membranes were purchased as pre-prepared 13 mm discs (Merck Millipore, UK).  To 












Sodium chloride 0.685 mM 40 0.137 mM 8.0063
Potassium chloride 27 mM 2.1 5.4 mM 0.402
Sodium phosphate 
dibasic
1.25 mM 0.175 0.25 mM 0.085
potassium 
phosphate dibasic 
2.2 mM 0.295 0.44 mM 0.059
Calcium chloride 6.5 mM 0.57 1.3 mM 0.114
Magnesium sulphate 5 mM 0.6 1 mM 0.12
Sodium bicarbonate 21 mM 1.76 4.2 mM 0.352
Glucose 27.5 mM 4.95 5.5 mM 0.99
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dish in a laminar flow hood to dry. The use of a laminar flow hood ensured that sterility 
was maintained. Samples were then stored in the sterile drying dish until required.  
To grow biofilms on the membranes, standard nutrient agar, simulated body fluid agar, 
and simulated body fluid agar with blood were prepared as detailed previously. 
Membranes were then placed on the surface of the nutrient media using sterile forceps. 
Membranes were gently pressed down to ensure that total contact between the 
membrane and the medium was achieved.  
The biofilm inoculum was prepared by making a 1:100 dilution of a stationary phase, 
overnight, culture of PAO1 DSM50071 in fresh TSB as detailed in chapter 4. To each 
membrane, a 5 μL volume of the 1:100 dilution was added. Plates were left partially 
uncovered in a laminar flow hood for 10 minutes for the inoculum to dry. Once the 
inoculum was dry the plates were covered and incubated at 37 °C for 18 hours. Once 
incubated, biofilms were imaged using a Canon EOS 500D digital camera.   
5.3.2.3 Preparation of a novel semi synthetic wound bed medium 
A semi synthetic wound medium was produced using porcine myocyte lysate (PML), 
simulated wound fluid, bovine serum albumin (BSA) and laked horse blood. To 
produce the myocyte lysate, 100 g of porcine muscle tissue was processed in a 
commercial food processor with 150 g of deionised water for 3 minutes or until a 
homogenous mixture was formed. The mixture was then centrifuged at 13,000 rpm for 
5 minutes and the supernatant was decanted and collected. The solid material, 
consisting of skin and connective tissue, was discarded. The collected supernatant was 
then gravity filtered through filter paper to remove any remaining solid material. The 
filtered liquid was then split into 10 mL aliquots and stored at -30 °C until required.  
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To prepare the wound bed medium, first a 5% solution of technical agar in deionised 
water was prepared and sterilised by autoclaving. The PML solution was then thawed 
at room temperature. Once totally thawed BSA was added to a final concentration of 
56 mg mL-1 and the mixture was placed on a rocker at room temperature until all BSA 
was dissolved. Once no visible BSA aggregates remained the PML/BSA solution was 
sterilised using a 0.2 μm syringe filter. A 100 μL volume of the filtered PML/BSA 
solution was streaked on nutrient agar and incubated at 37 °C for 18 hours to confirm 
sterility. This solution was then pre-warmed to 40 °C in a water bath. It should be 
noted that warming should not exceed 40 °C as this caused denaturation of the BSA 
and other proteins in the solution. However, warming was necessary to prevent gelling 
agents from setting rapidly on addition to the mixture. Once warm, the wound bed 
medium was prepared by adding 30 mL of warm PML/BSA solution, 10 mL of 
concentrated simulated body fluid stock solution, 7.5 mL of molten 5% agar solution 
and, 2.5 mL of laked horse blood to a falcon tube. The percentage concentrations of 
each component are shown in Table 5.2. The tube was inverted several times to ensure 
total mixing. While the medium was still liquid 1 mL volumes were pipetted into the 
wells of a 12 well tissue culture plate. These plates were stored at 4 °C for 18 hours to 
allow for the complete gelation of the medium. The final wound medium contained 
appropriate (i.e. x1) concentrations of all simulated body fluid components.   




Porcine myocyte lysate/bovine serum albumin 60%
5x simulated body fluid 20%
5% technical agar 15%
laked horse blood 5%
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5.2.3.4 Growth of biofilm on simulated wound bed medium 
To grow biofilms using the simulated wound bed medium as a nutrient source, plates 
were prepared as described above and 13 mm discs of each membrane were added to 
the surface of the medium and inoculated as detailed in section 5.3.2.2. Plates were 
then incubated at 37 °C for 18 hours. Biofilms were imaged using a Canon EOS 500 
digital camera. 
5.3.3 Methods of biofilm quantification 
Several methods of quantifying the biofilm grown on each membrane type were tested. 
These methods included fluorescent staining of the biofilm matrix proteins, crystal 
violet staining of the total biofilm biomass, live/dead staining of the biofilm bound 
cells and direct enumeration of viable cells in the biofilm. 
5.3.3.1 Fluorescent staining of biofilm matrix proteins 
To stain the biofilm matrix proteins, it was decided that the protein stain SYPRO ruby 
would be used and stained biofilms would be resuspended. The SYPRO ruby would 
then be quantified in the solution. As this stain has never been used to quantify 
resuspended biofilms the accuracy of quantifying SYPRO ruby in suspension was 
tested.  
A calibration curve of SYPRO ruby was prepared by making an 80 μL mL-1 solution 
of SYPRO ruby in deionised water. This solution was tested for fluorescence using a 
Varian fluorimeter (California, USA) set with an excitation wavelength of 450 nm and 
an emission wavelength of 610 nm. Doubling dilutions of this 80μL mL-1 stock 
solution were prepared in deionised water and each dilution was tested as described. 
Measurements were made in triplicate. The calibration curve was plotted as 
concentration of SYPRO Ruby against fluorescence (in arbitrary units).  
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To assess the accuracy of quantifying SYPRO Ruby in aqueous solution, three test 
samples were prepared. These solutions corresponded to a high concentration of 
SYPRO Ruby (25 μL mL-1), a moderate concentration (15 μL ml-1) and a low 
concentration (5 μL mL-1). These samples were then analysed using the fluorimeter as 
described previously. The fluorescence reading obtained was used to calculate the 
measured concentration of SYPRO ruby in the test samples. The percentage error was 
then calculated. 
5.3.3.2 Staining of the total biofilm biomass 
To stain the total biofilm biomass the crystal violet method of O’Toole and Koulter 
was adapted for use with membrane bound biofilm. Briefly, biofilms were grown on 
membranes using nutrient agar as a medium as detailed in section 5.3.2.2. After 
incubation, membranes were removed from the surface of the medium and any 
unbound cells were removed by gently submerging the membrane and biofilm in 
sterile deionised water taking care not to disrupt the biofilm. Membranes were then 
allowed to air dry for 10 minutes in a fresh 12 well plate. Once dry the membranes 
were covered with 2 mL of 0.1% crystal violet solution to ensure the membrane is 
completely covered. Crystal violet was added to the well by slowly pipetting down the 
inner was of the well so as not to disrupt the biofilm. Membranes were incubated in 
the crystal violet for 10 minutes at room temperature on a plate rocker. Once fully 
stained membranes were removed from the crystal violet and rinsed of any excess stain 
by gently submerging the membrane in deionised water 3 times. The membranes were 
then allowed to air dry in a fresh 12 well plate for 10 minutes. Once dry, 2 mL of 30% 
acetic acid in deionised water was added to each well to destain the biofilm. 
Membranes were destained for 10 minutes at room temperature on a plate rocker. Once 
membranes were destained, 100 μL of the resolubilised crystal violet in 30% acetic 
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acid was transferred to a 96 well plate and diluted in fresh destain solution as required. 
Absorbance of the resolubilised crystal violet was measured at 450 nm using a Fluostar 
Omega plate reader (BMG Labtech, Aylesbury, UK). Uninnoculated membranes were 
used as a control. A sample of 30% acetic acid in deionised water was used as a blank. 
Each membrane type was tested in triplicate using three biological replicates. 
5.3.3.3 Live/dead staining of biofilm bound bacterial cells 
To stain biofilm bound bacteria based on cellular viability BacLight Live/Dead 
fluorescent stain was used. Biofilms were grown as detailed in section 5.3.2.2. A 
working solution of BacLight reagent was prepared as per section 4.3.8.1. Once 
biofilms had formed, membranes were removed from the surface of the agar any 
remaining unbound cells were rinsed off by gently submerging the membrane in sterile 
deionised water 3 times. Membranes were placed in a fresh 12 well plate and allowed 
to dry for 10 minutes in a laminar flow hood to maintain sterility. A 100 μL volume 
of BacLight working reagent was pipetted on to the biofilm ensuring the whole biofilm 
was covered in the staining solution. BacLight reagent was added slowly to the surface 
of the biofilm so as not to disrupt it. The 12 well plates were then covered with 
aluminium foil, to protect them from light, and were incubated at room temperature 
for 30 minutes. After 30 minutes of staining membranes were rinsed of excess 
BacLight reagent by gently submerging in sterile deionised water 3 times. Membranes 
were placed on a microscope slide and allowed to air dry in a laminar flow hood in the 
dark for 10 minutes. Biofilms were then imaged as per section 4.3.8.3.   
5.3.3.4 Direct enumeration of viable biofilm bound cells 
Biofilms were grown on all membrane types using nutrient agar as a medium as 
detailed previously. After incubation membranes were removed from the medium and 
unbound cells were removed by gently submerging the membranes in sterile deionised 
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water 3 times. Membranes were then placed in 10 mL of sterile PBS (pH 7.4) and 
biofilms were resuspended by mechanical agitation with a sterile inoculation loop for 
15 s followed by three separate 10 s sets of vortexing to resuspend any aggregates.  
Once biofilms were resuspended and no aggregates were visible a 100 μL sample of 
the resuspended biofilm was serially diluted to 10-15. Each of the dilutions were then 
streaked on nutrient agar. Inoculated plates were allowed to dry in a laminar flow hood 
for 10 minutes and were then incubated at 37 °C for 16-18 hours. Visible colonies on 
the nutrient agar plates were counted and the cells per biofilm were calculated using 
the equation:  
𝐶𝐹𝑈𝐵𝐹 = 𝐶𝐶 × 𝐷𝐹    Equation 4 
Where CFUBF is the colony forming units per biofilm, CC is the colonies counted on 
the nutrient agar plate and DF is the dilution factor. Each membrane type was tested 
in triplicate using three biological replicates. 
5.3.4 Assessment of biofilm growth kinetics on novel wound model 
The biofilm formation kinetics of PAO1 DSM50071 were assessed on both nutrient 
agar and on the developed simulated wound medium. To assess growth kinetics plates 
were prepared and inoculated using polycarbonate membranes and either nutrient agar 
or simulated wound medium as the nutrient source. Plates were prepared by pipetting 
1 mL of molten nutrient agar or simulated wound bed medium into the wells of a 12 
well plate and storing at 4 °C overnight to allow for complete gelation of the medium. 
Polycarbonate membranes were sterilised in 70% ethanol and allowed to dry. Once 
dry, membranes were placed on the surface of the medium and inoculated. Once 
inoculated, biofilms were grown for 10 hours at 37 °C. Biofilms were sacrificed every 
2 hours and viable cells were enumerated as described previously. Data was plotted as 
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CFU per biofilm over time. Experiments were conducted in triplicate using biological 
replicates. 
5.3.5 Assessment of the antimicrobial efficacy of clinically relevant wound dressings 
against PAO1 biofilm 
To test the developed wound model in assessing the efficacy of wound therapies, the 
antimicrobial efficacy of four clinically relevant wound dressings was investigated. 
The wound dressings tested were Aquacel AG, Telfa AMD, Actilite and Inadine. The 
active ingredients of these dressings were silver, polyhexamethylene biguanide 
(PHMB), Manuka honey and iodine respectively. Treatment with non-medicated 
cotton gauze and application of no treatment were used as controls. 
Plates were prepared and biofilms grown on polycarbonate membranes as per section 
5.3.2.2 with one amendment. After inoculation samples were incubated at 37 °C for 6 
hours. This resulted in a reproducible biofilm with approximately 1 x 106 viable cells. 
This cell density was selected as it has been shown that wound healing ceases once an 
infected wound reached 1 x 106 CFU g-1 of infected tissue. After 6 hours of incubation 
plates were removed from the incubator and a 1 cm2 piece of a wound dressing was 
placed on the biofilm. The dressing was gently pressed down to ensure good contact 
between the dressing and the biofilm. The membranes with wound dressings applied 
were incubated for a further 24 hours at 37 °C. Following the 24 hours incubation with 
treatments the wound dressings were carefully removed, and the membranes were 
transferred to 10 mL of sterile PBS (pH 7.4). Biofilms were resuspended, diluted and 





5.3.6 Assessment of a the antibiofilm potential of furanone aerogels 
The efficacy of furanone-loaded aerogels against clinically relevant PAO1 biofilms 
was assessed using the simple wound model described above. 
5.3.6.1 Treatment of clinically relevant biofilms with furanone-loaded aerogels using 
a simple chronic wound biofilm model 
Wound bed medium was made, and plates were prepared as described previously in 
section 5.3.2.3. Polycarbonate membranes were inoculated, and clinically relevant 
biofilms were grown. Once biofilms were grown either a furanone-loaded aerogel or 
an unloaded aerogel was added to the surface of the membrane. Aerogels were gently 
pressed down to ensure good contact with the biofilm and medium. Biofilms were then 
incubated for a further 24 hours to simulate a standard wound dressing cycle. After 
further incubation aerogels were removed and biofilms were resuspended, and viable 
cell numbers obtained. 
5.3.6.2 Confirmation of furanone release into wound medium 
To confirm the release of furanone into the developed wound medium a 5% technical 
agar solution was prepared. To prepare the release medium 7.5 mL of sterile 5% agar 
solution was made up to 50 mL with deionised water and while still molten the agar 
was pipetted into 12 well plates in 1 mL volumes. This produced a semi solid medium 
with the same consistency, water content and agar content as the wound medium. Once 
the agar was set, furanone-loaded aerogels were placed on to the surface of the set agar 
and plates were incubated at 37 °C for 24 hours. After incubation, the aerogels were 
removed from the agar plates and the agar was liquefied by adding an additional 2 mL 
of deionised water and mixing thoroughly. The dissolved agar/furanone solution was 
then diluted, and the absorbance read over the full range of wavelengths (200 nm to 
800 nm) using a Varian Cary 50 UV Spectrophotometer (Varian, California, USA). 
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The total concentration of released furanone was calculated. The full absorbance 
spectrum of the released furanone was also assessed to ensure no changes in 
absorbance spectrum had occurred. Experiments were conducted in triplicate and data 
were expressed as absorbance (in arbitrary units) at each tested wavelength. 
5.3.7 Preparation of a modified semi-solid and liquid system. 
Due to limitations in the simple wound model, previously developed, a modified 
system in which a semi-solid artificial wound bed is kept in contact with a liquid phase 
beneath it was required. This system would be comprised of a synthetic wound fluid 
reservoir beneath a semi-solid wound bed held on a stainless-steel mesh platform. This 
method would allow for greater furanone release into the system. 
 5.3.7.1 Preparation of stainless-steel wound bed platforms 
To prepare the wound bed platforms stainless-steel mesh was cut to 50 mm x 50 mm 
square pieces. Two opposite edges of the mesh square were folded to a 90° angle to 
give a platform that was 50 mm x 30 mm x 10 mm (Figure 5.1). 
 
Figure 5.1 – (A) A plan view of the stainless-steel mesh and how it is measured 
and folded to prepare the wound bed platform. The mesh is folded along the red 
lines to an angle of 90° (B) The completed stainless-steel wound bed platform to 
be used in the modified wound model.  
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5.3.7.2 Preparation of a monolithic semi-solid wound bed 
The same procedure as detailed in section 5.3.2.3 was used to prepare the wound bed 
mixture. The medium was poured into Teflon lined containers (KitchenCraft, 
Birmingham, UK) measuring 75 mm x 45 mm in 10 mL volumes. These were then 
stored at 4 °C overnight to allow for complete gelation of the medium. Once the 
medium was set, the wound beds were carefully removed from the Teflon containers 
and trimmed to an appropriate size. Once trimmed the wound beds were carefully 
transferred to the mesh platforms as shown in Figure 5.2 a-b. 
 
Figure 5.2 – (a) The cast monolithic wound bed was removed from the Teflon 
lined container using a sterile palette knife. (b) Wound beds were placed on the 
stainless-steel gel holder and trimmed using the palette knife. During trimming 
any irregular edges or imperfections (such as bubbles in the gel) can be 
removed from the wound bed. 
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5.3.7.3 Setting up the modified wound model system 
Once the mesh platform and artificial wound beds were prepared the model was set 
up as follows. The mesh platforms were first sterilised by autoclaving. Wound beds 
were prepared and placed on sterile platforms as described above. These were placed 
in a plastic container (previously sterilised using 70% ethanol). Sterile simulated 
wound fluid was then added slowly to the container by allowing it to run down the 
inside of the container. This method of adding the fluid ensured that the delicate wound 
bed was not damaged or disturbed. A total volume of 20 mL of wound fluid was added 
to the container. This ensured that the surface of the liquid was in contact with the 
bottom of the wound bed. Once good contact between the liquid phase and the wound 
bed was achieved, a sterile polycarbonate membrane was placed on the surface of the 
wound bed. Membranes were inoculated as detailed in section 5.3.2.2. A cross section 
of a correctly set up wound model is shown in Figure 5.3 a and a top down image of 
an inoculated sample is shown in Figure 5.3 b. 
 
Figure 5.3 –A three-dimensional representation of a functioning modified wound 
model system and a correctly set up wound bed above a liquid phase 
(a)The steel mesh (black) supports the semi solid wound bed (orange) over a reservoir 
of wound fluid (pink). If complete contact between the underside of the wound bed and 
the surface of the fluid reservoir is achieved, furanone release from the developed 
aerogel system will be unimpeded. (b) shows an image of a correctly set up wound bed 
above a liquid phase and a membrane that has been seeded with 5 µL of inoculum. 
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5.3.8 Assessment of furanone-loaded aerogels using the modified wound biofilm 
model 
The efficacy of furanone-loaded aerogels for the treatment of wound biofilms was 
assessed using the developed modified wound bed/liquid model. Prior to treating 
biofilms with aerogels, the release of furanone into the modified model was 
investigated. 
5.3.8.1 Assessing furanone release into the modified wound model 
The release of furanones from the developed aerogel system into the modified wound 
model was assessed. The wound model was set up as described above with the 
omission of an inoculum. Furanone-loaded aerogels were placed onto the semi solid 
wound bed and were incubated at 37 °C temperature for 24 hours. After 24 hours the 
aerogel and membrane were removed and discarded. The semi solid wound bed was 
then placed into the fluid reservoir and the mixture was homogenised by vigorous 
pipetting. This was done so that any furanone that had been released from the aerogel 
but remained in the wound bed could be quantified along with the furanone in the 
liquid phase. The wound fluid/wound bed mixture was assessed using UV visible 
spectroscopy and concentrations of furanone release were calculated. The full 
absorbance spectrum of the released furanones were also assessed to measure any 
degradation that may have occurred.   
5.3.8.2 Preparation of furanone-loaded aerogels 
To prepare furanone-loaded aerogels for use in the developed wound model the 
previously detailed method was followed with one amendment. When adding 
furanone to the PVA sol, an excess was added so that the released portion (as 
determined in section 5.3.8.1) was equivalent to 4 mg for HDMF and 4.325 mg for 






    Equation 5 
Where FL is the amount of furanone to be loaded into the aerogel, Dd is the desired 
dose to be delivered to the biofilm and Fr is the percentage of total loaded furanone 
released into the wound medium (determined in 5.3.8.1). PVA sol phases with the 
adjusted furanone dose were then aliquoted and lyophilised as previously detailed. 
5.3.8.3 Assessment of the antibiofilm potential of furanone-loaded aerogels 
The efficacy of furanone-loaded aerogels was assessed using the protocol in 5.3.5 with 
one amendment. Once biofilms had been grown for 6 hours they were removed from 
the incubator and furanone-loaded aerogels were applied to the membranes ensuring 
good contact. Membranes treated with aerogels were then incubated for a further 24 
hours. After 24 hours of incubation the biofilms were resuspended, diluted and 
enumerated. 
5.3.9 Assessment of clinically relevant wound dressings using the modified wound 
biofilm model 
The modified wound model system was prepared as described above. Membranes 
were inoculated, and biofilms grown to the clinically relevant density (approximately 
106 CFU/biofilm). Five clinically relevant wound dressing materials (Sterile gauze, 
Aquacel Ag, Telfa AMD, Inadine, and Actilite) were trimmed to give 1 cm2 pieces 
using sterile scissors in a laminar flow hood to ensure sterility. Sterile, non-woven, 
gauze was used as a non-medicated control. Once clinically relevant biofilms had been 
grown, they were removed from the incubator and the pieces of each wound dressing 
were applied to the surface of the biofilm. Wound dressings were pressed down gently 
to ensure good contact between the dressing and the biofilm. Biofilms were them 
returned to the incubator and incubated at 37 °C for a further 24 hours. Following 24 
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hours of incubation, wound dressings were removed from the biofilms and 
resuspended. Resuspended biofilms were then diluted and plated to enumerate viable 





A novel in vitro chronic wound biofilm model was developed. Suitable growth 
surfaces and nutrient sources were assessed as well as methods of quantifying the 
biofilms formed. The model was then used to assess the efficacy of four common, 
clinically relevant, wound dressings against P. aeruginosa PAO1 biofilms. Finally, 
the model was used to assess the antibiofilm efficacy of the newly developed furanone-
loaded aerogels.  
5.4.1 Identification of a suitable growth substrate and nutrient source 
Suitable growth surfaces and nutrient sources were identified during the development 
of the wound model as follows.  
5.4.1.1 Identification of a suitable growth surface 
Various semi permeable membranes were assessed as potential growth surfaces for 
biofilms. The membranes tested were polycarbonate, nylon and nitrocellulose. To 
ensure any variation in biofilms was due only to the membrane choice standard 
nutrient agar was used.  
Biofilms formed easily on all membrane types on nutrient agar. Distinct 
morphological differences were seen between the three membrane types. Biofilms 
formed on polycarbonate presented as a dense central area of biofilm surrounded with 
a less dense ring of biomass surrounding it. Biofilms grown on nylon membranes were 
homogenous in terms of biomass density throughout the whole sample. A distinct 
beige/yellow colour was seen in samples grown on nylon. Biofilms grown on 
nitrocellulose were, again, homogenous in terms of biomass density. However, in 




Figure 5.4 – Morphology of biofilms grown on (a) polycarbonate membranes, (b) 
nylon membrane, and (c) nitrocellulose membrane using nutrient agar as a 
medium.  
Biofilms grown on polycarbonate had a distinct central mass surrounded by a less 
dense area of biomass. Biofilms grown on nylon appeared homogenous in terms of 
biomass distribution and had a distinct yellow colour. Biofilms grown on 
nitrocellulose membranes presented as a green/blue biofilm with a homogenous 
biomass density. Images shown are representative of 3 independent replicates. Each 
image shows a 10mm field of view. 
 
5.4.1.2 Identification of an appropriate wound-like nutrient source 
Biofilms were grown on all membrane types on SBF agar and SBF agar supplemented 
with laked horse blood. When grown with simulated body fluid agar as a nutrient 
source, biofilms on polycarbonate formed as very low-density biofilms which did not 
spread from the site of initial inoculation (Figure 5.5 a). When grown on nylon and 
nitrocellulose membranes with simulated body fluid agar, biofilms did not form at all 
(Figure 5.5 b - c). When simulated body fluid agar supplemented with laked horse 
blood was used, biofilms grown on polycarbonate membranes appeared denser than 
with SBF alone but still did not spread from the site of initial inoculation (Figure 5.5 
d). Biofilms grown on nylon membranes showed the same distinct yellow colour but 
were much less dense than was seen on nutrient agar (Figure 5.5 e). Finally, biofilms 
grown on nitrocellulose in the presence of simulated body fluid agar with blood did 




Figure 5.5 – Biofilms grown on simulated body fluid agar (a-c) and simulated 
body fluid agar supplemented with 5% laked hose blood (d-f) on three semi 
permeable membranes.  
On non-supplemented SBF agar biofilms grown on polycarbonate membranes (a) 
were low density and showed no spread from the initial inoculation point. Biofilms did 
not form on nylon (b) and nitrocellulose (c) membranes on this medium. In the 
presence of supplemented body fluid agar biofilms on polycarbonate membranes (d) 
were denser than with non-supplemented agar but still showed no spreading. Biofilms 
grown on nylon membranes (e) were low density but retained the yellow colour noted 
previously. (f) Biofilms did not form on nitrocellulose membranes in the presence of 
body fluid agar with blood. Images shown are representative of 3 independent 
replicates. Each image shows a 10mm field of view. 
 
Biofilms were then grown on a novel semi-synthetic wound bed agar (SWBA) with 
and without laked horse blood. On the SWBA, biofilms grown on polycarbonate, 
presented as well populated biofilms with distinct edges and an area of less dense 
biofilm at the edge (Figure 5.6 a). When grown on nylon membranes with SWBA, 
biofilms were low density with a yellow colour. Biomass density appeared 
homogenous throughout the biofilm (Figure 5.6 b). Biofilms grown on nitrocellulose 
membranes with SWBA appeared as dense biofilms with a cream/yellow colour and 
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homogenous biomass distribution (Figure 5.6 c). When grown in the presence of 
SWBA with 5% blood, biofilms on polycarbonate presented as very dense biofilms 
with no evidence of spreading but a noticeable three-dimensional architecture (Figure 
5.6 d). Biofilms grown on nylon membranes were low density and difficult to identify 
visually from the underlying membrane (Figure 5.6 e). Biofilms grown on 
nitrocellulose appeared as white/cream biofilms with low biomass density (Figure 5.6 
f).  
 
Figure 5.6 – Biofilms grown using simulated wound bed agar (a-c) and simulated 
wound bed agar supplement with 5% blood (d-f).  
When grown using simulated wound bed agar only biofilms on polycarbonate 
membranes (a) formed moderately dense biofilms with some heterogeneity in the 
distribution of biomass throughout the biofilm. Biofilms grown on nylon membranes 
(b) had low amounts of biomass and a yellow colour. Biofilms grown on nitrocellulose 
were dense cream/yellow biofilms. When using SWBA with blood as a nutrient source, 
biofilms on polycarbonate membranes (d) appeared as very dense with an obvious 
three-dimensional architecture. Biofilms grown on nylon membranes (e) were difficult 
to identify but appeared as low-density, diffuse, biofilms. Nitrocellulose bound 
biofilms (f) were seen to be white/cream masses with low to moderate biofilm density. 
Images shown are representative of 3 independent replicates. Each image shows a 
10mm field of view. 
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5.4.2 Selection of a biofilm quantification method 
To assess the antibiofilm effects of wound dressings using the newly developed model, 
a method of quantifying both treated and untreated biofilms was required. Several 
methods were considered, including staining of biofilm proteins, staining of whole 
biofilm biomass, viability staining of biofilm bound cells and direct enumeration.  
5.4.2.1 Biofilm matrix protein staining 
In order to stain biofilm proteins, the fluorescent protein stain SYPRO Ruby was used. 
The accuracy of SYPRO Ruby quantification in aqueous solution was investigated. A 
calibration curve of the fluorescence intensity of SYPRO Ruby against the 
concentration in simple aqueous solution was constructed and the curve was found to 
be acceptable for the interpolation and estimation of the concentration of SYPRO 
Ruby in an unknown solution (R2 = 0.9835). This calibration curve was then used to 
estimate the SYPRO Ruby concentration in three stock solutions of known 
concentration. It was found that estimating SYPRO Ruby concentration in aqueous 
solution was highly inaccurate despite the calibration curve being of acceptable quality 
for the purpose. When analysing the concentration of a 5 μL mL-1 solution, 
interpolation using this method gave an estimated concentration of 0.07 μL mL-1. 
Similarly, a 15 μL mL-1 solution was estimated to contain 2.73 μL mL-1 and a 25 μL 
mL-1 solution estimated to contain 20.43 μL mL-1. These estimates give average 
percentage errors of 98.67%, 81.79% and 18.28% respectively (Table 5.3). These data 
indicate that the use of SYPRO Ruby staining of biofilm proteins is an unsuitable 





Table 5.3 - The estimated concentration of SYPRO Ruby in a low, moderate and 
high concentration solution of SYPRO Ruby in simple aqueous solution. 
Estimation using the previously developed calibration curve was shown to be 
inaccurate resulting in 98.67%, 81.79% and 18.28% reductions in estimated 
concentrations compared to actual concentration for the low, moderate and high 
concentration solution respectively.  
 
5.4.2.2 Staining of total biofilm biomass 
To stain total biofilm biomass crystal violet was used. Prior to staining biofilms, each 
membrane type was used as a substrate to grow a biofilm with nutrient agar as a 
medium. It was found that quantitative crystal violet staining of each membrane type 
was possible. Nitrocellulose showed the lowest over all variability between replicates, 






























Figure 5.7 – Quantitative crystal violet staining of total biofilm biomass of 
membrane bound biofilms. 
 Biofilms grown on each membrane type were grown for either 24 or 48h on nutrient 
agar and biomass was quantified using crystal violet. Differences in biomass between 
the 24- and 48-h time points was apparent on each membrane type with nitrocellulose 
having the lowest overall inter replicate variability. Data shown represents the mean 
of three independent replicates ± S.D. 
Sample







Low Concentration 5 0 0.2 0 0.07 98.67
Moderate Concentration 15 3.516 3 1.68 2.73 81.79






It was also noted that biofilms grown on nitrocellulose membranes were very well 
destained, appearing as white masses on a stained membrane following the destaining 
step. This data suggests that the nitrocellulose substrate strongly binds the crystal 
violet stain. Conversely, the biofilm grown on the nylon membrane appeared as a 
purple mass on a partially destained membrane. The degree of biofilm destaining was 
difficult to establish with biofilms grown on the black polycarbonate membranes 















Figure 5.8 – Membrane bound biofilms following destaining with acetic acid.  
Following destaining it was found that biofilms formed on nitrocellulose were well 
destained appearing as white areas on a heavily stained membrane. Nylon bound 
biofilms were found to be destained less readily than those on nitrocellulose while the 
nylon membrane was easily destained. Assessment of the extent of biofilm destaining 
on black polycarbonate membranes was not possible. 
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5.4.2.3 Viability staining of biofilm bound cells 
To quantify cell viability in membrane bound biofilms the use of BacLight bacterial 
cell viability staining was investigated. It was found that BacLight was an unsuitable 
method of biofilm assessment. Both nylon and nitrocellulose membranes were white 
in colour and, as such, excessive reflection of the illuminating light occurred. This 
resulted in very bright images with little to no visible detail which persisted even when 
exposure time was significantly reduced. When BacLight stained biofilms, on black 
polycarbonate membranes, were imaged it was found that excessive non-specific 
staining of biofilm matrix occurred and, as such it, was not possible to enumerate 
stained cells within the biofilm. Washing away the surface biofilm matrix prior to 
staining was attempted but, when stained, the washed biofilm showed little to no cells 
present.  
5.2.4.4 Direct enumeration of biofilm bound cells 
Finally, direct enumeration of viable, biofilm bound, cells was assessed. It was 
discovered that biofilms grown on nitrocellulose membranes using nutrient agar as a 
medium contained 2.88 x 108 ± 5.70 x 107 viable cells after 24 hours of incubation at 
37 °C. This increased to 4.54 x 1011 ± 4.80 x 1010 viable cells after 48 hours. Similarly, 
biofilms grown on polycarbonate membranes were found to contain 2.89 x 1011 ± 2.55 
x 1010 viable cells after 24 hours and 6.99 x 1013 ± 1.55 x 1013 after 48 hours. However, 
biofilms grown on nylon membranes did not follow this pattern. At 24 hours biofilms 
on nylon membranes consisted of 4.17 x 1011 ± 3.79 x 1011 viable cell which 
subsequently decreased after 48 hours to 4.34 x 108 ± 1.72 x 108 viable cells (Figure 
5.9). It was noted that biofilms grown on polycarbonate were generally larger and 
more reproducible than those grown on either nylon or nitrocellulose membranes. For 
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this reason, polycarbonate membranes were selected as the substrate for the developed 





















Figure 5.9 – Viable cells isolated from biofilms grown on nitrocellulose, nylon and 
polycarbonate membranes using nutrient agar as a medium.  
Biofilms grown on nitrocellulose membranes had 2.88 x 108 ± 5.70 x 107 viable cells 
at 24 hours increasing to 4.54 x 1011 ± 4.80 x 1010 at 48 hours. Biofilms grown on 
nylon membranes had 4.17 x 1011 ± 3.79 x 1011 cells at 24 hours which decreased to 
4.34 x 108 ± 1.72 x 108 at 48 hours. Biofilms grown on polycarbonate membranes 2.89 
x 1011 ± 2.55 x 1010 viable cells at 24 hours and 6.99 x 1013 ± 1.55 x 1013 after 48 
hours. Data shown represents the mean of three independent replicates ± S.D. on a 
log10 scale.  
 
5.4.3 Characterisation and validation of the developed simple wound model  
Following the selection of a growth surface, nutrient source and method for 
quantifying the produced biofilm, characterisation of the biofilm formation kinetics 
was performed. To validate the model, the efficacy of clinically used wound dressings 
was assessed using the developed method. 
5.4.3.1 Biofilm formation on simulated wound bed medium 
Biofilm formation kinetics on both simulated wound bed medium and nutrient agar 
were investigated and compared. When using nutrient agar as a nutrient source, 
biofilms grown on polycarbonate membranes reached a peak viable cell density of 1.9 
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x109 CFU per biofilm. However, over the same 10-hour experimental period, biofilms 
grown on polycarbonate membranes using the newly developed simulated wound bed 
medium as a nutrient source reached a total viable cell density of 5.37 x 107 cells per 
biofilm. One-way ANOVA analysis of each time point (comparing biofilms grown on 
nutrient agar to biofilms grown on wound bed medium) showed that there was, in fact, 
no significant difference between the samples at any time point. A clinically relevant 
biofilm viable cell density was achieved after 6 hours incubation with a viable cell 
count of 1.69 x 106 ± 1.32 x 105 cells per biofilm (Figure 5.10). 
 



















Figure 5.10 – Biofilm formation kinetics of P. aeruginosa PAO1 DSM50071 on 
polycarbonate membranes using nutrient agar and simulated wound bed media 
as nutrient sources.  
In the presence of nutrient agar, POA1 biofilm total viable cell count steadily 
increased to a total viable cell density of 1.9x109 CFU per biofilm after 10 hours 
incubation. On wound bed medium a peak viable cell count of 5.37 x 107 per biofilm 
was reached after 10 hours and a clinically relevant bacterial load of 1.69 x 106 was 
reached in 6 hours. Data shown represents the mean of three independent replicates 
± S.D. on a log10 scale. One-way ANOVA analysis showed no significant difference 





5.4.3.2 Assessment of common antimicrobial wound dressings using a simple wound 
biofilm model 
The effect of common, clinically relevant, antimicrobial wound dressings against P. 
aeruginosa PAO1 biofilms was investigated. Biofilms grown on the simulated wound 
bed medium were found to be generally resistant to all dressings tested with no 
significant reduction in viable cells following any of the four treatments. It was noted 
that while the application of wound dressings did not reduce viable cell numbers in 
the biofilms, it did prevent the rapid growth of the biofilm which was observed when 
no treatment was applied. This effect was apparent for both the medicated dressings 






















































Figure 5.11 – The effects of treatment with common antimicrobial wound 
dressings on viable cell numbers in polycarbonate bound P. aeruginosa PAO1 
biofilms grown on simulated wound bed medium.  
When grown in the presence of the simulated wound bed medium PAO1 biofilms were 
found to be totally resistant to treatment with all dressings with no significant 
reductions in viable cell numbers after 24 hours. It was noted that the presence of any 
dressing (medicated and non-medicated) prevented further growth of the biofilm when 
compared to no treatment controls. Data shown represents the mean of three 
independent replicates ± S.D. on a log10 scale. Statistical analysis was by one-way 




5.4.3.3 Assessment of a the antibiofilm potential of furanone aerogels using a simple 
wound biofilm model 
The effect of furanone-loaded aerogels was assessed using the simple wound model. 
Clinically representative biofilms, containing approximately 106 CFU, were either left 
untreated or treated with an unloaded or furanone-loaded aerogel for a further 24 
hours. Again, when no treatment was applied, the biofilm continued to proliferate and, 
after 24 hours, contained approximately 9.36 x 1014 CFU. When treated with a blank 
aerogel the biofilm was also able to proliferate, though not significantly. Biofilms 
treated with blank aerogels contained 9.42 x 108 CFU after 24 hours of treatment. 
HDMF aerogel treated biofilms showed no significant increase in CFU numbers and 
sotolon aerogel treated biofilm showed a non-significant increase in CFU (containing 














































Figure 5.12 - The effects of treatment with blank and furanone-loaded aerogels 
on viable cell numbers in polycarbonate bound P. aeruginosa PAO1 biofilms 
grown using the simple wound biofilm model.  
When grown on wound bed medium PAO1 biofilms were not susceptible to treatment 
with any aerogel treatment with no significant reductions in cell numbers after 24 
hours. It was noted that the presence of any aerogel (blank and furanone-loaded) 
prevented any significant further growth of the biofilm when compared to no treatment 
controls. Data shown represents the mean of three independent replicates ± S.D. on a 
log10 scale. Statistical analysis was by one-way ANOVA with a Dunnet’s post-hoc test 
to compare all columns to the control (before treatment). 
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These data indicate that the developed simple would model is not suitable for the 
assessment of furanone-loaded aerogels against P. aeruginosa PAO1 biofilms. 
5.4.3.4 Furanone release and integrity in a simple wound bed model 
The ability of the aerogels to release their furanone pay load into the wound bed 
medium was assessed. As the furanone compounds have been shown to be unstable 
under several conditions, degradation of released furanones was assessed as well as 
the total concentration of released furanone. It was shown that, following release into 
the wound bed medium, both HDMF and sotolon remained unchanged in their λmax. 
The observed λmax of HDMF was 285 nm while the λmax of sotolon was 230 nm 
indicating that the furanones did not degrade upon release (Figure 5.13). 





















Figure 5.13 – Absorbance spectra of HDMF and Sotolon after being released 
from a PVA aerogel into the developed semi solid wound medium.  
Spectra recorded for both Sotolon and HDMF remained unchanged in their λmax 
showing maximum absorbances at 230 nm and 285 nm respectively. Data shown 
represents the mean of three independent replicates ± S.D.  
 
When the total quantity of furanone released into the simple wound model was 
assessed it was found that aerogels loaded with 4 mg of HDMF were able to release 
only 8.61% of their total pay load (0.344 mg total release) into the simple wound 
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model. Conversely, aerogels loaded with 4.33 mg sotolon were able to release 72.34% 






























Figure 5.14– Quantification of furanone release from loaded aerogels into the 
newly developed wound model.  
Aerogels loaded with an antibiofilm concentration of HDMF (4 mg) and Sotolon (4.33 
mg) released 8.61% and 72.34% of their total payload into the wound model, 
respectively. Data shown represents the mean of three independent replicates ± S.D.  
 
The limited release of HDMF into the simple wound model necessitated the 
optimisation of the wound model to allow for greater release of HDMF, thus, 
maximising the potential for successful inhibition of biofilm formation.   
5.4.4 Assessment and validation of the developed modified wound model.  
Following the failure of the simple model to assess the antibiofilm efficacy of aerogels 
a modified wound model system, consisting of a simulated wound bed and a wound 
fluid reservoir, was developed (section 5.3.7). This method was assessed for its ability 
to allow furanone release. It was then used to assess furanone-loaded aerogels and 




5.4.4.1 Furanone release and integrity in a modified chronic wound bed model 
The release of furanones into the new modified wound model was assessed. It was 
found that the furanone released into the new model was not degraded. Released 
HDMF showed a single clear peak at 285 nm when assessed using UV-Visible 
spectroscopy. Similarly, released sotolon was found to have a λmax of 230 nm (Figure 
5.15). 





















Figure 5.15 - Absorbance spectra of both HDMF and Sotolon after being released 
from a 10% PVA aerogel into the novel modified chronic wound model.  
Both Sotolon and HDMF remained unchanged in their λmax showing maximum 
absorbances at 230 nm and 285 nm respectively. Data shown represents the mean of 
three independent replicates ± S.D. 
 
Further, the concentration of each furanone released into the modified wound model 
over 24 hours was examined. It was found that aerogel, loaded with 4 mg of HDMF, 
released 57.47% of the total loaded drug (2.3 mg total HDMF release). This was an 
improvement over the 8.61% release in the simple wound model. Aerogels loaded 
with 4.33 mg of sotolon released just 39.10% of the total loaded volume (1.69 mg total 
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sotolon release). This was considerably lower than the 72.34% release observed for 


































Figure 5.16 - Quantification of furanone release from loaded aerogels into a 
modified wound model.  
Aerogels loaded with an antibiofilm concentration of HDMF (4 mg) and Sotolon (4.33 
mg) released 57.47% and 39.10% of their total payload into the wound model 
respectively. Data shown represents the mean of three independent replicates ± S.D. 
 
5.4.4.2 Treatment of biofilms with furanone-loaded aerogels on a modified wound 
model 
Following confirmation that furanone was released into the modified wound model at 
acceptable concentrations, loaded aerogels were assessed for their ability to treat 
clinically relevant biofilms. It was discovered that, as was the case in the simple model, 
a clinically relevant biofilm, left untreated for a further 24 hours would continue to 
proliferate. Such biofilms contained an average of 3.3 x 1013 cells per biofilm. This 
represented a 7.52 log increase in viable cells. Treatment of clinically relevant biofilms 
with an unloaded aerogel contained 1.10 x 109 cells per biofilm following treatment, 
representative of a 2.68 log increase in viable cells. Similarly, treatment with HDMF 
yielded biofilms containing 1.67 x 108 cells per biofilm after 24 hours treatment (a 
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2.20 log increase). Finally, when treated with sotolon-loaded aerogels, biofilms 
contained only 233 viable cells on average. This represents a log reduction of 3.65 
(Figure 5.17 a-b). It should be noted that statistical analysis was performed on log10 
transformed CFU values. This action limited any skew in the data making statistical 
analysis by one-way ANOVA appropriate.  
 
Figure 5.17 – Changes in bacterial cell numbers following treatment with 
unloaded and furanone-loaded aerogels expressed as (a) CFU/biofilm on a log 
scale and (b) Log10 CFU / biofilm.  
Controls in which no treatment was applied resulted in a 7.52 log increase in viable 
cells per biofilm (final CFU/ biofilm of 3.3 x 1013) treatment with an unloaded aerogel 
resulted in a 2.68 log increase giving a final biofilm with 1.10 x 109 CFU. Treatment 
with HDMF-loaded aerogel resulted in a 2.20 log increase in viable cells (final 
CFU/biofilm 1.67 x 108) this was not found to be significant. Treatment with sotolon-
loaded aerogels showed a significant log decrease in viable cells of 3.65 and resulted 
in biofilms with an average of 233 CFU/biofilm. Data shown represents the mean of 
three independent replicates ± S.D. Analysis is by one-way ANOVA of the log10 
values. *p=0.05, **p=0.01, *** p=0.001  
 
5.4.4.3 Assessment of clinically used wound dressings using the modified wound 
model. 
Currently used, clinically relevant wound dressings were re-evaluated using the newly 
developed model. It was shown, that when clinically representative biofilms were 
treated with non-medicated gauze, the biofilm proliferated and gave a biofilm with 
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7.36 x 1011 cells after 24 hours of treatment. This corresponded to a 4.39 log increase 
in viable cells during treatment. When treated with Aquacel Ag, viable cell numbers 
were reduced to 136 per biofilm or a 3.87 log decrease in 24 hours. Similarly, 
treatment with Inadine resulted in a 2.54 log reduction in cells with biofilm containing 
just 3273 cells on average following treatment. When treated with Telfa AMD, 
biofilms continued to proliferate and contained 5.60 x1010 viable cells after 24 hours. 
This corresponds to a 3.88 log increase (Figure 5.18 a-b). Finally, treatment with 
Actilite for 24 hours showed no significant increase or decrease in viable cell numbers. 
As before, data was transformed to the Log10 values prior to data analysis 
 
Figure 5.18 – Changes in viable cell numbers following treatment with clinically 
used wound dressings using a modified wound model.  
Treatment with gauze caused cells to proliferate with 7.36 x 1011 cells after 24 hours 
(4.39 log increase). Aquacel AG reduced bacterial numbers to approximately 136 per 
biofilm (3.87 log decrease). Inadine treatment reduced cell numbers to 3273 viable 
cells (2.54 log decrease). Telfa AMD had no bactericidal effect and biofilms 
proliferated during treatment with a final bacterial load of 5.60 x1010 cells per biofilm 
(3.88 log increase). Treatment with Actilite showed no significant change in viable 
cell numbers. Data shown represents the mean of three independent replicates ± S.D. 






Chronic wounds are highly complex environments that rely heavily on the delicate 
balance of pro- and anti-inflammatory cytokines, immune cells and external 
conditions such as moisture and pressure (Guo and DiPietro, 2010). When infected, 
the wound environment only becomes more complex. This inherent complexity 
presents a number of difficulties for anyone hoping to research wounds, wound 
infections, and the development of novel wound therapeutics. The most significant 
issue with such research is the challenge of accurately representing an infected wound 
using an in vitro model. While there are many in vitro wound infection models 
reported in the literature (Sun et al., 2008; Werthén et al., 2010; Kucera et al., 2014) 
these models often have one or more limitations. These can include the use of a 
nutrient profile that is not representative of a wound, a growth substrate that is not 
representative of a wound bed, or simply using materials with a high cost. 
The work detailed in this chapter aimed to develop a novel, low cost wound biofilm 
model that is suitable for the assessment of not only furanone-loaded aerogels but other 
wound dressings as well. 
The first stage of developing a novel wound model was to select a growth substrate. 
This work investigated the use of semi-permeable membranes (made from nylon, 
nitrocellulose and polycarbonate) as a growth substrate. Such membranes have been 
used in the colony biofilm model previously detailed in the literature (Merritt, Kadouri 
and O’Toole, 2005). The use of membranes as a substrate was investigated as precise 
quantification of the biofilm would be required at a later stage, and easy removal of 
the biofilm from the model was vital. This work showed that changes in growth 
substrate (while nutrient source remains the same) can have a significant effect on the 
339 
 
morphology of a P. aeruginosa PAO1 biofilms. When grown on polycarbonate 
membranes, biofilms appeared as an off-white mass with central area of high biomass 
and an outer ring of lower biomass. When grown on nylon, biofilm biomass was 
uniform across the sample and a more yellow biofilm was formed. When grown on 
nitrocellulose, biofilm biomass was relatively evenly distributed, but the biofilm 
presented as a blue/green colour. While these specific morphological changes have 
not previously been reported in the literature the idea that growth substrate can impact 
on biofilm properties has. For example, in 2019, Williams et al, showed that when 
biofilms grown using a CDC reactor were grown on polycarbonate, their susceptibility 
to antibiotics was significantly different to biofilms grown on collagen substrates. 
Further, this work showed that when grown on polycarbonate, biofilms formed by a 
wide range of organisms were often more susceptible to treatment with antibiotics. 
The authors showed that P. aeruginosa was more resistant to treatment with both 
tobramycin and ciprofloxacin when grown on collagen substrates. The authors suggest 
this may be due to a number of factors. They note that differences in substrate surface 
morphology may allow biofilms to penetrate deeper into the collagen substrate, 
allowing cells to better evade exposure to antibiotics (Williams et al., 2019). However, 
as the surface morphologies of the membranes used in this thesis are likely very similar 
to each other this may not explain the differences observed in this work. Further, the 
presence of a blue/green colour in the biofilm grown on nitrocellulose indicates a 
greater production of pyocyanin. Changes in the production of this virulence factor 
may not be explained by changes in substrate morphology. However, pyocyanin has 
been shown to increase the binding of eDNA (which is vital for biofilm formation) to 
P. aeruginosa cells (Das et al., 2013, 2016). If the surface of the nitrocellulose resulted 
in the formation of a poorly stable biofilm an increase in pyocyanin production, and 
340 
 
the subsequent increase in eDNA-cell linkages, may have increased biofilm integrity. 
However, this hypothesis would require further investigation to fully understand and 
this was not within the scope of this work.  
Due to the differences in biofilm morphology on each membrane, it was decided that 
all three membrane types would be assessed as a growth substrate alongside a range 
of different nutrient sources. This work showed that biofilms did not grow well on any 
tested substrate when SBF agar was used as a nutrient source. This medium contained 
only salts that are present in human serum and 5.5 mM glucose. As such, both carbon 
and nitrogen were limited and, therefore, minimal biofilm growth was expected. 
However, when biofilms were grown in the presence of simulated body fluid agar 
supplemented with 5% v/v of laked horse blood obvious biofilms were formed on both 
the polycarbonate and nylon membranes. No biofilm formed on the nitrocellulose 
membrane. Finally, biofilms were grown on each membrane using simulated wound 
medium, consisting of a mix of simulated wound fluid, protein, and muscle cell lysate 
(with and without laked horse blood). This experiment showed that the densest 
biofilms were grown on polycarbonate membranes using simulated wound bed 
medium with laked blood. This was an important finding because it is well known that 
the nutrients available to various species of bacteria can have a significant impact on 
their ability to form biofilms, the metabolic profile of the cells, and the long term 
maintenance of the biofilms (Anderl et al., 2003; Sauer et al., 2004; Cherifi et al., 
2017; She et al., 2019). The selection of simulated wound bed medium with laked 
blood ensured that the biofilms grown in the developed model closely resemble in vivo 
wound biofilms.  
Once a suitable nutrient source and growth substrate had been selected, a method of 
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quantifying the biofilms was required. Four potential options were identified; staining 
of matrix proteins with fluorescent SYPRO Ruby, staining of total biofilm biomass 
with crystal violet, staining live and dead cells using BacLight, and direct enumeration 
of viable, biofilm bound, cells. These methods were selected as each has been 
previously reported for the quantification of biofilm (Merritt, Kadouri and O’Toole, 
2005; O’Toole, 2011; Bauer et al., 2013; Stiefel et al., 2016).   
It was found that the use of SYPRO ruby as a biofilm stain was not appropriate as the 
quantity of the stain in simple aqueous solution could not reliably be measured, 
resulting in large underestimations. For this reason, the use of SYPRO ruby was not 
examined further as a method of biofilm biomass quantification.  
Crystal violet is a simple and effective method for measuring total biofilm biomass in 
microtitre plates (O’Toole, 2011). This work aimed to show that it is possible to use 
crystal violet staining to determine total biomass of membrane bound biofilms. It was 
found that when exposed to crystal violet stain, both the nitrocellulose and nylon 
membranes were heavily stained along with the biofilm. However, when the 
membranes and biofilms were washed and destained it was clear that the nitrocellulose 
membranes were not destained while the biofilm was effectively destained, appearing 
as a white mass on the purple membrane. Conversely, the nylon membranes appeared 
to be partially destained while the biofilm remained heavily stained (appearing as a 
light purple membrane with a dark purple biofilm). Due to their dark colour it was 
unclear if polycarbonate membranes were significantly stained by crystal violet. 
Following visual inspection of the membranes the biofilm, biomass was quantified by 
measuring the resolubilised crystal violet. Biofilm biomass was inconsistent between 
the three membrane types. However, it was expected that biofilms grown on different 
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membranes would be of different sizes following the observed differences in biofilm 
morphology on different membrane materials. 
The use of BacLight staining was then tested as a method for quantifying biomass of 
membrane bound biofilms. It was demonstrated that when used on the white nylon 
and nitrocellulose membranes the light used to excite the fluorescent stains was 
heavily reflected and, thus, the biofilms could not be visualised. When visualising 
biofilms grown on black polycarbonate membranes it was found that there was a 
significant amount of background staining of the biofilm matrix in addition to the 
staining of the bacterial cells. This meant that the numbers of viable and non-viable 
cells could not be accurately determined. Due to these issues the use of BacLight was 
not selected for use in this wound model.   
Finally, the use of direct enumeration of viable cells was assessed as a method of 
quantifying membrane bound biofilm. It was found that of all the quantification 
methods assessed, direct enumeration was the most accurate, giving the least amount 
of variability between replicates. This assessment showed a marked difference in the 
numbers of biofilm bound cells on each membrane type at the same time point. It was 
demonstrated that both nitrocellulose and polycarbonate membrane bound biofilms 
showed the expected increase in viable biofilm bound cells between the 24 hours and 
48 hour time points. However, it was found that the biofilm grown on polycarbonate 
had a greater number of viable cells after 48 hours growth (6.99 x1013 per biofilm) 
when compared to those biofilms grown on nitrocellulose membranes (4.54 x 1011) at 
the same time point. These data suggest that the biofilm may not grow as well, or as 
rapidly, on a nitrocellulose membrane when compared to polycarbonate. 
Alternatively, the difference may be due to difficulties in removing all of the biofilm 
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from the nitrocellulose membrane. It was clear that the use of a polycarbonate 
membrane for use in the wound model was preferable. For this reason, it was decided 
that the wound model being developed would use the wound-like medium 
supplemented with laked horse blood as a nutrient source, polycarbonate membranes 
as the growth substrate, and direct enumeration as the method of biofilm 
quantification.  
Once all elements of the wound model had been selected, the biofilm growth kinetics 
in the new wound model were investigated. For this, biofilms were grown on the 
developed simple wound model (wound medium and membrane only) and biofilms 
were sacrificed and quantified every two hours by direct enumeration. It was found 
that, for the first 10 hours, biofilm growth using the wound like medium supplemented 
with blood was not significantly different than biofilms grown using nutrient agar as 
a medium. This indicated that the developed wound-like medium had all the nutrients 
required for biofilm formation and that nutrient availability was not a limiting factor 
in biofilm growth during this time frame. After 12 hours of growth, the biofilms grown 
on the wound like medium had fewer viable cells per biofilm than those grown using 
nutrient agar. However, this difference was not found to be statistically significant. It 
was also noted that the biofilms grown using the wound like medium reached a CFU 
density of approximately 1 x 106 cells per biofilm after 6 hours. This is a significant 
cell density as it has been shown that once an infected wound surpasses 106 CFU per 
gram of tissue, wound healing stops and a wound becomes chronic (Bendy et al., 
1964). Following the assessment of biofilm growth kinetics, the finalised wound 
model protocol was developed. Biofilms would be grown on polycarbonate 
membranes using the wound-like nutrient medium. Biofilms would be grown for 6 
hours (to achieve a clinically representative cell density of approximately 106 cells per 
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biofilm) prior to treatment. Treatments would be applied for 24 hours and the treated 
biofilm would be quantified using viable cell counting.  
The developed model was then validated by assessing the efficacy of wound dressings 
that are in current use by tissue viability specialists and wound care clinics. The wound 
dressings included Aquacel AG, Telfa AMD, Inadine, and Actilite. These dressings 
contain a range of active ingredients (silver, PHMB, iodine, and manuka honey 
respectively). Non-woven gauze was used as a non-medicated control. When clinically 
representative biofilms, grown using the simple, wound medium only, model were left 
untreated, biofilms continued to proliferate as expected. However, when wound 
dressings were applied, the biofilms failed to grow beyond their pre-treatment state. 
Despite this stall in biofilm growth there was no significant reduction in viable cell 
numbers. The data generated here showed that the dressings which contained active 
ingredients were no more effective than non-medicated gauze. This finding was highly 
unexpected. Each of the active components of the tested dressings have been shown 
to be effective in killing biofilm bound bacteria using a range of methods such as 
fermenter grown biofilms, zone of inhibition assays, and crystal violet assays ( Hill et 
al., 2010; Park et al., 2013; Lu et al., 2019; Salisbury et al., 2019). As well as this, 
each of these dressings have been proven to be clinically effective as an antimicrobial 
dressing prior to commercialisation. The lack of efficacy observed using the simple 
wound model suggested that one or more aspects of model do not allow for the wound 
dressings to exert their antimicrobial effect. Alternatively, this finding may suggest 
that the biofilms grown using this model are not clinically representative and so 
respond to treatment very differently than in vivo biofilms.  
The simple wound model was then used to assess the efficacy of the furanone-loaded 
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aerogels as a treatment of wound biofilm. Again, the untreated biofilm continued to 
grow as expected. Treatment with the blank and furanone-loaded aerogels yielded 
similar results to the clinical wound dressings. No significant changes in biofilm 
bound viable cell numbers was observed when biofilms were treated with blank 
aerogels or aerogels loaded with either furanone. Again, this was unexpected. When 
the aerogels were removed following the 24 hours treatment period, they were fully 
rehydrated. This rehydration of the aerogel should have allowed the release of the 
furanone. It was hypothesised that the wound medium was limiting the release of the 
furanone. As there was only a 1 mL volume of wound medium for the furanone to 
release into it was hypothesised that the aerogel did release the furanone appropriately 
but that an equilibrium between the furanone concentration in the medium and the 
rehydrated gel was reached very rapidly. This equilibrium would have meant that no 
further drug release into the wound medium was possible (Frenning, 2011). An 
alternative hypothesis was that the furanones were released from the aerogel as 
expected but that they were rapidly degraded by an interaction with one or more 
components of the wound medium.  
To test these two hypotheses, loaded aerogels were prepared and allowed to release 
into soft agar of identical polymer concentration and volume as was used in the wound 
model. The quantity and integrity of the furanone released into the agar was assessed. 
It was found that the furanone released into the agar remained intact as evidenced by 
no changes in the UV absorbance spectrum. Both the HDMF and sotolon retained their 
expected λmax. However, when the concentration of furanone released into the agar 
measured it was found that HDMF released just 8.61% of the aerogel’s total loaded 
drug and sotolon released 72.34% of the total loaded drug. The incomplete release of 
each furanone may explain the limited effect against biofilm. As each aerogel was 
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loaded with an anti-biofilm concentration of each furanone, incomplete release would 
have meant that the therapeutic dose was never reached in the wound model. As 
previously stated, it was hypothesised that this was due to the limited volume of wound 
medium for the furanone to release into. This prompted work to modify the wound 
model to have a larger reservoir so that furanone release could be improved.  
Following the discovery that furanone release into the developed wound model was 
limited, the wound model was modified into a hybrid system that consisted of a wound 
bed made from the developed wound medium and a reservoir containing simulated 
body fluid. These modifications were made so that the wound model system provided 
a larger receiver phase for drug release. It has been noted previously that in diffusion-
based drug release systems (which the developed aerogels are believed to be) drug 
release will gradually reduce until an equilibrium state is reached (Frenning, 2011). 
The addition of a greater receiver volume would allow significantly more drug to be 
released before equilibrium is reached. When furanone release into the modified 
wound model was assessed, the release of HDMF was significantly increased while 
the release of sotolon was reduced when compared to the total release observed in the 
simple model. While the improvement observed in the release of HDMF into the 
modified wound model is promising, the reason for the reduction in sotolon release is 
unclear. However, despite this the modified wound model was used to assess the 
efficacy of both furanone-loaded aerogels and clinically used wound dressings.  
When assessed using the modified wound model, treatment of a clinically 
representative PAO1 wound biofilm with HDMF-loaded aerogels showed no 
significant reduction in biofilm bound cells after 24 hours of treatment. However, as 
no other work has assessed the use of HDMF against wound biofilm or using a wound 
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model, comparisons cannot be made. However, as noted in chapter 4, HDMF has been 
used to treat PAO1 biofilms using a standard microtitre plate assay (Choi et al., 2014). 
Here the authors showed that treatment of PAO1 biofilms grown in microtitre dishes 
with 0.1 µM and 1.0 µM HDMF resulted in 27.8% and 42.6% reductions in total 
biomass respectively. However, due to differences in strain, growth substrate, and 
nutrient medium it can be expected that the biofilms grown in this work would respond 
very differently to treatment when compared to this work. Furthermore, as detailed in 
chapter 4 of this work the strain used is deficient in four genes, mexR, nalC, mdrR1, 
and mdrR2. As previously noted these genes all encode repressors of either the 
MexAB-oprM or ErmAB multidrug efflux transporters (Maeda et al., 2012; Heacock-
Kang et al., 2018). It has been reported in the literature that that strains that lack the 
mexR and nalC genes in particular are more resistant to furanone treatment via 
enhanced furanone efflux. This increased resistance may explain the lack of 
antibiofilm effect observed when treating clinically representative biofilms with 
HDMF-loaded aerogels. However, when such biofilms were treated with sotolon-
loaded aerogels, a significant reduction in biofilm bound cells was observed. 
Following treatment, a 3.65 log decrease in biofilm bound cells was observed. This 
significant reduction resulted in post-treatment biofilms containing approximately 233 
viable cells. This indicates that sotolon-loaded aerogels are a potentially viable option 
for the reduction of biofilm bound viable bacterial cells in chronic wounds infected 
with P. aeruginosa PAO1. Further, if the hypothesis proposed in chapter 4 is correct 
and the strain used in this study has increased resistance to furanone treatment, a 
similar reduction in biofilm may be possible with significantly lower concentrations 
of sotolon for non-resistant strains.  
Finally, the efficacy of clinically used wound dressings was reassessed using the 
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modified wound model. It was found that the efficacy of the wound dressings was 
significantly impacted by the model. When assessed using the simple model no 
dressing was found to be more effective than the non-medicated control in killing 
biofilm bound cells. However, when these dressings were assessed using the modified 
model both Aquacel Ag and Inadine showed excellent antimicrobial action against 
biofilm bound PAO1 cells. Aquacel Ag treatment resulted in a 3.87 log decrease in 
viable biofilm bound cells. Inadine treatment gave 2.54 log decrease in biofilm bound 
cells. The significant reduction in viable cell numbers observed after treatment with 
Inadine is in keeping with the literature. In their 2010 study Hill et al. showed that P. 
aeruginosa biofilms, grown using an in vitro chronic wound infection model based on 
continuous drip feed growth, could be totally eradicated after treatment with Inadine 
(Hill et al., 2010). However, this same study showed that viable cell numbers in these 
biofilms were not significantly affected by treatment with Aquacel Ag. This is further 
supported by a 2015 study conducted by Priscilla et al. who also showed no significant 
antimicrobial effect of Aquacel Ag against mature P. aeruginosa biofilms grown on 
porcine skin explants (Phillips et al., 2015). An explanation for the observed 
differences between these studies and the results reported in this thesis may be found 
in the biofilms themselves. Both the work of Hill et al. and Priscilla et al. reported 
control biofilms containing approximately 108 cells per biofilm. This is a significantly 
higher cell density than was used in this thesis. The use of larger, more robust biofilms 
by Hill et al. and Priscilla et al. may have limited the efficacy of Aquacel Ag and of 
silver as an antimicrobial. Further, these variations in the efficacy of silver may have 
been caused by differences in bacterial strains used. For example, several papers have 
identified mechanisms of silver resistance including genetic elements such as 
plasmids, bacterial cooperation, and the production of virulence factors such as 
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pyocyanin (Silver, 2003; Muller and Merrett, 2014; Muller, 2018). Therefore, if the 
strains used in the published works had a greater resistance to ionic silver the results 
would differ greatly from the work reported here.   
The differences in antimicrobial data obtained using the simple wound model, the 
modified model, and other models reported in the published literature clearly highlight 
the need for accurate, clinically representative in vitro models of chronic wound 
infection. It is obvious that even small differences in nutrient availability, inoculum 
density, bacterial strain, and growth substrate can have a profound effect on the 
efficacy of the treatments being tested. With such a wide range of models available 
for researchers aiming to develop and assess novel antimicrobial wound therapies, it 
is vital that a model which is simple, robust, and which can yield clinically 














In order to grow biofilms that were representative of real-world wound biofilms a 
novel wound-like medium was developed. This wound bed medium was used to 
develop a simple chronic wound biofilm model. This model was shown to be effective 
in rapidly growing P. aeruginosa biofilms on a polycarbonate substrate. While 
biofilms grew on the model rapidly, they were found to not be susceptible to treatment 
with clinically used antimicrobial wound dressings and furanone-loaded aerogels 
alike. It was suggested that this may be due to the limited amount of the wound 
medium available for the active ingredients of the treatments to release into. This was 
subsequently shown to be the case for HDMF-loaded aerogels. The wound model was 
then redesigned to give a modified wound bed model. This modified model consisted 
of a wound bed prepared from the wound-like medium and a reservoir of simulated 
body fluid that would provide a greater receiver phase, thus allowing for greater 
release of the active antimicrobial ingredients to release from the dressing into the 
model. The modified model was then used to show that treatment of clinically 
representative chronic wound biofilms with HDMF-loaded aerogels had no significant 
effect on numbers of biofilm bound cells. However, treatment of such biofilms with 
sotolon-loaded aerogels resulted in significant reductions of biofilm bound cell 
numbers. This suggests that not only might sotolon make an effective treatment for 
the reduction of biofilm biomass in wounds chronically infected with P. aeruginosa, 
but also that minimally crosslinked PVA aerogels are an effective mechanism for 
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6.1 Introduction  
The focus of this thesis was broad. The development of a novel delivery method for 
furanone compounds has spanned several key areas including pharmaceutics, 
microbiology and materials science. Due to the highly multidisciplinary nature of this 
work, each chapter includes a discussion of the main findings of that section in the 
context of the relevant, field specific, literature. This chapter will discuss the primary 
findings from each chapter in the context of the project as a whole and consider the 
potential of delivering furanones in a controlled manner to inhibit biofilm formation 
in chronic wounds by P. aeruginosa.  
The main conclusions from this work have been: 
1. Amorphous PVA-borate hydrogels are an unsuitable vehicle for delivery of 
furanones to chronic wounds. 
2. Simple PVA aerogels can be loaded with, and release, furanone compounds. 
3. Furanones can effectively inhibit early biofilm formation by Pseudomonas 
aeruginosa PAO1 and can reduce biofilm biomass in established biofilms. 
4. The developed wound model is suitable for the growth of clinically 
representative P. aeruginosa wound biofilms.  
5. Sotolon-loaded PVA aerogels show potential as anti-biofilm treatments for 
wounds containing a P. aeruginosa biofilm. 
6.2 Hydrogels are unsuitable delivery vehicles for furanones 
PVA-borate hydrogels were assessed as potential delivery mechanisms for furanones. 
While a suitable production method and formulation of hydrogel were identified it was 
found that, during the process of loading the hydrogel, the furanone compounds were 
significantly degraded. This degradation presented primarily as changes in the UV 
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absorbance though other changes, such as changes in the colour of the solution were 
also observed. Three of the tested compounds; HDMF, sotolon and ascorbic acid all 
showed changes in their maximum UV absorbance (see chapter two) and an overall 
decrease in total absorptivity. Both HDMF and ascorbic acid showed a change in 
colour when loaded into the formulated hydrogel. While the colour change for HDMF 
was rapid, the change observed in ascorbic acid samples was delayed and occurred 
slowly over several days. Finally, while one furanone compound, MTHF did not 
display any obvious change in λmax, the total UV absorbance spectrum was altered and 
showed a compound that was absorbing across a broad range of wavelengths. 
Due to the process of preparing the hydrogels the furanones were exposed to a number 
of conditions that could potentially cause compound degradation. These were 
extended exposure to high temperature (90 °C for up to 3 hours), exposure to a solution 
of the borate crosslinker, and exposure to the elevated pH caused by the presence of 
the borate. Each of these scenarios was examined independently of the others to 
identify the cause of the degradation. However, it was found to be a combination of 
all of these factors that caused the changes in the compounds. Interestingly, it was 
shown that the effects of each factor were not the same for each furanone. A simple 
summary each tested condition and their effect on the furanone compounds can be 
seen in Table 6.1  
While this degradation of the furanone compounds was unexpected, it was in keeping 
with the available literature. As previously discussed in section 2.5 of chapter two, 
increased temperature and changes in pH have been shown to cause degradation in 
HDMF and ascorbic acid in aqueous solution (Shu, Mookherjee and Ho, 1985; 
Roscher, Schwab and Schreier, 1997; Yuan and Chen, 1998). This work showed that 
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the combination of factors needed to bring about changes in λmax and total absorptivity 
of a furanone was unique to each compound. This meant that for each of the four 
furanones to remain stable they could not be exposed to high temperatures, borate or 
significantly altered pH.  
Table 6.1 - A summary of the effect of each tested factor and its effect on each of 
the four furanone compounds. Cells highlighted in green showed no change in 
either total absorbance or λmax. Yellow highlighted cells indicate a change in 
either total absorbance or λmax and red highlighted cells show a change in both. 
The specific changes are detailed in each cell. 
 
One potential solution for this issue would be to different hydrogel types such as 
physically crosslinked gels prepared by freeze thaw. The use of such gels could 
minimise the conditions that degrade each compound (Hennink and van Nostrum, 
2012; Zhang, Zhang and Wu, 2013). The findings of these experiments prompted the 
development of both a novel cold-loading method for loading furanones into a 
hydrogel while minimising interactions with free borate as well as the development 
and characterisation of a novel PVA aerogel.   
6.3 Furanones can be loaded into simple PVA aerogels for direct 
delivery to chronic wounds 
To circumvent the issues caused by exposure to heat and free borate ions, furanones 






































with a furanone solution. It was hypothesised that, as this process was performed at 
room temperature, it would minimise the thermal degradation caused by the traditional 
hydrogel production method. Further, it was hypothesised that, because the hydrogel 
was crosslinked prior to drying, the presence of free borate in the system would be 
minimised, as much of it would be bound in crosslinks. It was found that a powdered 
form of the dried hydrogel was well rehydrated with deionised water, giving a high-
quality hydrogel that was not rheologically different to its pre-dried state. However, 
despite these promising findings, when the dried hydrogels were rehydrated with a 
furanone solution, the hydrogel either became discoloured, as was the case with 
HDMF and ascorbic acid-loaded samples, or the hydrogels remained entirely liquid 
when rehydrated, as with ascorbic acid and sotolon-loaded samples. This meant that, 
while exposure to high temperature could be minimised, the presence of any amount 
of borate would cause HDMF, sotolon and ascorbic acid to be degraded. Indeed, 
chemical crosslinking agents are known to potentially cause negative effects in the 
production of hydrogels. While this is not widely supported by the primary literature, 
many studies claim the use of physical crosslinking to be more advantageous as it can 
ameliorate issues with chemical crosslinking agents such as potential toxicity, 
crosslinker leeching, and interactions with drug payloads (Berger et al., 2004; Hu et 
al., 2019). 
These findings prompted the development of a drug delivery system that required no 
heating to produce and contained no borate crosslinker. To achieve this, a PVA aerogel 
was developed.  
The developed aerogels showed an interesting microstructure that appeared to be 
dependent on the concentration of the polymer solution used to produce them. It was 
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shown that at higher polymer concentrations (and therefore higher aerogel density) the 
internal structure was highly ordered with the fibrous structure aligning 
spontaneously. This structure became less ordered at lower polymer concentrations 
(and lower aerogel density). As discussed in chapter three it was believed that this was 
due to directional freeze concentration of the polymer (Butler, 2002; Zhang et al., 
2005). Whether this structure affected drug loading or drug release remains unclear. 
While optical and electron microscopy showed an ordered structure, X-ray CT 
scanning showed that this structure was not homogenous throughout the entire 
material, with many areas having a higher overall density than others. Despite this 
PVA aerogels could be loaded with furanone easily.  
As no heating or crosslinker were required for their production, it was hypothesised 
that each compound would be stable when loaded into the aerogels. This was found 
not to be the case for all furanones. When loaded with furanones, aerogels appeared 
to contain significantly higher concentrations of MTHF and ascorbic acid after 
lyophilisation when compared to the actual loaded dose. Conversely, concentrations 
of HDMF and sotolon were significantly decreased. This increase in concentration of 
MTHF was similar to that observed in the loaded hydrogels. The apparent increase in 
ascorbic acid was unexpected and was believed to be due to a form of degradation 
caused by exposure to an aqueous environment. The significant decrease in the 
concentrations of HDMF and sotolon was hypothesised to be due to the inherent 
volatility of the compounds. It was thought that the furanones were being lost while 
under vacuum during the lyophilisation process. Though there are no reports of this 
from the pharmaceutical sector, the loss of volatile compounds following 
lyophilisation is a known phenomenon in the food industry (Huang et al., 2016; Nöfer 
et al., 2018). However, when examining data from the food industry the effect of 
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drying method on furanones specifically is not clear as other factors such as enzymatic 
browning can produce furanones and furan derivatives, thus, making the true impact 
of lyophilisation on furanone loss unclear (de Torres et al., 2010). Despite this, it is 
clear that drying can impact on volatile compounds and so the aerogel freeze-drying 
protocol was optimised to minimise furanone loss. This optimisation greatly improved 
the concentration of retained furanone post freeze-drying.   
The final stage of aerogel characterisation was to demonstrate furanone release from 
a loaded gel. This was achieved in two formulations of aerogel for both HDMF and 
sotolon. MTHF and ascorbic acid showed total furanone release of more than 100% 
and so it was decided that these two compounds would be excluded from further 
formulation work.  
The work conducted in chapter two demonstrated that not only were PVA-borate 
hydrogels unsuitable for furanone delivery, but that the issues observed were caused 
by a combination of exposure to the borate crosslinker and the elevated temperatures 
required for hydrogel formation. The experiments detailed in chapter three showed 
that the use of a minimally crosslinked PVA aerogel can ameliorate these problems.  
These aerogels are easily loaded with furanones and do not cause significant 
degradation of HDMF and sotolon. These aerogels were then carried forward for 
assessment as a system for delivering furanones to bacterial biofilms.  
6.4 Furanones have potential as antibiofilm therapies against P. 
aeruginosa 
With a furanone delivery mechanism having been formulated and characterised, 
furanones were assessed for their ability to inhibit biofilm formation in P. aeruginosa.  
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It was shown, through differential staining, biochemical assays, and genetic 
characterisation, that the chosen strain was indeed P. aeruginosa DSM50071. It was 
also shown that the strain grew appropriately in the chosen medium and that it formed 
biofilm. 
The minimum inhibitory concentrations of each furanone were then assessed. It was 
found that the MIC for HDMF was significantly higher than previously reported in the 
literature (Choi et al., 2014). The MIC for ascorbic acid could not be compared to a 
similar study, but the reported MIC of the similar compound, sodium ascorbate, was 
significantly higher than the established MIC in this work. These differences were 
initially attributed to the use of a different bacterial strain to the published literature 
(Choi et al., 2014; El-Mowafy et al., 2014). The MIC for sotolon and MTHF could 
not be compared to other studies as there have been no published works using these 
compounds.   
It was then shown that both ascorbic acid and MTHF were not able to inhibit biofilm 
formation in P. aeruginosa at any fraction of the established MIC after 24 hours. While 
no data is available for MTHF, previous studies have shown the sodium salt of 
ascorbic acid is capable of reducing biofilm formation by P. aeruginosa at 
concentrations as low as one twentieth the MIC established in that study (El-Mowafy 
et al., 2014). Conversely, both HDMF and sotolon were able to significantly reduce 
biofilm at a one half the established MIC during the same time frame. HDMF could 
also inhibit biofilm formation at one quarter MIC. Following longer furanone 
treatments, it was shown that both HDMF and sotolon significantly reduced biofilm 
formation and maintained the reduction for up to 72 hours post treatment. This was 
then confirmed by using BacLight staining. It was also shown that the furanone 
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treatment did not result in significantly higher numbers of non-viable cells in the 
formed biofilm.  
Subsequently, both HDMF and sotolon were shown to be effective in reducing the 
mass of mature, 24 hours old biofilms while both ascorbic acid and MTHF had no 
effect. However, when applied to a mature, 48 hours old, biofilm it was found that 
HDMF caused a significant increase in biofilm biomass and sotolon showed no effect 
when applied to a similar biofilm. These data suggested that, while furanones could 
be very effective in reducing the biomass of wound biofilms, the time frame in which 
they remained effective may be narrow. As ascorbic acid and MTHF showed no effect 
they were excluded from further microbiological testing. 
Finally, it was demonstrated that both HDMF and sotolon retained their antibiofilm 
effects when delivered to a biofilm using the developed aerogel system. It was shown 
that when applied at the point of inoculation, both HDMF and sotolon-loaded aerogels 
were highly effective in reducing biofilm biomass versus an unloaded control. Sotolon 
reduced biomass by up to 100%. When applied to mature, 24 hour and 48 hours old 
biofilms, aerogel delivered HDMF showed a significant decrease in biofilm biomass. 
Conversely, aerogel delivered sotolon showed a significant reduction in biofilm 
biomass 48 hours post application to a 48 hours old biofilm. These findings, again, 
reinforce the hypothesis that furanones, even when delivered using the developed 
aerogels, can be an effective treatment, but only if used at the right time. 
The data presented in this chapter, while promising, had low applicability to real-world 
chronic wounds. Due to this limited applicability, it was decided that a more clinically 




6.5 The development of a clinically relevant wound model 
While promising, the data collected using the microtitre dish assays were of limited 
relevance to an in vivo wound infection. For these reasons, it was decided that an 
appropriate wound infection model should be used. However, when reviewing the 
literature to select the most appropriate model it was apparent that the available models 
had several limitations including non-representative nutrient profiles or poorly 
representative growth substrates. Therefore, the final experimental chapter of this 
thesis focused on the development of a novel in vitro chronic wound biofilm assay.   
The development of the wound model involved formulating a novel wound-like 
growth medium. This medium consisted of protein, salts, blood and muscle cell lysate. 
This growth medium, with a wound-like nutrient profile, was essential as it has been 
shown that nutrient availability can effect many aspects of biofilm formation and 
response to treatments (Anderl et al., 2003; Sauer et al., 2004; Cherifi et al., 2017; She 
et al., 2019). This medium proved to be excellent for biofilm growth and showed rates 
of growth similar to those observed with nutrient agar. 
However, the use of the wound-like medium as a nutrient source for biofilms gown on 
polycarbonate membranes alone was not a sufficient wound model. When testing both 
the loaded aerogels and the clinically relevant wound dressings there was no 
significant reduction in biofilm or bacterial killing. It was subsequently shown that 
this lack of antibiofilm effect was due to limited release of the active components from 
the aerogels into the medium. This prompted a modification of the model to add a fluid 
reservoir, consisting of a volume of simulated body fluid. This modification increased 
the volume of material into which the furanones could release. This modification 
vastly improved the efficacy of the furanone-loaded aerogels. Results showed that 
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treatment with subinhibitory concentrations of sotolon resulted in a 3.65 log decrease 
in viable cell numbers in biofilms. In addition to this, using the modified wound model 
to assess clinically used wound dressings showed clear antimicrobial efficacy for both 
Aquacel Ag and Inadine, as expected.  
This chapter aimed to develop a wound model capable of growing clinically 
representative P. aeruginosa wound biofilms for the assessment of novel wound 
dressings. A successful model was developed and used to show that PVA aerogels are 
a potentially excellent method to deliver antimicrobial compounds to infected chronic 
wounds. Furthermore, the data presented in this chapter clearly demonstrate that 
furanones, and sotolon in particular, have potential as novel anti-biofilm wound 
therapeutics.  
6.6 Conclusion  
The data presented in this thesis are promising. While the work of chapter two 
demonstrated that furanones are not suitable for use in every drug delivery mechanism, 
they can be delivered to bacterial biofilms using polymer aerogels. However, when 
used as antibiofilm agents the efficacy of furanones was variable. It is hypothesised 
that the efficacy of furanones largely depends on the time and, therefore, stage of 
biofilm formation at which they are applied. Unfortunately, it has not been possible to 
fully investigate this during the course of this project.  
The development of a novel PVA aerogel for the delivery of active compounds to 
bacterial biofilms during this project has opened up many possibilities for further 
study. The aerogels used here have undergone minimal optimisation and 
characterisation due to time and funding constraints. As such, in order to realise the 
full potential of the developed aerogels, significantly more work is needed. To this 
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end, an extensive research proposal has been developed and included as the final 
chapter in this thesis. The work described in this proposal will aim to further develop 
the polymer aerogel drug delivery system and do so specifically in the context of 


















Anderl, J. N. et al. (2003) ‘Role of nutrient limitation and stationary-phase existence 
in Klebsiella pneumoniae biofilm resistance to ampicillin and ciprofloxacin’, 
Antimicrobial Agents and Chemotherapy, 47(4), pp. 1251–1256. doi: 
10.1128/AAC.47.4.1251-1256.2003. 
Berger, J. et al. (2004) ‘Structure and interactions in covalently and ionically 
crosslinked chitosan hydrogels for biomedical applications’, European Journal of 
Pharmaceutics and Biopharmaceutics, 57(1), pp. 19–34. doi: 10.1016/S0939-
6411(03)00161-9. 
Butler, M. F. (2002) ‘Freeze Concentration of Solutes at the Ice/Solution Interface 
Studied by Optical Interferometry’, Crystal Growth and Design, 2(6), pp. 541–548. 
doi: 10.1021/cg025591e. 
Cherifi, T. et al. (2017) ‘Impact of Nutrient Restriction on the Structure of Listeria 
monocytogenes Biofilm Grown in a Microfluidic System’, Frontiers in Microbiology, 
8, p. 864. doi: 10.3389/fmicb.2017.00864. 
Choi, S. C. et al. (2014) ‘Inhibitory effects of 4-hydroxy-2,5-dimethyl-3(2H)-furanone 
(HDMF) on acyl-homoserine lactone-mediated virulence factor production and 
biofilm formation in Pseudomonas aeruginosa PAO1’, Journal of Microbiology, 
52(9), pp. 734–742. doi: 10.1007/s12275-014-4060-x. 
El-Mowafy, S. A., Shaaban, M. I. and Abd El Galil, K. H. (2014) ‘Sodium ascorbate 
as a quorum sensing inhibitor of Pseudomonas aeruginosa’, Journal of Applied 
Microbiology, 117(5), pp. 1388–1399. doi: 10.1111/jam.12631. 
372 
 
Hennink, W. E. and van Nostrum, C. F. (2012) ‘Novel crosslinking methods to design 
hydrogels’, Advanced Drug Delivery Reviews, 64, pp. 223–236. doi: 
10.1016/J.ADDR.2012.09.009. 
Hu, W. et al. (2019) ‘Advances in crosslinking strategies of biomedical hydrogels’, 
Biomaterials Science, 7, p. 843. doi: 10.1039/c8bm01246f. 
Huang, Q. et al. (2016) ‘Effect of Different Drying Method on Volatile Flavor 
Compounds of Lactarius deliciosus’, J Food Process Technol, 7(8). doi: 
10.4172/2157-7110.1000615. 
Nöfer, J. et al. (2018) ‘The Influence of Drying Method on Volatile Composition and 
Sensory Profile of Boletus edulis’. doi: 10.1155/2018/2158482. 
Roscher, R., Schwab, W. and Schreier, P. (1997) ‘Stability of naturally occurring 2,5-
dimethyl-4-hydroxy-3[2H]-furanone derivatives’, European Food Research and 
Technology, 204(6), pp. 438–441. doi: 10.1007/s002170050109. 
Sauer, K. et al. (2004) ‘Characterization of nutrient-induced dispersion in 
Pseudomonas aeruginosa PAO1 biofilm’, Journal of Bacteriology, 186(21), pp. 
7312–7326. doi: 10.1128/JB.186.21.7312-7326.2004. 
She, P. et al. (2019) ‘Effects of exogenous glucose on Pseudomonas aeruginosa 
biofilm formation and antibiotic resistance’, MicrobiologyOpen, 8(12). doi: 
10.1002/mbo3.933. 
Shu, C.-K., Mookherjee, B. and Ho, C.-T. (1985) ‘Volatile Components of the 
Thermal Degradation of 2,5 - dimethyl-4-hydroxy-3(2H)-furanone’, Journal of 
Agricultural and Food Chemistry, 07735, pp. 446–448. 
373 
 
de Torres, C. et al. (2010) ‘Effect of freeze-drying and oven-drying on volatiles and 
phenolics composition of grape skin’, Analytica Chimica Acta. Elsevier, 660(1–2), pp. 
177–182. doi: 10.1016/j.aca.2009.10.005. 
Yuan, J. P. and Chen, F. (1998) ‘Degradation of Ascorbic Acid in Aqueous Solution’, 
Journal of Agricultural and Food Chemistry, 46(12), pp. 5078–5082. doi: 
10.1021/jf9805404. 
Zhang, H. et al. (2005) ‘Aligned two- and three-dimensional structures by directional 
freezing of polymers and nanoparticles’, Nature Materials, 4(10), pp. 787–793. doi: 
10.1038/nmat1487. 
Zhang, H., Zhang, F. and Wu, J. (2013) ‘Physically crosslinked hydrogels from 
polysaccharides prepared by freeze–thaw technique’, Reactive and Functional 














Proposal for future work: 
“In-situ degrading polymer 
aerogels as drug delivery systems 












7.1 Introduction  
The work conducted during this project has provided promising data that suggests 
furanones have may potent antibiofilm effects when applied to early stage infections. 
This effect was apparent when applied both directly to the biofilm as a bolus dose, and 
when using an aerogel delivery system. Furthermore, it was shown that when added 
to a late-stage biofilm directly, furanones were able to effectively reduce biofilm 
biomass. It was suggested that the organism used in this work had a significantly 
higher resistance to furanones than expected when it was originally selected (through 
enhanced furanone efflux) and thus was able to remove the compound from the 
intracellular environment. This means that an effective intracellular dose was difficult 
to achieve. While interesting, the findings of this work are not broadly applicable to 
all P. aeruginosa strains and infections. This finding has provided an opportunity to 
further investigate the use of furanones and furanone-loaded aerogels as wound 
therapeutics. 
Based on findings detailed in the preceding experimental chapters, this chapter will 
discuss ways in which this research may be further developed and translated to gain 
maximum benefit from the use of furanones and furanone-loaded aerogels. This 
discussion will be presented in the form of a detailed project proposal and will have 
several primary objectives. First, to optimise and characterise the aerogels developed 
as part of this work. This will ensure a robust delivery vehicle for the furanone 
compounds. Aerogels will be optimised as in-situ degrading dressings which do not 
require removal from a wound upon dressing change. Second, to investigate the anti-
biofilm and anti-virulence effects of furanones against both susceptible and resistant 
organisms. This will take the form of furanone only treatments and furanones used in 




both early and late infection conditions. Third, to characterise the effects of the most 
potent furanone treatments (both furanone only and combination treatments) on 
mammalian cells. Finally, robust in vivo assessment of the developed wound dressings 



















7.2 Project summary 
Chronic wounds do not heal and, as such, present a significant socio-economic burden 
to health services and patients worldwide. Currently, there is no effective treatment 
(Martinengo et al., 2019) and chronic wounds are set to cost the UK NHS £9 billion 
per annum by 2023 (Guest et al., 2016). Those suffering from a chronic wound 
experience debilitating comorbidities such as persistent pain, reduced mobility, social 
isolation and negative effects on mental health (Renner and Erfurt-Berge, 2017).  
Chronic wounds are caused by an acute wound becoming stuck in an inflammatory 
state. This can be due to a number of factors including presence of foreign bodies, 
poor circulation or continued physical trauma (Frykberg and Banks, 2015). However, 
bacterial infection is the most common reason for this failure to heal. When present in 
wounds, bacteria mainly grow in the form of a biofilm. Here, the bacteria are protected 
by a self-produced polymer matrix (Malone et al., 2017), making them much more 
difficult, if not impossible to eradicate (Flemming et al., 2016).  
Topical antibiotics are not routinely used in the treatment of chronic wounds due to 
potential side effects such as irritation of the surrounding skin, sensitivity reactions, 
and potential systemic toxicity from prolonged use (Healy and Freedman, 2006). As 
an alternative, dressings which contain silver, iodine, and biguanide compounds are 
commonly used (e.g. AquacelAg, Inadine and Telfa AMD, respectively). However, 
these antiseptic dressings are expensive (some costing more than £20 per dressing). 
While they are the preferred course of treatment for such wounds, often the use of 
advanced dressings does not produce better clinical outcomes for patients in terms of 
wound healing (Dumville, Keogh, et al., 2015; Dumville, Stubbs, et al., 2015). 




cause additional trauma to the wound site by damaging newly formed epithelial and 
granular tissues, as well as potentially removing of portions of the stratum corneum, 
thus, affecting the overall integrity of the skin (Matsumura et al., 2013). Indeed, some 
97% of wound care specialists have reported further damage such as wound 
enlargement, pain or bleeding upon removal dressings (Charlesworth et al., 2014). In 
addition to the physical damages wound dressings can cause, the pain of removing an 
adhered dressing is a significant source of anxiety and worry for patients (Woo, 2010).  
It is clear, therefore, that alternative wound treatments are needed. This project will 
develop wound dressings which undergo complete matrix dissolution in the wound 
environment (therefore, not requiring removal upon dressing change) in order to 
deliver antibiofilm drug compounds to both acute and chronic wounds. Development 
of a material with these properties will allow clinicians to apply a dressing which will 
effectively prevent biofilm formation in contaminated wounds and promote the 
removal of biofilms in established chronic wounds. Further, this dressing will not 
become adhered to the wound bed, thus, removing the potential for further trauma 
upon dressing change. This would represent a significant improvement over current 
therapies.  
During this PhD, a minimally crosslinked PVA aerogel formulation has been 
developed for use as a wound drug delivery system. The developed aerogel has unique 
properties including high drug loading capacity and effective delivery of 
phytochemicals to bacterial biofilms. Further work is now required to optimise both 
physical and chemical characteristics of the aerogel in order to control parameters such 




(such as material porosity) in order to realise the potential of this PVA aerogel as a 
wound therapeutic.   
To achieve this, aerogels will be produced while modifying variables including 
polymer composition, polymer concentration, and cross-linking density. The produced 
aerogels will be extensively physically and structurally characterised to determine the 
effect of these changes on pore density, size, homogeneity, and structural 
homogeneity. Aerogels will then be loaded with a series of furanone compounds and 
drug release kinetics established via experimentation using an in-house method. 
Further, release mechanisms will be elucidated by using an appropriate mathematical 
model of drug release.  
The developed aerogel material undergoes complete dissolution in the wound 
environment and therefore 100% release of the loaded drug is achievable, facilitating 
the application of highly targeted doses of active compounds to patients.  
Following successful development of drug loaded aerogels, their antibiofilm efficacy 
against common wound pathogens will be demonstrated in vitro and their 
biocompatibility with human cells will be shown. The aerogels developed during this 
project will greatly improve clinical outcomes by simultaneously addressing issues 
surrounding antimicrobial compound delivery to wounds and potential trauma 








7.3 Background  
A chronic wound is any wound which fails to progress through the normal process of 
wound healing. The development of a chronic wound can have a significant impact on 
patients, not only in terms of their physical health but their also mental well-being. 
7.3.1 The process of wound healing 
Normal wound healing involves several distinct but overlapping processes in which 
numerous cell types coordinate both spatially and temporally to successfully close a 
wound. The first stage of wound healing is the haemostasis phase. After a wound is 
sustained, blood vessels constrict and platelets aggregate and form a fibrinous clot 
(Zaidi and Green, 2019). Haemostasis is followed by an inflammatory stage in which 
immune cells such as neutrophils are recruited to the injury site and act as a primary 
defence against infection. Following this, other immune cells are recruited. Cells, such 
as monocytes, are activated to become macrophages which further protect against 
bacterial infection. Numerous other cells including dendritic cells and T-cells are also 
involved in this complex stage. After the inflammatory stage is the proliferative phase. 
During this phase the formation of new blood vessels at the wound site occurs in a 
process known as angiogenesis. Angiogenesis is accompanied by the production of 
new connective tissue by dermal fibroblasts. This mix of new blood vessels and 
connective tissue is known as granulation tissue. This is followed closely by 
reepithelialisation in which new epithelial cells begin to form, beginning at the wound 
edge, and regenerate the protective layer of skin, thus, restoring barrier function 
(Rodrigues et al., 2019). When an acute wound is sustained in a healthy individual 





7.3.2 The development of a chronic wound 
Under normal circumstances wounds will progress through the processes detailed 
above and the wound will heal appropriately. However, both intrinsic and extrinsic 
factors can interrupt the transition from one phase to the next. When this occurs, 
wound healing will fail, and a chronic wound is formed. Internal factors capable of 
interrupting the wound healing process include underlying health conditions such as 
diabetes and genetic disorders like sickle cell disease (Morton and Phillips, 2016; 
Dewi and Hinchliffe, 2019). External factors include those such as the presence of a 
foreign body in the wound, or persistent low-grade trauma to the wound bed (Frykberg 
and Banks, 2015; Han et al., 2017; Waquad et al., 2020). However, the most common 
cause of failure to heal in wounds is bacterial infection (Leaper, Assadian and 
Edmiston, 2015). When present in a wound, bacteria primarily grow in communities 
encased in a polymer matrix known as a biofilm. When growing in this form, bacteria 
have high levels of protection against host immune defences (Pier et al., 2001). These 
biofilms elicit an inflammatory response from the hosts immune system but, due to 
the biofilms resilience against processes such as opsonisation and subsequent 
phagocytosis, they cannot be cleared (Mishra et al., 2012). When a biofilm is not 
cleared, the inflammatory processes continue, and this results in a persistent 
inflammatory state within the wound. As the inflammatory stage of wound healing is 
unable to be resolved the process of wound healing cannot continue and a chronic 
wound results (Schultz et al., 2017). These biofilms also provide the bacteria with 
greatly increased protection against treatment with antimicrobials, making them 
incredibly difficult, and often impossible, to eradicate (Mah and O’Toole, 2001; Mah, 
2012). Due to the resilience of biofilms, chronically infected wounds may persist for 




provided daily) and regular consultation with clinicians, such as tissue viability 
specialists, general practitioners, infection specialists, and vascular teams. The 
prolonged and involved nature of chronic wound care makes their treatment very 
expensive.  
7.3.3 The socio-economic impact of chronic wounds 
The treatment of wounds and their associated complications currently costs the NHS 
£5.3 billion per year (Guest et al., 2016). This is on par with the total cost of cancer 
care for the NHS in 2009/10 (Sullivan et al., 2011). Furthermore, this figure is 
predicted to increase to £9 billion per annum by 2023 (Guest et al., 2016). Chronic 
wounds are a persistent problem worldwide with some reports stating their prevalence 
at 2.21 per 1000 population (Martinengo et al., 2019). If these estimates are indeed 
correct that would suggest that, in the UK, approximately 150,000 people currently 
suffer from a chronic wound. However, it is likely that these estimates are significantly 
lower than the actual prevalence as chronic leg ulcers alone have been shown to affect 
731,000 people in the UK each year. With an associated cost to the NHS of £1.94 
billion per annum (Guest, Vowden and Vowden, 2017), leg ulcers represent a 
significant economic burden for the NHS. Furthermore, chronic ulcers (a chronic 
wound that was caused by an internal factor rather than an external injury) as a whole 
have been estimated to affect between 0.6-3% of people over 60 and up to 5% in 
people over 80 (Rayner et al., 2009). With over 390,000 people in the UK being over 
the age of 80 in 2019 (Office for National Statistics, 2020) this would suggest a 
potential 20,000 chronic ulcers in this age group alone. It is clear that chronic wounds 
are highly prevalent and, when the increasing age of the general population is 




7.3.4 Current chronic wound therapies 
Current guidance on the treatment of infected chronic wounds is contradictory and 
decisions on treatment are made on a case by case basis by clinicians. However, many 
clinicians are confused about when to use antimicrobial treatments or if their use is 
appropriate at all (Lipsky and Hoey, 2009). Many clinicians tend to avoid the use of 
topical antimicrobials as studies surrounding their efficacy remain inconclusive, and 
many cite other concerns such as difficulty in accurate dosing for topical preparations 
like creams and ointments (Lipsky and Hoey, 2009). Indeed, many health boards in 
England advise against the use of topical antimicrobials in wound treatment due to 
their broad spectrum of activity and concerns regarding the development of 
antimicrobial resistance (Cambridgeshire and Peterborough Foundation Trust, 2012; 
Brawn, 2015). The difficulty in accurate dosing of topical antimicrobials may, in fact, 
be a significant contributor to the development of resistance when using them. With 
inaccurate dosing, it is more likely that bacteria will be continuously exposed to sub-
lethal doses of antimicrobial compounds. This is well known to be a driver for the 
development of resistance. Further, the very design of some antimicrobial dressings 
greatly increases dosing inaccuracies. Examples of this include antimicrobial wound 
dressings such as Aquacel Ag, Inadine and Telfa AMD which contain silver, iodine, 
and PHMB respectively. While these compounds are effective antimicrobials, the 
dressings mechanism of drug release means that compound release from these 
dressings to the wound site is not consistent or repeatable. Dressings such as these 
require a moist environment in which to work as they must be rehydrated in order to 
initiate release of their active components. Other dressings made of alginates and 
foams also require a moisture in order to release their antimicrobial payload. This 




administered doses from such dressings (Thomas and McCubbin, 2003). In addition 
to this, some clinical guidelines suggest cutting antimicrobial dressings to fit the 
wound size and shape (Cambridgeshire and Peterborough Foundation Trust, 2012). 
This will effectively reduce the levels of antimicrobial being applied to the wound and 
further encourage underdosing. These limitations make it impossible for clinicians to 
be certain that an effective dose of antimicrobial has been delivered to the wound. The 
same holds true of topical antibiotic creams and ointments. Anabact gel containing 
0.75% metronidazole is occasionally applied to infected wounds. However, doses will 
vary considerably if applied in a thin layer or generously. Without applying exact 
weights, accurate dose measurement is impossible. Chronic underdosing in cases such 
as these has significant potential to encourage the development of antimicrobial 
resistance in infected wounds, which only makes eradication of the infection harder 
(Williamson, Carter and Howden, 2017; Carter et al., 2018).   
7.3.5 Preventing acute wound infection 
Infection in acute wounds can come from a number of sources. Several types of 
wounds present a significantly increased risk of wound infection. These include bite 
wounds (both bites by animal and humans), those wounds with visible contamination 
(for example with soil or gravel), wounds with foreign bodies present (such as shards 
of glass) and burn wounds (Church et al., 2006; Rothe, Tsokos and Handrick, 2015; 
WHO, 2020). Even simple injuries such as clean lacerations of  the hand have been 
shown to have an infection rate of approximately 4.8% (Roodsari, 2015). It has also 
been shown that in wounds a biofilm can be identified as soon as 6 hours after initial 
infection (Percival, McCarty and Lipsky, 2015). It is this biofilm that can eventually 
cause the prolonged inflammatory response that leads to failure to heal. Disinfection 




leading to biofilm development and chronic wound formation. Current treatment 
guidelines recommends the application of disinfectants such as iodine, or 
antimicrobials like silver sulfadiazine to high risk wounds such as animal bites and 
burns respectively (Rothe, Tsokos and Handrick, 2015; Cartotto, 2017). While 
effective, these treatments have the same limitations as those used in chronic wound. 
This means that, although antimicrobials are being used, it is likely that total 
disinfection will not be achieved and the possibility of remaining organisms forming 
a biofilm persists. The use of an antibiofilm agent in wound dressings may help to 
ameliorate this. Even if some bacterial cells remain in a wound following infection, 
the presence of a biofilm inhibitory compound would be of benefit. This would prevent 
any remaining cells from forming a biofilm and causing a chronic wound to form. 
Thus, a method of delivering biofilm inhibitory compounds to acute wounds would be 
of great value. 
7.3.6 Addressing chronic wound biofilm 
Over 90% of all chronic wounds contain microorganisms living within a biofilm 
(Attinger and Wolcott, 2012). Any effective treatment aimed at improving healing in 
chronic wounds must address bacterial biofilms as a priority. This means that quorum 
sensing inhibitors are excellent candidate molecules for use in chronic wound 
therapeutics. The use of furanones as effective quorum sensing inhibitors against a 
range of pathogens has been demonstrated (Ren, Sims and Wood, 2001; Hentzer et 
al., 2002, 2003; Wu et al., 2004; Lianhua et al., 2013; Choi et al., 2014). However, 
the application of non-optimal doses of compounds to wounds is not only problematic 
when delivering antimicrobials but would also likely be problematic when delivering 
antibiofilm compounds such as furanones. Indeed, it has been shown previously that 




many clinical isolates already (Maeda et al., 2012; García-Contreras et al., 2013). 
Underdosing must, therefore, be addressed in the development of an antibiofilm 
dressing. It is clear that a method of delivering precise doses of compounds, whether 
they are antimicrobials or antibiofilm agents, to infected wounds would be invaluable.  
The work proposed here will further develop a novel polymer aerogel drug delivery 
system capable of delivering active compounds directly to chronic wounds through in 
situ matrix dissolution (Figure 7.1). Further, the developed aerogels will be loaded 
with a range of furanone compounds with proven antibiofilm activity and their 
efficacy against a range of common biofilm forming wound pathogen under chronic 
wound conditions will be shown. By undergoing total matrix dissolution, the aerogels 
described here will deliver 100% of their drug payload allowing for precise dosing to 
be achieved in wounds for the first time. 
 
Figure 7.1 – A comparison of diffusional drug release achieved by formulations 
such as some polymeric hydrogels with the matrix dissolution mediated drug 
release of the aerogels proposed here.  
Diffusional drug release occurs with a concentration gradient where drug substances 
move from a higher concentration (within the drug delivery system) to a lower 
concentration (in the wound bed). When mediated by matrix dissolution drug is 




This project will address the significant problem of chronic wounds on two fronts. 
Firstly, by developing novel therapies for acute wounds which will prevent the early 
infections that cause a wound to become chronic. Secondly, by developing a wound 
dressing which will effectively reduce bacterial biofilm in chronic wounds which will 
allow the wounds to heal normally. The developed aerogel dressings will not require 
removal from the wound upon dressing change and so the trauma of dressing 
adherence, which commonly causes worsening of a wound, will be avoided. This 
represents a significant improvement over current clinically used chronic wound 
therapies. 
7.4 Aims and objectives  
To deliver in situ degrading aerogels for drug delivery to acute and chronic wounds 
this project has five primary aims. This project will determine: 
1. the effects of polymer choice, concentration and crosslinking density on the 
matrix dissolution properties of polymer aerogels so that aerogels with precise 
drug release profiles can be made. 
2. that antimicrobial aerogels deliver effective doses of furanones to ensure 
chronic wound bacterial biofilms can be eradicated 
3. that furanone-loaded aerogels effectively prevent biofilm formation by low 
concentrations of bacteria in an acute wound environment so that initial wound 
infection can be prevented. 
4. the biocompatibility of the developed antimicrobial aerogels so that aerogel 





5. the in vivo efficacy of the developed aerogels in a mouse model of chronic 
wound infection and acute burn wound infection. 
7.5 Proposed methods 
This project will deliver novel antibiofilm therapies for both acute wounds and chronic 
wounds, preventing early infections that cause wounds to become chronic and, in the 
case of chronic wounds, eradicating the bacterial biofilms that prevent normal healing. 
In order to generate primary project outcomes, the following research activities will 
be undertaken. 
7.5.1 Work Package 1 – Preparation of aerogel formulations (0-16 months) 
Over 450 aerogel formulations with varying polymer types and concentrations will be 
prepared in order to identify those formulations with appropriate matrix dissolution 
properties. This work will generate aerogel formulations designed for drug release to 
chronic wounds and acute wounds. This work package will also increase 
understanding of the factors affecting aerogel matrix dissolution and drug release.  
It is hypothesised that: 
• Aerogels with lower polymer concentrations will dissolve more rapidly in 
aqueous environments. 
• Aerogels with higher porosity will dissolve more rapidly in wound 
environments. 
• Higher degrees of polymer crosslinking will attenuate matrix dissolution rates 
and prolong drug release times. 
• Higher concentration of hydrophobic polymers in dual polymer aerogels will 




To assess these hypotheses, over 450 aerogel formulations will be prepared using 17 
polymers. A selection of 6 biocompatible synthetic polymers, or polymer precursors, 
will be used; 
• poly vinyl alcohol (PVA) 
• polyvinylpyrrolidone (PVP) 
• polyacrylic acid (PAA) 
• poly ethyene glycol (PEG)  
• Gantrez, 
• trimethyl orthosilicate (TMOS) 
 
In addition to these, 11 natural biocompatible polymers will be used:  




• guar gum 







Each of these polymers has previously been used to make hydrogels for biomedical 
purposes. As such, production of an aerogel for wound therapeutics using these 
polymers is possible but has never been explored.  
Single polymer aerogels will be produced from gels or sols containing 5% of each 
polymer by weight in an appropriate solvent. These single polymer aerogels will be 
prepared using three separate methods namely the lyophilisation method previously 
used in this work, the widely used critical point drying method (Baldino et al., 2020) 




preparation of single polymer aerogels, aerogels containing a blend of 2 polymers will 
be prepared.  
Aerogels containing each possible 2 polymer combination will be prepared. Gels and 
sols used to prepare the polymer blend aerogels will contain 5% total polymer by 
weight (i.e. 2.5% by weight of each polymer). Aerogels containing each polymer blend 
will be produced using the three methods named above. This work package will yield 
a potential 51 homopolymer aerogel formulations, and 408 dual polymer aerogels.  
Each viable aerogel formulation will be loaded with a standardised concentration of a 
furanone. Formulations will be subjected to in vitro drug release testing using standard 
dissolution apparatus. Release data will be interrogated using the, first and zero order, 
Higuchi, and Hopfenberg mathematical models to identify the method of drug release 
from the aerogels. This will give detailed data on the viable aerogel formulations to 
release both hydrophilic and hydrophobic drugs as well as the method of release of 
each. Those formulations exhibiting drug release by matrix dissolution rather than, for 
example, simple diffusion will be carried forward for physical characterisation. 
I will use SEM to obtain qualitative data on pore size and homogeneity and, in 
association with Professor Phillip Withers at the University of Manchester’s X-ray 
Imaging Facility, I will use micro CT to assess internal structural homogeneity and 
pore type. Our partnership with Dr Volkan Degirmenci, an expert in the assessment of 
porous materials, at the University of Warwick will allow me to use nitrogen 
physisorption porosimetry to assess total pore volume, pore size, and pore size 
distribution in the developed aerogels. These research activities will lead to robust 
physical data that will facilitate our understanding of the relationships between aerogel 




the subsequent tuning of selected formulations (total polymer concentration, polymer 
ratio for dual polymer aerogels and presence or degree of crosslinking) to generate 
novel aerogels with precise drug release profiles and matrix dissolution times. This 
data will show that a high degree of control over drug dissolution is practically 
achievable and that tailored release kinetics can be designed via selective changes in 
formulation. Changes in drug release profiles will be correlated to changes in the 
measured physical properties of the aerogels (higher porosity, overall pore size etc.). 
These activities will generate vital knowledge regarding the relationship between 
aerogel formulation, physical properties, and drug release, therefore allowing greater 
control over, and rational design of, aerogel properties in future materials.  
7.5.2 Work Package 2 – In vitro demonstration of aerogel-mediated delivery of 
furanones (16-24 months) 
Firstly, it will be shown that aerogel-delivered furanones effectively inhibit the 
formation of bacterial biofilms, demonstrating the potential of drug-loaded aerogels 
for application to chronic wounds. Biofilm inhibition will be defined as at least a 3-
log reduction in viable biofilm-bound bacterial cells, for which I will use the newly 
developed chronic wound biofilm model described in Chapter 5 of this work. I 
hypothesise that:  
• aerogels will be effective in delivering therapeutic doses of furanones to 
bacterial biofilms. 
• aerogels will be capable of delivering cocktails of several furanones to 
bacterial biofilms to achieve synergistic effects. 
• treatment with furanone-loaded aerogels will cause a reduction levels of 
secreted virulence factors including degradative enzymes and siderophores in 




To achieve these outcomes, loaded aerogels will be used to deliver furanones to 
biofilms under standard laboratory conditions. The efficacy of furanone-loaded 
aerogels to inhibit biofilm formation and reduce virulence factor production under 
chronic wound conditions will also be demonstrated. 
Six representative wound organisms will be used; Pseudomonas aeruginosa, 
Escherichia coli, Enterococcus faecalis, Staphylococcus aureus, Klebsiella 
pneumoniae, and Streptococcus pyogenes (Bowler, Duerden and Armstrong, 2001). 
In addition to being commonly isolated from wound environments, each of the named 
species has been shown to use either homoserine lactones or a furanosyl borate diester 
known as autoinducer-2 in its intercellular signalling (Balestrino et al., 2005; Li et al., 
2007; Siller et al., 2008; Zhao et al., 2010; Shao et al., 2012). This means that each of 
these organisms may be susceptible to the antagonistic effects of furanone treatment.  
The natural furanones HDMF and sotolon and the synthetic furanones C-30 and C-56 
will be investigated. The MIC of these furanone compound against each organism, in 
the planktonic growth state, will be established using the standard EUCAST 
microdilution method and validated using a colorimetric TTC bacterial cell viability 
assay.  
Following identification of the MIC of each furanones the minimum concentration of 
each furanone that effectively inhibits biofilm formation will be identified. Bacterial 
biofilms will be grown in nutrient rich medium (Deligianni et al., 2010) in both the 
absence and presence of each furanone. A range of decreasing concentrations of each 
of the four furanones (beginning with the established MIC for planktonic cells) will 
be added directly to biofilm the growth medium. The rate of biofilm inhibition will be 




et al., 2017) and validated by direct enumeration of viable bacterial cells. Combination 
therapy consisting of two furanones will also be assessed for biofilm inhibitory effects 
using a standard checkerboard assay (Orhan et al., 2005). This will identify synergistic 
effects that may allow for reductions in the concentrations of each furanone required 
to achieved effective biofilm inhibition. Similarly, combination treatments consisting 
of a furanone and classical antibiotics will also be tested to investigate the possibility 
of furanones potentiating biofilm killing by classical antimicrobials.  
Confocal microscopy and SEM will be used to assess the effects of treatments on 
biofilm morphology (Reichhardt and Parsek, 2019). Changes including loss of 3D 
biofilm architecture and alterations to bacterial size, shape and distribution of both live 
and dead cells within the biofilm will be assessed. Treatments causing the greatest 
reduction in viable, biofilm bound, cells and the greatest impact on biofilm 
morphology will be taken forward for antimicrobial aerogel preparation. 
Optimal aerogel formulations (as identified in work package 1) will be loaded with 
the most effective furanone treatments. This will be achieved by incorporating active 
compounds into the sol or gel phase prior to drying. I will also explore alternative drug 
loading strategies such as adsorption-based drug loading during supercritical drying 
(Lovskaya and Menshutina, 2020) to mitigate the effects of poor compound solubility 
on drug loading. 
To assess the efficacy of furanone-loaded aerogels, the novel chronic wound biofilm 
model that was developed during this PhD, which is highly representative of the in 
vivo wound scenario, will be used. Biofilms will be grown at a physiological 
temperature on semipermeable polycarbonate membranes with a wound-like, 




blood and proteins. This medium was developed to represent the nutrient profile in a 
wound environment and has been used, during this PhD, to assess the efficacy of both 
clinically used antimicrobial wound dressings and novel aerogel dressings against 
bacterial biofilms. Biological activity of aerogels in this model will be assessed using 
cell viability staining and direct enumeration. In addition, the activity of relevant 
bacterial virulence factors including degradative enzymes such as protease, elastase 
and collagenase, that increase tissue damage and delay wound healing will be 
measured. These virulence factors will be measured using commercially available 
protease and collagenase assay kits, and a congo-red elastase assay (Oshri et al., 2018). 
This will demonstrate that furanone-loaded aerogel treatment reduces virulence factor 
production, leading to important data on the likely amelioration of tissue damage 
resulting from aerogel treatment.  
Secondly, it will be demonstrated that the developed aerogels deliver effective doses 
of furanones, preventing biofilm formation in acute traumatic wounds using in vitro 
models of burn wound infection and contaminated lacerations. I hypothesise that:  
• rapidly degrading aerogels will effectively deliver a furanone payload to burn 
wounds and acute lacerations 
• the application of furanones to early stage infections in acute wound 
environments will prevent biofilm formation  
Furanone loaded aerogels will be prepared as described previously. Efficacy in 
treating and preventing infection in burn wounds will be tested using a well-
established ex vivo burn wound model (Alves et al., 2018) in which burns on porcine 




to the infected skin and following treatment antimicrobial efficacy will be assessed 
using direct enumeration and cell viability staining.  
To assess the efficacy of furanone-loaded aerogel dressings in acute lacerations with 
a foreign body, an adaptation of the model described by Kucera et al. (Kucera et al., 
2014) will be used in combination with the previously developed and more 
physiologically relevant wound bed medium. Firm polycarbonate coupons coated with 
104 bacterial cells will be used to represent a contaminated foreign body. Once wounds 
have been inoculated, aerogels will be applied to the wound and antibiofilm efficacy 
will be assess as previously described. 
7.5.3 Work Package 3 – Assessing the biocompatibility of developed aerogel wound 
treatments (24-36 months) 
This work package will establish the biocompatibility of the developed furanone 
aerogels in the context of wound healing. I hypothesise that: 
• Loaded aerogels will not induce significant cytotoxicity or genotoxicity in a 
range of mammalian cells vital in wound healing. 
• Furanone aerogels will not induce significant release of inflammatory 
cytokines from relevant cells 
• Furanone aerogels will not be detrimental to cell proliferative capacity during 
or after treatment. 
To test these hypotheses, cell death, proliferation, migration, genotoxicity and 
cytokine release in human skin cell lines (keratinocytes and primary fibroblasts) will 
be measured. Skin immune cell types will also be used (macrophages, dendritic cells 
and bone marrow-derived mast cells). These experiments will provide complete data 




viability following aerogel treatment will be assessed using a simple colorimetric 
assay such as MTT cytotoxicity assay. In parallel, alkaline comet assays will 
demonstrate any genotoxicity as a result of aerogel treatment (Baldrick et al., 2018). 
Clonogenic assays will assess post-treatment proliferation capacity of aerogel treated 
cells and wound scratch assays will assess the impact of aerogel exposure on cellular 
proliferation and migration and wound healing during treatment. The stimulation of 
cytokine release by aerogels will be demonstrated by measuring the release of several 
inflammation markers, including interleukin-1β, monocyte chemoattractant protein 1 
(MCP1 / CCL2), Tumour Necrosis Factor alpha (TNF-α) and interleukin 6 using 
commercially available ELISAs. 
An aerogel will be deemed suitable for further assessment if it shows a significant 
antibiofilm activity and is biocompatible as indicated by favourable response in all 
safety assays.  
7.5.4 Work Package 4 – In vivo demonstration of aerogel-mediated delivery of 
furanones to acute and chronic wounds (37-48 months):  
Once the in vitro efficacy and biocompatibility of furanone-loaded aerogels have been 
robustly demonstrated using clinically relevant model systems, in vivo effectiveness 
will then be demonstrated. Aerogels will be prepared aseptically to ensure sterile 
dressings are used throughout this in vivo work which will prove the clinical utility of 
then new dressings. To achieve this, two mouse models developed by collaborators at 
the Rumbaugh Lab in Texas Technical University will be used. These models have 
been used previously to study acute and chronic wound infections (Dalton et al., 2011; 
Everett et al., 2017). Firstly, a mouse model of chronic wound infection will be used 
to show the effective eradication of wound biofilms. Increases in wound closure rate, 




through the use of the In Vivo Imaging System (IVIS) (Fleming and Rumbaugh, 2018) 
and direct enumeration of bacteria. Histological analyses will allow for measurements 
of underlying tissue damage, inflammation and bacterial infiltration of deeper tissues. 
Secondly, an in vivo model of acute burn wound infection will be used to show 
antimicrobial aerogel efficacy in reducing bacterial loads (Rumbaugh et al., 1999). 
We will assess improvements in total acute wound closure and acute wound bacterial 
loads. Full details of the experimental design can be found in section 7.9. 
 7.6 Beneficiaries 
The primary beneficiaries of this work will be patients, both in the UK and worldwide, 
suffering from a chronic wound. A highly effective antimicrobial wound dressing 
would significantly reduce bacterial burden in established wounds allowing for normal 
wound healing to resume. This will reduce wound healing time, improve clinical 
outcomes, and reduce the incidence of comorbidities such as sepsis and mental health 
effects. Additionally, individuals such as those who sustain burns or heavily 
contaminated wounds who are at greater risk of developing a chronic wound will also 
benefit. By preventing or eradicating early infection in these individuals the number 
of wounds becoming chronic will be significantly reduced. Further, the development 
of an in situ dissolving wound dressing will eliminate the need for dressing removal. 
As the removal of adhered dressings is a source of significant anxiety and worry for 
patients, this too will be eliminated.  
Clinicians, such as the tissue viability teams in the South Eastern and Northern Health 
and social care trusts in Northern Ireland and the wider UK will also benefit from the 
development of these dressings. By completely dissolving in the wound environment 




administered to patients. This will be the first time that clinicians have been able to 
monitor doses of topically applied antimicrobials as closely as systemic antibiotics. 
This will allow clinicians to apply topical antimicrobials more sparingly and, thus, 
help to reduce the development of antimicrobial resistance in infected wounds. As 
such, consultant microbiologists such as Dr David Farren whose role in infection 
control seeks to reduce the development of antimicrobial resistance will see numerous 
benefits from this research. Furthermore, the successful use of extensive clinical input 
from project partners will effectively allow wound healing and tissue viability 
clinicians to have a direct effect on the development of new wound therapies. Having 
this clinical input will allow other clinicians to have greater confidence in the utility 
of the final product.   
The research detailed here will also benefit academic researchers in a range of 
disciplines including materials science and tissue engineering such as Prof. Shiela 
Macneil and Dr Ilida Ortega, University of Sheffield and Prof. Phillip Withers and 
Prof. Sarah Cartmell and their teams at the University of Manchester. By developing 
in situ dissolving polymer aerogels, new information on the relationship between the 
microstructure of porous materials and their ability to release active compounds by 
undergoing matrix dissolution will be gained. This information can then be used by 
local, national, and international research groups investigating drug delivery and 
materials for biomedical applications. Researchers in pharmaceutics and 
pharmaceutical technologies such as Dr Gareth Williams, (Fabrication and Synthetic 
Technologies for Advanced Drug Delivery cluster, University College London), and 
Dr Eneko Larraneta of Queens University Belfast will benefit from this greater 




Finally, the UK Industrial sector will benefit from this project. Specifically, companies 
who focus on designing wound therapeutics and smart dressings such as the University 
of Bath spinout company SmartWound. Similarly, larger international pharmaceutical 
companies such as ConvaTec and Systagenix will also benefit from research into in-
situ dissolving dressings. If successfully translated to the clinical setting the aerogel 
will need to be produced in large quantities by an industrial partner. As this product 
would be the first of its kind and the UK would be the sole producer of a product that 
can be used worldwide. This will provide revenue for the industrial manufacturer and 
also help to bolster the UK economy as well.  
7.7 Relevance to Research Councils/Innovate UK 
The project described here directly aligns with a number of Innovate UK (IUK) and 
research council themes and strategies and as such it is highly complementary to the 
current research profiles of the Medical Research Council (MRC) and UK Research 
and Innovation (UKRI), the Engineering and Physical Sciences Research Council 
(EPSRC), and of IUK 
This work directly aligns with the MRC priority challenge of tackling antimicrobial 
resistance (AMR). AMR currently causes approximately 700,000 deaths annually and 
this is set to rise to 10 million if suitable measures are not taken. This work will 
develop a method for delivering non-antibiotic antimicrobials or tightly controlled 
doses of antibiotics directly to infected wounds. It, therefore, has the potential to help 
reduce the use of both topical and systemic antibiotics for the treatment of chronic 
wound infections which can contribute to the development of AMR (Carter et al., 
2018). The successful prevention of infections in acute wounds will reduce the 




systemic antibiotics. This will result in reduced selection pressures which encourage 
the development of resistance in bacterial populations. Additionally, the developed 
aerogel will allow delivery of 100% of the antimicrobial payload allowing for more 
accurate dosing of active compounds. For these reasons this project also falls under 
the UKRI general theme of “Tackling Antimicrobial Resistance”. 
This work also aligns with the EPSRC “Healthcare Technologies” theme. As this 
project proposes the development, characterisation and assessment of novel materials 
for use as an efficient and versatile drug delivery vehicle it will address the 
“Developing Future Therapies” grand challenge as stated by the EPSRC. It will also 
address the cross-cutting capability of “Advanced Materials”. This material will be 
used for the delivery of both classical antimicrobials and novel non-antibiotic 
antimicrobial materials (such as metallic nanoparticles and graphene family materials) 
as well as complex drug cocktails. As such this work addresses several aspects of the 
challenge; administration of a novel therapeutic agents, targeting of a specific site, 
allowing co-delivery of multiple compounds and achieving controlled release of any 
agents delivered.  
Finally, this work is in-line with the ethos of IUK as it will produce a novel and 
innovative product which, to the author’s knowledge, would be the first of its kind. In 
addition to this, this project has significant potential to impact upon the UK economy 
through the possibility of spin-out company development to take advantage of any 
intellectual property. As well as the innovative nature of the proposed project the work 
detailed here aims to address the IUK “Ageing Society” grand challenge. This strategy 
aims to ensure that people have a minimum of 5 additional, good quality, years of life 




this project is designed to address this grand challenge. With chronic wounds come 
other health effects such as chronic pain, risk of sepsis and even mental health effects. 
Chronic wounds can clearly impact on the quality of life of patients who experience 
them. Therefore, any new intervention aimed at reducing the impact of chronic 
wounds on patients could make a significant difference in the quality of life of the 
elderly.  
7.8 Project partners  
This project will have both academic and clinical partners. Collaboration with the 
Welsh Wound Innovation Centre (WWIC) will provide vital clinical input from the 
beginning of the project. This clinical input will involve advice from practicing and 
research wound management clinicians on the design of the aerogel wound dressings. 
The development of novel materials for healthcare purposes has primarily been within 
the remit of engineering and materials science only. As such many novel materials are 
poorly optimised for clinical use. By involving wound management clinicians, steps 
can be taken to ensure that any developed materials meet the needs of both clinicians 
and patients. This needs driven design approach will greatly increase the likelihood of 
successful clinical translation.  
To assist in the physical characterisation of the developed materials a collaboration 
has been sought with Professor Phillip Withers at the Royce Institute, part of the 
University of Manchester. Professor Withers will assist in the micro CT analysis of 
the developed aerogels. In addition to the collaboration with Professor Withers, a 
partnership with Dr Volkan Degirmenci of the University of Warwick has been 
established. Dr Degirmenci will provide access to, and assistance in using, the nitrogen 




Finally, to conduct robust in vivo investigations into the efficacy of the developed 
aerogels a collaboration has been established with Dr Kendra Rumbaugh at the Texas 
Technical University in Lubbock Texas. Dr Rumbaugh will provide assistance with 
conducting in vivo experiments using two mouse models which have been developed 
by her group. These models include a model of acute burn wound infection and a 
biofilm associated chronic wound infection model.  
7.9 Ethical implications 
Adult, Swiss Webster mice will be used in the project detailed in this application. 
Swiss Webster is a well-characterized outbred strain of white mice, which is 
susceptible to infection with both pathogens proposed for use in this work 
(Pseudomonas aeruginosa and Staphylococcus aureus) and have been used 
extensively by the Rumbaugh group at Texas Technical University. The use of mice 
in this work is appropriate as no sufficient in vitro model of wound healing is available.  
7.9.1 Experimental design 
Mice will be anesthetized by intraperitoneal injection of sodium pentobarbital. Once 
effective anaesthesia is reached, the backs of the animals will be shaved and a full-
thickness, dorsal, 1.0 x 1.0 cm excisional skin wound will be administered. Wounds 
will be to the level of panniculus muscle and will be made with surgical scissors. 
Wounds will then be infected with approximately 104 - 105 colony-forming units of 
bacteria. Wounds will then be covered with a semipermeable polyurethane dressing 
(such as OPSITE). Warmed Ringer’s lactate will then be administered to mice as fluid 
replacement and animals will be allowed to recover under heating pads. The use of an 
adhesive dressing prevents contractile wound healing and ensures that the 




wound healing is more representative of human processes. It has previously been 
shown that this infection is biofilm-associated and is therefore representative of human 
chronic wound infection.  
A modified burned-mouse model of Stieritz and Holder (Stieritz and Holder, 1975) 
will be used as it closely resembles human acute wound sequelae. Briefly, adult, male 
and female Swiss Webster mice will be anesthetized, their backs will be shaved, and 
a non-lethal, third-degree thermal injury will be induced by scalding a 4.5 × 1.8 cm 
area of shaved skin with 90°C water. Fluid replacement therapy will be administered 
immediately following the burn, by the subcutaneous administration of 900 mL warm 
lactated rings. Wounds will then be infected with approximately 102 colony-forming 
units of bacteria.  
7.9.2 Experimental endpoints 
Endpoints for chronic wound experiments will be at 0, 7, 14, and 21 days post 
infection. Endpoint for acute wound experiments will be 72 h post infection. However, 
any animal found to be showing 3 or more of the NIH's morbidity endpoint clinical 
signs, or to be moribund, or unable to obtain food or water, will be judged to be at or 
near the endpoint and humanely euthanized. 
7.9.3 Justification of sample size 
Prior work and G-power software calculations performed in the Rumbaugh lab has 
shown that, typically, 9-12 mice will be needed per group to detect changes in bacterial 
load and wound closure at a P value of 0.05, at 95% confidence. However, as this is a 
first exploration of the efficacy of these dressings exact sample size estimates cannot 
be made. Experiments have been carefully designed so that data from as many 




7.9.4 Addressing bias 
Animals will be randomly assigned into treatment groups upon arrival to the animal 
facility. Treatments with either drug-loaded, or non-loaded aerogels will be blinded to 
the staff administering them and groups will be given letter identifiers. This identifier 
will be carried through the entire experiment and all tissues and samples obtained will 
be similarly labelled. All subsequent evaluation including histopathology, bacterial 
load determination, and wound closure rates, and statistical analysis will be performed 
on blinded samples.  
7.9.5 Statistical analysis 
Dr Rumbaugh will retain the blinded identifier key until statistical analysis of the data 
is performed by the applicant. Statistical analysis will be conducted utilizing GraphPad 
Prism, employing statistical ANOVA tests, with post-hoc Tukey tests. The data will 
be tested appropriately depending on normality and P values less than 0.05 will be 
considered significant. 
7.10 Stakeholder engagement and dissemination plan 
Stakeholder engagement will be considered a priority throughout this project. 
Engagement with potential clinical end users of the developed aerogel wound 
dressings will be through established collaborations with WWIC. By having clinicians 
involved in the design and development of the aerogel wound dressings from the early 
stages we aim to increase end user confidence that this dressing will meet both their 
needs and the needs of their patients.  
As they are important stakeholders, patient involvement will also be used during this 
project. By engaging with patient groups, such as those run through organisations like 




understanding of patients’ needs and therefore tailor the design of the aerogels 
appropriately.   
We will engage with academic stakeholders by disseminating our findings in high 
impact academic and clinically relevant journals as well as presenting at relevant 
conferences. We will also engage with academic stakeholder by hosting visits to the 
laboratories at Ulster University so that individuals may learn to use our chronic 
wound model for the assessment of antimicrobial wound therapies.    
Initially, the objectives and then the findings of the project will be shared widely with 
potential stakeholders via web-based press releases (1-2 per year) from the 
communication office at Ulster University. A dedicated web page will be hosted on 
the University website and provide project information, updates and contact details to 
any interested parties for further engagement. Links to this information will be posted 
on the individual web page and social media profiles of each investigator. Tackling 
AMR–including chronic wound causing bacteria, and healthcare acquired infections–
is a UKRI Cross Council initiative and to ensure relevant researchers benefit from our 
work, we will publish high impact papers in peer reviewed journals (e.g. Advanced 
Materials, Nature Microbiology) and deliver keynote presentations at leading 
conferences (e.g. Advanced Materials and Nanotechnology, Wounds UK and the 
Microbiology Society Annual Conference). 
Once expected outcomes are achieved, we have identified follow on funding streams 
to translate our technology to the clinic. Firstly, we will seek UKRI research councils 
and charities funding, namely MRC (infection & immunity or antimicrobial resistance 
panel), MRC CiC (confidence in concept/P2D), Life Arc (MRC tech), Blond McIndoe 




The generated knowledge will be useful not only for wound healing but also be 
important for other biomedical applications in which aerogel materials could be of use. 
Additionally, the findings of this work may be important to understand the in vivo 
efficacy profile of quorum sensing inhibitors (particularly in wound infections) as 
knowledge in this area is limited  
7.11 Justification of Resources 
7.11.1 Staff Directly Incurred Costs 
Funds are requested for 100% time of a PDRA across the 4-year period in order to 
complete the detailed research activities.  
7.11.2 Travel and Subsistence 
Total funds requested: £11350. Funds are requested for attendance at 4 UK 
conferences of relevant disciplines (Advanced Materials and Nanotechnology, 
Wounds UK conference, Microbiology Society General conference, and Porous 
Materials conference). Attendance at these conferences is required for dissemination 
of key project findings, networking and development of collaborations. Costs for 
travel to these conferences includes flights/travel £150, accommodation £150, 
subsistence £50, and registration fee £300. Cost of £650 per conference. TOTAL 
COST FOR UK CONFERENCES = £2600. 
Funds are also requested for travel to 2 international conferences (European Wound 
Management Association). Attendance at these international meetings is also required 
for dissemination of key project findings, networking and development of 
collaborations. Costs include flights/travel £500, accommodation £750, subsistence 
£300, and registration fee £500. Cost of £2050 per conference. TOTAL COST FOR 




Travel to project collaborators and partners. Travel will include 8 trips to UK based 
partners (x2 trips to University of Warwick for porosimetry experiments, x2 trips to 
University of Manchester for micro CT experiments, x 4 trips to Welsh Wound 
Innovation Centre). This travel is necessary for work essential to the completion of the 
project Travel costs to UK partners and collaborators includes flights/travel £150, 
accommodation £200, subsistence £50. This represents a cost of £400 per trip. 
TOTAL COST FOR TRAVEL TO UK PARTNERS = £3200. 
Funds for travel to non-UK collaborators have also been requested (x1 trip to Texas 
Technical University). This travel is required for the completion of in vivo work 
essential to the completion of the project. Costs for travel include flights £1000, 
Accommodation £300 and Subsistence £150. TOTAL COST OF TRAVEL TO 
NON-UK PARTNERS = £1450 
7.11.3 Other Directly Incurred Costs 
Total funds requested: £206758. Funds requested for WP1 are detailed here. 
Chemicals and reagents including polymers £7250 and crosslinkers £1291 are required 
for the preparation of aerogel formulations. Funds for characterisation of aerogel 
formulations include 50h scanning electron microscopy £6,000, 20 days for micro CT 
(in collaborations with Prof. Phillip Withers at the University of Manchester/Royce 
Institute) using Zeiss Versa system £10155 and 25 h of staff time £1068. TOTAL 
COST FOR WP1 = £25764 
Funds for WP2 include the purchase of microorganisms £600, furanones £3830, 
microbiological culture media (inc. tryptone soy broth, nutrient broth, Mueller Hinton 
broth and technical agar) £1500, bacteriological stains (crystal violet and BacLight 




£1400, protease and collagenase kits and elastin-congo red substrate £1760, other 
laboratory consumables (inc plasticware and polycarbonate coupons for acute 
laceration model) £ 2320. Funds for imaging of microbiological samples are also 
requested (SEM 25h, Confocal 25h, Bright field 15h) £6200. Costs for bulk production 
of critical point dried aerogels for acute and chronic wound via Suprex are also 
requested. The production of these samples will cost £10000. TOTAL COSTS FOR 
WP2: £29720 
Requested funds for biocompatibility testing in WP3 are; purchase of human cell lines 
for in vitro testing £3500, consumables for cytotoxicity, clonogenic and wound scratch 
assays £1660, ELISA kits, 96 well plates and lids for inflammatory marker panel 
£3270. Funds for RT-qPCR testing includes reagents (RNEasy, Light Cycler plates 
and seals, Sybr Stain, Bioanalyser kit and consumables) £5950. Funds for xCelligence 
plates and electrodes will be £1500. Other required materials include cell culture 
medium and medium supplements £920 and general laboratory consumables £1450. 
TOTAL COST FOR WP3 = £18250 
Funds for WP4 – Note: all costs from collaborator Kendra Rumbaugh at Texas 
Technical University (all costs converted from USD). Funds for Animals and animal 
housing £4859, lab and pathology processing fees £1620, microscopy core facility 
(use of the IVIS system) £1620, consumables (chemicals, media, and plasticware) 
£4049. Staff costs - Kendra Rumbaugh time £7748, Research Technician time £22921, 
facilities and administrative costs £22693. TOTAL COST FOR WP4 = £65510 
Funds are requested for collaboration with Welsh Wound Innovation Centre. 
Requested funds will cover x1 full-day focus group for clinical input on dressing 




£160, facilities costs £112) £12553.25. Costs also included for x3 half day follow up 
meetings for clinical input on dressing design. TOTAL COST: £40,544  
Finally, funds are requested for the purchase of equipment for the completion of this 
project. The equipment to be purchased includes;  
1. WR CDL1000L UV Crosslinker for PVP and PAA aerogel synthesis £1500 
2. QuorumTech E3100 critical point dryer for aerogel supercritical drying £6000 
3. critical point dryer accessories (inc. sample pots, servicing kit and spare 
components, seals, washers etc) £3200 
4. Cleaver Scientific SWB-20L-3 stirring water bath for gel preparation £1700 
5. full set of Gilson pipettes (5 pipettes total) for RNA work £1190 
6. Sciquip Mutichanel pipettes (2 pipettes total) and Sciquip serological pipette 
gun for cell biology work £450, 
7. SiQuip DryBlock Heat block for use in ex vivo burn wound model £230 
8. Thermo x4Pro 240V50/60Hz benchtop centrifuge for use in biocompatibility 
testing £9900 
9. Kern inverted compound microscope for cell biology and biocompatibility 
work £2800.  
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Proctor, C. R., McCarron, P. A. and Ternan, N. G. (2020) ‘Furanone quorum-sensing inhibitors 
with potential as novel therapeutics against Pseudomonas aeruginosa’, Journal of Medical 
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Abstract: Micro- organisms use quorum sensing (QS), a cell density- dependent process, to 
communicate. This QS mode of interchange leads to the production of a variety of virulence 
factors, co- ordination of complex bacterial behaviours, such as swarming motility, degradation 
of host tissue and biofilm formation. QS is implicated in numerous human infections and 
consequently researchers have sought ways of effectively inhibiting the process in pathogenic 
bacteria. Two decades ago, furanones were the first class of chemical compounds identified as 
Pseudomonas aeruginosa QS inhibitors (QSIs). P. aeruginosa is a ubiquitous organism, capable 
of causing a wide range of infections in humans, including eye and ear infections, wound 
infections and potentially fatal bacteraemia and thus novel treatments against this organism are 
greatly needed. This review provides a brief background on QS and the use of furanones as 
QSIs. Based on the effectiveness of action, both in vivo and in vitro, we will explore the use of 
furanones as potential antimicrobial therapeutics and conclude with open questions. 
 
